66th ASH Annual Meeting: Author Index H

Ha, Z.

2672 - Combinatorial Effect of Chronic Alcohol Drinking and Age Perpetuates Myeloid-Biased Hematopoiesis Via Hematopoietic Stem Cell Senescence

Haaf, J.

4967 - Modulating G-CSFR Signaling Using De Novo Designed Cytokines

Haag, M.

969 - Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy
1828 - Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts

Haag, S.

4828 - A Phase 1 Study of P-BCMA-ALLO1, a Non-Viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM): Results from Optimized Lymphodepletion Cohort

Haaksma, L. H.

4329 - Leukemic Phenotype Determines Prognostic Relevance of Limit of Quantification for Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia

Haar, E. V.

1176 - Medical Problems of Mothers of Children with Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT): Autoimmunity and Psychological Symptoms
1178 - Analysis of Screening for Autism Spectrum Disorders in Children Affected By Fnait with and without Intra-Cranial Hemorrhage
1179 - Fetal and Neonatal Alloimmune Thrombocytopenia: Risk of ICH in Second Pregnancy and Treatments to Maintain an Adequate Platelet Count

Haas, J.

318 - Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in KMT2A-Rearranged BCP-ALL

Haas, S.

1292 - Mapping Genotype to Phenotype in Clonal Hematopoiesis Uncovers Downregulated MHC-II Molecules in DNMT3A^R882- Mutant Hematopoietic Stem Cells
1460 - Data-Informed, Refined Immunophenotypic Classification of Adult T-Lineage Acute Lymphoblastic Leukemia

Haase, D.

666 - Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))
4308 - Rapid, Reliable, and Comprehensive Identification of MDS-Defining Cytogenetic Changes By a FISH-Panel Containing Six Probes in a Real-World Population of Patients with Suspected AML

Haase, V. H.

- Hypoxia-Inducible Factor Activators: A Novel Class of Oral Drugs for the Treatment of Anemia of Chronic Kidney Disease

Habashy, A.

3495 - CMV Reactivation Kinetics in Patients Undergoing Haploidentical Stem Cell Transplantation Using Low-Dose Post-Transplant Cyclophosphamide: A Single Center Experience

Habeck, C.

23 - Iron Repletion of Iron-Deficient Blood Donors Affects Brain Iron, Myelin, and Neural Network Activation Patterns

Häberle, S.

4775 - MP0621 (cKit x CD16a x CD47), a Multi-Specific Switch-Darpin with Conditional Blockade of CD47 Targeting Hematopoietic Stem Cells: Preclinical Evaluation of a Next-Generation Conditioning Agent for Stem Cell Transplantation

Habermann, B.

3970 - Development of an Early and Complete Examination Protocol for Women and Girls with Inherited Bleeding Disorders (WGBD)
3974 - Interim Results of a New Examination Protocol for Women and Girls with Inherited Bleeding Disorders (WGBD)

Habermann, T. M.

580 - A Phase 1/1b Study of Parsaclisib Plus Standard Immunochemotherapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma
1624 - Assessment of the Optimized HLH Inflammatory (OHI) Index in a Prospective Cohort of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
1629 - Subsets of Follicular Lymphoma (FL) 3B Have Divergent Biological Behavior and Clinical Outcome: Results from the Prospective Multicenter MER and LEO Cohorts
1637 - Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study
1652 - Outcomes in Early Relapse of Follicular Lymphoma Versus Early Histologic Transformation Following Firstline Immunochemotherapy in Follicular Lymphoma
1710 - Characteristics and Outcomes of Incidentally Diagnosed Diffuse Large B Cell Lymphoma (DLBCL)
2283 - Impact of COVID-19 on Multidisciplinary Lymphoma Tumor Boards: An Analysis of Practice and Care Changes
2345 - Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study
2977 - Subtype-Specific Mechanisms of Treatment Resistance and Relapse in Diffuse Large B Cell Lymphoma (DLBCL)
3007 - Frontline R-CHOP and BR Have Similar Outcomes By SUV_max in Follicular Lymphoma
3019 - Clinical Characteristics and Outcomes of Aggressive Transformation in Splenic Marginal Zone Lymphoma: An International Study of 111 Patients
3093 - Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study
3301 - Clinicopathological and Gene Expression Analysis of Hyaline Vascular Castleman Disease
3736 - Occurrence and Predictors of Patient Reported Fertility Discussions in Non-Hodgkin Lymphoma Patients: Utilizing the Lymphoma Epidemiology of Outcomes (LEO) Cohort Study

Habib, A.

524 - Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma
2009 - A Real-World Analysis of the Safety and Efficacy of BCMA-Directed CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment
2404 - Treatment of Relapsed/Refractory Multiple Myeloma with Ciltacabtagene Autoleucel or Idecabtagene Vicleucel in Racial Minorities—a Multicenter Study
2411b - Real-World Efficacy Outcomes of Ciltacabtagene Autoleucel in Relapsed Refractory Multiple Myeloma: A Comparative Study with the Cartitude-1 Trial
2411g - Evaluation of Teclistamab in BCMA-Directed Therapy Exposed Versus Naïve in Relapsed/Refractory Multiple Myeloma
2432 - Real-World Experience of Venetoclax Target Dosing with Concomitant Posaconazole in Adult Patients with Acute Myeloid Leukemia
4507 - Steroid Prophylaxis in Patients Receiving CAR T-Cell Therapy for Relapsed and Refractory Non-Hodgkin Lymphoma
5170d - Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients

Habib, D.

2811 - Updated Results of the Combination of Mini-Hyper-CVD with Inotuzumab Ozogamicin and Blinatumomab in Patients with Relapsed/Refractory B-Cell ALL
4194 - Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia: 3-Year Update

Habib, R.

1104 - Small Activating RNA-Mediated Induction of HBG Via Liposome Delivery for In Vivo Treatment of Sickle Cell Disease and Beta-Thalassemia

Habibi, A.

2500 - Voxelotor Impact after 6 Months on Blood Rheology in Patients with Sickle Cell Disease
2506 - Improvement in Kidney Function after 6 Months of Voxelotor in Sickle Cell Disease Patients
2508 - Parameters Associated with Improved Peripheral Oxygen Extraction in Sickle Cell Patients Treated with Voxelotor
2511 - Evaluation of Sleep Apnea in Adult Sickle Cell Disease; About 107 SS and Sβ°Thal Patients
2520 - Improvement in Cerebral Vasoreactivity after 6 Months of Voxelotor Measured By Near-Infrared Spectroscopy (NIRS) in Sickle Cell Disease Patients
2644 - Transcriptomic Analysis Shows a Common Multi-Organ Inflammatory/Complement Signature in Hemolysis-Induced Damage
3890 - Protection Against Coronary Atherosclerosis in High Cardiovascular Risk Sickle Cell Disease Patients: A Beneficial Role of Intravascular Hemolysis?
3891 - Unique Nature of Sickle Cell Diastolic Cardiomyopathy: A Tailored Echocardiographic Definition to Refine Prognostic Stratification in Young Adults
3892 - Very Premature Bioprosthetic and Valve Repair Degeneration in Sickle Cell Disease Patients
4875 - Erythroid-Specific Chimerism Analysis after Allogeneic-Hematopoietic Stem Cell Transplantation Using a Human Leukocyte Antigen-Identical Sibling Donor in Sickle Cell Disease Patients

Hablesreiter, R.

44 - Tracing Clonal Hematopoiesis and Tumor-Specific Mutations in Hematopoietic Progenitors of B Cell Non-Hodgkin Lymphoma (NHL) Patients
2956 - Intra-Tumor Heterogeneity in Core-Binding Factor Acute Myeloid Leukemia
4613 - Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial

Habringer, S.

1460 - Data-Informed, Refined Immunophenotypic Classification of Adult T-Lineage Acute Lymphoblastic Leukemia

Habtermariam, B.

4838 - BEAM-201 for the Treatment of Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL): Initial Data from the Phase (Ph) 1/2 Dose-Exploration, Dose-Expansion, Safety, and Efficacy Study of Multiplex Base-Edited Allogeneic Anti‑CD7 CAR-T-Cells

Habza, A.

1289 - Emergence of DNA Damage Repair Clonal Hematopoiesis after Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors

Haces-Tirado, G. E.

2555 - Early Treatment Use of Fostamatinib for Immune Thrombocytopenia (ITP): Efficacy and Safety As Second/Third ITP Treatment Lines in Clinical Practice in Spain

Hacini, M.

3150 - Bosutinib for Patients with Previously Treated Chronic Myeloid Leukemia: Results from the French Observational Boseval Study

Hackanson, B.

2864 - A Prospective, Multicenter Study Assessing Functional and Psychosocial Parameters in AML Patients ≥ 60 Years Receiving Induction Chemotherapy

Hackenbroch, C.

186 - Platelets-Derived Integrin and Tetraspanin-Rich Tethers (PITTs) Drive Pulmonary Inflammation

Hackenbruch, C.

1504.1 - Trial in Progress: Phase I Trial Evaluating an Immunopeptidome-Defined Multi-Peptide Vaccine Against Acute Myeloid Leukemia Stem and Progenitor Cells

Hackeng, T. M.

2603 - Citrullination in the C-Terminus of Tissue Factor Pathway Inhibitor-Alpha Impairs the Inhibition of Factor V Activation, and the Synergy with Protein S in Factor Xa Inactivation
3987 - Tissue Factor Pathway Inhibitor Modulates Endothelial and Vascular Smooth Muscle Cell Functions By Drifting Cellular Phenotypes
3994 - Citrullination of TFPI By PAD4 Impairs Its Natural Anticoagulant Activity Towards Factors Xa, VIIa and Tissue Factor, and Reduces Binding to Its Cofactor Protein S

Hackett, L.

1615 - Mechanistic Insights and Therapeutic Potential of a PRMT5 Inhibitor Combined with Venetoclax in B Cell Malignancies
1865 - Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Hackman, G. L.

1400 - Targeting Lipid Droplet Biogenesis to Enhance Ferroptosis in Acute Myeloid Leukemia

Hadala, J. T.

1025 - Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial
3261 - Biomarker Analyses of the CC-92480-MM-001 Trial to Guide Combinatorial Strategies for Mezigdomide

Haddad, C.

1328 - Genomic Landscape of Germline RUNX1 variants in Adult Myeloid Neoplasia According to Functional Impact

Haddad, C.

35 - First Results of High Throughput Pipeline for Serotypic and TCR Clonotypic Specificities in Aplastic Anemia and Large Granular Lymphocyte Leukemia Uncovering Antigenic Peptides Relevant to Disease Etiology
1254 - Budd-Chiari Syndrome: Pathogenetic Factors and Completeness of Screening for Paroxysmal Nocturnal Hemoglobinuria
1688 - Low-Count T-/NK-Large Granular Lymphocytic Leukemia: A Nosologically Distinct Disease Subtype at the Crossroads between Lymphoproliferation, Autoimmunity and Immunodeficiency
2920 - Distinct Phenotypes of Myeloid Neoplasia Associated with Truncating C-CBL Mutations
3199 - Could Somatic Gene Rescue Explain Frequency of Compound Heterozygous and Concurrent Receptor Tyrosine Kinase Mutations in Hematological Diseases?
4084 - An Immunogenetic Perspective on Bone Marrow Failure Syndromes: The KIR-HLA System
4573 - Elucidating the Somatic Genetic Rescue Underlying Del(20q) Myeloid Neoplasms

Haddad, F. G.

Haddad, G.

1080 - A Single Mutation in the SENP1 Region Regulates the Excessive Erythropoiesis in the Andes

Haddad, P. A.

2945 - Development and Validation of the Blastic Plasmacytoid Dendritic Cell Neoplasm Prognostic Score
3084 - The Role of Intensive Chemotherapy and Radiotherapy in Plasmablastic Lymphoma: Optimizing Survival Outcomes
4243 - Acute Erythroid Leukemia Clinicopathologic Determinants of Survival: Analysis of a Pooled Database

Haddadi, S.

1629 - Subsets of Follicular Lymphoma (FL) 3B Have Divergent Biological Behavior and Clinical Outcome: Results from the Prospective Multicenter MER and LEO Cohorts
3007 - Frontline R-CHOP and BR Have Similar Outcomes By SUV_max in Follicular Lymphoma
3093 - Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study

Haddadin, M.

2125 - Association between Malnutrition and Inpatient Mortality in Hematopoietic Stem Cell Transplant (HSCT) Population: A Nationwide Inpatient Sample (NIS) Database Analysis
2421 - The Burden of Leukemia in the United States from 1990 to 2021
3206 - Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome – a Multicenter Retrospective Analysis
3550 - Pre-Hematopoietic Cell Transplantation (HCT) Frailty Is Associated with Lower Cognitive Function and Health-Related Quality of Life (HRQOL) in Older Adults Undergoing HCT

Haddish-Berhane, N.

1989 - Less Frequent Teclistamab Dosing in Responders: Modeling and Simulation Data from the Majestec-1 Study in Relapsed/Refractory Multiple Myeloma

Hadidi, D.

160 - The Caprini Score in Black and Latino Patients: A Proposed Race- and Ethnicity-Adjusted Model for Perioperative Venous Thromboembolism Risk Assessment

Hadjadj, J.

2674 - Clinical Efficacy of Erythroid Stimulating Agent (ESA) and Luspatercept (LUSPA) in Vexas Syndrome with or without Myelodysplastic Syndrome (MDS) : A Multicenter Retrospective Study By the Frenvex Group
4553 - Characteristics and Therapeutic Response of Erdheim-Chester Disease Associated with Myeloid Neoplasm, an Observational Multicenter Study

Hadjivassileva, T.

4193 - Impact of Disease Burden, CAR-T Expansion, and Mononuclear Cell Recovery on Overall Response and Duration of Response in Zuma-3 Pivotal Study

Hadland, B. E.

377 - Dilanubicel, a Non-HLA-Matched Pooled Universal Product, Transforming Single Cord Blood Transplantation Success Rates

Hadorn, N.

1120 - Transcriptomic Profiling Supports the Phenotypic Classification of Stable-State Sickle Cell Disease Patients

Hadoux, J.

1289 - Emergence of DNA Damage Repair Clonal Hematopoiesis after Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors

Hadrup, S. R.

691 - T-Cell Monitoring for the Recently Expanded Repertoire of HLA Class I-Restricted Minor Histocompatibility Antigens Using Barcoded Peptide-MHC Multimers

Hadzic, A.

3918 - L-Asparaginase Treatment Induces Reversible Immunoregulatory and Immunosuppressive Effects in Non-Malignant B Cells in a Model of T-Cell Dependent B Cell Activation

Haeno, H.

346 - Clonal Origin of Therapy-Related Myeloid Neoplasms after Autologous Stem Cell Transplant

Hafer, R.

3063 - The Risk of Developing Non-Melanoma Skin Cancers in Patients with Cutaneous T-Cell Lymphoma
5111 - Comparison of Zanubrutinib and Ibrutinib As Treatments for Waldenstrom Macroglobulinemia: A Real-World Retrospective Study

Haferlach, C.

664 - Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database
666 - Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))
899 - Secondary Cytogenetic and Molecular Genetic Abnormalities in Newly Diagnosed Multiple Myeloma Patients
1458 - C/EBP Family Member Gene Fusions and Cooperating Genomic Events Define Two Distinct Molecular Sub-Groups in Adult B Precursor ALL
1819 - Similarities and Differences of DNMT3A, TET2 and ASXL1 Mutations across Ccus, MDS and AML
1836 - Two Ways to Complex Karyotype in MDS - the Role of Del(5q) and TP53
3219 - Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
4104 - Telomere Content Diversity in Myeloid Neoplasia Could Inform on Differential Sensitivity to Telomerase Inhibitors
4213 - Integrateall, a Machine Learning Pipeline for Multi-Level Data Extraction from RNA-Seq Profiles Unravels Novel Drivers and Systematic Subtype Classification in B-Cell Precursor ALL
4318 - Clonal Hematopoiesis Can Precede AML with Defining Cytogenetic Abnormalities - the Frequencies Vary Considerably
4688 - Prevalence and Mutational Make-up of Secondary Hematologic Neoplasms in Multiple Myeloma Patients after CAR-T Cell Therapy
- The Application of Artificial Intelligence in Hematological Diagnostics

Haferlach, T.

31 - Genetic Determinants of Hypercoagulability in Complement and Hemostatic Systems Shape the Thrombotic Risk of Paroxysmal Nocturnal Hemoglobinuria
61 - Single-Cell Multiomics Unveils Venetoclax-Resistant Monocytic Differentiation and Immune Evasion in TP53 Mutant AML Clones
105 - Enhancing Personalized Prognostic Assessment of Myelodysplastic Syndromes through a Multimodal and Explainable Deep Data Fusion Approach (MAGAERA)
664 - Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database
665 - Landscape of Immune Cell States and Ecosystems in Patients with Myelodysplastic Syndrome to Refine Prognostic Assessment and Predict Treatment Response. a Study By i4MDS Consortium
666 - Newly Developed Prognostic Score for Myelodysplastic Syndrome (MDS) with Isolated 5q Deletion (IPSS-del(5q))
844 - The Prognostic Impact of Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia with FLT3-ITD Mutations
899 - Secondary Cytogenetic and Molecular Genetic Abnormalities in Newly Diagnosed Multiple Myeloma Patients
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
1351 - Parallel Sequencing of Transposons and Transcriptomes in Single Cells for Genome-Wide Cancer Gene Discovery
1819 - Similarities and Differences of DNMT3A, TET2 and ASXL1 Mutations across Ccus, MDS and AML
1836 - Two Ways to Complex Karyotype in MDS - the Role of Del(5q) and TP53
2221 - A Comprehensive, Artificial Intelligence, Digital Twin Platform Based on Multimodal Real-World Data Integration for Personalized Medicine in Hematology
2732 - A Unified Post-Transcriptional Mechanism Regulates Intron Retention in Splicing Factor-Mutant MDS
3199 - Could Somatic Gene Rescue Explain Frequency of Compound Heterozygous and Concurrent Receptor Tyrosine Kinase Mutations in Hematological Diseases?
3205 - Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia
3214 - The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms
3219 - Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
3597 - The “David Vs Goliath” Study: Application of Large Language Models (LLM) for Automatic Medical Information Retrieval from Multiple Data Sources to Accelerate Clinical and Translational Research in Hematology
3598 - Artificial Intelligence-Powered Digital Pathology to Improve Diagnosis and Personalized Prognostic Assessment in Patient with Myeloid Neoplasms
4104 - Telomere Content Diversity in Myeloid Neoplasia Could Inform on Differential Sensitivity to Telomerase Inhibitors
4149 - Proteolytic Control and Therapeutic Targeting of Oncogenic Gene Expression in Acute Myeloid Leukemia
4318 - Clonal Hematopoiesis Can Precede AML with Defining Cytogenetic Abnormalities - the Frequencies Vary Considerably
4585 - Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab
4688 - Prevalence and Mutational Make-up of Secondary Hematologic Neoplasms in Multiple Myeloma Patients after CAR-T Cell Therapy
4981 - Generation of Multimodal Longitudinal Synthetic Data By Artificial Intelligence to Improve Personalized Medicine in Hematology
4989 - An Artificial Intelligence-Based Federated Learning Platform to Boost Precision Medicine in Rare Hematological Diseases: An Initiative By GenoMed4all and Synthema Consortia

Haffner-Luntzer, M.

3287 - Novel NOTCH1 Effector NFIL3 Is a Therapeutic Target to Combat Drug Resistance and Improve Patient Outcomes in Newly Diagnosed and Relapsed-Refractory Multiple Myeloma

Hafsaoui, A. Y.

521 - Baseline Neurological Morbidity Assessment in Adult Patients with Sickle Cell Disease : The Montreal Brain-SCD Cohort
5068 - Validitation of the Rowland Universal Dementia Assessment Scale (RUDAS) for the Detection of Cognitive Impairment Among Adults with Sickle Cell Disease
5069 - How Does Cognition Impact Healthcare Transition Skills, Engagement and Utilization in Young Adults Living with Sickle Cell Disease?

Hagar, R.

2239 - Reproductive Health Surveys Administered in Sickle Cell Clinics Can Inform Personalized Care and Multidisciplinary Collaboration
3622 - Establishing a Definition of Transition of Care in Sickle Cell Disease: National Alliance of Sickle Cell Disease Centers Consensus

Hagelaar, R.

2735 - Single-Cell Whole Genome Sequencing Reveals the Evolution and Migration of Lymphoma

Hageman, L.

Hagemeister, F. B.

4454 - Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma

Hagemeister, F.

3001 - Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma

Hagemeister, F.

4511.1 - Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Hagen, M.

684 - Update on Monocentric CD19-CAR T-Cell Therapy in 30 Patients with Autoimmune Disease
4835 - Distinct Safety and Toxicity Profile of CD19-Directed CAR T-Cell Therapy in Systemic Lupus Erythematosus Versus B-Cell Lymphoma – a Single-Center Experience

Hagen, P.

3378 - Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)
3309.1 - A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis

Hagenacker, T.

3309 - Gain or Amplification of 1q21 in Systemic Light Chain Amyloidosis Is Associated with Advanced Mayo Stage, Plasma Cell Disease and Worse Overall Survival

Hagerman, A.

946 - Modeling Clonal Hematopoiesis Due to Chromosome 13q Deletion in Human Hematopoietic Stem Cells

Hagihara, M.

4925 - The Outcome of Fertility Preservation Strategy in Female Hematopoietic Stem Cell Transplant Recipients of Reproductive Age. Retrospective Study from the Kanto Study Group for Cell Therapy

Hagleitner, M. M.

2830 - A Non-Canonical Lymphoblast in Refractory Childhood T-Cell Acute Lymphoblastic Leukemia
2985 - High Clinical Benefit of Diagnostic RNA Sequencing in Pediatric T-Cell Lymphoblastic Lymphoma for the Identification of Potentially Targetable Risk Groups

Hagner, P. R.

955 - Deciphering the Mechanism of Action of the Novel Celmod, Golcadomide, during Germinal Center B Cell Immune Response and in a Preclinical Mouse Model of Follicular Lymphoma
1409 - Genomic and Single Cell Investigation of MRD Clonality in Genetically Engineered Mouse Models of Multiple Myeloma
1617 - Golcadomide Extends Survival of Lymphoma GEMM Mice in Combination with a CD20xCD3 T-Cell Bispecific through Increased T-Cell Activation and Infiltration
1881 - Multi-Omics Integration to Elucidate the Cis-Regulatory Network Re-Wiring upon NSD2 Degradation in t(4;14) Multiple Myeloma
2523 - Degradation of Ikaros Induces Neutropenia through Altered Transcriptional Programming across Multiple Stages of Neutrophil Development and Maturation
2525 - Constructing a Computational Workflow for the Identification of Novel Cellular and Molecular Drivers of Human Granulopoiesis
2527 - KLF5 Is a Key Regulator of IMiD-Induced Neutropenia
2739 - Golcadomide-Mediated Degradation of Aiolos/Ikaros Synergizes with BET Inhibitors through Bidirectional Restructuring of the Directly Regulated Epigenetic Environment in DLBCL
4650 - BCMA Mutational Screening Reveals Differential Cytotoxic Activity between T-Cell Engagers in Preclinical Co-Culture Models

Hagstroem-Andersson, A. K.

2769 - Unraveling How Treatment Shapes Clonal Evolution and Resistance in Murine KMT2A-Rearranged Leukemia with Subclonal Kras^G12D
4298 - Targeting Cholesterol Homeostasis Enhances Phagocytosis of Acute Myeloid Leukemia Cells

Hague, C.

2388 - Evolution of Treatment Patterns and Survival Outcomes in European Patients with Multiple Myeloma from 2012-2023 through the Honeur Federated Data Network

Hahn, C. N.

1267 - Higher Rate of Red Blood Cell (RBC) Alloimmunization in RBC-Transfused Myelodysplastic Syndrome Compared to Acute Myeloid Leukemia
3208 - Dynamic Assessment of RBC-Transfusion Dependency (RBC-TD) Improves the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification of MDS
3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
4596 - Pathogenic Germline Variants in the DNA Damage Repair Pathway Are Enriched in Patients with Hematologic Malignancies with Prior Exposure to Cytotoxic Therapies Compared to Patients with Multiple Cancers without Prior Exposure
4928 - Clonal Architecture of Donor-Derived Leukemia/Clonal Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplant

Hahn, C. K.

335 - SEC62 Regulates HLA-E Expression in Diffuse Large B-Cell Lymphoma to Function As a Mechanism of Immune Evasion

Hahn, D.

568 - PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial

Hahn, M.

2670 - Primary Hematopoietic Cells of Vexas Patients Are Highly Sensitive to Treatment with TAK-243 and Pevonedistat

Hahn, S. B.

2904 - Extended Vs Standard Hypomethylating Agent Dosing in Combination with Venetoclax in Newly Diagnosed Acute Myeloid Leukemia

Hahn, T. E.

930 - Uncovering the Genetics of Poor and Exceptional Survivorship after Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (HCT)

Hahn, U.

460 - Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early-Stage Classical Hodgkin Lymphoma
3101 - Durability of Complete Responses in Patients from the ECHELON-3 Study
4483 - Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study
4489 - Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

Hahn, W.

1822 - Supervised Machine Learning Predicts Transformation Risk and Key Features throughout the Patient Journey in Myelodysplastic Neoplasms
2211 - Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients

Hähnel, P. S.

722 - Acute Resistance to BET Inhibitors Remodels Compensatory Transcriptional Programs Via p300 Co-Activation

Haiat, S.

2424 - Treatments and Outcomes of Adult Patients with AML in the Real-Life – First Report of the French Observational ALFA-PPP Study

Haider, A.

3344 - Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant

Haider, I.

703 - Trajectories of Frailty Categorization over Time Among Real-World Patients with Multiple Myeloma: A Prospective Cohort Study (MFRAIL)

Haider, M. S.

3287 - Novel NOTCH1 Effector NFIL3 Is a Therapeutic Target to Combat Drug Resistance and Improve Patient Outcomes in Newly Diagnosed and Relapsed-Refractory Multiple Myeloma

Haight, A.

4888 - A Pilot Multi-Pronged Approach to Measuring Endothelial Dysfunction and Predict the Development of Endothelial Disorders and Death Post Hematopoietic Cell Transplantation (HCT)

Haikala, H.

4814 - Bone Marrow Stromal Cells Hamper Leukemia Cell Induced NK Cell Activation and Cytotoxicity

Haiman, C.

4703 - The Impact of Lifestyle Factors and Occupational Exposure on Multiple Myeloma Risk in the Multiethnic Cohort Study

Haimed, A.

4015 - Systematic Review of Pediatric Venous Thromboembolism Associated with Inferior Vena Cava (IVC) Anomalies

Haindl, N.

3918 - L-Asparaginase Treatment Induces Reversible Immunoregulatory and Immunosuppressive Effects in Non-Malignant B Cells in a Model of T-Cell Dependent B Cell Activation

Haines, J. R.

1446 - Inhibiting Free Fatty Acid Transport to Improve CAR-T Cell Therapy of Relapsed B-Cell Acute Lymphoblastic Leukemia

Haines, S.

873 - Molecular Consequences and Targeting of PPM1D Mutations and Overexpression in Myeloproliferative Neoplasm Stem Cells

Hainzl, D.

1381 - S227928: A Novel Anti-CD74 ADC with MCL-1 Inhibitor Payload for the Treatment of Acute Myeloid Leukemia (AML) and Other Hematologic Malignancies

Haioun, C.

575 - Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa
649 - Senior-IPI: An Easily Applicable and Meaningful Prognostic Index for First-Line LBCL Patients Older Than 80 Years Treated with Age-Adapted Immunochemotherapy
1597 - Single-Cell Atlas of Diffuse Large B-Cell Lymphoma Reveals Integrated Malignant B Cell and Tumor Microenvironment Characteristics Associated with Clinical Response
3840 - Cold Autoimmune Hemolytic Anemia Secondary to Mycoplasma Pneumoniae Infection in Adults: Results from a Large French Observational Study (MYCOLD study)
4467 - Long-Term Follow-up Study of Patients Aged 80 Years or Older Treated By Attenuated Chemotherapy Mini-CHOP Plus Anti-CD20 for DLBCL, Update of the LNH03-7B and LNH09-7B Lysa Trials

Hair, A.

994 - Common Lymphoid Progenitors and B Cell Subpopulations in the Bone Marrow Are Predictive of Treatment-Free Remission in Chronic Myeloid Leukemia

Haissaguerre, M.

1289 - Emergence of DNA Damage Repair Clonal Hematopoiesis after Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors

Haj, A. K.

17 - Leveraging Population-Scale Multiomic Datasets to Elucidate the Risk of Thrombosis Associated with Protein S (PROS1) Deficiency
18 - Use of Large-Scale Genomic Datasets to Identify Additional Modifiers of Thrombosis Risk Among 26,436 Carriers of the Factor V Leiden and Prothrombin G20210A Mutations
133 - Coagulation Factor XII (F12) Haploinsufficiency Is Protective Against Venous Thromboembolism
143 - Using Large-Scale Multiomic Datasets to Assess the Population Frequency of ADAMTS13 Loss-of-Function Variants in the United States and United Kingdom
1196 - Rare Germline Loss-of-Function Variants in C1-Inhibitor (SERPING1) Are Associated with Venous Thromboembolism in Population-Scale Sequencing Datasets

Haj Yahia, M.

4476 - Warburg-Effect Driven Lactic Acidosis Is Associated with Early Death in Patients with Lymphoma

Hajek, R. A.

726 - Mitigating Therapy-Related Myeloid Neoplasia in p53-Mutant Clones through Targeted DNA Repair Pathway Inhibition with PARP Inhibitors

Hajek, R.

487 - Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study
676 - Results of the Phase II Randomized Trial EMN15/HOVON147: Carfilzomib-Lenalidomide-Dexamethasone Vs Lenalidomide-Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma
770 - Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study
772 - Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial
889 - Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis
1887 - Composition and Fitness of T and NK Cells in Extramedullary Myeloma Tumor Microenvironment
1934 - Depletion of Mature B Cells and of Normal Plasma Cells (PC) behind the Higher Incidence of Infections after Anti-BCMA VS Anti-GPRC5D Bispecific Antibodies (bsAb) in Relapsed Refractory Multiple Myeloma (RRMM)
1962 - Predictive Value of Clonal Plasma Cells in Autografts Assessed By Next Generation Flow Cytometry on Pre-Transplant Bone Marrow MRD in Multiple Myeloma Patients
1999 - A Multicenter Phase 2 Study Evaluating the Optimized Schedule of Belantamab Mafodotin 1.9 Mg/Kg Q8W Plus Bortezomib and Dexamethasone in Relapsed Refractory Multiple Myeloma
2000 - Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)
2378 - Risk Groups in Relapsed and Refractory Multiple Myeloma Treated By Lenalidomide Based Triplets – Analysis of the Czech Myeloma Group
3352 - Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study
4758 - Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry
5156 - Teclistamab in Relapsed and Refractory Multiple Myeloma Patients – Czech Multi-Center Real World Evidence Analysis

Hájek, R.

494 - Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial
2388 - Evolution of Treatment Patterns and Survival Outcomes in European Patients with Multiple Myeloma from 2012-2023 through the Honeur Federated Data Network
3270 - Insights into Biological Mechanisms Responsible for Egression of Circulating Tumor Plasma Cells (CTCs) in Multiple Myeloma

Hajela, P.

738 - Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE^®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study

Hajicek, N.

48 - Mechanism of Hyperactive PLCγ1 Signaling in T-Cell Leukemia/Lymphoma

Hajiyianni, M.

4701 - MRD By Flow Cytometry and FDG-PET/CT for the Post-Induction Response Assessment in Patients with Multiple Myeloma Treated in the Phase 3 GMMG HD7 Study
5140 - Long-Term Follow-up Analysis of Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma Patients from the GMMG Myeloma Registry Following the Randomized Phase III GMMG-HD6 Trial

Hajj, C.

3040 - Very Low Dose Radiotherapy (VLDRT) with 4 Gy for Potentially-Curable Indolent Non-Hodgkin Lymphomas

Hajjar, K. A.

3961 - Proteolysis of Annexin A2 Leads to Inflammasome-Mediated Proinflammatory Response in Human Sepsis

Hakimi, Z.

5085 - Real-World Clinical Outcomes for Complement Inhibitor Experienced and Naïve Paroxysmal Nocturnal Hemoglobinuria Patients Prescribed Pegcetacoplan in Europe and Canada

Hakimian, B.

2104 - Comparison of Tacrolimus/Methotrexate and Post-Transplant Cyclophosphamide Graft-Versus Host Disease Prophylaxis for Haploidentical and Matched Allogeneic Stem Cell Transplantation Demonstrates Improved Overall Survival and Reduced Mortality, Shorter Length of Stay, Less Peritransplant Toxicity with Post-Transplant Cyclophosphamide

Hakobyan, M.

1341 - Mutant Idh1 Blocks Neutrophil Maturation By Repressing Myeloid Progenitor Programs

Hakobyan, N.

5170g - Multiple Myeloma (MM) Clinical Characteristics, Prognostic Factors and Survival in Adolescents and Young Adults (AYA)

Hakoniemi, M.

4265 - Encouraging Efficacy of Bexmarilimab with Azacitidine in Relapsed or Refractory MDS in Bexmab Ph1/2 Study

Halaburda, K.

305 - Improved Outcomes in Paroxysmal Nocturnal Hemoglobinuria Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study

Halahleh, K.

595 - Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
664 - Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database
2184 - Significant Growth in HCT Use for Haemoglobinopathies in the Last Decade Driven By Sickle Cell Disease across All Ages with Excellent Outcomes: An Analysis of EBMT Haemoglobinopathies Working Party
2188 - Outcome of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia with Wilms Tumor 1 (WT1) Mutation: A Study from the ALWP/EBMT
3070 - Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
3219 - Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
4465 - Dose-Adjusted EPOCH-R Is Superior to R-CHOP in Frontline Treatment of Mediastinal Large B-Cell Lymphoma
4939 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults. a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
4942 - Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party

Halamish, I.

1748 - Reduction in Platelet Counts May Predict the Development of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma

Halawani, A. J.

2531 - Multinational Assessment of Absolute Neutrophil Counts and White Blood Cell Counts Among Healthy Individuals with the Duffy Null Phenotype or Genotype

Halbach, S.

3392 - FLT3-ITD Driven CMTM6 Expression Contributes to Immune Escape of Acute Myeloid Leukemia

Halbert, C. H.

- Structural Racism, the Social Determinants of Health, and Healthcare Outcomes – Understanding Inequity and What to Do About It

Haldar, R.

1346 - Single Cell Genotype-Phenotype Analysis Demonstrates That Post-MPN AML Is Driven By Clonal Evolution and Loss of Transcriptional Heterogeneity within Stem Cell Compartments
1347 - Dnmt3a Mutation Promotes Expansion of a Quiescent Myeloid Progenitor Population in Npm1^c-Flt3^ITD Acute Myeloid Leukemia

Halder, R.

3154 - Response Adapted Dasatinib De-Escalation Strategy Compared to Upfront Low-Dose Dasatinib: A Prospective Cohort Study

Halene, S.

1810 - Clonal Dissection of MDS and Secondary AML Resolves Shared Splicing Neoantigens and Mechanistic Underpinnings of Hypomethylating Agent Therapeutic Response
1815 - MISTRG6kit^W41: Enhanced Engraftment in a Cytokine Humanized Patient-Derived Xenotransplantation Mouse Model
4117 - Unraveling the Drivers of the Stress Granule Signature in Splicing Factor-Mutant Myeloid Malignancies
4436 - Clinically Driven Algorithms Identify Patients with Large Granular Lymphocytic Leukemia at Risk of Significant Cytopenia Requiring Treatment
4585 - Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab
- Exploiting Epitranscriptomic Vulnerabilities: M6a and Splicing Factor Mutations in Myelodysplastic Syndrome (MDS)/Leukemia

Haley, C.

2758 - Combined CXCR-4 Inhibition with Novel Agent GPC-100 (burixafor) and Beta 2 Adrenergic Receptor Blockade Enhances Cytarabine Response for Acute Myeloid Leukemia Blasts on Stroma

Haley, J. S.

444 - Genome-First Determination of the Prevalence and Penetrance of Eight Germline Myeloid Malignancy Predisposition Genes: A Study of Two Population-Based Cohorts

Haley, K. M.

3698 - Patient Satisfaction at United States Hemophilia Treatment Centers in 2023

Halfon-Domenech, C.

310 - Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and Outcomes
1330 - Novel Germline ZCCHC8 Mutations Causes Dyskeratosis Congenita with Genetic Rescue By Uniparental Disomy of Chromosome 12q
2814 - How to Administer Pegaspargase during Induction Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents? Results of the Caall-F01, a Multicentre Randomized Clinical Trial from the French Pediatric Cancer Society (SFCE)

Halfond, A.

1558 - Multimodal Atlas of Paired Diagnosis and Relapse AML Reveals Surface Antigens for Multi-Specific Immunotherapy

Halilovic, E.

1560 - Predictors of Response and Rational Combinations for the Novel MCL-1 Inhibitor MIK665 in Acute Myeloid Leukemia

Halim, A.

4714 - Early Detection and Monitoring of Multiple Myeloma By a Blood-Based Multi-Transcript Molecular Signature

Halimeh, S.

3970 - Development of an Early and Complete Examination Protocol for Women and Girls with Inherited Bleeding Disorders (WGBD)
3974 - Interim Results of a New Examination Protocol for Women and Girls with Inherited Bleeding Disorders (WGBD)

Halimi, D.

3913 - Patients (pts) with Optimized Hemophagocytic Lymphohistiocytosis (HLH) Inflammatory (OHI) Index-Confirmed Diagnosis of Malignancy-Associated HLH (mHLH) and Emapalumab Treatment

Hałka, J.

970 - A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) – Topline Results

Halka, J.

2854 - The Premature Reduction of Venetoclax in an Initial Cycle of Ven-AZA Regimen for Unfit AML Patients Leads to Shortened Overall Survival - a Retrospective Study of Polish Adult Leukemia Group (PALG)

Halkes, C. J.

33 - Dynamics of Oligoclonal Hematopoiesis in Severe Aplastic Anemia Patients Undergoing Immunosuppressive Treatment: Longitudinal Somatic Mutation Analysis from the EBMT Race Trial
302 - Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study
595 - Role of Age and Donor Type in 3646 Severe Aplastic Anemia Patients Undergoing Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
691 - T-Cell Monitoring for the Recently Expanded Repertoire of HLA Class I-Restricted Minor Histocompatibility Antigens Using Barcoded Peptide-MHC Multimers

Hall, A.

1984 - Belantamab Mafodotin Plus Cyclophosphamide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Interim Results from the UK Myeloma Research Alliance Prommise Clinical Trial
3354 - Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome – Long-Term Follow-up of the Ukmra Optimum/Muknine Trial
3792b - Evaluating Barriers to Enrolment into Multiple Myeloma (MM) Clinical Trials: Results from Health Care Professionals and Patient Survey from the UK Myeloma Research Alliance Equity, Diversity and Inclusivity (EDI) Working Group

Hall, A. C.

4256 - Randomized Phase II Trial of Dendritic Cell/AML Fusion Cell Vaccination Compared to Standard of Care Therapy in AML CR1

Hall, C.

943 - Elevated Clonal Hematopoiesis in Environmentally Exposed Responders Has Distinct Age-Related Patterns and Relies on IL1RAP for Clonal Expansion

Hall, E. M.

2817 - Role of B Cell Recovery in Relapse Risk and CD19 Phenotype Following Real-World Use of Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia: A Multi-Institutional Retrospective Study

Hall, K.

559 - Spatial Transcriptomics Characterize Dynamic and Polarized Niche for Embryonic Hematopoiesis at Single-Cell Level
1306 - Characterization of Multicellular Niches Supporting Hematopoietic Stem Cells within Distinct Zones
4042 - Ex Vivo Expansion of Human Hematopoietic Stem Cells By Mimicking Intrinsic and Extrinsic Factors in Adult Bone Marrow

Hall, K.

3521 - Intermediate Dose Post-Transplant Cyclophosphamide Is Associated with Faster Engraftment and Similar Other Outcomes When Compared with Full Dose Post-Transplant Cyclophosphamide Among Patients Undergoing Allogeneic Transplantation: A Single Center Retrospective Analysis

Hall, L.

2808.1 - A Children’s Oncology Group Clinical Trial of Long-Term Outcomes in Survivors of Down Syndrome-Associated Acute Leukemia (ALTE22C1): Clinical Trial in Progress

Hall, M.

3682 - Ketamine Use in Hospitalized Children and Young Adults with Sickle Cell Disease

Hall, M. S.

4820 - Leveraging Stage-Specific Promoters to Enhance Immune Cell Engineering in iPSC-Derived Cells for Cancer Immunotherapy

Hall, S.

2017 - Off the Shelf Stem Cell Derived Innate Lymphoid Cells Ameliorate Gvhd through IL-9 Induced-T Cell Senescence

Hall, S.

4430 - Risk of Hematologic Malignancy Following Infectious Mononucleosis Caused By Epstein-Barr Virus: A Danish and Swedish Observational Study over 40 Years

Hall, T. D.

196 - Modeling GATA2 Deficiency in Mice: The R396Q Mutation Disrupts Normal Hematopoiesis

Hallack Neto, A. E.

1692 - The Number of Extranodal Sites Matters! a Proposal for a Feasible Prognostic Model in Nodal PTCL. a Collaborative Study grupo De Estudio Latino-Americano De Linfoproliferativos (GELL) & T-Cell Brazil Project (TCBP)
3064 - Central Nervous System Involvement in Aggressive ATLL: Can We Predict the Risk in a Devastating Complication? Epidemiology and Clinical Features from Latin America. a Collaborative Study from Grupo De Estudio Latino-Americano De Linfoproliferativo (GELL) & T-Cell Brazil Project (TCBP)

Hallek, M.

1846 - In-Depth Immune and Metabolic Profiling of GAIA/CLL13 Patients to Uncover Treatment-Specific Changes to the T-Cell Compartment
1859 - Impact of Ibrutinib on Quality of Life in Patients with Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia: Results from the Phase III CLL12 Trial
3250 - Venetoclax May Overcome the Prognostic Disadvantage of Short Telomeres Regarding Progression Free Survival in Previously Untreated CLL Patients with Coexisting Conditions: A Study By the German CLL Study Group (GCLLSG)
4608 - Biallelic Deletion 13q in Chronic Lymphocytic Leukemia Treated with Targeted Agents
4618 - Efficacy and Safety of Acalabrutinib Treatment in Very Old (≥80y) and/or Frail Patients with Chronic Lymphocytic Leukemia (CLL) – Primary Endpoint Analysis of the Phase II CLL-Frail Trial
4626 - Telomere Length Associations with Characteristics and Outcome in Patients Treated with Venetoclax-Based First-Line Combinations in the GAIA/CLL13 Study

Hallek, M. J.

367 - Targeting Lymphoma Associated Myeloid-Monocytic Cells through CSF1R Blockade Enhances CAR-T Cell Response in Aggressive B Cell Lymphoma
3238 - Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial
4613 - Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial

Halloun, J.

912 - CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes
1748 - Reduction in Platelet Counts May Predict the Development of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma

Halper-Stromberg, E.

3173 - High Molecular Risk Mutations (HMR) Drive Progression of CALR-mutated Myeloproliferative Neoplasm (MPN)

Halperin, E.

1246 - Imaging Predictors of Intracerebral Hemorrhage in Patients with Brain Tumors Treated with Anticoagulation
1762 - Interferon Inhibits Netosis in Neutrophils Derived from Patients with Myeloproliferative Neoplasms in a Neutrophil Subpopulation-Specific Manner

Halpern, A. B.

265 - CLAG-M or FLAG-Ida Followed Immediately By Allogeneic Hematopoietic Cell Transplantation for Adults with Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasm
657 - A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia
658 - Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study
1530 - 4q Copy Neutral Loss of Heterozygosity and KMT2A Partial Tandem Duplication Identified By Chromosomal Genomic Array Testing (CGAT) Correlated with Decreased Overall Survival in Acute Myeloid Leukemia (AML)
4209 - Extended Follow-up of Dose-Adjusted EPOCH (DA-EPOCH) Plus Inotuzumab Ozogamicin (InO) in Adults with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Safe and Effective Salvage Therapy
4288 - Phase I Trial Combining Venetoclax with Cladribine, Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) for Patients with Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms

Halpin, A.

4261 - Final Analysis of a Phase I Study of Escalating Doses of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubcin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia

Halpin, M.

2661 - Targeting Inflammation in Tet2 Mutant Clonal Hematopoiesis Via Inhibition of Brd4 Demonstrates Activity in Both Murine and Human Models
2978 - Temporally Controlled MYC Overexpression in Chronic Lymphocytic Leukemia Accelerates Progression and Promotes Large B Cell Lymphoma Transformation

Halsey, C.

200 - The Impact of Lineage on CNS Infiltration Dynamics in Infant Leukaemia
1444 - Results of the ALL-IC REL 2016 Registry Trial: 1^st Relapses of Childhood ALL Treated in High-Middle Income Countries
2805 - Diagnosing and Staging Central Nervous System Involvement in Pediatric ALL: A Global Survey on Its Heterogeneity
2831 - Cerebrospinal Fluid Flow Cytometry Improves Patient Stratification in Central Nervous System Acute Lymphoblastic Leukaemia but Requires Careful Standardization: Results from the ALLTogether1 CSF-FLOW Sub-Study

Halter, J.

4917 - Developing Evidence-Based Guidelines for Optimal Patient Communication Prior and Post Allogeneic Stem Cell Transplantation

Ham, J. D.

915 - One-Step Construction of Allogeneic CAR-NK Cells Preventing Rejection and Mediating Enhanced Anti-Tumor Responses

Ham, M.

5057 - Costs of Healthcare Resource Utilization in the Management of Patients with Higher-Risk Myelodysplastic Syndrome in Canada

Hama, A.

4565 - Genetic Mutational Profile Influences the Morphological Characteristics of Abnormal Monocytes in Patients with Juvenile Myelomonocytic Leukemia

Hamacher, C.

4244 - Does Time Matter from Diagnosis to Induction in Acute Myeloid Leukemia?

Hamad, M. A.

3925 - Enhanced Detection and Functional Analysis of Reticulated Platelets in Myocardial Ischemia/Reperfusion Injury

Hamad, N.

582 - A Randomized Phase 2, Investigator-Led Trial of Glofitamab-R-CHOP or Glofitamab-Polatuzumab Vedotin-R-CHP (COALITION) in Younger Patients with High Burden, High-Risk Large B-Cell Lymphoma Demonstrates Safety, Uncompromised Chemotherapy Intensity, a High Rate of Durable Remissions, and Unique FDG-PET Response Characteristics
618 - A Systematic Review of Communication Tools to Improve Reproductive and Sexual Health Outcomes in Female Cancer Patients Identified Significant Gendered Data Gaps in Care
1951 - Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry
2359 - Underweight Body Mass Index Is an Independent Risk Factor for Overall Survival in Diffuse Large B-Cell Lymphoma Treated with Rituximab, Prednisolone, Cyclophosphamide, Vincristine, and Doxorubicin: A Lymphoma and Related Diseases Registry Study
2379 - Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study
2385 - Treatment of First Relapse of Multiple Myeloma in Australia and New Zealand (ANZ): Treatment Patterns and Outcomes: An ANZ Myeloma and Related Diseases Registry (ANZ MRDR) Analysis
2428 - Acute Leukaemia in Pregnancy: A Systematic Review of Maternal and Fetal Outcomes
3519 - A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) with ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD) in Matched Donor Hematopoietic Cell Transplants (HCT)
3799 - Real-World Patterns of Care and Outcomes for Non-Favourable Risk Acute Myeloid Leukemia Treated with Intensive Chemotherapy across Australia and New Zealand- Data Linkage between the ALLG National Blood Cancer Registry (NBCR) and the Australia and New Zealand Transplant and Cellular Therapy (ANZTCT) Registry
4416 - Practices and Outcomes during a Watch and Wait Approach for Follicular Lymphoma: A Study from the Australasian Lymphoma Alliance
4733 - Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study
4917 - Developing Evidence-Based Guidelines for Optimal Patient Communication Prior and Post Allogeneic Stem Cell Transplantation
5126 - Body Mass Index and Clinical Associations in Australasian Lymphoma Patients: A Lymphoma and Related Diseases Registry Study

Hamadani, M.

Hamadeh, I. S.

4735 - Frailty and Outcomes after Bispecific T-Cell Engager Therapy for Patients with Relapsed/Refractory Multiple Myeloma

Hamadeh, Z.

1538 - Optical Genome Mapping As Standard-of-Care in Acute Leukemia: Diagnostic and Clinical Impacts 10 Months Post-Implementation

Hamamoto, K.

4108 - HoxBlinc LncRNA Reprograms CTCF Independent TADs to Drive Leukemic Transcription and HSC Dysregulation in NUP98 Fusion Transformed Leukemia

Hamamoto, K.

4537 - Growth Retardation and Adult Height in Children with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors

Hamamura, A.

2621 - Immediate Therapeutic Intervention for Acute Mortality in Immune-Mediated Thrombotic Thrombocytopenic Purpura with Positive Chest Findings at Initial Presentation

Hamarsha, Q.

1257 - Anticoagulation Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis
1919 - Diagnostic Test Accuracy of Cardiac Imaging for AL Amyloidosis: A Systematic Review and Meta-Analysis
1920 - Diagnostic Test Accuracy of Bone Scintigraphy in the Diagnosis of Attr Amyloidosis: A Systematic Review and Meta-Analysis
1925 - Diagnostic Test Accuracy of Serum and Urine Immunofixation and Free Light Chains in the Diagnosis of Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
1926 - Diagnostic Test Accuracy of Cardiac Biomarkers for Light Chain Amyloidosis: A Systematic Review and Meta-Analysis
2633 - Thrombolytic Therapy for Venous Thromboembolism in the Pediatric Population: A Systematic Review and Meta-Analysis

Hamasaki Kubo, Y.

3542 - Modified Psychosocial Assessment of Candidates for Transplantation Predicts Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation

Hamashima, A.

26 - Chromatin Modifier Hmga1 Maintains Hematopoietic Stem Cell Integrity in Stress Conditions

Hamberg Levedahl, K.

1565 - Resistance to FLT3 Inhibitors in FLT3-Mutated AML Is Associated with CD45RA⁺CD200^-leukemic Cells and Can be Overcome By Combination with SMAC Mimetics

Hamblin, A.

1909 - A Novel Segmentation-Based Purity-Informed Approach Accurately Detects Total Copy Number and Its Subclonal Fraction in Myeloma Targeted Panel Sequencing Data
3146 - RUX-AZA Response in AP/BP-MPN Is Driven By Release of the Differentiation Block in Mutant HSPCs: A Single-Cell Multi-Omic Analysis of Responders on the Phase Ib Phazar Study
3333 - Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial

Hamburger, E.

573 - Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort

Hamby, M.

573 - Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort

Hamdan, A.

2397 - Real Word Autologous Transplant Utilization and Outcomes By Race and Ethnicity

Hamdan-Mansour, R.

1260 - Evaluation of Risk Assessment Models for Predicting Venous Thromboembolic Events in Cancer Patients Using Implanted Central Venous Access Devices

Hameed, M. S.

2008 - Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy in Relapsed and Refractory Multiple Myeloma – a Meta-Analysis

Hamel, J. F.

3483 - Sequential Intensified Conditioning Regimen Allogeneic Transplantation in Younger Adult Patients with Adverse-Risk Acute Myeloid Leukemia: A Multi-Center Prospective Study from the Acute Leukemia French Intergroup on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Hamel, J. F.

4909 - Cyclosporine Versus Cyclosporine Plus Mycophenolate Mofetil in Reduced Intensity Allogeneic Stem Cell Transplantation for Intermediate-Risk AML: A Multi-Center Randomized Study from the Acute Leukemia French Intergroup, on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Hamer, L.

199 - The Fetal Specific Gene LIN28B Is Essential for Human Fetal B-Lymphopoiesis and Initiation of KMT2A-AFF1+ Infant Acute Lymphoblastic Leukemia

Hamer-Maansson, J. E.

3136 - Clinical and Molecular Characterization of Disease Progression in Patients (Pts) with Low-Risk Myelofibrosis (MF) Enrolled in the MOST Study
3145 - Molecular Predictors of Disease Progression to Myelofibrosis (MF) in Patients (Pts) with Polycythemia Vera (PV) Enrolled in Reveal
4546 - Clinical Outcomes in Patients with Myelofibrosis Treated with Ruxolitinib and Anemia-Supporting Medications

Hamerschlak, N.

1692 - The Number of Extranodal Sites Matters! a Proposal for a Feasible Prognostic Model in Nodal PTCL. a Collaborative Study grupo De Estudio Latino-Americano De Linfoproliferativos (GELL) & T-Cell Brazil Project (TCBP)
2310 - Thalassemia Scenario in Brazil: A Descriptive Study
2348 - Real-World Analysis of Patients with CLL Treated with Ibrutinib: A Retrospective Analysis of the Brazilian Registry of CLL

Hamid, M. A. B.

2541 - The Quiet Defenders: Immunoglobulin Levels As Predictors of Mortality in Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

Hamid, O.

3922 - Multiplex Analysis of Peripheral Blood in Cancer Patients Predicts Humoral and Cellular Responses to Sars-Cov-2 Vaccines

Hamid, S.

3432 - Correlation of Serum Inflammatory State and Macrophage Phenotype with CAR T Cell Expansion and Clinical Outcomes
4392 - Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis

Hamidi, H.

4722 - Using Single Cell Multi-Omic Clonal Tracking in SMM to Identify Clones That Progress to MM and Harbor Treatment Resistance Features

Hamidieh, A. A.

5079 - Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Outcomes in Leukocyte Adhesion Deficiency Type -I

Hamil, A.

916 - W-NK1 Choreographs Innate and Adaptive Immune Responses to Provide a Robust and Durable Anti-AML Response
3450 - WU-CART-007 (WT-7), an Allogeneic CAR T-Cell Targeting CD7 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL): Phase 2 Results
3461 - WU-CART-007 (WT-7) Is an Effective Treatment for Adolescent Patients with Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) – Subgroup Analysis of WU-CART-007 1001

Hamilton, A.

1867 - Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)

Hamilton, B. K.

694 - Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients
2145 - Prevalence and Outcomes of Opportunistic Infections in Steroid Refractory Graft Versus Host Disease Patients Treated with Ruxolitinib, Ibrutinib, and Belumosudil
2170 - Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
3488 - Factors Associated with Platelet Engraftment Following Allogeneic Hematopoietic Cell Transplantation
4902 - Cytokines associated with organ manifestations in chronic graft-versus-host disease
4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

Hamilton, G.

502 - Vivovec™ Surface-Engineered Lentiviral Particles Mediate In Vivo CAR T Generation with Potent and Highly Durable Activity in Non-Human Primates

Hamilton, J.

3410 - Dynamics of Circulating Tumor DNA As a Predictor of Outcomes with Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma from the Transcend NHL-001 Study

Hamilton, K.

5170h - Improving Specialty Access for Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Plasma Cell Disorders (PCDs): 10 Years of Experience and a Successful Model of Care

Hamilton, M.

69 - CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up
96 - Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms
251 - DNA Methylation Analysis of Commpass Reveals Distinct Epigenetic Programs of High-Risk Disease
368 - CCL8/CCL13-Producing Tumor-Associated Macrophages Linked to Poor Outcomes after CAR T Cell Therapy for LBCL
454 - Integrating Genomic & Transcriptomic Features for Noninvasive Detection, Characterization, and Monitoring of T-Cell Lymphomas
911 - CD22-Directed CAR T Cell Single Cell Multiomic Features Associated with Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
1359 - Ectopic NSD2 Remodels H3K36me2 and DNA Methylation to Promote Oncogenic Gene Expression in Multiple Myeloma
2064 - CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma
2223 - Direct Method for Estimating the Fraction of T and B/Plasma Cell-Derived DNA
2993 - Resolving the Microarchitecture of Classic and Transformed Follicular Lymphoma By Single Cell Alignment to Spatial Transcriptomes
3258 - Integrated Coding and Non-Coding Transcriptional Single-Cell Atlas of Multiple Myeloma: Unraveling the Effects of Myeloma Genotype on the Bone Marrow Microenvironment
4654 - Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients
4658 - Immune Profiling Reveals Distinct Features of Multiple Myeloma Subtypes Defined By Multi-Omics Network Analysis
- Damage to Engineered T Cell Genomes

Hamilton-Dutoit, S.

2997 - Impact of the Immune Landscape in Follicular Lymphoma: Insights into Histological Transformation in the Rituximab Era

Hamlin, D. K.

2014 - CD45-Directed Radioimmunotherapy with the Alpha-Emitter Astatine-211 As Conditioning for Autologous Hematopoietic Stem/Progenitor Cell Gene Therapy: Results from a Nonhuman Primate Model
4779 - Humanization of Clinically Used Murine CD45 Antibody for Optimized CD45-Targeted Radioimmunotherapy

Hamlin, P. A.

340 - Single-Agent Mosunetuzumab Produces High Complete Response Rates in Patients with Newly Diagnosed Follicular Lymphoma: Primary Analysis of the Mithic-FL1 Trial
569 - Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin
1668 - Brentuximab Vedotin-Based Regimens for Older Patients with Newly Diagnosed Classical Hodgkin Lymphoma – International, Multi-Center Real-World Experience
1707 - High Grade B-Cell Lymphoma with MYC/BCL6-Rearrangements (R) May Have Inferior Outcomes Compared to BCL2-R Disease
1867 - Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)
2336 - Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
3053 - Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma
3743 - End-of-Life Care Patterns in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Real-World Setting
4346 - Molecular Features Are Associated with Disease Stage in Diffuse Large B-Cell Lymphoma and Reveal Heterogeneity in Patient Outcomes
4429 - Improved Outcomes for Primary Refractory Classical Hodgkin Lymphoma: A Retrospective Analysis
4434 - Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study
4451 - Angioimmunoblastic Versus Non-Angioimmunoblastic Nodal T-Follicular Helper Cell Lymphomas: Single Center Retrospective Analysis on 208 Cases
4474 - A Prospective Geriatric Assessment (GA) Study Predicting Toxicities in Older Adults (OA) with Non-Hodgkin Lymphoma (NHL): Timed up and Go Test (TUG) Time Emerges As a Functional Vital Sign
4485 - Sequential R-CHOP/(R)-ICE and Dose-Adjusted EPOCH-R Are Both Appropriate Frontline Treatments for Newly Diagnosed Primary Mediastinal B-Cell Lymphoma: Results of a Retrospective Analysis
5101 - Impact of the Diagnosis-to-Treatment Interval (DTI) on Outcomes in Older Adults with Diffuse Large B-Cell Lymphoma (DLBCL) Treated in the Real-World Setting

Hammam, H.

3495 - CMV Reactivation Kinetics in Patients Undergoing Haploidentical Stem Cell Transplantation Using Low-Dose Post-Transplant Cyclophosphamide: A Single Center Experience

Hammer, E.

3147 - Chronic Kidney Dysfunction Induced By Jak2V617F-Mediated Mesangiolysis

Hammer, R. D.

262 - Stabilization of HIF-1α By the Prolyl Hydroxylase Inhibitor Roxadustat Reduces Gastrointestinal Graft-Versus-Host Disease

Hammerl-Steiner, A.

3793 - Real-World Comparison of Outcomes of Patients Treated with HMA Monotherapy Versus HMA-Ven – Insights from 1634 Patients Included within the Austrian Myeloid Registry of the AGMT Study Group

Hammond, D.

Hammond, S. P.

3500 - BK Virus Reactivation and Disease after Allogeneic Hematopoietic-Cell Transplantation: A Natural History Study

Hamouche, R.

465 - Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium

Hamova, I.

2979 - Vitreous Body Cell Free DNA Sequencing As a Reliable Method for Vitreoretinal Lymphoma Diagnostics

Hamp, E.

4304 - Characterization of Sole Loss of the Y Chromosome and Associated Effects on Adaptive Immunity in Adult Male Patients with Acute Myeloid Leukemia (AML)

Hampel, P. J.

580 - A Phase 1/1b Study of Parsaclisib Plus Standard Immunochemotherapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma
982 - Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort
1651 - Correlation between Peak Absolute Lymphocyte Count Post Brexucabtagene Autoleucel Infusion and Outcomes in Mantle Cell Lymphoma
1856 - Outcomes with Venetoclax-Based Treatment in Patients with Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)-Treated, Chemotherapy-Naïve Chronic Lymphocytic Leukemia (CLL): An International Retrospective Study
2274 - Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy
3007 - Frontline R-CHOP and BR Have Similar Outcomes By SUV_max in Follicular Lymphoma
3245 - A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL
4616 - Serum Immunoglobulins Are an Independent Prognostic Marker of Time to First Therapy in Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) and Monoclonal B-Cell Lymphocytosis (MBL)
5099 - Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy

Hampton, H. R.

3223 - Clinical Response to Azacitidine in Myelodysplastic Neoplasms Is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor Cells In Vivo

Hampton, K.

1893 - Age-Associated Macrophage Polarization to an M2 Phenotype Drives Myeloma Proliferation in the Aged Bone Marrow By Loss of Tumor-Associated Phagocytosis
4113 - Repolarisation of M2 Macrophages Via Cgas-Sting Activation Enhances Phagocytosis of Acute Myeloid Leukaemia

Hampton, K.

2585 - Unmet Needs of Patients with Hemophilia a/B with or without Inhibitors: Real-World End-of-Study Results from the explorer6 Non-Interventional Study

Hamrouni, S.

3840 - Cold Autoimmune Hemolytic Anemia Secondary to Mycoplasma Pneumoniae Infection in Adults: Results from a Large French Observational Study (MYCOLD study)

Hamulyák, E. N.

1246 - Imaging Predictors of Intracerebral Hemorrhage in Patients with Brain Tumors Treated with Anticoagulation
1250 - Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase Therapy

Hamza Bin Waqar, S.

895 - Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma

Han, B.

2687 - Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition
2699 - KP104, a Bifunctional C5 Mab-Factor H Fusion Protein, Demonstrates Sustained Long-Term Efficacy and Safety in Complement Inhibitor-Naïve PNH Patients: Updated Results from a Phase 2 Study at 36/38 Weeks of Obd Treatment
4079 - Oral Iptacopan Monotherapy Leads to Long-Term Improvements in Patient (Pt)-Reported Health-Related Quality of Life (HRQoL) and Investigator-Assessed Signs and Symptoms of Paroxysmal Nocturnal Hemoglobinuria (PNH): 48-Week (Wk) Results from the Phase III APPLY-PNH and APPOINT-PNH Trials

Han, B.

4077 - Effective Treatment of Refractory Aplastic Anemia with Romiplostim after Failure of Multiple Thrombopoietin Receptor Agonists: A Single-Center Retrospective Study

Han, B.

304 - Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
2688 - Efficacy and Safety of HRS-5965 Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Have Not Received Complement Inhibitors: A Proof-of-Concept, Multicenter, Randomized, Open-Label Study
3836 - Part a Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Patients with Warm Autoimmune Hemolytic Anemia (wAIHA): Multicenter, Open-Label, Phase 2b Study

Han, F.

1232 - Coagulation Abnormalities in Post-Acute COVID-19 Syndrome: A Cross-Sectional Study

Han, G.

4106 - Uncovering the HOXA9 Translational Regulatory Complex That Promotes AML Leukemic Stem Cells

Han, G.

1590 - Dissecting the Interplay between Primary Central Nervous System Lymphoma Cells and the Microenvironment Using Single-Cell Transcriptomic Analysis

Han, H.

1167 - Multicellular Derived S100A8/A9 Maintains Megakaryocytes in an Immature State in Immune Thrombocytopenia

Han, H.

3529 - Haploidentical Transplant Using Selective Ex-vivo TCR-Αβ Depleted and Upfront Memory T-Cell Add-Back Is Associated with Lower Chronic Gvhd and More Favorable Gvhd-Free/Relapse-Free Survival As Compared to Matched Related and Unrelated Donor Transplant for Adults with Hematological Malignancies

Han, I.

1194 - Fibrin and Fibrinogen Play Complex Opposing Roles in Metastasis

Han, J. J.

4296 - Serial Next-Generation Sequencing for Detection of Germline Predisposition in Acute Myeloid Leukemia

Han, J. X.

465 - Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium

Han, J.

4095 - Robust Immune Reconstitution in Fanconi Anemia Mice Post in Utero Hematopoietic Stem Cell Transplantation

Han, J.

5066 - Understanding the Menopause Transition in Sickle Cell Disease: An Interim Analysis of the Implementation of the Adapted Menopause Transition Questionnaire

Han, J. L.

2041 - Tandem CAR-T-Cell Therapy Targeting CD5 and CD7: Facilitating Condition-Free Engraftment of Epitope-Edited Allogeneic HSCs

Han, J.

956 - A Highly Selective and Orally Bioavailable CK1α Molecular Glue Degrader Targets B-Cell Lymphoma Cells

Han, J.

1495 - PHI-101, a Novel FLT3 TKI, Shows Clinical Efficacy in Relapsed/Refractory FLT3-Mutated AML

Han, K.

4 - Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate

Han, K. L.

4853 - Early Leukapheresis in Patients with B-ALL Yields an Activated, Early Memory T-Cell Phenotype Associated with Response to CAR T-Cell Therapy

Han, L.

4088 - Adenine Base Editing Improves Erythropoiesis in Diamond-Blackfan Anemia Syndrome Patient-Derived Induced Pluripotent Stem Cells

Han, L.

2680 - C-Type Natriuretic Peptide Signaling Promotes Bone Marrow Hematopoietic Regeneration and Alleviates Systemic Lymphopenia

Han, L.

3411 - IL-2-Inducible T Cell Kinase Deficiency Enables Development of Sustainable Chimeric Antigen Receptor T Cell Therapy

Han, L.

3586 - Discovery of BTC-86, a Novel Second-Generation Menin-MLL Inhibitor to Overcome the Acquired Resistance in MEN1 for R/R Acute Leukemia

Han, L.

4105 - STAG2 Mutations Drive Development of Myelodysplastic Syndromes by Promoting R-Loop-Mediated Genomic Instability and Activation of cGAS-STING

Han, L.

921 - A Novel Generation of Anti-CD7 Universal CAR-T Therapy for Patients with Relapsed or Refractory CD7 Positive T-ALL/Lbl: A Phase I Clinical Trial

Han, M.

2127 - Efficacy and Safety of a Modified Conditioning Regimen Based on Mitoxantrone Hydrochloride Liposome and Busulfan/Cyclophosphamide for Patients with Refractory and Relapsed Acute Myeloid Leukemia
2828 - Efficacy and Safety of Blinatumomab As Maintenance Therapy in Patients with High-Risk B-Lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation

Han, M.

2144 - The Comparison between Chimeric Mouse-Human and Humanized Anti-CD25 Monoclonal Antibody for Steroid-Refractory Acute Graft-Versus-Host Disease

Han, Q.

2788 - Targeted Therapy with CX4945 Biomimetic Nanodrug Delivery System for High-Risk B-Cell Acute Lymphoblastic Leukemia

Han, Q.

4782 - Prediction of Organs Toxicity during CAR T-Cell Therapy By Using Cell-Free DNA Markers

Han, R.

3339 - Clonal Hematopoiesis of Indeterminate Potential Does Not Impact Overall Survival in Multiple Myeloma

Han, S.

593 - Bi-Allelic GPRC5D Alterations Provide Proliferative Advantage in Presence of Talquetamab
3267 - GPRC5D Status Impacts CD38 Expression in Multiple Myeloma

Han, S.

4705 - Classic Anti-Myeloma Treatments Alter Circulating Immune Cell Subsets with Potential Implications for T Cell Immunotherapies in Multiple Myeloma

Han, S.

4707 - Efficacy and Safety of T-Cell Engagers Compared to Standard of Care for Relapsed/Refractory Multiple Myeloma Treatment: A Real-World RCT Mimicking Analyses
5048 - Discrete Choice Experiment to Assess Treatment Preferences of Patients with Multiple Myeloma, Their Caregivers, and Physicians in Korea (CAREMM-2304)

Han, S.

5170a - Clinical Characteristics and Outcomes of BCMA-Targeted CAR-T Cell Recipients with Coronavirus Disease 2019 during the Omicron Wave: A Retrospective Study

Han, S.

571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort
4423 - Association of Body Composition Factors and Toxicity in Patients with Advanced Stage Hodgkin Lymphoma Receiving BV-AVD

Han, T.

820 - Transcription Factor Programming of Human iPSC-Derived Sinusoidal Vascular Endothelial Cells Enhances Co-Cultured Hematopoietic Stem and Progenitor Cell Transplantation
2043 - Generation of Functional iPSC-Derived CAR-T Cells for Cancer Immunotherapy Via G9a/GLP Inhibition

Han, T. T.

2938 - Molecular Measurable Residual Disease before Transplantation Independently Predicts Survival and Relapse Risk in Adult KMT2A-Rearranged Acute Myeloid Leukemia
3511 - Comparison of Two Conditioning Regimens for Haploidentical Stem Cell Transplantation in Patients with Severe Aplastic Anemia

Han, W.

2160 - Evaluation of the Real-World Efficacy of Hetrombopag for the Treatment of Thrombocytopenia Post Allogeneic Hematopoietic Stem Cell Transplantation

Han, W.

2187 - Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study
2938 - Molecular Measurable Residual Disease before Transplantation Independently Predicts Survival and Relapse Risk in Adult KMT2A-Rearranged Acute Myeloid Leukemia

Han, W.

3405 - Changes in Glycosylation on the Cell Surface Result in Highly Potent and Long-Lasting Allogeneic CAR-T Therapy in Patients

Han, W.

4606 - Rewiring Cancer Drivers to Induce Apoptosis By Transcriptional Chemical Inducers of Proximity in Chronic Lymphocytic Leukemia

Han, W.

25 - Dnmt3a Controls Hematopoietic Stem Cells Via DNA Methylation-Independent Regulation of Telomeres
628 - EZH2-Mediated Methylation Regulates JARID2 Protein Stability in Normal and Neoplastic Hematopoiesis
3398 - In Vivo and Ex Vivo Expansion of Functional Human Repopulating Cells through JARID2 Inhibition

Han, X.

2902 - Venetoclax, Azacitidine, Combined with Low-Dose Cytarabine in Older Newly Diagnosed Acute Myeloid Leukemia：the Result of a Prospective, Multicenter, Open, Randomized Controlled Trials

Han, X.

4158 - Integrated Stress Response Activation Induced By Usnic Acid Alleviates BCL-2 Inhibitor ABT-199 Resistance in Acute Myeloid Leukemia

Han, X.

423 - Elucidating the Structural Dynamics and Native Modifications of α2-Macroglobulin from Native Platelet Samples By Cryo-EM Coupled with "Build and Retrieve" (BaR) Data Processing

Han, X.

821 - Bone Marrow Microenvironment Dictates the Progression of Clonal Hematopoiesis through Stromal-Macrophage Cell-Cell Interactions
2451 - ICAM4 Mediates Human Erythroid Centered Island Formation
4093 - Germline DDX41 Mutations Disrupt Hematopoiesis and Microenvironment in Patient-Derived Bone Marrow Organoids

Han, X.

3845 - HLTF Regulates Erythroid Differentiation through Transcription Factors and Chromatin Landscape Modulation

Han, Y.

1767 - Olverembatinib-Therapy in Patients with Accelerated-Phase Chronic Myeloid Leukaemia: A Multi-Centre Retrospective Study from China
4528 - Olverembatinib-Based Therapy in Patients with Philadelphia Chromosome-Positive Acute Leukemia: A Multi-Centre Retrospective Study from China

Han, Y.

4529 - Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis

Han, Y.

1782 - A Predictive Model for Progression to Overt Primary Myelofibrosis in Early/Prefibrotic Primary Myelofibrosis Patients

Han, Y.

438 - SNORD113-114 Cluster Maintains Hematopoietic Stem Cell Self-Renewal Via Orchestrating the Translation Machinery

Han, Y. H.

4028 - Rh Antigens Immunogenicity Prediction Using in silico analysis of HLA Binding

Han, Y.

2138 - Effective Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease with Human Induced Pluripotent Stem Cell Derived Mesenchymal Stromal Cells (iMSC) in a Clinical Setting
3504 - Efficacy and Safety of Hetrombopag in Promoting Platelet Engraftment after Allogeneic Stem Cell Transplantation: A Prospective, Single-Arm Clinical Trail

Han, Y.

1167 - Multicellular Derived S100A8/A9 Maintains Megakaryocytes in an Immature State in Immune Thrombocytopenia
1200 - The C553-C581 Disulfide of Human Factor XI Is Crucial for Its Activation and Is Targeted By Thiol Isomerase Pdir
1507 - Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens As Induction Therapy for Newly Diagnosed Patients with Immunophenotypically Mature Monocytic AML
3494 - Short-Term Blinatumomab Prior to Allo-HSCT for High-Risk B-ALL
4287 - Hypomethylating Agent and Venetoclax in Newly Diagnosed and Relapsed CBFβ::MYH11(+) Acute Myeloid Leukemia
4893 - Sitagliptin for Prophylaxis of aGVHD in Alternative Donor Transplantations: Updated Results of 2 Years Follow-up of a Superiority, Randomized Controlled Phase III Trial

Han, Y.

411 - MLL1 Complex Is a Critical Regulator of Fetal Hemoglobin Repression

Han, Z.

468 - Randomized Phase 2 Trial of the Anti-PD-L1 Monoclonal Antibody Durvalumab Plus Lenalidomide Versus Single-Agent Durvalumab in Patients with Refractory/Advanced Cutaneous T Cell Lymphoma

Hanackova, V.

1711 - PCNSL Patients Treated with the Matrix Regimen in the Real World Have Similar Outcome to Those in the IELSG 32 Trial

Hanada, S.

3059 - Treatment and Outcome of ATL Diagnosed in 2021 to 2023 By the Kagoshima ATL Registry

Hanamoto, H.

1310 - Long-Term Follow-up of Patients with Aplastic Anemia Enrolled in Phase 2/3 Trials of Immunosuppressive Therapy Plus Romiplostim As a First-Line Treatment: Two-Year Interim Analysis

Hanasoge-Nataraj, R.

373 - Significant Incidence of Mixed Donor Chimerism Despite TBI Conditioning in Paediatric B-ALL Patients Bridged to Transplant with Blinatumomab – a Report from the UK and Ireland Paediatric Bone Marrow Transplant/Cellular Therapies Group

Hanbali, A.

1142 - Steroid Pre-Busulfan Based Reduced-Intensity Conditioning in Matched Related Hematopoietic Stem Cell Transplantation: Outcomes in Young and Adult Sickle Cell Disease Patients
4536 - Evaluating the Safety and Efficacy of Tyrosine Kinase Inhibitors in Pregnant Patients with Chronic Myeloid Leukemia: A Comprehensive 15-Year Single-Center Study

Hancock, B.

3474 - Development of Induced Pluripotent Stem Cell-Derived T Cells Exhibiting Phenotypic and Functional Attributes of Primary CAR T Cells
4801 - Next-Generation Off-the-Shelf CAR T-Cell Therapy Developed to Eliminate a Broad Spectrum of Pathogenic Cells in Hematological Diseases in the Absence of Conditioning Chemotherapy

Hancock, H.

463 - Dual-Targeted Therapy with Ruxolitinib Plus Duvelisib for T-Cell Lymphoma
569 - Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin
3068 - Pembrolizumab for Front-Line Treatment of Extranodal NK/T-Cell Lymphoma
4451 - Angioimmunoblastic Versus Non-Angioimmunoblastic Nodal T-Follicular Helper Cell Lymphomas: Single Center Retrospective Analysis on 208 Cases

Hancock, T.

1910 - Preliminary Observations Using 99m-Tc-Peptide p5+14 for the Detection of AL Amyloidosis Using SPECT/CT and Planar Gamma Scintigraphic Imaging
4641 - Characterization of AT02 Bioactivity and an Assessment of Its Potential Use As an Amyloid-Clearing Therapeutic for AL Amyloidosis

Handa, H.

3290 - Role of Ras-Related C3 Botulinus Toxin Substrate 1 in p53-Related Proliferation and Drug Sensitivity in Multiple Myeloma

Handa, S.

4512 - Role of HMGA2 Overexpression Caused By Specific Genetic HMGA2 Aberrations in Disease Progression in Calreticulin-Mutated Myelofibrosis Patients

Handa, S.

243 - TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms
4520 - High-Resolution Chromosomal Microarrays Reveals Exon-Level Deletion in Chromosome 12q14.3 in Patients with Myeloproliferative Neoplasms

Hande, V.

3161 - Making Treatment Free Remission “Feasible” in Low- and Middle- Income Countries - Outcomes, Patterns of Failure and Compliance of Treatment Free Remission (TFR) in Chronic Myeloid Leukemia (CML) from a Tertiary Care Cancer Centre in India

Handfield, L. F.

944 - Clonal Haematopoiesis with TP53 Mutations Exhibits Abnormal Erythropoiesis and Erythroid Metabolic Stress
1284 - DNMT3A-Mutant Clonal Haematopoiesis Is Associated with Worse Recovery after ST-Elevation Myocardial Infarction Via Increased Inflammation

Handgretinger, R.

3563 - Addition of Anti-T-Lymphocyte-Globuline As Graft Versus Host Disease Prophylaxis for Matched Unrelated Donors Equalizes Outcomes with Matched Sibling Donors: Results from the AML SCT-BFM 2007 Trial

Handunnetti, S. M.

4384 - Marginal Zone Lymphoma Is Associated with Dysregulated Peripheral Blood Immunity Which Is Not Changed By Ibrutinib-Venetoclax Treatment

Hänel, G.

2957 - High Grade B-Cell Lymphoma with BCL2 and MYC Rearrangement (Double-Hit High-Grade Lymphoma; DH-HGL): Establishment of a Human Model System for Ex Vivo and In Vivo Studies

Hänel, M.

84 - Impact of Clonal Heterogeneity in Newly Diagnosed, Transplant-Eligible Multiple Myeloma – Subgroup Analysis of the GMMG HD6 Phase III Trial
114 - Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma
364 - Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
493 - Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial
769 - Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
1766 - Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) – an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)
1963 - Quality of Life in the Multicenter, Randomized, Phase 3 GMMG-HD6 Trial Applying Elotuzumab, Lenalidomide, Bortezomib and Dexaemethason in Patients with Newly-Diagnosed Multiple Myeloma
2934 - The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients
5140 - Long-Term Follow-up Analysis of Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma Patients from the GMMG Myeloma Registry Following the Randomized Phase III GMMG-HD6 Trial
1527.1 - Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1-Mutated AML – the SAL/AMLCG Vincent Trial

Hanel, W.

1403 - Targeting the DNA Damage Response through TBL1X in Mantle Cell Lymphoma
1719 - Nivolumab in Combination with Dose Adjusted (DA) R-EPOCH for First-Line Treatment of Large B-Cell Lymphoma: Results from a Phase II Trial
3747 - Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy Is Associated with Inferior Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma
4438 - Final Results of a Phase II Study of Brentuximab Vedotin and Lenalidomide in Relapsed and Refractory T-Cell Lymphomas
4460 - Patterns of Use and Outcomes of Novel Agents in Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Single-Center Retrospective Analysis
4507 - Steroid Prophylaxis in Patients Receiving CAR T-Cell Therapy for Relapsed and Refractory Non-Hodgkin Lymphoma

Haney, D. N.

4255 - Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML

Haney, M.

154 - Large-Scale In Vivo Zebrafish Drug Screen Uncovers Novel Insights into Leukemia Stem Cell Biology

Haney, M.

1064 - Defining the Impacts of Iron Overload in Children Receiving Hematopoietic Stem Cell Transplantation for Non-Malignant Hematologic Disorders: A Multicenter Analysis

Hang, M.

4135 - An Open-Label, Multicenter, Phase Ib Study of the Anti-TIM3 Monoclonal Antibody BC3402 in Combination with Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Hangse, T.

3919 - Expanding the Role of SH2B3: T Cell Large Granular Lymphocytosis (LGL) and Common Variable Immune Deficiency in the Setting of Biallelic SH2B3 Mutations

Hangse, T.

22 - Anti-HLA Antibody Specificities Are Differentially Associated with Immune Platelet Transfusion Refractoriness in Patients at Lower Calculated Panel Reactive Antibody (cPRA) Levels

Hanh, M.

1673 - Beyond Classical Hodgkin Lymphoma: Long-Term Risks and Secondary Cancers-Insights from the Texas Cancer Registry

Haniffa, M.

2659 - Multimodal Single Cell Analysis Reveals Hematopoietic Changes across the Human Lifespan

Hanke, F.

708 - Single Vs. Tandem Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Real-World Multi-Center Study from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)
3560 - Impact of FLT3 Inhibitor Maintenance Therapy on Post-Transplant Outcomes in FLT3-Mutated AML Patients: A Real World Analysis from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)

Hankin, M.

997 - Hematological Improvement and Other Clinical Benefits of Elritercept As Monotherapy and in Combination with Ruxolitinib in Participants with Myelofibrosis from the Ongoing Phase 2 Restore Trial
1825 - Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)
4591 - Hematologic Improvement and Fatigue Reduction with Elritercept (KER-050) in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS) with Non-Transfusion Dependent Anemia: New Analyses from an Ongoing Phase 2 Trial
3228.1 - Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)

Hankins, J. S.

Hanley, D. M.

686 - Phase II Study of Longitudinal Geriatric Assessment with Risk-Adapted Interventions to Reduce Non-Relapse Mortality in Allogeneic Hematopoietic Cell Transplantation for Older Patients with Advanced Myeloid Malignancies

Hanley, M. J.

3108 - Brigatinib Monotherapy in Children with R/R ALK+ ALCL, IMT, or Other Solid Tumors: Updated Results from the Brigaped (ITCC-098) Phase 1 Dose-Escalation Study

Hanlon, D.

1056 - Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager

Hann, W.

4445 - Delays to Diagnosis of Peripheral T-Cell Lymphoma and Clinical Utility of Molecular Profiling: A UK Multicentre Real-World Study

Hann, W.

571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

Hanna, D.

1419 - Co-Targeting BCL-2 and MCL1 (via CDK9) in Pre-Clinical Models of High-Risk Acute Lymphoblastic Leukemia
4187 - Retrospective Cohort Analysis of Response and Survival of Children, Adolescents, and Young Adults (CAYA) with Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoma (T-LL) Treated with Curative Intent: A TACL Consortium Study

Hanna, J.

1473 - Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients between 65-75 Years and Treated with Intensive Induction Chemotherapy Versus Hypomethylating Agents and Venetoclax: A Propensity Score Adjusted Cohort Study
1488 - A Comprehensive Analysis of FLT3 Mutation Profiles and Clinical Outcomes in Adult Patients with Acute Myeloid Leukemia: A Single Institution Experience
1911 - Assessing the Efficacy and Safety of Reduced Dexamethasone Duration in Newly Diagnosed AL Amyloidosis Versus Standard Therapy
2848 - Salvage Reinduction Chemotherapy Versus Alternative Regimens after Failed AML Intensive Induction Regimen, a Single Center Experience
2862 - Impact of Cytogenetic Response on Long-Term Survival in Acute Myeloid Leukemia: A Retrospective Cohort Study
2868 - Outcomes of Blast-Phase MPN and JAK2, MPL, and CALR Mutated de Novo AML Compared to AML with Wild-Type JAK2, MPL, and CALR Genes: A Propensity Score-Adjusted Cohort Study
4248 - Survival Outcomes of Patients Diagnosed with Myeloid Sarcoma Versus Acute Myeloid Leukemia: A Retrospective Cohort Study
4249 - Comprehensive Analysis of KMT2A Alterations in Acute Myeloid Leukemia and Their Impact on Survival and Response Rates; A Single Center Experience
4297 - The Prognostic Significance of Chromosome 17 Addition Vs. Complete and Partial Loss in Patients with Acute Myeloid Leukemia, a Single Center Experience

Hanna, K.

5136 - Pattern of IgG Testing and Immunoglobulin-Replacement Therapy in Patients with Non-Hodgkin Lymphoma

Hanna, M. S.

2614 - Phase 1, 3-Sequence Interaction Study of Intravenous Vlx-1005 and Argatroban Shows a Favorable Safety, Pharmacokinetic and Pharmacodynamic Profile in Healthy Volunteers

Hanna, R.

2691 - Outcomes of Immunosuppressive Therapy in Children Less Than Three Years of Age with Idiopathic Severe Aplastic Anemia: A North American Collaboration
4955 - Reni-Cel, an Investigational AsCas12a Gene-Edited Cell Medicine, Led to Sustained Hemoglobin Normalization and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease Treated in the RUBY Trial

Hanna, R. M.

2613 - Real-World Effectiveness of Ravulizumab Among Adults with Atypical Hemolytic Uremic Syndrome (aHUS) Who Switched to Ravulizumab within 3 Months of Eculizumab Treatment: A Physician Panel-Based Chart Review Study (aHUS IMPACT)

Hanna, R.

3470 - Cost-Effective Manufacture and Promising Initial Efficacy of huCART19 Cells Manufactured Using the Clinimacs Prodigy Platform

Hannah, R.

190 - Delayed Trp53 Activation Protects Dnmt3a-Mutant Haematopoietic Stem Cells from Inflammatory Attrition
2659 - Multimodal Single Cell Analysis Reveals Hematopoietic Changes across the Human Lifespan

Hannemann, C.

2542 - Tetraspanin CD37 Regulates Platelet Hyperreactivity and Thrombosis

Hannigan, K.

463 - Dual-Targeted Therapy with Ruxolitinib Plus Duvelisib for T-Cell Lymphoma
4429 - Improved Outcomes for Primary Refractory Classical Hodgkin Lymphoma: A Retrospective Analysis

Hannun, Y. A.

939 - Multiomic Analyses of Erythropoiesis and Anemia Mechanisms Reveal a Signaling Network with Converging Cytokine and Sphingolipid Inflammatory Pathways

Hanona, P.

1145 - Higher Number of M1 Macrophages and Activated Dendritic Cells Linked to Longer Overall Survival in Patients with Acute Myeloid Leukemia

Hanoun, C.

84 - Impact of Clonal Heterogeneity in Newly Diagnosed, Transplant-Eligible Multiple Myeloma – Subgroup Analysis of the GMMG HD6 Phase III Trial
364 - Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
769 - Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
1963 - Quality of Life in the Multicenter, Randomized, Phase 3 GMMG-HD6 Trial Applying Elotuzumab, Lenalidomide, Bortezomib and Dexaemethason in Patients with Newly-Diagnosed Multiple Myeloma
3383 - Idecabtagene Vicleucel (ide-cel) Shows Similar Efficacy and Toxicity in Patients with Multiple Myeloma Aged 70 and Older Compared to Younger Patients: A Multicenter Cohort Study
4759 - Efficacy of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma and Prior Central Nervous System Manifestation: A Retrospective Real-World Analysis
4857 - Analysis of Early Apheresis Immunophenotype, Batch Data Variables and Clinical Outcomes for Optimization of CAR-T-Cell Therapy in Aggressive B-Cell Lymphomas

Hanoun, M.

631 - IDH2 Mutations from Clonal Hematopoiesis and Acquired IKZF1 Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma
1436 - Outcome of Patients with Hematologic or Molecular Relapsed/Refractory (R/R) Acute T- Lymphoblastic Leukemia - Data from the GMALL Study Group
2179 - Outcome after Allogeneic Stem Cell Transplant in Adults with Inherited Myeloid Malignancies – a Multicenter Retrospective Analysis on Behalf of the German Cooperative Transplant Study Group
2211 - Age-Stratified Game-Theory-Informed Machine Learning of Molecular Alterations Unveils Prognostic Divergence in 3062 Pediatric and Adult Acute Myeloid Leukemia Patients
2934 - The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients
3818 - Outcomes of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Multicenter Real-World Analysis
1527.1 - Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1-Mutated AML – the SAL/AMLCG Vincent Trial

Hansen, A.

3751 - Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Extranodal (EN) B-Cell Non-Hodgkin Lymphoma (NHL): Results from a Multicenter Analysis

Hansen, A.

537 - LDB1 Establishes Multi-Enhancer Networks to Regulate Erythroid Gene Expression

Hansen, B. T.

1458 - C/EBP Family Member Gene Fusions and Cooperating Genomic Events Define Two Distinct Molecular Sub-Groups in Adult B Precursor ALL
4213 - Integrateall, a Machine Learning Pipeline for Multi-Level Data Extraction from RNA-Seq Profiles Unravels Novel Drivers and Systematic Subtype Classification in B-Cell Precursor ALL

Hansen, D. L.

115 - Incidence and Risk of Therapy-Related Myeloid Neoplasms in Solid Cancer: A Danish National Population-Based Matched Cohort Study
3099 - Outcome of T-Cell/Histiocyte-Rich Large B-Cell Lymphoma in Denmark 2008-2022
5179 - Incidence and Risk of Therapy-Related Myeloid Neoplasms in Non-Myeloid Hematological Malignancies: A National Population-Based Matched Cohort Study

Hansen, D. K.

Hansen, D. K.

934 - Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
1995 - Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Final Results of a Phase II Study
2004 - Predictive Markers for Outcomes after Disease Progression Post BCMA-Directed CAR T-Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma
3337 - Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab
4645 - The Differential Effects of Bridging Therapy on Immune Microenvironment and Outcomes with Idecabtagene-Vicleucel in Multiple Myeloma
4740 - Activity and Safety of Venetoclax (VEN)-Based Treatment in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (R/R MM)

Hansen, E.

3743 - End-of-Life Care Patterns in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Real-World Setting
5101 - Impact of the Diagnosis-to-Treatment Interval (DTI) on Outcomes in Older Adults with Diffuse Large B-Cell Lymphoma (DLBCL) Treated in the Real-World Setting

Hansen, H.

1104 - Small Activating RNA-Mediated Induction of HBG Via Liposome Delivery for In Vivo Treatment of Sickle Cell Disease and Beta-Thalassemia

Hansen, I. D.

3184 - Statins Enhance the Efficacy of Pegylated Interferon-alpha2 in Patients with Ph-Negative Chronic Myeloproliferative Neoplasms. Results from a Danish Single-Institution Cohort Study

Hansen, J. W.

3201 - Oral Vitamin C Supplementation Modulates Inflammatory Cytokines in Clonal Cytopenia of Undetermined Significance and Low-Risk Myeloid Malignancies: Results from EVI-2 Trial

Hansen, K. C.

3835 - Arginine Metabolism Is a Biomarker of Red Blood Cell and Human Aging

Hansen, L. K.

747 - Acalabrutinib and Rituximab in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma Including a Matched Population-Based External Comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) Phase II Trial

Hansen, T.

499 - Selective Support of CAR-T Cell Therapies By Cis-Targeted IL-2 Enhances Anti-Tumor Activity and Obviates the Need for Lymphodepletion in Non-Human Primates

Hansmann, L.

4082 - The Impact of Body Mass Index (BMI) in Patients with Aplastic Anemia Receiving Weight-Adjusted Horse Anti-Thymocyte Globulin (hATG) on Outcome, Response and Relapse Rate

Hanson, C. A.

397 - Prevalence, Genetic Predispositions and Clinical Consequences of Non-CLL-Type MBL: Screening in 10,330 Individuals

Hanson, E.

402 - Pediatric RISE: Development of a Poverty-Targeted Cash Support Intervention for Pediatric Cancer

Hanson, G.

3967 - Real-World Patterns of Additional Factor Treatment Use Among Hemophilia a Patients on Regular Prophylaxis in the United States: Results from the Picnichealth Database

Hanson, S.

1989 - Less Frequent Teclistamab Dosing in Responders: Modeling and Simulation Data from the Majestec-1 Study in Relapsed/Refractory Multiple Myeloma

Hanssens, L.

4834 - Phase I/II Clinical Trial on CD19-Chimeric Antigen Receptor (CAR) T Cells Generated with an Automated Process, from Fresh Apheresis, and Reinfused As Fresh Drug Product for Pediatric/Young Adult Patients with Relapsed/Refractory (r/r) B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

Hansson, L.

4634 - Severity of COVID-19 in Individuals with Chronic Lymphocytic Leukemia throughout the Pandemic in Sweden: A Nationwide Multiple Register Cohort Study Conducted from 2020 to 2023

Hansson, M.

674 - Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial

Hantel, A.

5073 - Assessing the Contribution of Duffy Null Phenotype to Disparities in Eligibility Criteria for Clinical Trials for Newly-Diagnosed Colorectal Cancer
5171 - Impact of Social Determinants of Health on Overall Survival in Patients with AML By European Leukemianet Risk Group

Hantrakool, S.

1776 - Vitamin D Deficiency Negatively Affects Responses in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Hantrakun, N.

1776 - Vitamin D Deficiency Negatively Affects Responses in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Hanzhen, Z.

4372 - EBV-Infected NKTCL Upregulated MHC-II Imprinted T Cell Exhaustion By Interacting with LAG3

Hao, F.

2978 - Temporally Controlled MYC Overexpression in Chronic Lymphocytic Leukemia Accelerates Progression and Promotes Large B Cell Lymphoma Transformation

Hao, M.

1029 - CAR-T Cell Therapy in Advanced Myeloma with Extramedullary Disease – an In Vivo Imaging and Molecular Monitoring Study (CARAMEL): First Results of Cu-64 Radiolabelled Nanoparticle PET-CT and PET-MRI

Hao, M.

743 - Single-Cell RNA Analysis of Bone Marrow Mononuclear Cells Reveals Abnormal Activation of T Cells and Monocytes, and Identifies CD35 As a Novel Biomarker and Therapeutic Target in Waldenstrom Macroglobulinemia
832 - TENT5C As a Target of Chromatin Remodeler SMARCA2 Participates BTK Inhibitor Resistance in Mantle Cell Lymphoma By Regulating ATP Metabolism
1410 - Synergistic Induction of Senescence-Driven Immune Responses and Myeloma Cell Cytotoxicity By CDK4/6 Inhibitors and Daratumumab Combination Therapy
1905 - 26S Proteasome Non-Atpase Subunit 3 (PSMD3/Rpn3) Is a Potential Therapeutic Target in Multiple Myeloma
1932 - Clinical Implications of Residual Immunophenotypically Normal Plasma Cells within Bone Marrow at Various Disease Stages in Multiple Myeloma
3262 - Critical Roles of LILRB4 in Promoting PIM Kinase Mediated Cell Proliferation and Tumorigenesis in Multiple Myeloma
4338 - Genomic Evolution By Serial Single-Cell Sequencing Identifies High Tumor Expression of LYN As a Promoter of Resistance in Waldenstrom’s Macroglobulinemia Undergoing Ibrutinib Monotherapy
4349 - Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenström Macroglobulinemia
4668 - TRIM28 Serves As a Key Regulator of Protein Homeostasis and Mediates Proteasome Inhibitor Resistance in Multiple Myeloma

Hao, Q.

956 - A Highly Selective and Orally Bioavailable CK1α Molecular Glue Degrader Targets B-Cell Lymphoma Cells

Hao, S.

4073 - Antithymocyte Globulin Enhances Myeloid-Derived Suppressor Cell Expansion and Function in Severe Aplastic Anemia

Hao, S.

4762 - Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Hao, S.

3240 - Preliminary Data of a Single-Arm, Phase II Study of Orelabrutinib with/without Rituximab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma after BTK Inhibitor Therapy

Hao, Y.

581 - Fixed-Duration Epcoritamab + R-CHOP Induces High Complete Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Withhigh-Risk Features: Long-Term Results from the Epcore NHL-2 Trial
1627 - Fixed-Duration Epcoritamab in Combination with Bendamustine + Rituximab for First-Line Treatment of Follicular Lymphoma: Initial Results from Epcore NHL-2 Arm 3
3106 - Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

Hao, Y.

42 - Recurrent ASXL1 Mutations Promote Myeloid Malignancies through Unleashed Condensation

Hao-Shen, H.

751 - JAK2-V617F-Driven Myeloproliferative Neoplasms (MPN) Are Initiated By a Subset of HSCs Marked By High Expression of the Vwf-GFP Reporter Gene

Haouy, S.

1592 - Circulating Cell-Free DNA in Classical Hodgkin Lymphoma in Children, Adolescents and Young Adults. Results from the Holy Study, a French Ancillary Study of Euronet PHL-C2 Protocol

Hapgood, G.

4416 - Practices and Outcomes during a Watch and Wait Approach for Follicular Lymphoma: A Study from the Australasian Lymphoma Alliance

Happ, L.

3409 - Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Haque, N.

2909 - Degrading SMARCA2/4 Relieves the Differentiation Block in AML Via Chromatin Alterations Affecting S100A8/9

Haque, T.

353 - Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study
655 - Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1867 - Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)

Hara, H.

1051 - Ex Vivo Lentiviral Hematopoietic Stem Cell (HSC) Gene Therapy May Represent a Curative Therapy for the Life-Threatening Inborn Error of Immunity Severe Combined Immunodeficiency Due to Adenosine Deaminase (ADA) Deficiency (ADA-SCID)

Hara, R.

2204 - Functional Analysis of EBV-Derived microRNAs in Systemic Chronic Active EBV Disease Using Novel Antisense Oligonucleotides

Hara, T.

3089 - Real-World Experience of Pola-R-CHP Therapy in Diffuse Large B-Cell Lymphoma Aged 80 or Older

Harada, J.

4515 - Cbl^Q367P Cooperates with Loss of Tet2 to Drive a Cnl-like Disease Via the NF-Kb Pathway

Harada, K.

1173.1 - Delivering Transcutaneous Auricular Neurostimulation to Reduce Heavy Menstrual Bleeding in Von Willebrand Disease Patients

Harada, S.

260 - Gvhd-Induced Inflammatory Memory in Intestinal Stem Cells Enhances IFN-y-Induced Antigen Presentation and Apoptosis of Intestinal Epithelial Cells
902 - Ropeginterferon Alfa-2b Induces Apoptosis and Differentiation of Leukemia Stem Cells and Separates GVL Effects from Gvhd after Allogeneic Hematopoietic Cell Transplantation
903 - Early Initiation of Calcineurin Inhibitor Induces CD8⁺ Transitory Exhausted-like and CD4⁺ Cytotoxic T Cells, Maintaining Responsiveness to PD-1 Blockade and Contributing to the Development of Chronic Gvhd after Post-Transplant Cyclophosphamide
3096 - Reduced FDG Uptake in the Brain on Baseline 18FDG PET/CT Predicts Worse Prognosis of Newly Diagnosed Intravascular Large B-Cell Lymphoma and Advanced-Stage Diffuse Large B-Cell Lymphoma

Harada, T.

1884 - Steric Hindrance By APRIL in Binding of BCMA-Directed Bispecific Antibodies: A Novel Refractory Mechanism of BCMA-Directed Immunotherapies in Multiple Myeloma
4683 - Development of a Novel and Rapid Diagnostic Technique for Cardiac Amyloidosis Using Raman Spectroscopy

Haradhvala, N.

761 - Polyfunctional Effector PD-1⁺ CD8⁺ T Cells and M1 Macrophages Promote Immune Checkpoint Blockade Response in Richter Syndrome Mouse Models

Haradhvala, N. J.

645 - Cytokine-Linked Remodeling of the Immune Microenvironment Is a Hallmark of Transformation in Follicular Lymphoma
1895 - Single-Cell RNA-Sequencing of 6 Million Tumor and Immune Cells in 365 Patients with MGUS and SMM Demonstrates Complex Progressive Changes in Immune Cell Functionality with a Distinct Footprint on Tumor Cell Biology and Disease Control
4637 - Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages

Haraguchi, K.

3059 - Treatment and Outcome of ATL Diagnosed in 2021 to 2023 By the Kagoshima ATL Registry

Haraguchi, K.

4851 - Novel Method to Evaluate the Quantitative Immune Functionality of CAR T-Cells to Analyze the Localization Change of CAR Molecules

Haran, A.

1668 - Brentuximab Vedotin-Based Regimens for Older Patients with Newly Diagnosed Classical Hodgkin Lymphoma – International, Multi-Center Real-World Experience
3189 - DNMT3A, TET2, and ASXL1 (DTA) Mutations Are Associated with Thrombosis and Bleeding in Patients with Myeloproliferative Neoplasms
4269 - For Patients with Adverse-Risk Acute Myeloid Leukemia, Frontline FLAG Ida with Venetoclax Is Safe and Efficacious

Haran, H.

4237 - High Burden of Healthcare Utilization in Older Acute Myeloid Leukemia Patients Treated with First-Line Venetoclax-Based Therapies

Haratake, T.

3301 - Clinicopathological and Gene Expression Analysis of Hyaline Vascular Castleman Disease

Harb, D.

2349 - Indirect Comparisons of the Efficacy of Epcoritamab Vs Glofitamab in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Harbhajan, M.

746 - MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naïve Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA Analyses

Hardee, M.

2900 - Superior Survival with Intensive Chemotherapy, Compared to Hypomethylating Agent + Venetoclax, in Patients with Intermediate/Adverse Risk Acute Myeloid Leukemia Unable to Proceed to Transplant

Hardefeldt, P.

2823 - A UK Intention to Treat Analysis of Brexucabtagene Autoleucel for Relapsed or Refractory Adult Acute Lymphoblastic Leukaemia Following 1 Year of Therapy Access

Hardin, H.

197 - PARP Inhibitor Treatment Increases DNA Damage in Bone Marrow and Drives Compensatory Changes in Multiple Hematopoietic Stem and Progenitor Cell Populations Contingent on Brca1 Genotype

Harding, L.

3139 - Reticulin-Free Quantitative Assessment of Bone Marrow Fibrosis in Myeloproliferative Neoplasms; Time to Sell the Family Silver?

Harding, M.

2066 - Phase 1 Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients with CD7+ T-Cell Non-Hodgkin Lymphoma

Harding, S. J.

1015 - Differential Detection of Clonal Bone Marrow Plasma Cells in IgA Vs. IgG Monoclonal Gammopathy of Undetermined Significance and Its Association with Disease Progression
4984 - Deep Learning Unveils Characteristics of Immune B Cell Aging in >17,000 Samples and Identifies Changes in the Immunoglobulin Repertoire Distribution and the Development of Monoclonal Gammopathy

Harding, S. J.

3279 - Early Serum Protein Clonal Dynamics Preceding Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma Years before Diagnosis

Hardison, R. C.

537 - LDB1 Establishes Multi-Enhancer Networks to Regulate Erythroid Gene Expression
2740 - Defining Oncogenic Transcriptional Networks Regulated By LDB1 in T-Cell Acute Lymphoblastic Leukemia

Hardouin, G.

36 - Vexas Syndrome Is a New Cause of p53-Mediated Erythroblastopenia

Hardwick, J.

2711 - The LMO2-LDB1-TAL1 Complex Regulates Transcription Networks in AML Relapse
4666 - Unraveling the Kinase-Independent Autoregulatory Mechanism of PIM2 in Multiple Myeloma

Hardwick, P.

3365 - Combination Regimens in MM Post Autologous Hematopoietic Cell Transplantation (AHCT) to Eliminate MRD Utilizing Iberdomide (COMMANDER): Results of Dose-Finding Component of a Phase 1b/2 Trial
3449 - Phase 2 Trial of Siltuximab for the Treatment of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Related to CAR-T Cell Therapy

Hardy, E. L.

1226 - “Endothelialized” Hemostasis-on-a-Chip Reveals Rapid Platelet Recruitment By Locally Concentrated Ultra-Large Von Willebrand Factor (VWF) Release from Endothelial Cells Surpasses Plasma and Platelet VWF in Initiating Hemostasis

Hardy, N. M.

68 - Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

Hare, L.

1581 - NPM::ALK Transcript Levels and Anti-ALK Autoantibody Titers As Biomarkers for Outcome in Pediatric ALK+ Anaplastic Large Cell Lymphoma Treated with Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy: COG ANHL12P1

Harel, R.

1862 - Phase II Prospective Trial of Fixed Duration Obinutuzumab, Ibrutinib and, Venetoclax in an Elderly Cohort of Patients with Richter's Syndrome-Givers Regimen

Harel, S.

1980 - Effect of Daratumumab on Renal Outcome in Newly Diagnosed Multiple Myeloma with Light Chain CAST Nephropathy
4760 - Immunological Predictive Markers of Response to Idecabtagene Vicleucel Therapy in Multiple Myeloma : A Real-World Experience from St Louis Hospital (France)

Hari, P. N.

1929 - Enhanced Prognostic Value of the SKY92 Classifier over High-Risk Cytogenetic Aberrations in Multiple Myeloma: Results from the Prommis Real-World Study
2379 - Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study
4733 - Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study
4787 - PI3 Kinase Pathway Regulates CAR T Cell Trogocytosis
4812 - CD47-CD138 Bispecific Antibody Exhibits Selective Targeting of Multiple Myeloma

Harig, A.

1527.1 - Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1-Mutated AML – the SAL/AMLCG Vincent Trial

Harigae, H.

1453 - Combined Targeting Patient-Specific Anti-Apoptotic Molecules and CXCR4-Expressing CAR-T Cells Eliminated High-Inflammation State Leukemia with Poor-Prognostic Mutations
2534 - RNA Methyltransferase Mettl16 Is Indispensable for the Survival of Naïve CD4⁺ T Cells In Vivo
3034 - Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update
4037 - Transcription Factor Gata2 Regulates the Myeloid-Lymphoid Fate Decision in Multipotent Progenitors

Harila, A.

2212 - Mapping the Spatial Proteome of Individual Leukemia Cells Undergoing Fludarabine Treatment
2805 - Diagnosing and Staging Central Nervous System Involvement in Pediatric ALL: A Global Survey on Its Heterogeneity
2831 - Cerebrospinal Fluid Flow Cytometry Improves Patient Stratification in Central Nervous System Acute Lymphoblastic Leukaemia but Requires Careful Standardization: Results from the ALLTogether1 CSF-FLOW Sub-Study

Harimadhavan, M.

3708 - Clinical Characteristics and Outcomes of Patients with Paroxysmal Nocturnal Hemoglobinuria: A Retrospective Study from a Tertiary Care Centre in South India

Harkins, R. A.

2970 - Collective Analysis of Genomic Data Sets to Assess the Impact of Eligibility Criteria on Molecular Subsets in First-Line Clinical Trials for Patients with Diffuse Large B-Cell Lymphoma
4364 - Evaluating the Clinical Utility of Real-Time Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Diffuse Large B-Cell Lymphoma

Harle, D. W.

381 - Multi-Omics Immune Profiling of Graft-Versus-Host Disease (GvHD) in Humans

Harlev, S.

1714 - Inflammation-Based Scores Predict Survival after CD3xCD20 Bispecific T Cell Engagers in R/R LBCL
1748 - Reduction in Platelet Counts May Predict the Development of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma

Harman, J.

201 - Differential Gene Expression in KMT2A::AFF1 Leukemia Is Driven By Enhancer Heterogeneity
2772 - First-in-Class Targeted Protein Degrader of MLLT1/3 for the Treatment of Advanced AML and ALL Including Menin Inhibitor Resistant / Refractory Disease

Harman, J. R.

199 - The Fetal Specific Gene LIN28B Is Essential for Human Fetal B-Lymphopoiesis and Initiation of KMT2A-AFF1+ Infant Acute Lymphoblastic Leukemia

Harmon, A.

516 - CD117 Antibody Conditioning and Multiplex Base Editing Enable Rapid and Robust Fetal Hemoglobin Reactivation in a Rhesus Autologous Transplantation Model

Harmon, L.

4092 - Germline Variant Burden Warrants Universal Genetic Testing in Pediatric AML
- Germline Genetic Variation in Acute Leukemia

Harney, A. M.

826 - REM-422, a Small Molecule MYB mRNA Degrader, Demonstrates Anti-Leukemic Activity As Monotherapy and in Combination with Standards of Care in Preclinical Models of AML

Harnik, Y.

4813 - A Spatial Atlas of Human Gastro-Intestinal Acute Gvhd Reveals Epithelial and Immune Dynamics Underlying Disease Pathophysiology

Harnois, M.

408 - Understanding the Lived Experience of Fatigue in Adolescents and Young Adults with Myeloproliferative Neoplasms: A Mixed Methods Study
533 - Sex-Related Differences in CML Outcomes in a Real-World Prospective Registry (GQR LMC-NMP)
1783 - Distinguishing Germline from Acquired Pathogenic CSF3R Variants: Key Diagnostic Features and Clinical Implications

Haro, B.

90 - Affinity-Tuned T-Cell Engager for Dual Targeting of B-Myeloid Mixed-Phenotype Acute Leukemia (B-MPAL)

Haroche, J.

4553 - Characteristics and Therapeutic Response of Erdheim-Chester Disease Associated with Myeloid Neoplasm, an Observational Multicenter Study

Haroon, A.

1142 - Steroid Pre-Busulfan Based Reduced-Intensity Conditioning in Matched Related Hematopoietic Stem Cell Transplantation: Outcomes in Young and Adult Sickle Cell Disease Patients

Harpell, L.

3959 - A Therapeutic siRNA Targeting Plasminogen Acts As a Long-Lasting Antifibrinolytic in Nonhuman Primates

Harper, A. R.

945 - Causes and Consequences of Clonal Hematopoiesis with Unknown Drivers in 409,553 Whole-Genome Sequenced UK Biobank Participants

Harper, E.

1263 - Targeted Therapies Associated with Increased Risk for and Incidence of Thrombosis in the Treatment of Breast Cancer
2335 - Anaphylaxis Associated with Calaspargase in Pediatric Patients with Acute Lymphoblastic Leukemia
4022 - Evaluating the Incidence and Risk Factors Associated with Deep Venous Thrombosis and Pulmonary Embolism in Patients with Multiple Sclerosis

Harper, J. S.

2362 - Real-World Treatment Patterns and Clinical Outcomes Among Patients with Diffuse Large B-Cell Lymphoma in a US Healthcare Claims Database
2381 - Characteristics, Treatment Patterns, and Outcomes of Patients with Multiple Myeloma Retreated with Daratumumab in Real-World Clinical Practice in the USA
2395 - Frontline Treatment Patterns in Patients with Newly Diagnosed Multiple Myeloma - Real-World Evidence from a Large Community-Based Oncology Practice Network in the US

Harper, J.

1288 - Dnmt3a Mutant Hematopoietic Stem Cells Produce Hyperactive T Cells with Increased Alloimmune and Anti-Leukemic Activity

Harrell, K.

3624 - One ST3P Further: Optimizing Transition Care for Pediatric Sickle Cell Patients at Atrium Health

Harrington, A. M.

4258 - Outcome of Patients with TP53 Mutated Relapsed/Refractory AML with Lintuzumab-Ac225 in Combination with CLAG-M Following Venetoclax Plus Hypomethylating Agent Therapy

Harrington, C.

1654 - Real World Treatment Outcomes in the First Line Management of Waldenström Macroglobulinemia from the Global Patient Derived Data Registry, Whimsical

Harrington, M.

2357 - Travel Time from Cancer Center Is Associated with Disparities in Non-Hodgkin Lymphoma Diagnosis Among People Living with HIV in Malawi

Harrington, P.

1788 - QRISK3: A New Marker for Thrombotic Events in Essential Thrombocythemia and Polycythemia Vera at Diagnosis and during Follow up
1804 - Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort
4547 - Rapid and Sustained Recovery of Cellular Immunity in Patients with Myelofibrosis on Momelotinib Therapy
4557 - Mympnvoice – a Novel Smartphone App for Monitoring Patient Reported Outcomes and Biometric Data in Patients with Myeloproliferative Neoplasms

Harris, A.

5132 - Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study

Harris, A. C.

664 - Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database
3219 - Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database

Harris, A.

3516 - Five-Year Outcomes of the “Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease (GVHD) Prophylaxis: A Randomized Controlled Trial” (‘ABA2’)

Harris, C.

2342 - Multi-Centre Real-World Outcomes of Large B-Cell Lymphoma Patients Treated with 2L Axicabtagene Ciloleucel in the UK
4445 - Delays to Diagnosis of Peripheral T-Cell Lymphoma and Clinical Utility of Molecular Profiling: A UK Multicentre Real-World Study

Harris, E. I.

570 - Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma
4415 - A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study

Harris, E. M.

795 - Pediatric Autoimmune Hemolytic Anemia Is Associated with a High Incidence of an Underlying Immune Disorder and High Mortality Rate
1189 - Real World Romiplostim Dosing and Response in Pediatric Immune Thrombocytopenia
2540 - Circulating T Follicular Helper Cells in Pediatric Immune Cytopenias

Harris, E. M.

547 - Critical Bleeding in Adults and Children with Immune Thrombocytopenia: A Multicentre Cohort Study

Harris, E.

1425 - Clinical and Molecular Characterization of TP53-Mutant Acute Lymphoblastic Leukemia

Harris, F.

1122 - Exploring N-Terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) in Children with Sickle Cell Disease (SCD) and Vaso-Occlusive Pain Episodes (VOE)
1123 - Secretory Phospholipase A₂(sPLA₂) in Patients with Sickle Cell Disease (SCD) Hospitalized for Vaso-Occlusive Pain Episodes (VOE)
2518 - Procalcitonin Elevation in Children with Sickle Cell Disease (SCD) Requiring Hospitalization for Acute Vaso-Occlusive Pain (VOE)

Harris, J.

504 - Overcoming the Lack of CD2:CD58 Costimulation in Chimeric Antigen Receptor T-Cell Immunotherapies

Harris, J.

184 - HDL and HDL-Mimetic Nanoparticles Prevent Induced TTP and Interrupt the Course of Ongoing Episodes of the Disease

Harris, K.

1293 - iPSC Reprogramming Identifies the Role of Cryptic Drivers in Preleukemic Clonal Evolution

Harris, K. M.

396 - Identifying Determinants of Sickle Cell Disease Knowledge, Awareness, and Management in St. Louis Area School Districts

Harris, L. H.

4129 - Developing a Pediatric-Relevant Murine MLL-r B-ALL Model to Study Factors Involved in Lineage Switching

Harris, M. H.

311 - Feasibility of Adjusting Risk Group and Risk Group-Based Therapy during Induction in the Treatment of B-Cell Acute Lymphoblastic Leukemia: Results from DFCI ALL Consortium Protocol 16-001

Harris, M.

3178 - Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor–Naïve Patients with Myelofibrosis

Harris, R.

4190 - Evaluation of Methotrexate Pharmacogenomic Variants to Predict Acute Neurotoxicity in Children with Acute Lymphoblastic Leukemia

Harris, R. E.

2519 - Acupuncture Ameliorates Heightened Inflammatory/Immune Responses Accompanied with Improvement in Clinical Outcomes in Patients with Sickle Cell Disease

Harris, R. E.

2516 - Self-Administered Acupressure Improves Pain and Quality of Life in Patients with Sickle Cell Disease
3881 - Altered Cerebral Functional Connectivity in Patients with Sickle Cell Disease

Harris, R.

2100 - Preclinical Proof of Concept for Decentralized Manufacturing of a MAGE-A4/CD8alpha-Expressing Autologous T-Cell Therapy for Solid Tumors

Harris, Z. I.

2253 - Addressing the Use of Direct Anticoagulants in Antiphospholipid Syndrome – Quality Improvement Initiative

Harrison, C.

968 - Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial

Harrison, C.

104 - Clinical Relevance of the Integrative Analysis of Gut Microbiome and Metabolomics in Myeloid Neoplasms: Correlations with Genomic Profiles, Treatment Response/Complications and Clinical Outcome
482 - Efficacy and Safety of Fedratinib in Patients with Myelofibrosis and Low Baseline Platelet Counts in the Phase 3 Randomized FREEDOM2 Trial
485 - Dynamics of Calr variant Allele Frequency with Therapy in Myeloproliferative Neoplasms
997 - Hematological Improvement and Other Clinical Benefits of Elritercept As Monotherapy and in Combination with Ruxolitinib in Participants with Myelofibrosis from the Ongoing Phase 2 Restore Trial
1788 - QRISK3: A New Marker for Thrombotic Events in Essential Thrombocythemia and Polycythemia Vera at Diagnosis and during Follow up
1804 - Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort
3146 - RUX-AZA Response in AP/BP-MPN Is Driven By Release of the Differentiation Block in Mutant HSPCs: A Single-Cell Multi-Omic Analysis of Responders on the Phase Ib Phazar Study
3168 - Treatment of Myeloproliferative Neoplasms with Janus Kinase Inhibitors: A Meta-Analysis of Cardiovascular Safety
3178 - Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor–Naïve Patients with Myelofibrosis
3186 - Interim Analysis of Promise, a Clinical Study Combining the BET Inhibitor OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis Experiencing an Inadequate Response to Ruxolitinib
3191 - Improvement in Serum Albumin As a Measure of Improved Metabolic Profile in Pacritinib-Treated Patients: A Retrospective Analysis of Patients Treated across Three Clinical Trials
3671 - Bridging the Knowledge Gap: Positive Impact of a Patient-Co-Created Bespoke Information Resource for Young People with Myeloproliferative Disorders
4547 - Rapid and Sustained Recovery of Cellular Immunity in Patients with Myelofibrosis on Momelotinib Therapy
4557 - Mympnvoice – a Novel Smartphone App for Monitoring Patient Reported Outcomes and Biometric Data in Patients with Myeloproliferative Neoplasms
1808.1 - Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial
3191.2 - Odyssey: A Phase 2 Open-Label Study of Momelotinib in Combination with Luspatercept in Patients with Transfusion-Dependent Myelofibrosis
4569.3 - A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy

Harrison, C.

1808.2 - POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Harrison, D. A.

2795 - Activity of Orally Available CBP/p300 Degraders in Pre-Clinical Models of Multiple Myeloma

Harrison, J.

25 - Dnmt3a Controls Hematopoietic Stem Cells Via DNA Methylation-Independent Regulation of Telomeres

Harrison, K.

2322 - Chive-Impact: Establishing the Clonal Hematopoiesis and Inflammation in the Vasculature (CHIVE) Registry and Biorepository in Underserved Areas

Harrison, S. J.

355 - Direct Visualisation of BCMA Bispecific Antibody and the Myeloma Immune Microenvironment
653 - DNA Damage Repair Pathway Variants Are Frequent in Patients Undergoing CAR-T Cell Therapy for Lymphoma and Associated with Increased Risk of Myeloid Neoplasia Post Cytotoxic Therapy
1029 - CAR-T Cell Therapy in Advanced Myeloma with Extramedullary Disease – an In Vivo Imaging and Molecular Monitoring Study (CARAMEL): First Results of Cu-64 Radiolabelled Nanoparticle PET-CT and PET-MRI
2002 - Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial
3390 - Updated Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2–4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison
4511 - Bridging Radiotherapy to Axicabtagene Ciloleucel (axi-cel) Is Associated with Favourable Outcomes for Large B-Cell Lymphoma (LBCL) in Third-Line and Beyond: An Australian Single-Centre Real-World Experience
4758 - Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry

Harrivel, V.

226 - Flow MRD Monitoring Combining Laip/Dfn and CD34+CD38- LSCs Is a Strong Predictor of Outcome in Adult AML Independently of the ELN-2022 Risk: First Results from the Multicentric Acute Leukemia French Intergroup MRD Flow Network
4080 - High Proportion of PNH Type II Neutrophils, I.e. Relative Percentage ≥3%, Is Associated with Thrombosis in Patients Displaying a PNH Clone >1%: Evidence from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study

Harro, C.

3060 - Impact of Clonal T-LGL Populations in Peripheral Blood on Clinical Outcomes in Cutaneous T-Cell Lymphoma

Harrod, M.

158 - Improving Guideline Concordant Primary Prevention Aspirin Use through a Multiclinic Antithrombotic Stewardship Intervention

Harrop, S.

1700 - Real-World Outcomes of Patients with High-Grade B-Cell Lymphoma with MYC and BCL2 rearrangements Treated in the Contemporary Era
- Heterozygous Germline TET2 Loss Function Variants Predispose to Development of Nodular Lymphocyte Predominant Hodgkin Lymphoma

Harrup, R.

476 - Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare
1727 - Durvalumab and Acalabrutinib for Relapsed/Refractory (r/r) High-Grade B-Cell Lymphoma: MoST15, Open Label Phase II Sub-Study of the Molecular Screening and Therapeutics in Leukaemia and Lymphoma (MoST-LLy) Framework
1873 - Reduction of Tumor Lysis Syndrome Risk after Debulking with Obinutuzumab in Patients Treated with Venetoclax–Obinutuzumab in the Randomized Phase 3 CRISTALLO Trial
3237 - CRISTALLO: Results from a Phase III Trial of Venetoclax–Obinutuzumab Versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine–Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia without Del(17p) or TP53 Mutations

Harrysson, S.

654 - Temporal Trends in Relative Survival of Diffuse Large B-Cell Lymphoma in Sweden and Denmark in the Era of Targeted and Cellular Therapies: A Population-Based Binational Study

Harstead, E.

2076 - CD123-CAR T Cells Manufactured in the Presence of Dasatinib Induce High Grade CRS and/or IEC-HS without Improving Efficacy in Pediatric Patients with Recurrent/Refractory Leukemia

Harstrick, A.

738 - Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE^®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study

Hart, A.

550 - T Cell Clonality in Paediatric Immune Thrombocytopenia

Hart, A.

4685.1 - Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)

Hart, C.

555 - Sustained Improvement of Survival in Patients Receiving Emicizumab Prophylaxis Instead of Immunosuppression during Early Management of Acquired Hemophilia a (AHA)

Hart, K.

46 - SF3B1 Mutation Drives Loss of Y Chromosome in Chronic Lymphocytic Leukemia

Harte, S. E.

2516 - Self-Administered Acupressure Improves Pain and Quality of Life in Patients with Sickle Cell Disease
2519 - Acupuncture Ameliorates Heightened Inflammatory/Immune Responses Accompanied with Improvement in Clinical Outcomes in Patients with Sickle Cell Disease
3881 - Altered Cerebral Functional Connectivity in Patients with Sickle Cell Disease

Hartigan, A. J.

513 - Initial Results from the BEACON Clinical Study: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease with Severe Vaso-Occlusive Crises
516 - CD117 Antibody Conditioning and Multiplex Base Editing Enable Rapid and Robust Fetal Hemoglobin Reactivation in a Rhesus Autologous Transplantation Model

Hartke, A.

1348 - CSF3R^T618I Is Stabilized By Calnexin and Induces Unfolded Protein Response (UPR) and ER-Phagy: A Pro-Survival Pathway for Oncogenic Misfolded CSF3R Proteins in Chronic Neutrophilic Leukemia (CNL)

Hartley-Brown, M. A.

677 - Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial
3360 - Phase II Trial of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
- Adult BMT/Cellular Therapy

Hartling, H. J.

4609 - Improved Innate Immune Function upon Preemptive Short-Term Acalabrutinib and Venetoclax in Newly Diagnosed CLL Patients with High Risk of Infections: Translational Findings from the Prevent-Acall Clinical Trial

Hartman, L.

2828.1 - Trial in Progress: Update on the TACL T2020-003 Randomized Phase 2 Trial to Improve Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL-2)

Hartmann, A. M.

318 - Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in KMT2A-Rearranged BCP-ALL
1458 - C/EBP Family Member Gene Fusions and Cooperating Genomic Events Define Two Distinct Molecular Sub-Groups in Adult B Precursor ALL
4213 - Integrateall, a Machine Learning Pipeline for Multi-Level Data Extraction from RNA-Seq Profiles Unravels Novel Drivers and Systematic Subtype Classification in B-Cell Precursor ALL

Hartmann, B. L.

3793 - Real-World Comparison of Outcomes of Patients Treated with HMA Monotherapy Versus HMA-Ven – Insights from 1634 Patients Included within the Austrian Myeloid Registry of the AGMT Study Group

Hartmann, G.

1160 - Immune Training Enhances Anti-Viral Responses and Improves Outcomes in Pax5^-/+ Mice Susceptible to Chronic Infection

Hartmann, K.

4569.1 - Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis

Hartmann, M.

1341 - Mutant Idh1 Blocks Neutrophil Maturation By Repressing Myeloid Progenitor Programs

Hartmann, M.

2543 - Low Thrombopoietin and Elevated Fas-L Are Independent Predictors of Immune Thrombocytopenia

Hartmann, T. N.

1298 - SPARC Stabilizes Integrin α4-VCAM-1 Interactions and Is Regulated By Intracellular Rac in NPM1-Mutated AML
4365 - Identification of Ikaros As Novel Interaction Partner of Cyclin D1/CDK4 in MCL

Hartnack, M.

1366 - Loss of IRF2BP2 Drives an Actionable IL-1β/IL-1R Signaling Loop in DLBCL

Hartung, E. E.

2764 - The Transcription Factor IRF8 Regulates the Sensitivity of AML Cells to LSD1 Inhibition and All-Trans Retinoic Acid

Hartzler, N.

2432 - Real-World Experience of Venetoclax Target Dosing with Concomitant Posaconazole in Adult Patients with Acute Myeloid Leukemia

Harvey, A.

2289 - Demystifying the Delivery and Adverse Event Management of Bispecific Antibodies in the Community Setting

Harvey, D.

1993 - Feasibility and Target AUC Accuracy of Personalized High Dose Melphalan in Myeloma

Harvey, E.

1141 - Adding CD117 Antibody to Alemtuzumab, Low Dose Total Body Irradiation (TBI), and Sirolimus for Matched Related Donor (MRD) Hematopoietic Cell Transplant (HCT) in Sickle Cell Disease (SCD): Initial Results

Harvey, K.

3784 - Single Center Real World Experience of Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma
5168 - Effect of Talquetamab on Responses in Patients with Relapsed and Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies

Harvey, R. C.

308 - Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial

Harvey-Jones, V.

2446 - The Effects of an Online Curriculum Based Approach to CME on Hematologist/Oncologists’ Ability to Treat Patients with BTK Inhibitors for Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Harwood, M.

4053 - Mosaic Chromosomal Alterations Driving Clonal Hematopoiesis Show Shared and Divergent Patterns of Accumulation Among Humans of Diverse Ancestries

Harzer, M.

3792d - Activity of CAR-T Cells and Bispecific Antibodies in Multiple Myeloma with Extramedullary Involvement

Hasabou, N.

2889 - Timing of Response with Gilteritinib Monotherapy in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Hasan, M.

944 - Clonal Haematopoiesis with TP53 Mutations Exhibits Abnormal Erythropoiesis and Erythroid Metabolic Stress
1284 - DNMT3A-Mutant Clonal Haematopoiesis Is Associated with Worse Recovery after ST-Elevation Myocardial Infarction Via Increased Inflammation
2967 - Role of Clonal Hematopoiesis (CH) in Lymphoma: Prevalence and Clinical Impact in Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL)
4046 - Luspatercept Reduces Clonal Hematopoiesis-Associated Cardiac Stress Via Modulation of mTORC1 and Inflammatory Signaling Pathways

Hasan, R.

2967 - Role of Clonal Hematopoiesis (CH) in Lymphoma: Prevalence and Clinical Impact in Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL)

Hasan, R.

3526 - Presence of Anti-D and Passive Transfer of Anti-D in Bone Marrow Transplant Patients Does Not Affect Transplant Outcomes

Hasanali, Z. S.

1033 - P2RX5-Directed CAR-T Cells for Genotype-Guided Treatment of Lymphoid and Plasma Cell Malignancies in Patients of African Ancestry
3266 - Mast Cells Support Multiple Myeloma Survival and Engraftment through Secreted Factors
3373 - Belantamab Mafodotin As Pre- and Post-Autologous Stem Cell Transplant (ASCT) Consolidation and Maintenance for Multiple Myeloma (MM) with < Complete Response after Induction: Interim Results of the Ongoing Phase 2 BLAST Study
5207 - Analysis of the Hematology Health Equity Literature: Trends By Topic and Disparity, across Journals, and over Time

Hasegawa, K.

4721 - Health Related Quality of Life (HRQoL) in Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review (SLR) and Meta-Analysis

Hasegawa, Y.

903 - Early Initiation of Calcineurin Inhibitor Induces CD8⁺ Transitory Exhausted-like and CD4⁺ Cytotoxic T Cells, Maintaining Responsiveness to PD-1 Blockade and Contributing to the Development of Chronic Gvhd after Post-Transplant Cyclophosphamide

Hasegawa, Y.

260 - Gvhd-Induced Inflammatory Memory in Intestinal Stem Cells Enhances IFN-y-Induced Antigen Presentation and Apoptosis of Intestinal Epithelial Cells
902 - Ropeginterferon Alfa-2b Induces Apoptosis and Differentiation of Leukemia Stem Cells and Separates GVL Effects from Gvhd after Allogeneic Hematopoietic Cell Transplantation
903 - Early Initiation of Calcineurin Inhibitor Induces CD8⁺ Transitory Exhausted-like and CD4⁺ Cytotoxic T Cells, Maintaining Responsiveness to PD-1 Blockade and Contributing to the Development of Chronic Gvhd after Post-Transplant Cyclophosphamide
1311 - Frequent Loss of HLA-B*40:02 from Leukocytes in Male Patients with Hepatitis-Associated Aplastic Anemia
2121 - Kinetics of Recipients with Thrombocytopenia and Its Impact on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Retrospective Study
3569 - To What Extent Have Post-Transplant Outcomes Improved Following the Introduction of Tyrosine Kinase Inhibitors in Elderly Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia? a Retrospective Nationwide Survey in Japan

Haseley, A.

1082 - A Novel GATA1 (E200K) Germline Mutation Causing Hydrops Fetalis with Spontaneous Resolution of Erythropoiesis

Haseley, M.

540 - STAT5 Facilitates Terminal Erythroid Maturation in Concert with the Integrator Complex

Hasenclever, D.

3221 - Targeting of Various Inflammatory Circuits Does Not Ameliorate Ineffective Hematopoiesis: Results of the Lucas and Canfire Studies Investigating IRAK4 or IL-1β Blockade to Target Anemia in Lower-Risk MDS

Hasenkamp, J.

3383 - Idecabtagene Vicleucel (ide-cel) Shows Similar Efficacy and Toxicity in Patients with Multiple Myeloma Aged 70 and Older Compared to Younger Patients: A Multicenter Cohort Study
4759 - Efficacy of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma and Prior Central Nervous System Manifestation: A Retrospective Real-World Analysis

Haseyama, Y.

3096 - Reduced FDG Uptake in the Brain on Baseline 18FDG PET/CT Predicts Worse Prognosis of Newly Diagnosed Intravascular Large B-Cell Lymphoma and Advanced-Stage Diffuse Large B-Cell Lymphoma

Hashem, H.

2136 - Age Is a Crucial Determinant of GFRS with Incidence of Severe Chronic GVHD Reducing over Time in Haemopoietic Cell Transplantation for Transfusion Dependent Thalassaemia: Real World Data from 2010-2021. an Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party

Hashemi, J.

4370 - Plasma Proteomics Differentiates between Patients with B-Cell Lymphomas

Hasheminasab, S. A.

1909 - A Novel Segmentation-Based Purity-Informed Approach Accurately Detects Total Copy Number and Its Subclonal Fraction in Myeloma Targeted Panel Sequencing Data

Hasheminasabgorji, E.

4642 - Immune and Tumor Mediators of Resistance to Daratumumab-IMiDs Based Therapies in Relapsed Multiple Myeloma

Hashiguchi, J.

3096 - Reduced FDG Uptake in the Brain on Baseline 18FDG PET/CT Predicts Worse Prognosis of Newly Diagnosed Intravascular Large B-Cell Lymphoma and Advanced-Stage Diffuse Large B-Cell Lymphoma

Hashii, Y.

1426 - Prognostic Factors for T-Cell Acute Lymphoblastic Leukemia in Children and Young Adults: ALL-T11 Study Conducted By Japan Children’s Cancer Group and Japan Adult Leukemia Study Group

Hashim, H. F.

1132 - Analysis of the Pilot Study of the International Hemoglobinopathy Research Network (INHERENT)

Hashimoto, D.

902 - Ropeginterferon Alfa-2b Induces Apoptosis and Differentiation of Leukemia Stem Cells and Separates GVL Effects from Gvhd after Allogeneic Hematopoietic Cell Transplantation
903 - Early Initiation of Calcineurin Inhibitor Induces CD8⁺ Transitory Exhausted-like and CD4⁺ Cytotoxic T Cells, Maintaining Responsiveness to PD-1 Blockade and Contributing to the Development of Chronic Gvhd after Post-Transplant Cyclophosphamide
3096 - Reduced FDG Uptake in the Brain on Baseline 18FDG PET/CT Predicts Worse Prognosis of Newly Diagnosed Intravascular Large B-Cell Lymphoma and Advanced-Stage Diffuse Large B-Cell Lymphoma

Hashimoto, D.

260 - Gvhd-Induced Inflammatory Memory in Intestinal Stem Cells Enhances IFN-y-Induced Antigen Presentation and Apoptosis of Intestinal Epithelial Cells

Hashimoto, K.

2534 - RNA Methyltransferase Mettl16 Is Indispensable for the Survival of Naïve CD4⁺ T Cells In Vivo
4037 - Transcription Factor Gata2 Regulates the Myeloid-Lymphoid Fate Decision in Multipotent Progenitors

Hashimoto, M.

877 - Luspatercept Promotes Heme Biosynthesis and Erythroblast Island Formation in a Novel Low-Risk MDS Mouse Model
4035 - Loss of Cpt1a Results in Elevated Mitochondrial Reactive Oxygen Species from Glucose-Fueled Mitochondrial Oxidative Phosphorylation and Defective Hematopoietic Stem Cells

Hashmi, H. S.

Hasle, H.

322 - Comparison of the WHO and ICC Classifications of Cytogenetic Abnormalities in Childhood Acute Myeloid Leukemia
323 - Measurable Residual Disease Monitoring during Treatment for Pediatric Acute Myeloid Leukemia in First Relapse Predicts Outcome
2954 - Presence of Leukemia-Related Basophils and Mast Cells with Atypical Immunophenotype during Induction Should Not be Interpreted As Measurable Residual Disease in Children with Acute Myeloid Leukemia with RUNX1::RUNX1T1

Hasle, V.

4585 - Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab

Hasler, J. S.

3739 - Disparities in Psychological Distress and Coping Behaviors Amongst Patients with Indolent Hematologic Malignancies

Haslett, L.

1104 - Small Activating RNA-Mediated Induction of HBG Via Liposome Delivery for In Vivo Treatment of Sickle Cell Disease and Beta-Thalassemia

Haslinger, C.

557 - Post Partum Haemorrhage (PPH): Time to Change Perception of Pathophysiology and Approach to Therapy? Uterine Atony in Developing PPH Is Rare with Disturbances of Coagulation Being Early and Frequent

Hass, A.

2785 - LY4152199, a First-in-Class BAFF-RxCD3 Bispecific Antibody for the Treatment of B Cell Malignancies

Hassan, E.

2637 - Rapido: Results from a UK-Wide Audit of 2477 Patients Who Received a Reversal Agent for a Direct Oral Anticoagulant

Hassan, H.

4678 - Differences in Immune Cell Populations between Individuals with or without MGUS
4681 - Model for Predicting Day-100 Stem Cell Transplant-Related Mortality in AL Amyloidosis
5158 - Impact of Social Determinants of Health on Survival Outcomes in Multiple Myeloma Patients at a Major Cancer Center

Hassan, K.

4918 - Risk of Relapse Post Reduced Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with High-Risk Myeloid Neoplasms Based on Ptcy Vs TAC/MTX Gvhd Prophylaxis

Hassan, M. A.

4536 - Evaluating the Safety and Efficacy of Tyrosine Kinase Inhibitors in Pregnant Patients with Chronic Myeloid Leukemia: A Comprehensive 15-Year Single-Center Study

Hassan, R.

3319 - A Comparative Study of Plasma Cell Detection By Peripheral Smear and Peripheral Blood Flow Cytometry
4685.1 - Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)

Hassan, T.

5066 - Understanding the Menopause Transition in Sickle Cell Disease: An Interim Analysis of the Implementation of the Adapted Menopause Transition Questionnaire

Hassan, T.

2652 - Fat Mass Obesity-Associated (FTO) Driven Gene Regulatory Networks Control Hematopoietic Stem Cell Expansion and Homing

Hassanain, H.

1673 - Beyond Classical Hodgkin Lymphoma: Long-Term Risks and Secondary Cancers-Insights from the Texas Cancer Registry

Hassanain, H. S.

5131 - Statins May Improve Outcomes and Toxicities in Patients Undergoing CD19-Specific CAR T-Cell Therapy for Aggressive B-Cell Lymphomas

Hasselbach, H. C.

4569.3 - A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy

Hasselbalch, H. C.

1806 - Identification of Calr Mutations in Individuals of the Background Population Reveals Undiagnosed Myeloproliferative Neoplasms and Surprisingly Stable Low Levels of Calr Mutant Allele Burden in Individuals Not Developing Myeloproliferative Neoplasm during 10-14 Year Follow-up
3184 - Statins Enhance the Efficacy of Pegylated Interferon-alpha2 in Patients with Ph-Negative Chronic Myeloproliferative Neoplasms. Results from a Danish Single-Institution Cohort Study
4545 - Circulating Extracellular Matrix Fragments As Biomarkers in Myeloproliferative Neoplasms – Baseline Data from the Daliah Trial

Hasselbalch Riley, A. C.

1594 - NOTCH1 Mutations Are Associated with Therapy-Resistance in Patients with B-Cell Lymphoma Treated with CD20xCD3 Bispecific Antibodies

Hasselkus, R.

4819 - Successful Generation of iPSC-Derived CD4⁺ and CD8⁺ CAR T Cells with Αβ-like T Cell Function, Including Antigen-Dependent Expansion and IL-2 Production

Hassell, K. L.

1116 - Circulating Peripheral Blood Mononuclear Cells from Adults with Sickle Cell Disease (SCD)- Associated Pulmonary Hypertension (PH) Patients Have Increased Iron Content and a Unique Multi-Omic Signature
1143 - Peripheral Blood Macrophages (PBMCs) from Adults with Sickle Cell Disease Have a Unique Phenotype
3874 - Low Dose Clodronate Improves Exercise Tolerance, Right Ventricular Function, and Alters Resident Lung Macrophage Phenotypes

Hassenpflug, W. A.

141 - Recombinant ADAMTS13 Prophylaxis in Pediatric Patients with Congenital Thrombotic Thrombocytopenic Purpura: Results from the Phase 3 Randomized, Crossover Study and the Phase 3b Continuation Study
4002 - Mutation Analysis of the ADAMTS13 Gene in Patients with Congenital Thrombotic Thrombocytopenic Purpura from the rADAMTS13 Phase 3 Study

Hasserjian, R. P.

1830 - Genetic Diversity Drives Differing Morphological and Clinical Presentation and Survival in Myelodysplastic-Type CMML with a Low Absolute Monocyte Count
- The Spectrum of Ph Negative Disease: CNL and CSF3R-Related Disorders

Hasskarl, J.

4311 - IL-1RAP Is a Targetable Surface Antigen in Relapsed/Refractoy AML
2883.2 - Resolve AML 001: An Adaptive Open-Label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of Cctx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients with r/r AML

Hasson, S.

4141 - RGT-61159, Best-in-Class Small Molecule Inhibitor of MYB Via Selective RNA Splicing Alteration, Showed Robust Anti-Tumor Activity across AML Tumor Models Harboring Common Genetic Lesions

Hassoun, H.

248 - Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease
671 - A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma
672 - Immune-MRD Status Informs Tumor-MRD Outcome Prognostication in Multiple Myeloma Patients on Lenalidomide Maintenance
1944 - Impact of Absolute Lymphocyte Count at Pre-Apheresis and Pre-Lymphodepletion on Chimeric Antigen Receptor (CAR)-T Therapy Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)
4735 - Frailty and Outcomes after Bispecific T-Cell Engager Therapy for Patients with Relapsed/Refractory Multiple Myeloma

Hatabah, D.

1122 - Exploring N-Terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) in Children with Sickle Cell Disease (SCD) and Vaso-Occlusive Pain Episodes (VOE)
1123 - Secretory Phospholipase A₂(sPLA₂) in Patients with Sickle Cell Disease (SCD) Hospitalized for Vaso-Occlusive Pain Episodes (VOE)
2518 - Procalcitonin Elevation in Children with Sickle Cell Disease (SCD) Requiring Hospitalization for Acute Vaso-Occlusive Pain (VOE)

Hatakeyama, M.

1850 - Impact of Docirbrutinib (AS-1763) Treatment in CLL: Preclinical Data and Early Clinical Biomarkers

Hatano, K.

3541 - Treatment Outcomes of Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed after Allogeneic Stem Cell Transplant in the Era of Novel Immunochemotherapeutic Agents
4870 - Appropriate Threshold of Quantitative Cytomegalovirus DNA Polymerase Chain Reaction for Preemptive Treatment in Stem Cell Transplant Recipients

Hatchell, N.

5085 - Real-World Clinical Outcomes for Complement Inhibitor Experienced and Naïve Paroxysmal Nocturnal Hemoglobinuria Patients Prescribed Pegcetacoplan in Europe and Canada

Hatcher, J. M.

834 - Development and Characterization of Novel Dual HCK/BTK Bifunctional Protacs That Potently Inhibit Kinase Function and Demonstrate Robust in Vitro and In Vivo Degradation of Targets for the Treatment of MYD88-Mutated B-Cell Malignancies
2972 - Discovery of Undocumented, Cancer-Specific and Pro-Inflammatory Isoforms of WNK2 That Are Highly Expressed in MYD88 Mutated Waldenström’s Macroglobulinemia and Represent Novel Therapeutic Targets.
2986 - Analysis of Alternative Splicing in Waldenstrom’s Macroglobulinemia Reveals Novel Targets, Insights into IgM Production and Improved Gene Level Expression Estimates
4359 - Development and Characterization of a Novel Bifunctional Protac Jh-XIII-05-1 That Shows Potent IRAK1 and IRAK4 Kinase Inhibition and Target Degradation and Is Highly Active in MYD88 Mutated B-Cell Lymphoma Cells Alone and in Combination with BTK- and BCL2- Inhibitors

Hatchi, E.

4105 - STAG2 Mutations Drive Development of Myelodysplastic Syndromes by Promoting R-Loop-Mediated Genomic Instability and Activation of cGAS-STING

Hatic, H.

570 - Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma

Hatsell, S. J.

2473 - TMPRSS6 Inhibition Rapidly Reverses Liver Iron Overload and Prevents an Increase of Splenic Pro-Inflammatory Macrophages in a Mouse Model of Beta-Thalassemia

Hatskovska, V.

4967 - Modulating G-CSFR Signaling Using De Novo Designed Cytokines

Hatta, S.

2534 - RNA Methyltransferase Mettl16 Is Indispensable for the Survival of Naïve CD4⁺ T Cells In Vivo
4037 - Transcription Factor Gata2 Regulates the Myeloid-Lymphoid Fate Decision in Multipotent Progenitors

Hatta, Y.

1426 - Prognostic Factors for T-Cell Acute Lymphoblastic Leukemia in Children and Young Adults: ALL-T11 Study Conducted By Japan Children’s Cancer Group and Japan Adult Leukemia Study Group
2819 - JALSG Ph (-) B-ALL213 Study: Pediatric-Type Chemotherapy Improves Prognosis in Adult Ph-Negative Acute Lymphoblastic Leukemia Patients, Including Older Adults
4925 - The Outcome of Fertility Preservation Strategy in Female Hematopoietic Stem Cell Transplant Recipients of Reproductive Age. Retrospective Study from the Kanto Study Group for Cell Therapy

Hattig, Z. S.

4092 - Germline Variant Burden Warrants Universal Genetic Testing in Pediatric AML

Hatton, R.

4905 - Abatacept and Post Transplant Cyclophosphamide Based Regimen for Graft Versus Host Disease Prevention in High-Risk Stem Cell Transplantation from Unrelated Donor Is Safe and Feasible, with Low Non- Relapse Mortality

Hattori, D.

3090 - Short Diagnosis to Treatment Interval Is Associated with Poor Outcomes in Relapse or Refractory Diffuse Large B-Cell Lymphoma
4459 - Low Immunoglobulin G and Low Lymphocyte-Monocyte Ratio at the End of Treatment Predict Early Progression in Diffuse Large B-Cell Lymphoma

Hattori, H.

2225 - A Novel and Highly-Specific qRT-PCR System for Mutant NPM1 MRD Detection

Hattori, K.

572 - Interim Analysis Data from Multi-Center Retrospective Observational Study of Effectiveness, Safety, and Treatment Status of Tirabrutinib in 161 Japanese Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma: Rosetta Study
741 - Spatially Resolved Single-Cell Transcriptomics of T Cells in Follicular Lymphoma Reveals Distinct Immune Ecosystems

Hatzi, K.

577 - Final Analysis of the Safety and Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma

Hatzieleftheriou, M. I.

3860 - Abrupt Increases in Ferritin Levels May Indicate a Malignant Process and Not Changes in Iron Overload in Thalassemic Patients

Hatzimichael, E.

1991 - Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM Patients with One Prior Line of Lenalidomide-Containing Therapy: A Phase 2 Study of the Greek Myeloma Study Group
4619 - Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study

Hauber, B.

2591 - Patient and Caregiver Preferences for Hemophilia Prophylactic Treatments: A Discrete Choice Experiment

Haubner, A.

3690 - Use of Chronic Blood Transfusion Therapies and Pharmaceutical Disease Modifying Treatments in Sickle Cell Disease: A Retrospective Cohort Analysis (2014-2021)

Hauch, O.

5196 - Indirect Treatment Comparison of Ivosidenib and Other Therapies in Patients with Newly Diagnosed Acute Myeloid Leukemia

Hauck, Q.

3335 - Prevalence and Clinical Implications of Germline Variants in Multiple Myeloma Patients

Hauer, J.

1160 - Immune Training Enhances Anti-Viral Responses and Improves Outcomes in Pax5^-/+ Mice Susceptible to Chronic Infection

Hauer-Jensen, M.

1230 - Enhanced Thrombotic Susceptibility, Endotheliopathy, and Abnormal Cognitive Behavior for up to 5 Months after Sars-Cov-2 Infection in a Mouse Model of Long COVID

Haug, J.

559 - Spatial Transcriptomics Characterize Dynamic and Polarized Niche for Embryonic Hematopoiesis at Single-Cell Level
1306 - Characterization of Multicellular Niches Supporting Hematopoietic Stem Cells within Distinct Zones
4042 - Ex Vivo Expansion of Human Hematopoietic Stem Cells By Mimicking Intrinsic and Extrinsic Factors in Adult Bone Marrow

Haugen, K. L.

2274 - Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy

Haughey, M.

956 - A Highly Selective and Orally Bioavailable CK1α Molecular Glue Degrader Targets B-Cell Lymphoma Cells

Haukås, E.

1988 - Selinexor with Alternating Bortezomib or Lenalidomide Plus Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients (SABLe), Nordic Myeloma Study Group 29/21
4730 - Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study

Haunstrup, T.

1860 - Excellent Clinical Outcomes in Deeply Mutated IGHV Chronic Lymphocytic Leukemia upon Fludarabine and Cyclophosphamide Plus Rituximab

Häupl, B.

152 - The Transcriptional Activators p300/Crebbp Are Context-Dependent Functional Repressors of Interferon Genes, Offering Therapeutic Promise in AML
205 - Posttranslational Changes in Histone Modification Driven By USP48 Loss Increase Sensitivity to Hypomethylating Agents in Acute Myeloid Leukemia
229 - Pathogenesis and Clinical Relevance of Diffuse Large B-Cell Lymphoma Proteogenotypes
433 - Hematopoietic Differentiation from Single Codon Perspective

Hauptrock, B.

776 - Follow-up of the Randomized ASAP Trial Shows No Survival Advantage for Patients with Poor Responsive or Relapsed AML Who Received Intensive Salvage Chemotherapy for Remission Induction Prior to Allogeneic Transplantation Compared to Immediate Allogeneic Transplantation

Hauser, S. L.

3469.1 - A Study of Kyv-101, a CD19 CAR T Cell Therapy, in Participants with Treatment Refractory Progressive Multiple Sclerosis

Havasi, A.

3328 - An International Study of 343 Newly Diagnosed MM Patients with Acute Renal Failure Due to Cast Nephropathy: Assessment of Factors Affecting Renal Response

Havasov, E.

637 - Cross-Talk between Leukemic Blasts and T Cells Drives Targetable T Cell Dysfunction in the AML Tumor Microenvironment

Havenaar, F. R.

1619 - Oncogenic CARD11 Mutations and Autonomous BCR Signaling Act As Functionally Equivalent Alternative Drivers in ABC-DLBCL

Haverkate, N.

2011 - Long-Lasting AML-Specific Antibody Responses after Allogeneic Hematopoietic Progenitor Cell Transplantation

Haverkos, B. M.

982 - Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort
1690 - Asparaginase Treatment Patterns, Toxicity, and Outcomes Among Patients with Extranodal NK/T-Cell Lymphoma: A North American Multicenter Retrospective Cohort Study
4437 - Real-World Treatment Patterns in Patients with Mycosis Fungoides or Sézary Syndrome Treated with Mogamulizumab in the United States: A Retrospective Database Analysis
4510 - Preliminary Safety and Tolerability of CD19x22 CAR-T Cell Therapy in Adolescent and Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Haviland, M.

5136 - Pattern of IgG Testing and Immunoglobulin-Replacement Therapy in Patients with Non-Hodgkin Lymphoma

Havlicek, E.

2629 - Hospital-Acquired Venous Thromboembolism (HA-VTE) Epidemiology and Risk Factors Among Critically Ill Children and Young Adults with Diabetic Ketoacidosis

Havranek, O.

230 - Exploiting TCF3-Driven Oncogenic Circuits in Burkitt Lymphoma
2979 - Vitreous Body Cell Free DNA Sequencing As a Reliable Method for Vitreoretinal Lymphoma Diagnostics

Hawaldar, K.

3944 - Clinical Burden of Illness in Patients with Persistent or Chronic Primary Immune Thrombocytopenia Treated with Advanced Therapies in the United States

Hawk, A.

3899 - Sickle Pain-Related Impact (SPiRIt): A Prospective Study of Impact of Chronic Pain in Sickle Cell Disease
5110 - Association of Race, Ethnicity, and Social Deprivation on the Incidence and Severity of Adverse Events in Induction in Children with Acute Lymphoblastic Leukemia

Hawkes, E. A.

567 - Creation of a Multistate Model to Improve Prognostication across the Disease Course in Advanced Stage Classic Hodgkin Lymphoma (cHL): A Report from the Holistic Consortium
2267 - Toxicity Outcomes in Phase 1 Lymphoma Trials: Variable Reporting with High Use of Minimising Language in Published Abstracts at International Conferences
2359 - Underweight Body Mass Index Is an Independent Risk Factor for Overall Survival in Diffuse Large B-Cell Lymphoma Treated with Rituximab, Prednisolone, Cyclophosphamide, Vincristine, and Doxorubicin: A Lymphoma and Related Diseases Registry Study
3006 - Multiomics Analysis of Paired Diagnosis and Relapse DLBCL Biopsies Shows a Reduction in T Cell Infiltration and Function at Relapse
3019 - Clinical Characteristics and Outcomes of Aggressive Transformation in Splenic Marginal Zone Lymphoma: An International Study of 111 Patients
3080 - Treatment Duration and Risk of Fatal Infections in Patients with B-Cell Non-Hodgkin Lymphoma Achieving Complete Response with Odronextamab
4376 - T Cell CD62L Expression Following Nivolumab Therapy Is Associated with Long Term Response to Rituximab-Nivolumab in Treatment Naïve Follicular Lymphoma: Results from the 1^st FLOR Study
4416 - Practices and Outcomes during a Watch and Wait Approach for Follicular Lymphoma: A Study from the Australasian Lymphoma Alliance
4501 - Preliminary Results of a Phase 1, Dose-Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
5126 - Body Mass Index and Clinical Associations in Australasian Lymphoma Patients: A Lymphoma and Related Diseases Registry Study
5139 - Toxicity Outcomes in Phase 1 Interventional Studies in Plasma Cell Dyscrasias: Heterogeneous Reporting and High Usage of Minimising Language
4502.2 - Australasian Leukaemia & Lymphoma Group NHL32 Block PCNSL: An Open Label Phase II Study of Pembrolizumab Following Chemoimmunotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma - Trial in Progress

Hawkins, A.

3750 - Public Insurance As a Proxy Measure of Household Poverty-Exposures Among Children with Hematologic Malignancies

Hawkins, E.

355 - Direct Visualisation of BCMA Bispecific Antibody and the Myeloma Immune Microenvironment

Hawkins, G.

2050 - Potent Target-Specific Efficacy of CAR T Cells Directed Toward the AML and KMT2A-Rearranged Specific Antigen CLEC2A
3413 - Discovery and Immunotherapeutic Targeting of the Tumor-Specific Target LAMP5 in Acute Myeloid Leukemia
3417 - Effective Dual Targeting of PRAME and WT1 with CD33-Gated ARTEMIS^® Antibody-TCR Platform in Acute Myeloid Leukemia
4793 - Preclinical Efficacy of CD276 (B7-H3) CAR T in Acute Myeloid Leukemia

Hawkins, H.

664 - Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database
3206 - Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome – a Multicenter Retrospective Analysis
3219 - Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database

Hawkins, J.

1268 - Standardized Prophylactic Platelet Transfusion Dose for Infants Decreases Platelet Exposure without Increasing Bleeding or Transfusion Frequency

Hawkins, M.

4506 - Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes after CAR T-Cell Therapy for Lymphoma

Hawkins, P. N.

890 - Defining a New “Mayo Stage IIIc” Ultra Poor Risk Category in Systemic AL Amyloidosis: Incorporating Echocardiographic Global Longitudinal Strain to the European Modified Mayo Staging System
4684 - Prognostication in IgM and Lymphoplasmacytic Lymphoma Associated Systemic AL Amyloidosis

Hawley, N.

784 - Bringing Hematological Malignancy Clinical Trials to Patients: Mayo Clinic LLS Impact Experience

Hawse, W.

2020 - Deletion of AMPK in Human T Cells Decreases Glycolytic Compensation and Severity of Xenogeneic Gvhd without Impairing GVL Potential

Hawula, Z.

3006 - Multiomics Analysis of Paired Diagnosis and Relapse DLBCL Biopsies Shows a Reduction in T Cell Infiltration and Function at Relapse

Hay, A. E.

286 - COVID-19 Humoral Immunity Improves with Third and Subsequent Vaccine Doses in Patients with Plasma Cell Dyscrasias, Particularly in Those Receiving antiCD38 Therapy

Hay, A. M.

3847 - Got Oxygen? the Impact of Band 3 on RBC Function during Exercise

Hayakawa, F.

2819 - JALSG Ph (-) B-ALL213 Study: Pediatric-Type Chemotherapy Improves Prognosis in Adult Ph-Negative Acute Lymphoblastic Leukemia Patients, Including Older Adults

Hayakawa, J.

3123.3 - Trial in Progress: Phase 1/2 Study of Cereblon-Modulating Agent Golcadomide (BMS-986369/CC-99282) in Relapsed or Refractory (R/R) T-Cell Lymphomas (TCLs) (GOLSEEK-3)

Hayani, A.

4204 - A Retrospective Study of Inotuzumab Ozogamicin in Individuals with Down Syndrome and B-Cell Acute Lymphoblastic Leukemia

Hayase, N.

3089 - Real-World Experience of Pola-R-CHP Therapy in Diffuse Large B-Cell Lymphoma Aged 80 or Older

Hayashi, R. J.

2110 - Successful Allogenic Stem Cell Transplantation Using Radiation-Free Reduced Intensity Conditioning in Idiopathic Pediatric Severe Aplastic Anemia - a Single Center Experience

Hayashi, R. J.

313 - Genomic Biomarkers of Poor Outcome in Patients with T-Cell Lymphoblastic Lymphoma
375 - Alemtuzumab, Fludarabine, Melphalan, and Thiotepa As Reduced-Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Inborn Errors of Immunity
2838 - Immunoglobulin Sequencing Biologically Distinguishes B-Lymphoblastic Lymphoma from Acute Lymphoblastic Leukemia and Reveals a Spectrum of Disease Dissemination across Clinical Stages

Hayashida, H.

2725 - ETV6 Contributes to Maintenance of Leukemia Stem Cells in Acute Myeloid Leukemia with High EVI1 Expression
4148 - Statins Kill Acute Myeloid Leukemia Cells through Low-Density Lipoprotein Receptor-Mediated Unfolded Protein Response Activation

Hayashida, M.

2162 - Novel Insights into Predictors, Optimized Treatments, and Prognosis Factors for Virus-Induced Hemorrhagic Cystitis Post-Hematopoietic Stem Cell Transplantation: A Single-Institution Study of 427 Japanese Patients

Hayden, A. R.

574 - Utility of the Central Nervous System International Prognostic Index (CNS-IPI) in Patients with Primary Mediastinal B-Cell Lymphoma Treated with Rituximab-Containing Chemoimmunotherapy

Hayden, C.

3163 - BCR::ABL1 transcript Type Does Not Impact Allogeneic Stem Cell Transplant Outcome in Chronic Myeloid Leukaemia

Hayden, J.

3763 - Design and Methodological Considerations for Real World Data-Derived Progression-Free Survival in Multiple Myeloma

Hayden, P. J.

4733 - Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study

Hayden, P. J.

2379 - Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study

Hayder, N.

822 - Spatial Transcriptomics Identifies Aberrant Communication between Dendritic Cells and Leukemia Stem Cells As a Therapeutically Targetable Axis in Juvenile Myelomonocytic Leukemia
871 - Development of a First-in-Class CAR-T Therapy Against Calreticulin-Mutant Neoplasms and Evaluation in the Relevant Human Tissue Environment
2525 - Constructing a Computational Workflow for the Identification of Novel Cellular and Molecular Drivers of Human Granulopoiesis
2527 - KLF5 Is a Key Regulator of IMiD-Induced Neutropenia

Haydu, J.

1867 - Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)

Hayer, K.

1033 - P2RX5-Directed CAR-T Cells for Genotype-Guided Treatment of Lymphoid and Plasma Cell Malignancies in Patients of African Ancestry
1361 - Targeting HMGA1 Epigenetic Regulators and Downstream ETV5 Pathways with Histone Deacetylase Inhibitors in Combination Therapy for Relapsed, Pediatric B-ALL

Hayer, K.

4170 - PAX5 Loss Compromises CD22 Protein Levels and Responses to Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

Hayes, A.

3915 - HLH: Time to Transplant; A 10-Year UK Retrospective Cohort Study

Hayes, K.

1389 - Decitabine-Venetoclax Treatment Reactivates Endogenous Retrovirus RNA Signaling in AML Cells and Induces T Cell Activation
2766 - Transcriptomic Signature of Resistance to Decitabine/Venetoclax in AML Patients

Hayes, S.

4081 - Population Pharmacokinetics/Pharmacodynamics and Clinical Pharmacology of Zaltenibart (OMS906) in Healthy Subjects and Patients with PNH

Hayes-Lattin, B.

695 - Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702
2292 - Impact of Social Determinants of Health on Access to Blood and Marrow Transplantation for Acute Myeloid Leukemia
2859 - NCAM1 (CD56) As a Predictor of Response to Standard Intensive Induction in Newly Diagnosed Acute Myeloid Leukemia
2887 - Purine-Analog Based Intensive Chemotherapy (IC) Combined with Venetoclax (VEN) Is Highly Active in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
4312 - PTPN11 Mutations Are Associated with Shorter Survival in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax
4314 - Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML

Haylock, A. B.

2798 - Relative Influence of Socioeconomic and Biological Determinants of Outcomes in Adult Acute Lymphoblastic Leukemia

Haymaker, C. L.

455 - An Integrated Spatial, Codex, and Genomic Analysis Predicts Responsiveness and Survival in the Phase II Combination of Pembrolizumab and Romidepsin in PTCL
736 - Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)
1047 - A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
4737 - Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM)

Haymaker, K.

800 - The Amyloidogenic Transthyretin V122I Variant Increase Severity of Cardiac Phenotype and Mortality in Sickle Cell Disease

Hayman, S. R.

83 - Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma
1955 - Impact of Serial Serum Free Light Chain Measurements on Response and Progression Assessments in Multiple Myeloma Patients with Measurable Disease
2274 - Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy
2400 - Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis
3308 - Predictors of Liver Response in Light Chain (AL) Amyloidosis: A Study with 130 Patients
3315 - Impact of Multiple High-Risk Cytogenetic Abnormalities on the Survival Outcomes of Patients with Primary Plasma Cell Leukemia
4695 - Frailty-Based Outcomes with Bispecific Antibodies in Older Patients with Multiple Myeloma
4704 - Flow Cytometry-Based Assessment of the Proportion of Monoclonal Plasma Cells in Synthetic Phase (S-phase) Is an Independent Marker of Adverse Prognosis in Patients with Newly Diagnosed Multiple Myeloma
4711 - Radiomics-Based Biomarkers for Risk Stratification in Newly Diagnosed Multiple Myeloma
4716 - Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma
4728 - Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes
5047 - Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization
5149 - Characteristics and Outcomes of Patients with Second Hematological Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
4685.1 - Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)

Haymart, B.

699 - Treatment Versus Prophylactic Apixaban or Rivaroxaban for Extended Venous Thromboembolic Disease Management

Haynes, A. G.

1120 - Transcriptomic Profiling Supports the Phenotypic Classification of Stable-State Sickle Cell Disease Patients

Haynes, D.

1023 - Tolerability and Clinical Activity of Novel First-in-Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Haynes, E.

3100 - Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications

Haynes, K. A.

4807 - Obesity Attenuates CAR T-Cell Function in Pediatric B-Cell Acute Lymphoblastic Leukemia

Haynes, M.

3474 - Development of Induced Pluripotent Stem Cell-Derived T Cells Exhibiting Phenotypic and Functional Attributes of Primary CAR T Cells

Hayoz, S.

1578 - Clonal Hematopoiesis in Diffuse Large B-Cell Lymphoma: Clinical and Molecular Correlations

Hays, M.

292 - Intranasal Fentanyl and the Impact of an Emergency Department Pain Protocol on Hospital Admission Rates

Hayward, J.

644 - CD19-CD28 (RO7443904) Combination with Glofitamab Enhances T-Cell Proliferation and Effector Function in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)

Hazama, M.

4172 - Therapeutic Repurposing of Brincidofovir in Non-Hodgkin Lymphoma – Potential Synergy with Immune Checkpoint Blockade

Hazar, V.

1444 - Results of the ALL-IC REL 2016 Registry Trial: 1^st Relapses of Childhood ALL Treated in High-Middle Income Countries

Hazelwood, A. R.

202 - In Vivo Genetic Screen Identifies Chromatin Remodeling Gene SET As a Collaborating Oncogenic Driver in Initiation and Maintenance of Acute Lymphoblastic Leukemia

Hazenberg, E.

3884 - Hindsight 20/20: The Role of Hemoglobin F in Sickle Cell Retinopathy

Hazenberg, M. D.

2011 - Long-Lasting AML-Specific Antibody Responses after Allogeneic Hematopoietic Progenitor Cell Transplantation
2379 - Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study
2483 - Alterations in the Immune Phenotype of Adaptive Immune Cells in Sickle Cell Disease: A Conventional and Computational Flow Cytometry Analysis
2643 - Anti-Platelet IgG-Fc Glycosylation As a Novel Regulator in Platelet Transfusion Refractoriness
3527 - Dynamics of Immune Reconstitution in Adults with Sickle Cell Disease Undergoing Nonmyeloablative Matched Sibling Donor Stem Cell Transplantation: A Conventional and Computational Analysis

Hazra, A.

3310 - Soluble BCMA Dynamics in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1
3369 - Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study

Hazra, R.

624 - Heme-Mediated Tau Phosphorylation Is Critical for Neuroaxonal Damage and Cognitive Impairment in Sickle Cell Disease

Hazra, S.

2000.2 - A Phase I/II Study of AZD0305, a Novel Antibody-Drug Conjugate (ADC) Targeting GPRC5D, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

He, A.

2411a - Comparison of Nutritional and Immunological Scoring Systems Predicting Prognosis before Anti-B Cell Maturation Antigen Chimeric Antigen Receptor-T Therapy in Multiple Myeloma, a Retrospective Study Based on Legend-2
3165 - Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

He, A.

3587 - Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel LP-168 (Rocbrutinib) Combinations Targeting BCL-2 Protein Members for Chronic Lymphocytic Leukemia

He, A.

3982 - Factor VIII Coagulant Activity (FVIII:C) As an Independent Predictor of Bleeding across Different Subtypes of Von Willebrand Disease (VWD)

He, B.

839 - Tucidinostat Plus Pediatric-Inspired Chemotherapy As First-Line Therapy for Newly Diagnosed ETP-ALL/Lbl: An Open-Label, Single-Arm, Phase 2 Trial
3412 - IKZF1 Deletion Confers Resistance to CAR19 in r/r B-ALL Via CD19 Intron Retention

He, C.

923 - A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory Multiple Myeloma Including Those with Extramedullary Disease

He, C.

2996 - Spatial Multi-Omics Treatment Paradigms in a Phase II Clinical Study of Early Relapsed/Refractory Diffuse Large B-Cell Lymphoma

He, C.

2699 - KP104, a Bifunctional C5 Mab-Factor H Fusion Protein, Demonstrates Sustained Long-Term Efficacy and Safety in Complement Inhibitor-Naïve PNH Patients: Updated Results from a Phase 2 Study at 36/38 Weeks of Obd Treatment

He, C.

2232 - Targeted Non-Viral Gene Delivery through Transcutaneous Ultrasound Enables Robust, Redosable, Titratable, and Durable FVIII and FIX Gene Expression in the Liver in Murine Models

He, C.

3336 - Identifying 5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA and Treatment Response in Multiple Myeloma with a Multi-Step Machine Learning Approach
4042 - Ex Vivo Expansion of Human Hematopoietic Stem Cells By Mimicking Intrinsic and Extrinsic Factors in Adult Bone Marrow

He, D.

5114 - Overall Survival Associated with Real-World Treatment Sequences in Patients with CLL/SLL in the United States

He, F.

875 - Monocyte-Driven Aberrant Inflammation in Myeloproliferative Neoplasms Is Regulated By Galectin-1
1169 - Altered Calcium Signaling Via STIM1 Drives Aberrant Megakaryopoiesis and Myelofibrosis

He, F.

1387 - An Orally Active Pan-BCR::ABL1 Degrader Tgrx-3247 Potently Targets a Wide Spectrum of Orthosteric, Allosteric and Compound Mutations Resistant to TKI Therapies

He, G.

304 - Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
2687 - Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition
2702 - Torque Teno Viruses Infection Associated with Suboptimal Hematological Recovery of Severe Aplastic Anemia

He, G.

3165 - Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications
3567 - Comparisons between Haploidentical Hematopoietic Stem Cell Transplantation and Eltrombopag Adding to Standard Immunosuppression in Patients with Severe Aplastic Anemia

He, H.

2123 - Intensified Conditioning Containing Decitabine Versus Standard Myeloablative Conditioning for Adult Patients with KMT2A-Rearranged Leukemia: A Multicenter Retrospective Study

He, H.

3940 - Obinutuzumab Is a Promising Alternative for the Treatment of Relapsed or Refractory Autoimmune Hematological Disorders

He, H.

2072 - Autologous B Cell Maturation Antigen (BCMA) and CD19 Dual Targeting Fastcar-T Cells (GC012F/AZD0120) As First-Line Therapy for Elderly Patients with Newly Diagnosed Multiple Myeloma Patients
3451 - GPRC5D-Targeted CAR T-Cell Therapy CT071 for the Treatment of Refractory/Relapsed Multiple Myeloma

He, H.

208 - CBX250 Is a Novel Cathepsin G Peptide-HLA-Targeting T Cell Engager That Exhibits High Tumor Antigen Selectivity and Potent Antileukemic Activity In Vivo
4818 - Cord-Derived Invariant Natural Killer T Cells As Novel Cell Therapy to Improve the Outcome of Hematopoietic Stem Cell Transplantation

He, H.

1050 - Updated Results from a Phase Ⅱ Clinical Trial：Safety and Efficacy of Azacitidine and Chidamide Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia

He, J.

441 - Outcomes of Hematopoietic Stem Cell Transplantation for High-Risk Marrow Features without Malignancy in Shwachman-Diamond Syndrome
2703 - Incidence of Myeloid Malignancy in Shwachman-Diamond Syndrome: An International Cohort Study

He, J.

3594 - AI-Based Fine Morphological Subtyping of Myeloma Single Cells for Predicting FISH Abnormalities

He, J.

4855 - Efficacy and Safety of Single-Dose Versus Split-Dose Mecapegfilgrastim with Etoposide for Autologous Peripheral Blood Stem Cell Mobilization: A Prospective, Randomized Clinical Trial

He, J.

2888 - A Prospective Clinical Study of Venetoclax Plus Azacitidine for the Maintenance Treatment of Post-Remission Acute Myeloid Leukemia

He, J.

4114 - An Aberrantly Overexpressed Short Isoform of TET1 Lacking a DNA Binding Domain Drives Aberrant 5-Hydroxymethylation Marks, Oncogenic Pathways, and Growth in Acute Myeloid Leukemia

He, J.

933 - Real-World Characteristics and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab Step-up Doses in Academic Vs. Community Settings
2392 - Real-World Talquetamab Utilization Patterns and Dose Schedules in the United States: An Analysis Using Claims Data
5157 - Patient Characteristics, Treatment Patterns and Early Outcomes of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Initiated on Talquetamab: An Electronic Medical Record and Chart Review Study

He, J.

482 - Efficacy and Safety of Fedratinib in Patients with Myelofibrosis and Low Baseline Platelet Counts in the Phase 3 Randomized FREEDOM2 Trial

He, L.

1354 - AML Stem Cell Clearance By Inhibiting Selenoprotein Biosynthesis That Causes Cgas-Sting Activation and Ferroptosis
2727 - Modulating mRNA Translation Fidelity As a Novel Mechanism for AML Chemoresistance

He, M.

692 - Immunopeptidome Divergence between Mismatched HLA Haplotypes and Survival after Haploidentical HCT: A Retrospective Study from the CIBMTR
930 - Uncovering the Genetics of Poor and Exceptional Survivorship after Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (HCT)

He, N.

695 - Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702

He, P.

2107 - Efficacy and Safety of Mitoxantrone Hydrochloride Liposome in Combination with Thiotepa-Busulfan-Fludarabine As an Intensive Conditioning Regimen Preceding Salvage Allogeneic Stem Cell Transplantation in Relapsed or Refractory Acute Myeloid Leukemia
4488 - Zanubrutinib Plus R-CHOP (ZR-CHOP) in Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients Who Were Positron Emission Tomography-Positive after Two Cycles of R-CHOP: A Single-Arm, Open-Label, Multicenter Prospective Study

He, P.

3036 - Phase 1 Study of TT-01488, a Novel, Non-Covalent, Reversible BTK Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies

He, Q.

1557 - Uncovering Therapeutic Resistance in BPDCN through Single-Cell Transcriptome Profiling

He, R.

244 - TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance
1797 - The Mutational Landscape of Polycythemia Vera and Its Phenotypic and Prognostic Correlates
2667 - A Clinical Overview of Clonal Cytopenia of Undetermined Significance in the Presence of ZRSR2 Mutations
2686 - DNMT3A Mutant Clonal Hematopoiesis in Vexas Syndrome Epigenetically Potentiates IL-13 and IL-15 Inflammatory Pathways and Is Associated with Increased Mortality
2869 - Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hotspots: A Retrospective Study of 82 Patients
3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
3218 - PPM1D Somatic Mutations in Myeloid Neoplasms: Clinical Profile, Clonal Characteristics and Impact of Concurrent Somatic TP53 Mutations
3291 - Targeting of the CD161 Inhibitory Receptor Enhances Bone Marrow-Resident Memory CD8⁺ T Cell-Mediated Immunity Against Multiple Myeloma
3447 - Long-Term Remission and Survival in Patients with Rituximab-Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Treatment with U16 (CD20 CAR-T cells)
4586 - PHF6 Mutation in Chronic Myelomonocytic Leukemia Is Associated with Chronic Thrombocytopenia and Predicts Superior Overall and Leukemia-Free Survival

He, S.

2753 - Elucidating Transcriptional Heterogeneity in Venetoclax Resistant AMLs

He, T.

1735 - Updated Results from a Multicenter, Phase II Study of Zanubrutinib in Combination with Rituximab and Methotrexate, Followed By Zanubrutinib Maintenance in Patients with Secondary Central Nervous System Lymphoma

He, T. C.

1337 - Evi1 Governs Kdm6b-Mediated Histone Demethylation to Regulate the Laptm4b-Driven mTOR Pathway in Hematopoietic Progenitor Cells

He, W.

3202 - Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Combination with Azacitidine in Treatment of Patients with Myelodysplastic Syndrome (MDS)
4855 - Efficacy and Safety of Single-Dose Versus Split-Dose Mecapegfilgrastim with Etoposide for Autologous Peripheral Blood Stem Cell Mobilization: A Prospective, Randomized Clinical Trial

He, X.

559 - Spatial Transcriptomics Characterize Dynamic and Polarized Niche for Embryonic Hematopoiesis at Single-Cell Level
1062 - Overcoming Immune Escape Via Targeting Akt-Wnt/β-Catenin By Artificial-Intelligence-Powered Peptide-Producing mRNAs
1306 - Characterization of Multicellular Niches Supporting Hematopoietic Stem Cells within Distinct Zones
4042 - Ex Vivo Expansion of Human Hematopoietic Stem Cells By Mimicking Intrinsic and Extrinsic Factors in Adult Bone Marrow

He, X.

4205 - A Phase 2 Clinical Trial of Anti-CD19 CAR-T (pCAR-19B) in Chinese Pediatric and Young Adult with Relapsed/Refractory (R/R) CD19+ B-ALL: The First Pivotal Study in an Asian Population

He, X.

5159 - Comparison of Ixazomib, Lenalidomide Plus Dexamethasone (IRd) and Bortezomib, Lenalidomide Plus Dexamethasone (VRd) in Newly Diagnosed Multiple Myeloma in China

He, X.

2038 - Armored Multivalent CAR-T Cells Targeting BCMA, GPRC5D, and CD38 Eradicate Antigen-Heterogeneous Multiple Myeloma, Address Antigen Escape and Enhance Expansion

He, X.

54 - Targeting PRMT9 Overcomes Venetoclax Resistance in AML By Modulating Splicing and Inhibiting Translation
1398 - High HDAC8 Creates Targetable Vulnerabilities in Acute Myeloid Leukemia through Dysregulation of BRCA1-Related RNA Splicing Machinery and Defective DNA Damage Repair
2738 - Modeling the Initiation and Progression of Human MLL-Rearranged Precursor B Cell Acute Lymphoblastic Leukemia in Mice
3590 - Targeting Cytidine Triphosphate Synthase 1 Promotes Anti-AML Immunity

He, X. D.

2915 - FLT3-ITD Mutation Expands HSPC Compartment to Initiate AML Development

He, X.

971 - Venetoclax and Decitabine Compared with Standard Intensive Chemotherapy As Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia: Updated Results of a Multicenter, Randomized, Phase 2b Trial
3494 - Short-Term Blinatumomab Prior to Allo-HSCT for High-Risk B-ALL

He, Y.

4748 - Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study
4762 - Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

He, Y.

2127 - Efficacy and Safety of a Modified Conditioning Regimen Based on Mitoxantrone Hydrochloride Liposome and Busulfan/Cyclophosphamide for Patients with Refractory and Relapsed Acute Myeloid Leukemia
2828 - Efficacy and Safety of Blinatumomab As Maintenance Therapy in Patients with High-Risk B-Lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation

He, Y.

1028 - A Single-Center, Single-Arm, Phase I Clinical Trial of Anti-BCMA/GPRC5D Bispecific CAR T-Cells in Patients with Refractory and Relapsed Multiple Myeloma with Extramedullary Disease

He, Y.

2899 - A Multicenter Clinical Study of Cccg - APL-2017 in the Treatment of Children with Acute Promyelocytic Leukemia

He, Y.

1413 - Novel Role of Chidamide in Tumor-Associated Macrophages Reprogramming and Immunotherapy Enhancement through RNA Splicing
1675 - The Efficacy and Safty of Chidamide and Azacitidine Combined with Chemotherapy As a First-Line Treatment in T Follicular Helper Lymphomas: A Comprehensive Retrospective Study

He, Y.

10 - In a Mouse Model of β-Thalassemia Intermedia Pregnancy, Maternal Iron Overload and Anemia Adversely Impact Fetal Development Regardless of Fetal Genotype

He, Y.

3573 - A Pragmatic Monitoring Model for Non-Relapse Mortality Risk Based on Machine Learning in Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation
4941 - Favorable Outcomes in Pediatric R/R-ALL Following Immunotherapy with CAR-T and UCB Combined to TCR_αβ-Depleted Haplo-HSCT

He, Y.

2160 - Evaluation of the Real-World Efficacy of Hetrombopag for the Treatment of Thrombocytopenia Post Allogeneic Hematopoietic Stem Cell Transplantation

He, Y.

300 - Effects of Low-Molecular-Weight Heparin on Pregnancy Outcomes in Protein S Deficiency: A Prospective, Randomized Controlled Phase II Clinical
712 - Updated Outcome from Biomarker MSC-C5b-9-Guided All-Trans Retinoic Acid Treatment for Resistant/Recurrent ITP: A Multicenter, Randomized, Open-Label, Phase 3 Clinical Trial
1486 - Clinical Features and Prognostic Nomogram for Therapy-Related Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
3511 - Comparison of Two Conditioning Regimens for Haploidentical Stem Cell Transplantation in Patients with Severe Aplastic Anemia
3703 - Outcome for Mothers and Neonates Among Pregnant Women with Von Willebrand Disease: A Prospective Nationwide Multicenter Study

He, Y.

378 - A Multi-Center Clinical Trial of Allogeneic Hematopoietic Stem Cell Transplants in Transfusion Dependent Thalassemia

He, Y.

263 - Targeting the Hypoxic Microenvironment in Cutaneous Chronic Graft-Versus-Host Disease through PI3Kδ Inhibition
3391 - Tissue-Resident Double Negative T Cells Mediate Salivary Gland Damage in Chronic Oral Graft-Versus-Host Disease

He, Z.

1773 - Analysis of the Impact of TKI Dose Adjustment Under the Guidance of Blood Concentration Monitoring on the Efficacy, Safety and Quality of Life in Patients with CML

He, Z.

2474 - TGF-β1 Reverses Hemoglobin Switching in Erythroid Progenitor Cells before Erythropoietin Induction

Headley, M. B.

905 - Donor XCR1⁺ and CD11b⁺ Dendritic Cells Determine the Severity of Th1 and Th17-Dependent Acute Gvhd within the Gastrointestinal Tract

Healey, A.

2327 - Baseline Characteristics of Individuals with Paroxysmal Nocturnal Hemoglobinuria in an App-Based Home-Reported Outcomes Study to Evaluate Disease Burden

Healton, S. E.

1707 - High Grade B-Cell Lymphoma with MYC/BCL6-Rearrangements (R) May Have Inferior Outcomes Compared to BCL2-R Disease

Healy, J.

1053 - Efficacy and Safety of Giroctocogene Fitelparvovec in Adults with Moderately Severe to Severe Hemophilia Α: Primary Analysis Results from the Phase 3 ΑFFINE Gene Therapy Trial
3575 - Results from the Hemophilia Α Cohort of the Non-Investigational Lead-in Study: Prospective Collection of Bleeding Rate in Participants with Hemophilia Α Prior to Phase 3 Study (AFFINE) of Giroctocogene Fitelparvovec
5082 - Treatment Adherence, Satisfaction and Quality of Life of Adult Patients with Severe Haemophilia a: Results from a Real-World Survey of Physicians and Patients

Healy, S.

2966 - Multiomic Profiling Reveals Pleiotropic Effects of Somatic IRF4-C99R Mutations in Primary Mediastinal Large B-Cell Lymphomas

Heaney, N.

968 - Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial

Hearnden, C.

3080 - Treatment Duration and Risk of Fatal Infections in Patients with B-Cell Non-Hodgkin Lymphoma Achieving Complete Response with Odronextamab

Hearty, C.

933 - Real-World Characteristics and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab Step-up Doses in Academic Vs. Community Settings
3783 - Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes in Black Patients with Multiple Myeloma Treated with Teclistamab
3792g - Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes of Patients with Multiple Myeloma Treated with Teclistamab within Vs. after the First Year of FDA Approval

Heath, J. M.

514 - Prime Editing Enables Precise and Efficient Single Amino Acid Substitutions to Shield CD34+ Hematopoietic Stem Cells from Anti-CD117 Antibody-Based Conditioning

Heath, S. E.

224 - Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

Heavican-Foral, T. B.

1357 - Tet2 Loss and IDH2^R172K Mutation Develop T_FH-Cell-like Lymphoma with Restricted T_H1 Differentiation Program and Cognate Interaction with B Cells

Hebart, H. F.

859 - Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First – Line Treatment for Waldenström’s Macroglobulinemia: Results of the Multicenter Phase II trial (ECWM-2) of the European Consortium for Waldenström’s Macroglobulinemia
4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Hebbard, P.

3635 - Patient Decision Aid for Extended Duration Thromboprophylaxis for Major Abdominopelvic Cancer Surgery: A Usability Study

Heberling, L.

961 - Chemotherapy or Stem Cell Transplantation in Adult High Risk Ph/BCR::ABL1-Negative ALL Patients with Early MRD Negativity: Results of the Randomized GMALL Trial 08/2013

Hébert, A.

298 - Clinical Outcomes of Neonatal Central Line-Related Thrombosis: A Multicentric Retrospective Cohort Study

Hebert, K.

3516 - Five-Year Outcomes of the “Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease (GVHD) Prophylaxis: A Randomized Controlled Trial” (‘ABA2’)
4866 - Expression of HLA-B*35 Is Associated with an Increased Risk of CMV Viremia and Clinically Significant CMV Infection in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation
4885 - Early CMV Viral Load Burden Predicts Late Clinically Significant CMV Infections in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation

Hebert, N.

290 - Oxygen Gradient Ektacytometry Is Associated with Markers of Hemolysis and Inflammation in a Large Sickle Cell Disease Cohort within the GenoMed4ALL Project
1105 - Single Cell Hemoglobin Quantification Reveals HbF and HbS Increases in Sickle Erythrocytes from Patients Treated with Hydroxyurea
4875 - Erythroid-Specific Chimerism Analysis after Allogeneic-Hematopoietic Stem Cell Transplantation Using a Human Leukocyte Antigen-Identical Sibling Donor in Sickle Cell Disease Patients

Hebishy, A.

3555 - Outcomes of Hematopoietic Stem Cell Transplantation in Primary Plasma Cell Leukemia: A Systematic Review and Meta-Analysis

Hecht, A.

3207 - Preliminary Safety and Efficacy of Luspatercept Initiated at Maximum Approved Dose in Patients with Transfusion Dependent Anemia Due to Very Low, Low and Intermediate Risk MDS with Ring Sideroblasts: First Results of the Lusplus Trial

Hecht, E.

1139 - Motivators and Barriers for People with Sickle Cell Disease Participating in Clinical Trials: United States Findings from the Listen Survey

Hecker, J. S.

631 - IDH2 Mutations from Clonal Hematopoiesis and Acquired IKZF1 Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma
895 - Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
2666 - Single Cell Multiomic Analysis of Bone Marrow Hematopoietic Stem/Progenitor Cells from Individuals with Clonal Hematopoiesis Reveals Potential Mechanisms of Anemia Development
2676 - Single-Cell Transcriptomics of Bone Marrow Mesenchymal Stromal Cells Identifies Altered CLCF1 Signaling in DNMT3A-Mutated Clonal Hematopoiesis
4688 - Prevalence and Mutational Make-up of Secondary Hematologic Neoplasms in Multiple Myeloma Patients after CAR-T Cell Therapy

Heckman, C. A.

1548 - Efficacy of the Peptide Drug Conjugates Melflufen and OPDC3 in Venetoclax Resistant Acute Myeloid Leukemia
1560 - Predictors of Response and Rational Combinations for the Novel MCL-1 Inhibitor MIK665 in Acute Myeloid Leukemia
2757 - Integrative Analysis of Transcriptomic and Proteomic Data Identifies Patterns of Primary Resistance to Venetoclax-Azacitidine and Reveals Targetable Vulnerabilities in Acute Myeloid Leukemia (AML)
4648 - Deciphering Variability in Light Chain Amyloidosis and Amyloidosis with Co-Occurring Multiple Myeloma By Single-Cell RNA Sequencing

Hedberg, P.

4634 - Severity of COVID-19 in Individuals with Chronic Lymphocytic Leukemia throughout the Pandemic in Sweden: A Nationwide Multiple Register Cohort Study Conducted from 2020 to 2023

Hedgepeth, E.

2730 - CBL Loss or Mutations Reduces MHCII Expression through Downregulating ERG in Myeloid Malignancies

Hedvat, M.

1408 - JNJ-87801493 (CD20xCD28), a Potential First-in-Class CD20 Targeted CD28 Costimulatory Bispecific Antibody, Enhances the Activity of B-Cell Targeting T-Cell Engagers in Preclinical Models

Heemskerk, M. H.

691 - T-Cell Monitoring for the Recently Expanded Repertoire of HLA Class I-Restricted Minor Histocompatibility Antigens Using Barcoded Peptide-MHC Multimers

Heenan, J.

5147 - Impact of Socioeconomic Status on Utilisation of ASCT and Overall Survival in Multiple Myeloma: A Report from the Australian and New Zealand (ANZ) Myeloma and Related Diseases Registry (ANZ MRDR)

Heeney, M. M.

175 - Individualized, PK-Guided Dosing of Hydroxyurea for Young Children with Sickle Cell Anemia: Final Results from the Hydroxyurea Optimization through Precision Study (HOPS)
180 - Pharmacokinetics/Pharmacodynamics, Safety, and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease Aged 6 to <12 Years: 2-Year Data from the Phase 2 Solace-Kids Study
513 - Initial Results from the BEACON Clinical Study: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease with Severe Vaso-Occlusive Crises

Heerema, N. A.

1564 - Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial
2797 - Examining Disparities By Race, Ethnicity, and Socioeconomic Factors in Children and Young Adults with Relapsed Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
2813 - Utility of a Second Interim Maintenance Phase to Improve Outcomes for Pediatric Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
4324 - Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age
4325 - IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy

Heery, C. R.

1031 - Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial
4825 - Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 34-Month Median Follow-up

Heesen, C.

2073 - CD19-Directed CAR T Cell Therapy in 4 Patients with Refractory Multiple Sclerosis

Heestermans, R.

3312 - Comprehensive (Epi)Genetic Tumor Characterization and Disease Follow-Up in Multiple Myeloma Using Blood-Derived Cell-Free DNA

Hefazi, M.

907 - Caspase-1 Inhibition Ameliorates CAR T-Cell Apoptosis and Tumor Cell Pyroptosis to Enhance the Efficacy and Safety of CAR T-Cell Therapy
908 - Intrinsic Immunosuppressive Features of Monocytes Suppress CART19 through IL-1 Pathway Modulation in Mantle Cell Lymphoma
1798 - Pacritinib Therapy for JAK2 Inhibitor-Naïve or -Experienced Patients with Myelofibrosis: Mayo Clinic Series of 60 Consecutive Patients Treated Outside of Clinical Trials
2852 - Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
2869 - Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hotspots: A Retrospective Study of 82 Patients
4247 - Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
4808 - Identification of T Cell Senescence As a Cell Fate Limiting the Antitumor Activity of 41BB-Costimulated CART Cells
4918 - Risk of Relapse Post Reduced Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with High-Risk Myeloid Neoplasms Based on Ptcy Vs TAC/MTX Gvhd Prophylaxis

Heffernan, T.

153 - Pharmacological Targeting of the Heme-Regulated Inhibitor Kinase Overcomes Ineffective Erythropoiesis in Patients with Myelodysplastic Syndromes with Ringed Sideroblasts and Sickle Cell Disease
208 - CBX250 Is a Novel Cathepsin G Peptide-HLA-Targeting T Cell Engager That Exhibits High Tumor Antigen Selectivity and Potent Antileukemic Activity In Vivo

Hefter, M.

3513 - Omitting Ciprofloxacin Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation Does Not Result in Inferior Outcomes

Hege, K.

709 - Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children

Hegemann, I.

1124 - Large Scale Analysis of the Real-World Association between Fetal Hemoglobin and Vaso-Occlusive Crises in Sickle Cell Disease
2248 - Noninvasive, Accessible, Smartphone App for at-Home Hemoglobin Monitoring in Sickle Cell Disease

Hegenbart, U.

287 - Development of a Risk Prediction Model for 6-Month Early Mortality in Patients with Systemic Light Chain Amyloidosis Treated with Daratumumab-Based Frontline Therapy
4681 - Model for Predicting Day-100 Stem Cell Transplant-Related Mortality in AL Amyloidosis
1927.1 - Expanding the Eureka Study: Integrating a Comprehensive Clinical Registry with Molecular Profiling to Advance AL Amyloidosis Research

Heger, J. M.

367 - Targeting Lymphoma Associated Myeloid-Monocytic Cells through CSF1R Blockade Enhances CAR-T Cell Response in Aggressive B Cell Lymphoma
4355 - Lymphovista HL - a Validated Assay for Genotyping and MRD Assessment in Hodgkin Lymphoma

Heggen, C.

3636 - Uncovering Root Causes Underlying Gaps in the Evaluation and Integration of the Latest Clinical Evidence in Congenital Thrombotic Thrombocytopenic Purpura: Key Findings from a National Hematology Care Team Survey
3679 - Differences in Treatment Decision-Making in Frontline Management of Lower-Risk Myelodysplastic Syndromes between Academic and Community Practice Settings: Results from a Nationwide Survey
5034 - Advancing Patient-Centered Care to Overcome Health Disparities in Multiple Myeloma: Key Findings from a Quality Improvement Initiative
5035 - Collaborative Strategies to Enhance Treatment and Integration of Cellular Therapies in Multiple Myeloma: Results from Nationwide Multiple Myeloma Patient and Provider Surveys

Hehir-Kwa, J. Y.

1459 - Challenging Conventional Diagnostic Methods By Comprehensive Molecular Diagnostics: Results of a Nationwide Prospective Comparison in Children with Acute Lymphoblastic Leukemia

Hei, Y. J.

4135 - An Open-Label, Multicenter, Phase Ib Study of the Anti-TIM3 Monoclonal Antibody BC3402 in Combination with Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Heibl, S.

3793 - Real-World Comparison of Outcomes of Patients Treated with HMA Monotherapy Versus HMA-Ven – Insights from 1634 Patients Included within the Austrian Myeloid Registry of the AGMT Study Group

Heiblig, M.

2079 - Myeloid Neoplasia after CD19 Directed CAR-T Cells : Cumulative Incidence, Risk Factors and Outcome
4275 - Real-World Multicenter Comparison of Venetoclax and Azacitidine Versus Intermediate or High Dose Cytarabine-Based Salvage for Patients with AML in First Relapse after Front Line Intensive Chemotherapy. a Dataml-IPC-Auraml Consortium Study

Heiblig, M.

211 - Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia
227 - Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor Acute Myeloid Leukemia - a Study from the Acute Leukemia French Intergroup
349 - Early Versus Late Onset of ESA in Lower Risk Anemic MDS Patients: Results of the GFM Randomized Phase III EPO-Pretar Trial
846 - Measurable Residual Disease (MRD) Determinants, Kinetics and Its Impact on Survival in Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia in Frontline Setting : A Multicentric Study from French Auraml Group
1475 - Infectious Complications Among Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia: A Multicentric Real-Life Analysis of the French Auraml Group
1518 - Azacitidine and Venetoclax As a Salvage Therapy for Relapse after Allogeneic Transplantation for Acute Myeloid Leukemia : A Multicentric Study from French Auraml Group
2424 - Treatments and Outcomes of Adult Patients with AML in the Real-Life – First Report of the French Observational ALFA-PPP Study
2674 - Clinical Efficacy of Erythroid Stimulating Agent (ESA) and Luspatercept (LUSPA) in Vexas Syndrome with or without Myelodysplastic Syndrome (MDS) : A Multicenter Retrospective Study By the Frenvex Group
3564 - Allogeneic Hematopoietic Cell Transplantation in Newly Diagnosed and Relapse/Refractory AML Patients Post Venetoclax-Azacitidine Treatment: A Multicenter Real-Life Analysis By the French Auraml Group
4312 - PTPN11 Mutations Are Associated with Shorter Survival in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax
4335 - Azacytidine and Venetoclax As a Salvage Therapy in Measurable Residual Disease (MRD) Relapse Post Intensive Chemotherapy or Allogenic Stem Cell Transplantation in Acute Myeloid Leukemia Patients : A Multicentric Study from French Auraml Group

Heide, M.

2957 - High Grade B-Cell Lymphoma with BCL2 and MYC Rearrangement (Double-Hit High-Grade Lymphoma; DH-HGL): Establishment of a Human Model System for Ex Vivo and In Vivo Studies

Heidegger, S. M.

264 - Immunomodulatory Microbial Metabolites Protect Against Graft-Vs-Host Disease and Enhance Anti-Leukemia Responses in Mice and Patients Receiving Stem Cell Transplantation
780 - Recovery of the Intestinal Microbiome in Patients at Day +100 after Allogeneic Stem Cell Transplantation Is Defined By Microbial Metabolite Profiles and Linked to Long-Term Outcomes
4904 - Loss of Microbiota-Derived Metabolites Is Associated with Mucosal-Barrier-Injury Bloodstream Infection in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Heidel, F.

114 - Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma
844 - The Prognostic Impact of Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia with FLT3-ITD Mutations
3383 - Idecabtagene Vicleucel (ide-cel) Shows Similar Efficacy and Toxicity in Patients with Multiple Myeloma Aged 70 and Older Compared to Younger Patients: A Multicenter Cohort Study

Heidel, F. H.

52 - Overcoming Ven/Aza Resistance through Imetelstat-Mediated Lipophagy in Acute Myeloid Leukemia
242 - Revised ELN Criteria in Polycythemia Vera Identify an Increased Risk Phenotype for Thrombotic Events Beyond Conventional Risk Stratification. a Multicenter Cooperative Study
406 - Intraindividual Comparison of Recognition of Symptom Burden in MPN between Patient- and Physician-Reported Assessment and Its Impact on Survival – an Analysis By the German Study Group for MPN (GSG-MPN)
847 - Prognostic Impact of Subclinical FLT3-ITD Microclones in Patients with Acute Myeloid Leukemia
1090 - Reliable Assessment of Iron Deficiency in Patients with Myeloproliferative Neoplasms through Fluorescence Spectroscopy-Based Measurement of Zinc Protoporphyrin (ZPP)
1348 - CSF3R^T618I Is Stabilized By Calnexin and Induces Unfolded Protein Response (UPR) and ER-Phagy: A Pro-Survival Pathway for Oncogenic Misfolded CSF3R Proteins in Chronic Neutrophilic Leukemia (CNL)
2951 - Prognostic Role of NGS-Based MRD Assessment in FLT3-TKD Mutated Patients with Acute Myeloid Leukemia
2956 - Intra-Tumor Heterogeneity in Core-Binding Factor Acute Myeloid Leukemia
3147 - Chronic Kidney Dysfunction Induced By Jak2V617F-Mediated Mesangiolysis
4519 - The Histone Methyltransferase DOT1L Cooperates with LSD1 to Control Cell Division in Blast-Phase MPN
1808.2 - POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Heidel, R. E.

1910 - Preliminary Observations Using 99m-Tc-Peptide p5+14 for the Detection of AL Amyloidosis Using SPECT/CT and Planar Gamma Scintigraphic Imaging
4641 - Characterization of AT02 Bioactivity and an Assessment of Its Potential Use As an Amyloid-Clearing Therapeutic for AL Amyloidosis

Heidenreich, O.

2199 - Optimization of Targeted Lipid Nanoparticle for the Treatment of RUNX1::ETO Driven AML
4062 - Characterizing the Bone Marrow Stromal Niche in Pediatric Acute Myeloid Leukemia
4963 - The Nanoparticle-Mediated Delivery of Therapeutic Sirnas Targeting the KMT2A::Afdn Fusion Gene in AML

Heidenreich, O.

1299 - Single-Cell Dissection of the B-ALL Niche Reveals Distinct Mesenchymal Stromal Cell Subtypes with Differential Leukemic Cell Support and Relapse Implications

Heidenreich, S.

3547 - Early Tapering of Immunosuppression in MRD Positive Myelofibrosis Patients Induces Molecular Response and Excellent Outcome after Hematopoietic Stem Cell Transplantation

Heidmann, J. C.

1759 - Intense Monitoring of JAK2V617F and Wild-Type Hematopoiesis during IFNα Exposure to Dissect Its Mechanism of Action
2668 - Distinct Effects of Cigarette Smoke and e-Cigarette Aerosols on Inflammation and Stem Cell Proliferation in Clonal Hematopoiesis
3134 - Uncovering Non-Canonical Signalling Mediated By JAK2V617F in Myeloproliferative Neoplasms
4058 - Leveraging Clonal Competition between Chip and Aggressive Malignant Clones As a Novel Therapeutic Approach

Height, S.

2237 - Utilising Patient-Reported Experience Measures to Drive Healthcare Improvements: The Application of Validated PREM Survey Tools in a Haemoglobinopathy Network in South London

Heikamp, E.

825 - The Histone Acetyltransferase MOZ (KAT6A) Is a Molecular Dependency and Therapeutic Target in NUP98-Rearranged Acute Myeloid Leukemia
4162 - Transient Menin Inhibition Is Sufficient to Induce Irreversible Polycomb-Mediated Silencing and Potent Anti-Proliferative Effects in MLL-Rearranged AML

Heiland, D. H.

856 - Modulation of the Tumor Microenvironment By CCL19 in Primary CNS Lymphomas
4374 - The Effect of Ibrutinib on the Myeloid Cell Compartment in Central Nervous System Lymphoma Slice Cultures

Heilmeier, B.

364 - Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
769 - Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)

Heilpern-Mallory, D.

155 - Pharmacological Targeting of IRF4 As a Therapeutic Strategy for Multiple Myeloma
1903 - Comprehensive Characterization of the Plasma Proteome of Multiple Myeloma and Its Precursor Conditions and Identification of a Proteomic Signature to Improve Risk Prediction of Disease Progression

Heimall, J.

3639 - International Clinical Consensus on Leukocyte Adhesion Deficiency-I: A Modified Delphi Analysis

Heimbruch, K. E.

1064 - Defining the Impacts of Iron Overload in Children Receiving Hematopoietic Stem Cell Transplantation for Non-Malignant Hematologic Disorders: A Multicenter Analysis

Heimlich, J. B.

4577 - Bone Marrow Spatial Multi-Omics Identifies Reduced Interactions between Hematopoietic Stem Cells and Myeloid Cells in Myelodysplastic Syndrome

Hein, N.

1408 - JNJ-87801493 (CD20xCD28), a Potential First-in-Class CD20 Targeted CD28 Costimulatory Bispecific Antibody, Enhances the Activity of B-Cell Targeting T-Cell Engagers in Preclinical Models

Heine, A.

4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Heinicke, T.

840 - Update on GMALL Trial 08/2013 Shows Durable Favorable Outcome of Newly Diagnosed Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) with Imatinib, Dose-Reduced Induction Followed By Stem Cell Transplantation
4945 - Prognostic Impact of t(9;11) and Del(7q) As Intermediate-Risk Abnormalities in AML Following Allo-Transplant: Insights from the ELN 2022 Classification – an EBMT ALWP Study

Heinrich, M. C.

1765 - Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial

Heinrich, P.

264 - Immunomodulatory Microbial Metabolites Protect Against Graft-Vs-Host Disease and Enhance Anti-Leukemia Responses in Mice and Patients Receiving Stem Cell Transplantation

Heinze, D.

4819 - Successful Generation of iPSC-Derived CD4⁺ and CD8⁺ CAR T Cells with Αβ-like T Cell Function, Including Antigen-Dependent Expansion and IL-2 Production

Heiser, D.

2774 - Selective SMARCA2 Degradation Promotes Leukemic Differentiation and Synergizes with CDK9 Inhibition to Potently Induce Death in Pre-Clinical Models of Acute Myeloid Leukemia
3215 - Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies

Heiss, J. D.

3122 - Phase 1 Study of Escalating Doses of Ibrutinib in Teddi-R with Isavuconazole for Relapsed and Refractory Primary DLBCL of the CNS

Heissigerova, J.

2979 - Vitreous Body Cell Free DNA Sequencing As a Reliable Method for Vitreoretinal Lymphoma Diagnostics

Heisterkamp, N.

625 - Mitochondrial RNA Methylation By METTL17 Rewires Metabolism and Regulates Retrograde Mitochondrial-Nuclear Communication in AML

Heitmann, J. S.

1406 - Perforin-Induced Killing in Leukemic Cells Is Driven By NFAT2-Mediated Cytoskeletal Remodeling
1504.1 - Trial in Progress: Phase I Trial Evaluating an Immunopeptidome-Defined Multi-Peptide Vaccine Against Acute Myeloid Leukemia Stem and Progenitor Cells
2883.1 - A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of Cln‑049 for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease

Heitmeier, S.

3988 - Treatment with a Novel Small Molecule Dual Factor IIa/Xa Inhibitor Protects Against Coagulopathy and Organ Dysfunction in a Baboon Model of Staphylococcus Aureus Sepsis

Hejab, A.

4231 - Saudi Acute Myeloid Leukaemia (AML) Genome Reveals Significant Differences from That in the Western Population
4536 - Evaluating the Safety and Efficacy of Tyrosine Kinase Inhibitors in Pregnant Patients with Chronic Myeloid Leukemia: A Comprehensive 15-Year Single-Center Study

Hejazi, A.

2627 - Comparison of Riete and Some Scores for Predicting Cancer in Unprovoked Thrombosis

Hejmadi, S.

1494 - Exploring the Burden of Acute Myeloid Leukemia Attributable to Smoking in G20 Countries: A Three-Decade Analysis from the Gbd 2021
3095 - Global Burden and Trend of Burkitt Lymphoma in 38 OECD Countries from 1990-2021: A Benchmarking Global Analysis for the Gbd 2021

Helbich, S. S.

2536 - Deep Cellular and Molecular Characterization Reveal a Distinct Phenotype and Metabolic Signature of Human Senescent CD8⁺ T Cells: Implication for Cancer Cellular Therapy

Helbig, G.

399 - Hematopoietic Stem Cell Transplantation in Hepatosplenic T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
970 - A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) – Topline Results

Helbig, G.

305 - Improved Outcomes in Paroxysmal Nocturnal Hemoglobinuria Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in 2011-2020: A Retrospective EBMT-Saawp Study
4949 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Neoplasms with Accompanying Paroxysmal Nocturnal Hemoglobinuria – a Study on Behalf of Cmwp and Saawp of the EBMT

Helble, J.

208 - CBX250 Is a Novel Cathepsin G Peptide-HLA-Targeting T Cell Engager That Exhibits High Tumor Antigen Selectivity and Potent Antileukemic Activity In Vivo

Helby, J.

1087 - Risk of Fractures in Individuals with Hemochromatosis HFE C282Y Homozygosity and in Individuals with Low or High Levels of Plasma Iron, Transferrin Saturation, or Ferritin: A Prospective Study of 142,146 General Population Individuals
3334 - Absolute Risk of Multiple Myeloma Is Quite Modest in Individuals with Incidentally Discovered Vertebral Fractures: A Prospective Cohort Study of 9,065 CT-Scanned Danish General Population Individuals with Independent Validation in a UK General Population Cohort
3831 - Satisfy: A Eurobloodnet Multicenter, Single-Arm Phase 2 Trial of Mitapivat in Adult Patients with Erythrocyte Membranopathies and Congenital Dyserythropoietic Anemia Type II – Results from the 8-Week Dose-Escalation Period

Held, G.

4383 - Immune Cell Infiltration Impacts Chemotherapy Efficacy in B-NHL
4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Held, J.

1074 - RBC eNOS Regulates O₂ Delivery Phenotype during Circulatory Transit Via Control of Intracellular pH
2453 - Oxygen Responsive Myosin Activation Governs Oscillatory Piezo1 Signaling in RBCs during Circulatory Transit

Held, L. M.

4383 - Immune Cell Infiltration Impacts Chemotherapy Efficacy in B-NHL

Held, N. M.

5173 - CNS Status at Diagnosis Can Identify Acute Myeloid Leukemia Patients with Poor Induction Outcomes

Helfand, A.

4245 - Epidemiology, Outcomes, and Healthcare Utilization in Acute Myeloid Leukemia: A Study Using the National Inpatient Sample - 2021

Hélias-Rodzewicz, Z.

3908 - Prognostic Value of BRAFV600E in Peripheral Blood of Children with Langerhans Cell Histiocytosis: A Multicenter Project of the European Consortium for Histiocytosis

Hellemann, G. S.

801 - Evaluating High-Sensitivity Troponin Levels in Patients with Sickle Cell Disease Presenting to the Emergency Department

Hellenbrand, D.

1174 - The Use of ATP-Release Identifies Platelet Function Disorders in Patients with Bleeding Disorder of Unknown Cause (BDUC) and Normal LTA Results

Hellewell, E. M.

2170 - Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

Hellmich, C.

1893 - Age-Associated Macrophage Polarization to an M2 Phenotype Drives Myeloma Proliferation in the Aged Bone Marrow By Loss of Tumor-Associated Phagocytosis
4113 - Repolarisation of M2 Macrophages Via Cgas-Sting Activation Enhances Phagocytosis of Acute Myeloid Leukaemia

Hellmuth, A. S.

417 - Autosomal Recessive COPZ1 Mutations Cause Isolated Severe Neutropenia or Complex Syndrome with Severe Neutropenia

Hellmuth, J. C.

568 - PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial
4796 - Dissection of Single-Cell Landscapes for the Development of Chimeric Antigen Receptor T Cells in Hodgkin Lymphoma

Hellstrom Lindberg, E.

27 - Stable Contribution of Lineage-Restricted Stem Cells to Steady-State Aged Human Hematopoiesis
1830 - Genetic Diversity Drives Differing Morphological and Clinical Presentation and Survival in Myelodysplastic-Type CMML with a Low Absolute Monocyte Count
2358 - Improving Quality of Life Based on Electronic Patient Reported Outcomes in Patients with CLL and MDS: The Mypal Study
3198 - Large-Scale Transcriptome Analysis Supports Genomic Taxonomy and Predicts Response to Hypomethylating Agents in Myelodysplastic Neoplasms

Hellström, M.

1623 - Plasma Proteomic Profiling Identifies Prognostic Biomarkers in Mantle Cell Lymphoma
2995 - Rule-Based Machine Learning Analysis of the Blood Proteome Identifies MCL Patients with High Risk of Early Disease Progression
4370 - Plasma Proteomics Differentiates between Patients with B-Cell Lymphomas

Hellwig, D.

4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Helm, D.

1563 - ACSL4-Associated Lipid Metabolism Is a Distinct Therapeutic Vulnerability in KMT2A-Rearranged Acute Myeloid Leukemia

Helma, J.

1392 - Potent Activity of Duocarmyin- and Mmaf-Conjugated FLT3-Directed Antibody-Drug Conjugates Towards Acute Myeloid Leukemia Stem Cells in Vitro and In Vivo

Helms, W.

2785 - LY4152199, a First-in-Class BAFF-RxCD3 Bispecific Antibody for the Treatment of B Cell Malignancies

Helmstädter, M.

1298 - SPARC Stabilizes Integrin α4-VCAM-1 Interactions and Is Regulated By Intracellular Rac in NPM1-Mutated AML

Helmy, R.

4461 - Use of Doxorubicin-Containing Regimens Is Not Associated with Hemolytic Complications in Severely G6PD Deficient Patients with Lymphoma

Helou, Y.

4819 - Successful Generation of iPSC-Derived CD4⁺ and CD8⁺ CAR T Cells with Αβ-like T Cell Function, Including Antigen-Dependent Expansion and IL-2 Production

Helton, N.

1333 - Recurrent Amplification of Chromosome 7 in Murine AML with Dnmt3a^R878H and Npm1^cA Mutations Identifies Gab2 As a Possible Therapeutic Target in AML
4100 - VISTA As a Mediator of Immune Suppression in AML Initiated By DNMT3A and NPM1 mutations

Hem, J.

872 - Mutation-Specific Differences in the Relationship between Obesity and Clonal Hematopoiesis, with a Focus on JAK2^V617F and MPN Prevention

Hemani, H.

2051 - Deciphering the Impact of Immunological Aging in CLL CAR T Cell Therapy

Hemann, M.

4265.2 - A Multi-Site Break through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress)

Hematti, P.

2102 - Outcomes after Matched Sibling Donor Versus Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis
3289 - Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment
3448 - Phase 1 Study of Trispecific Anti-CD20, Anti-CD19, Anti-CD22 (CAR20.19.22) T Cells for Relapsed, Refractory B-Cell Malignancies
3459 - Cytogenetic Abnormalities Following CAR T Cell Therapy for B-Cell Malignancies
4791 - Activation-Inducible Bispecific BCMA-CD24 CAR-T Cells Precisely and Safely Control Multiple Myeloma Growth

Hembree, M.

1062 - Overcoming Immune Escape Via Targeting Akt-Wnt/β-Catenin By Artificial-Intelligence-Powered Peptide-Producing mRNAs
1306 - Characterization of Multicellular Niches Supporting Hematopoietic Stem Cells within Distinct Zones

Hemmaway, C.

845 - Impact of Cytogenetics, Induction Chemotherapy and MRD on Outcomes of Intensively Treated AML with KMT2A Rearrangements – Experience from UK NCRI AML17 and AML19

Hemmer, M. V.

733 - Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial

Hemmer, M. T.

609 - Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Henaoui, I.

4952.1 - MO-TRANS: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study of Mocravimod (MOC) As Adjunctive and Maintenance Treatment in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Henden, A. S.

3006 - Multiomics Analysis of Paired Diagnosis and Relapse DLBCL Biopsies Shows a Reduction in T Cell Infiltration and Function at Relapse

Henderson, A. M.

2597 - Medical and Surgical Management for Heavy Menstrual Bleeding in Women with Ehlers-Danlos Syndrome

Henderson, I.

1847 - Single-Cell Transcriptional Characteristics of the Unresponsive Cluster Surviving Anergy in IGHV1-69 CLL

Henderson, J.

643 - Comprehensive Characterization and Validation of the Tumor Microenvironment in Patients with Relapsed/Refractory Large B-Cell Lymphoma Identifies Subgroups with Greatest Benefit from CD19 CAR T-Cell Therapy
4373 - Generation of a Patient Derived T-Cell Prolymphocytic Leukemia Xenograft Model to Evaluate Pre-Clinical Treatment with Small Molecule Inhibitors In Vivo
4377 - Radiation Therapy and Monocyte Activation in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy
1674.3 - Interim PET-Adapted De-Escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Safety and Efficacy Study

Henderson, J.

4680 - Epidemiological Characteristics and Clinical Outcomes of Patients with Monoclonal Gammopathy of Renal Significance (MGRS) Diagnosed in a Large Safety-Net Hospital in the US

Henderson, L.

2134.1 - Trial in Progress: Cureaa - a Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) #2207

Henderson, R.

4445 - Delays to Diagnosis of Peripheral T-Cell Lymphoma and Clinical Utility of Molecular Profiling: A UK Multicentre Real-World Study

Henderson, T. O.

1429 - Clinical Implications of Treatment-Related Clonal Hematopoiesis in Adolescent and Young Adult Survivors of Acute Lymphoblastic Leukemia

Hendricks, J.

2429 - Understanding Barriers to Hematopoietic Cell Transplant (HCT) Access: Socio-Demographic Characteristics and Area Deprivation Index (ADI) of Patients Referred to the National Institutes of Health (NIH) for HCT

Hendricks, R. M.

444 - Genome-First Determination of the Prevalence and Penetrance of Eight Germline Myeloid Malignancy Predisposition Genes: A Study of Two Population-Based Cohorts

Hendrickson, S.

1842 - Results of a Phase I/II Study of Tagraxofusp in Combination with Decitabine for Patients with Myelodysplastic/Myeloproliferative Neoplasms and Higher Risk Myelodysplastic Syndromes

Hendrie, P. C.

4288 - Phase I Trial Combining Venetoclax with Cladribine, Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) for Patients with Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms

Hendrix, L.

4430 - Risk of Hematologic Malignancy Following Infectious Mononucleosis Caused By Epstein-Barr Virus: A Danish and Swedish Observational Study over 40 Years

Hendrix, M.

4780 - ER Stress Sensor PERK Boosts T Cell Pathogenicity in Gvhd through Regulating ERAD

Hendrix, R.

4232 - Intranasal Corticosteroid Use and Risk of Invasive Fungal Sinusitis in Acute Myeloid Leukemia, Myelodysplastic Syndrome and Post Transplant Patients

Hendry, E. A.

3682 - Ketamine Use in Hospitalized Children and Young Adults with Sickle Cell Disease

Heneghan, M. M.

4187 - Retrospective Cohort Analysis of Response and Survival of Children, Adolescents, and Young Adults (CAYA) with Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoma (T-LL) Treated with Curative Intent: A TACL Consortium Study
2828.1 - Trial in Progress: Update on the TACL T2020-003 Randomized Phase 2 Trial to Improve Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL-2)

Heng, K. K.

3529 - Haploidentical Transplant Using Selective Ex-vivo TCR-Αβ Depleted and Upfront Memory T-Cell Add-Back Is Associated with Lower Chronic Gvhd and More Favorable Gvhd-Free/Relapse-Free Survival As Compared to Matched Related and Unrelated Donor Transplant for Adults with Hematological Malignancies

Henia, M.

1912 - Incidence and Prevalence of Clinically Detected Smoldering Multiple Myeloma Among the General Population

Henig, I.

608 - Comparable Outcomes of Point-of-Care and Commercial CD19 CAR-T Therapies: A Patient-Matched Analysis in Large B-Cell Lymphoma
1748 - Reduction in Platelet Counts May Predict the Development of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma
3482 - The Ability of Currently Used Scoring Systems to Predict 30 and 100-Days Non-Relapse Mortality Among Older Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
4269 - For Patients with Adverse-Risk Acute Myeloid Leukemia, Frontline FLAG Ida with Venetoclax Is Safe and Efficacious

Henikoff, S.

2028 - Prediction of Therapeutic Potential of CD19 CAR-T Cells for LBCL By Histone Mark Analyses of Core Epigenetic Programming

Henkin, S.

811 - The AI-Mayo PE (AIM PE) Study: Validation of an Artificial Intelligence Algorithm Using Electrocardiograms to Predict Pulmonary Emboli

Hennessy, F.

5075 - Health-Related Quality of Life, Work Productivity and Activity Impairment, and Fatigue in Patients with Idiopathic or Lymphocytic Hypereosinophilic Syndrome: A Real-World Survey

Hennessy, K.

1097 - Donor Trait Status Determines Haematological Outcomes Post-Haemopoietic Stem Cell Transplantation in Transfusion Dependent Thalassaemia Independent of HLA Matching and Chimerism Status
3518 - Abatacept Abrogates the Risk of Acute GvHD in Both Matched and Mismatched Transplantation for Haemoglobinopathies and Bone Marrow Failure

Hennessy, M.

2821 - Ponatinib Monotherapy after Combination with Chemotherapy in Patients with Newly Diagnosed Ph+ ALL: Post Hoc Subgroup Analysis of the Phase 3 Phallcon Study

Henrich, J.

1275 - Ribosomal RNA Transcription Is Differentially Regulated Across the Hematopoietic Tree

Henrick, P.

4433 - Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors

Henriksson, C.

2556 - Patients with Immune Thrombocytopenia Have Higher Proportion of Ultra Large VWF Multimers and Lower ADAMTS13 Activity Than Healthy Controls

Henry, C.

11 - PORT-77, a Novel and Potent Inhibitor of ABCG2, Protects Against Skin Photo Toxicity and Liver Damage in a Mouse Model of Erythropoietic Protoporphyria (EPP)

Henry, C. J.

4807 - Obesity Attenuates CAR T-Cell Function in Pediatric B-Cell Acute Lymphoblastic Leukemia

Henry, D. H.

1270 - Tolerance of Anemia: Autologous Stem Cell Transplantation Among Bloodless Medicine Patients Can be Safely Conducted at Lower Hemoglobin Thresholds
3709 - Inhibitors Significantly Impair Quality of Life for Hemophilia a Patients
5107 - Barriers to CAR-T Therapy Adoption: Comparing Access in Academic and Community Settings in the US

Henry, M.

531 - Real-World Generalizability of Clinical Trial Cytomolecular Features By Race and Ethnicity in Pediatric Acute Myeloid Leukemia (AML)
4208 - Safety and Feasibility of Blinatumomab As Frontline Therapy for Pediatric Patients with B-Acute Lymphoblastic Leukemia and Lymphoma: St. Jude Total Therapy Study XVII

Hensch, L.

820 - Transcription Factor Programming of Human iPSC-Derived Sinusoidal Vascular Endothelial Cells Enhances Co-Cultured Hematopoietic Stem and Progenitor Cell Transplantation
2043 - Generation of Functional iPSC-Derived CAR-T Cells for Cancer Immunotherapy Via G9a/GLP Inhibition

Hensel, M.

84 - Impact of Clonal Heterogeneity in Newly Diagnosed, Transplant-Eligible Multiple Myeloma – Subgroup Analysis of the GMMG HD6 Phase III Trial
1963 - Quality of Life in the Multicenter, Randomized, Phase 3 GMMG-HD6 Trial Applying Elotuzumab, Lenalidomide, Bortezomib and Dexaemethason in Patients with Newly-Diagnosed Multiple Myeloma

Henskens, Y.

1174 - The Use of ATP-Release Identifies Platelet Function Disorders in Patients with Bleeding Disorder of Unknown Cause (BDUC) and Normal LTA Results
2251 - Health Related Quality of Life (HrQoL) in Patients with Bleeding Disorder of Unknown Cause (BDUC)

Hensley, C.

3926 - Large Scale Manufacturing of GMP Grade Cord Blood Derived Megakaryocytes for Chemotherapy Induced Thrombocytopenia

Hensley, E.

1136 - How to Lose an App in 10 Days: Exploring Digital Health Engagement in Sickle Cell Disease
3898 - Exploring Differences in Hospital Readmissions in Patients with Sickle Cell Disease By Examining Patterns with mHealth-Acquired Pain and Physiologic Data

Hentemann, M.

1373 - Identifying ‘Druggable’ Targets and Preclinically Overcoming Non-Genetic/Adaptive Resistance to Menin Inhibitors in AML with MLL1r or mtNPM1

Hentgen, V.

1117 - Autoimmune and Inflammatory Diseases in Children with Sickle Cell Disease: A French Multicenter Observational Study on Diagnostic and Therapeutic Issues

Hentschel, H.

90 - Affinity-Tuned T-Cell Engager for Dual Targeting of B-Myeloid Mixed-Phenotype Acute Leukemia (B-MPAL)

Hentze, M.

9 - Inflammation-Driven NFκB Signaling Represses Ferroportin Transcription in Macrophages Via HDAC 1 and 3

Heo, B.

3557 - The Expression of TIM3 on Marrow-Infiltrating T Cells Is Increased in Patients with Blood Cancers Who Relapse Early after Hematopoietic Stem Cell Transplantation

Heo, D. S.

3102 - Spectrum: Phase II Study of Tislelizumab Plus Pemetrexed in Patients with Relapsed or Refractory (R/R) Primary Diffuse Large B-Cell Lymphoma (DLBCL) of the Central Nervous System (CNS): The Korean Cancer Study Group LY22-07

Heo, S. G.

1898 - Single-Cell RNA Sequencing of Circulating Myeloma Cells: Clinical Implications in Times of Immunotherapies

Hepzhibah, J.

3078 - Impact of Consolidation Radiotherapy in Bulky Diffuse Large B Cell Lymphoma By PET Based Response Assessment

Heras, I.

598 - HCT-Adapted ELN 2022 Risk Classification: Validation of a Very Poor Risk Group (Adverse-Plus) in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)
2108 - Impact of Ptcy on Early Cardiac Toxicity after HLA-Matched Allo-HCT in Patients with Acute Myeloid Leukemia. Study on Behalf of the Grupo Español De Trasplante Hematopoyético y Terapia Celular (GETH-TC)
3531 - Current Prophylaxis and Treatment of Gvhd: Analysis of a Large Real-World Cohort. Spanish Group of Hematopoietic Transplantation and Cellular Therapy (GETH/TC)
3565 - Allogeneic Stem Cell Transplantation As Consolidation Therapy in Patients with Relapsed-Refractory B-Cell Lymphoma Exposed to Bispecific Antibodies: A Study on Behalf of Grupo Español De Transplante y Terapia Celular (GETH-TC)
4884 - Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation in a Spanish Multicenter Cohort on Behalf of Geth

Heravi, O.

5170g - Multiple Myeloma (MM) Clinical Characteristics, Prognostic Factors and Survival in Adolescents and Young Adults (AYA)

Herbaux, C.

239 - Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy: A Descar-T Study By Lysa Group
469 - Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes
577 - Final Analysis of the Safety and Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma
748 - Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)
1657 - 5-y Follow-up of Combination of Ibrutinib, Obinutuzumab and Venetoclax for Patients with Newly Diagnosed Mantle Cell Lymphoma, the Oasis Trial
4479 - Valemetostat Monotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma: Primary Results of the Phase 2 Valym Study from the Lysa

Herbert, K.

582 - A Randomized Phase 2, Investigator-Led Trial of Glofitamab-R-CHOP or Glofitamab-Polatuzumab Vedotin-R-CHP (COALITION) in Younger Patients with High Burden, High-Risk Large B-Cell Lymphoma Demonstrates Safety, Uncompromised Chemotherapy Intensity, a High Rate of Durable Remissions, and Unique FDG-PET Response Characteristics

Herbreteau, L.

528 - Hemophagocytic Lymphohistiocytosis-like Syndrome after Anti-CD19 CAR T-Cells for B-Cell Lymphoma and B-Cell Acute Lymphoblastic Leukemia: A Lysa, Sfce and Graall Study from the Descar-T Registry

Hercus, C.

2224 - Unraveling Immunogenomic Features Germane to Pathobiology of Myelodysplastic Syndromes

Heredia Cano, A.

4401 - Impact of Bone Marrow Evaluation Using Bone Marrow Biopsy, Flow Cytometry, and PET/CT in B-Cell Non-Hodgkin Lymphomas

Herek, T. A.

1357 - Tet2 Loss and IDH2^R172K Mutation Develop T_FH-Cell-like Lymphoma with Restricted T_H1 Differentiation Program and Cognate Interaction with B Cells

Hergalant, S.

2224 - Unraveling Immunogenomic Features Germane to Pathobiology of Myelodysplastic Syndromes
3174 - DNA Methylation Profiling Reveals Multiple Hits in MAPK Pathway in Triple Negative MDS/MPN with SF3B1 Mutation and Thrombocytosis

Hergott, C. B.

188 - In Vivo barcoded CRISPR-Cas9 Screen Identifies Ncoa4-mediated Ferritinophagy As a Dependence in Tet2-Deficient Haemopoiesis
4060 - Loss of Negative Metabolic Feedback Drives TET2 Mutant Inflammation

Herhaus, P.

780 - Recovery of the Intestinal Microbiome in Patients at Day +100 after Allogeneic Stem Cell Transplantation Is Defined By Microbial Metabolite Profiles and Linked to Long-Term Outcomes
3513 - Omitting Ciprofloxacin Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation Does Not Result in Inferior Outcomes
4904 - Loss of Microbiota-Derived Metabolites Is Associated with Mucosal-Barrier-Injury Bloodstream Infection in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Herishanu, Y.

1862 - Phase II Prospective Trial of Fixed Duration Obinutuzumab, Ibrutinib and, Venetoclax in an Elderly Cohort of Patients with Richter's Syndrome-Givers Regimen

Herishanu, Y.

4504 - CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia

Heritage, T.

2395 - Frontline Treatment Patterns in Patients with Newly Diagnosed Multiple Myeloma - Real-World Evidence from a Large Community-Based Oncology Practice Network in the US

Héritier, S.

3908 - Prognostic Value of BRAFV600E in Peripheral Blood of Children with Langerhans Cell Histiocytosis: A Multicenter Project of the European Consortium for Histiocytosis

Heritier, S.

548 - Adolescents and Young Adults with Secondary Chronic Immune Thrombocytopenia: A Switzerland/France Collaboration Project

Heritier, S.

303 - Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve Severe Aplastic Anemia: Results of the Diaamond-Ava-First Trial
1318 - Cellular and Cell-Free Genomic Characterization of Patients Receiving Avatrombopag and Immunosuppressive Therapy for Treatment-Naïve Severe Aplastic Anemia

Herledan, C.

3667 - Impact of Health Literacy in Hematology Outpatients Receiving Oral Anticancer Drugs and Followed By the Oncoral Multidisciplinary City-Hospital Educational Follow-up

Herlin, M. K.

322 - Comparison of the WHO and ICC Classifications of Cytogenetic Abnormalities in Childhood Acute Myeloid Leukemia

Herling, C.

2094 - Cellular Composition and Clinical Factors Influencing Manufacturing Outcomes for Anti-BCMA CAR T Cell Therapy in a Large Real-World Cohort of Relapsed/Refractory Multiple Myeloma
2158 - CT-Based Muscle Quality and Visceral Obesity Prior to Allogeneic Hematopoietic Stem Cell Transplantation Is of Prognostic Relevance in Patients with Acute Myeloid Leukemia
4334 - Measurable Residual Disease Detection of IDH1 or IDH2 Mutations Post but Not Prior to Allogeneic Hematopoietic Stem Cell Transplantation Show High Prognostic Relevance in Patients with Acute Myeloid Leukemia

Herling, M.

1877 - The Differences between Ide-Cel and Cilta-Cel in Relapsed Myeloma at Single Cell Resolution
2158 - CT-Based Muscle Quality and Visceral Obesity Prior to Allogeneic Hematopoietic Stem Cell Transplantation Is of Prognostic Relevance in Patients with Acute Myeloid Leukemia
4334 - Measurable Residual Disease Detection of IDH1 or IDH2 Mutations Post but Not Prior to Allogeneic Hematopoietic Stem Cell Transplantation Show High Prognostic Relevance in Patients with Acute Myeloid Leukemia

Herman, A.

172 - A Novel Small Molecule Drug-Based Approach for Treating Beta-Globinopathies

Herman, D.

2668 - Distinct Effects of Cigarette Smoke and e-Cigarette Aerosols on Inflammation and Stem Cell Proliferation in Clonal Hematopoiesis

Herman, M.

2100 - Preclinical Proof of Concept for Decentralized Manufacturing of a MAGE-A4/CD8alpha-Expressing Autologous T-Cell Therapy for Solid Tumors

Hermange, G.

752 - Amplification of Von Willebrand Factor-Positive CALR^mut Disease-Initiating Hematopoietic Stem Cells Is Associated to the Activation of the PERK/EiF2a Branch of Unfolded Protein Response

Hermann, A.

3265 - Characterization of Linvoseltamab’s BCMA Binding Epitope and Efficacy Against BCMA Mutations in Relapsed/Refractory Multiple Myeloma
3283 - A CD38xCD28 Costimulatory Bispecific Antibody Demonstrates Potent Preclinical Combinatorial Activity with a BCMAxCD3 T Cell-Engager

Hermans, C.

719 - Association between Hemophilia Joint Health Score and Quality of Life Using Results from the Xtend-1 Efanesoctocog Alfa Phase 3 Trial
1205 - Impact of Emicizumab on Mental Liberation in Adult Patients with Severe and Moderate Factor VIII Deficiency
1212 - Mim8 Prophylaxis Beyond Bleeding: Investigating Multifaceted, Patient-Reported Outcomes for Hemophilia A in the FRONTIER2 Study
2636 - Levels, Determinants and Predictive Value of D-Dimer in Patients on Long-Term Direct Oral Anticoagulant for Venous Thrombo-Embolic Disease

Hermans, C.

3972 - Pain Reduction Following Treatment of Bleeding Episodes with Eptacog Beta in Adults and Adolescents with Hemophilia A or B Complicated By Inhibitors

Hermans, I.

2067 - A Phase 1 Dose Escalation and Expansion Trial of Third-Generation CD19-Directed CAR T-Cells Incorporating CD28 and Toll-like Receptor 2 (TLR2) Co-Stimulation for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (ENABLE-1)

Hermans, J.

4005 - The Quest for Effective and Well-Tolerated Treatment for Congenital TTP: Half a Century of Experience in the United Kingdom

Hermansen, E.

4730 - Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study

Hermine, O.

2793 - APR-246 Overcomes Resistance to Asparaginase in Lymphoid Malignancies By Targeting Metabolic Cell Vulnerabilities
3656 - Real-World Practice Patterns of Patient Management in the Peri-CAR T-Cell Therapy Setting for Patients with Mantle Cell Lymphoma: An International Survey on Behalf of the EBMT Lymphoma Working Party

Hermine, O.

36 - Vexas Syndrome Is a New Cause of p53-Mediated Erythroblastopenia
239 - Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy: A Descar-T Study By Lysa Group
621 - Rap-536, a Murine Luspatercept Analog Ameliorates Anemia and Vaso-Occlusion in Experimental Model of Sickle Cell Disease
1496 - Results of a Phase 1, First-in-Human Study of INA03, an Anti-CD71 Antibody-Drug Conjugate in Patients with Relapsed or Refractory (R/R) Acute Leukemias
1596 - Predictive Power of Early, Sequential Minimal Residual Disease and Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Monitoring in Young Patients with Mantle Cell Lymphoma in the Lyma Trial: A Lysa Study
1608 - Modeling NK-Cell Lymphoma in Mice Reveals Cell-of-Origin, Microenvironment, and Therapeutic Targets
2286 - Reducing Infection Risks of Anti-BCMA Bispecific Antibodies in Multiple Myeloma: In-Hospital Vs. Hospital-at-Home Treatment
2486 - Inhibition of the Complement Alternative Pathway Attenuates Hemolysis and Preserves Renal Function in a Mouse Model of Sickle Cell Disease
3839 - Protein S Enhances the Phagocytosis of Phosphatidylserine-Positive Erythrocyte: Implications for the Erythrocytes Turnover
3842 - Hereditary Erythrocytosis: Results from Europe's Largest Idiopathic Erythrocytosis Database
3870 - Complement Activation and Its Implication in the Pathophysiology of Hemolytic Anemia and Aging in Mouse Models of Sickle Cell Disease and Beta-Thalassemia
4343 - Inflammatory Waldenström Macroglobulinemia Is Associated with Clonal Hematopoiesis: A Multicentric Cohort
4360 - Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network
4950 - Outcome of Patients with HTLV-1 Adult T-Cell Leukemia/Lymphoma (ATL) after Allogeneic SCT: Results of the EBMT LWP
5141 - Infection Risk and Efficacy of Anti-BCMA Bispecific Antibodies in Multiple Myeloma: A Real-World Propensity Score-Matched Study
4422.3 - Trials in Progress: Carman - an International, Randomized Phase II Study Evaluating Early Treatment Intensification in Patients with High Risk Mantle Cell Lymphoma Using CAR-T-Cell Treatment after an Abbreviated Induction Therapy with Rituximab and Ibrutinib and 6 Months Ibrutinib Maintenance (Arm A) As Compared to Standard of Care Induction and Maintenance (Arm B)
4569.1 - Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis
- Ineffective Erythropoiesis in Thalassemia and Sickle Cell Disease

Hermiston, M. L.

313 - Genomic Biomarkers of Poor Outcome in Patients with T-Cell Lymphoblastic Lymphoma
2817 - Role of B Cell Recovery in Relapse Risk and CD19 Phenotype Following Real-World Use of Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia: A Multi-Institutional Retrospective Study
2838 - Immunoglobulin Sequencing Biologically Distinguishes B-Lymphoblastic Lymphoma from Acute Lymphoblastic Leukemia and Reveals a Spectrum of Disease Dissemination across Clinical Stages
4187 - Retrospective Cohort Analysis of Response and Survival of Children, Adolescents, and Young Adults (CAYA) with Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoma (T-LL) Treated with Curative Intent: A TACL Consortium Study
2828.1 - Trial in Progress: Update on the TACL T2020-003 Randomized Phase 2 Trial to Improve Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL-2)

Hermosín, L.

597 - Donor Cell-Derived Hematologic Neoplasms: Role of Germline Predisposition and Clonal Hematopoiesis

Herms, L.

2410 - Real-World Utilization of Bispecific Antibodies for Treatment of Relapsed/Refractory Multiple Myeloma in the US Community Oncology Setting
3094 - Trends in Real-World Characteristics and Outcomes of Patients with Diffuse Large B-Cell Lymphoma Treated in the US Community Oncology Setting Pre- and Post-CAR-T Approvals

Hernáez Arrazola, M.

1889 - Mapping Disease Transitions from Premalignant, Asymptomatic to Advanced Myeloma through Integrative Epigenomic and Transcriptional Analyses

Hernaez, M.

670 - An IFNγ-Mediated Immune Inflamed Microenvironment State in Multiple Myeloma with TP53 Loss That Can be Therapeutically Exploited
879 - Unveiling ZMAT2 and SMARCD3 As Therapeutic Targets to Mitigate Aberrant Hematopoiesis in MDS
4798 - Molecular Mechanisms Promoting Long-Term Cytopenia after BCMA CAR-T Therapy in Multiple Myeloma

Hernandez, A.

1718 - Using Polatuzumab Plus Chemotherapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real-World Study from the Grupo De Estudio De Linfoproliferativos De Latinoamerica (GELL)
3718 - Uncovering the Epidemiology, Therapy Patterns and Outcomes of MALT Lymphoma in Latin America: A Multinational Retrospective Cohort Study

Hernandez Alvarez, B.

417 - Autosomal Recessive COPZ1 Mutations Cause Isolated Severe Neutropenia or Complex Syndrome with Severe Neutropenia
4967 - Modulating G-CSFR Signaling Using De Novo Designed Cytokines

Hernandez Boluda, J. C.

241 - Prognostic Value of Response to First-Line Hydroxyurea According to Ipset Stratification in Essential Thrombocythemia
1790 - Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia
3558 - Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques
3559 - Impact of Donor Type on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis
4894 - Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT

Hernandez, B.

2492 - Long-Term Therapy with GBT021601 and Moderate Chronic Transfusion Therapy Prevent the Development of Hyperalgesia
4956 - Rheological Comparison of Red Cells from Individuals with SCD Treated with Gene Therapy, Haploidentical Transplantation or Hydroxyurea

Hernandez, C.

4244 - Does Time Matter from Diagnosis to Induction in Acute Myeloid Leukemia?

Hernandez, C.

482 - Efficacy and Safety of Fedratinib in Patients with Myelofibrosis and Low Baseline Platelet Counts in the Phase 3 Randomized FREEDOM2 Trial

Hernandez Flores, I.

1431 - Premature Immune Aging in Survivors of Childhood Hematologic Malignancies

Hernandez, F. M.

597 - Donor Cell-Derived Hematologic Neoplasms: Role of Germline Predisposition and Clonal Hematopoiesis
3049 - The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin’s Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

Hernández Garcia, M. T.

365 - Clinical Value of Peripheral Residual Disease (PRD) and Measurable Residual Disease (MRD) in Newly Diagnosed Elderly Patients in the GEM2017FIT Trial
489 - Reevaluating the IMWG Multiple Myeloma Complete Response Criterion in the Era of Mass Spectrometry: A Critical Analysis
678 - GEM2017Fit Phase 3 Trial in Fit Elderly Patients (Aged 65-80) with Newly Diagnosed Myeloma: Impact of Daratumumab at Induction and/or Consolidation
3374 - Survival Improvement of Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma in Two Consecutive Randomized Phase III Trials: Long-Term Follow up of GEM05 and GEM12 Trials

Hernandez, G.

2547 - Declining Autophagic Flux Underlies Mitochondrial and Platelet Defects in Aging

Hernandez, M.

3718 - Uncovering the Epidemiology, Therapy Patterns and Outcomes of MALT Lymphoma in Latin America: A Multinational Retrospective Cohort Study

Hernandez, M. T.

1957 - Unraveling Long-Term Survival of Multiple Myeloma Patients, the GEM2000 Experience

Hernandez Parets, D. E.

2781 - The Cyclin-G Associated Kinase (GAK) Is a Critical Targetable Dependency for Successful Mitosis By Diffuse Large B-Cell Lymphomas Linked to Retinoblastoma Loss of Function

Hernandez Rivas, J. M.

844 - The Prognostic Impact of Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia with FLT3-ITD Mutations
898 - Early Relapse in Patients with Newly-Diagnosed Multiple Myeloma: A European Myeloma Network/Harmony Alliance Analysis Including 10843 Patients
962 - Prognostic Impact of the Genetic Risk at Baseline Associated to the MRD Clearance in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Preliminary Results of Pethema LAL19 Trial
1437 - Similar Outcome of Adolescents and Young Adults (AYA) and Older Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) without Philadelphia Chromosome (Ph-) Included in the Pethema LAL-2019 Trial
2226 - Development and Validation of Novel Machine Learning-Based Risk Scores for Multiple Myeloma: Insights from the Harmony Alliance Big Data Platform
2844 - Dissecting the Role of Acquired Regions of Homozygosity Detected By Microarray Along the Genome of a Large Cohort of Adult Patients with B-Cell Precursor Acute Lymphoblastic Leukemia
- Panel Discussion: Real World Experience with Establishing Registries and Reporting Results (Panelist 1)

Hernandez Rivas, J. A.

1871 - First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis
3254 - Initiating First-Line (1L) Fixed-Duration (FD) Ibrutinib and Venetoclax (Ibr+Ven) in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Improves Overall Survival (OS) Outcomes to Rates Approximating an Age-Matched General European Population
4403 - Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study
4422 - Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance?
5164 - Real-World Evidence of First-Line Therapy in Transplant Eligible Multiple Myeloma Patients: Insights from the Cimma Study

Hernandez, R.

2555 - Early Treatment Use of Fostamatinib for Immune Thrombocytopenia (ITP): Efficacy and Safety As Second/Third ITP Treatment Lines in Clinical Practice in Spain
4390 - Determining Outcome in IgM Gammopathies: Integration of Molecular, Flow Cytometry and Clinical Factors in an International, Multicenter Series (the SAL-TO Study)

Hernández Sánchez, A.

790 - Independent, International Validation and Refinement of a Machine Learning Algorithm to Classify Acute Leukemia Using Routine Laboratory Features
844 - The Prognostic Impact of Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia with FLT3-ITD Mutations
962 - Prognostic Impact of the Genetic Risk at Baseline Associated to the MRD Clearance in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Preliminary Results of Pethema LAL19 Trial
2844 - Dissecting the Role of Acquired Regions of Homozygosity Detected By Microarray Along the Genome of a Large Cohort of Adult Patients with B-Cell Precursor Acute Lymphoblastic Leukemia

Hernández Santamaría, T.

1790 - Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

Hernandez, S.

2046 - Nonclinical Toxicology, Biodistribution, and Pharmacokinetics of UB-VV111, an In Vivo Anti-CD19 CAR T Cell Therapy

Hernandez Woodbine, M. J.

2407 - Cytomegalovirus Infections Following CAR T-Cell Therapy: A Systematic Review and Meta-Analysis

Hernandez-Collazo, Y.

2131 - A Phase II Study of Low Dose Melphalan with Thiotepa and Fludarabine As Preparative Regimen for Alternative Donor Transplantation

Hernández-Díaz, P.

2096 - Assessing CAR-T Cell Product Quality: The Crucial Role of Metabolic and Persistence Analysis after Antigen Stimulation

Hernandez-Ilizaliturri, F.

72 - Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study
78 - Multiomic Evaluation of Immunologic Changes in Chronic Lymphocytic Leukemia with Venetoclax Treatment
111 - Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study
861 - Iopofosine I 131 in Previously Treated Patients with Waldenstrom Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM)
1036 - Transcriptomic Analysis of αCD19 CAR T Cells Reveals Venetoclax-Induced Changes in T Cell Quality and Function
3053 - Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma
3409 - Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL
3453 - A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001) and Orthogonal IL-2 (STK-009) in Subjects with Relapsed or Refractory CD19 Expressing Hematologic Malignancies (NCT05665062)
4392 - Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis

Hernandez-Ilizaliturri, F.

3642 - Impact of Rapid Latex Immunoassay (LIA) Implementation on Management of Heparin Induced Thrombocytopenia (HIT): A Retrospective Single Institution Study

Hernández-Navarro, A. K.

4030 - Reassessing Blood Product Irradiation in Haploidentical Transplantation: A Single-Center Perspective

Hernandez-Rivas, J. A.

4619 - Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study

Hernández-Sánchez, A.

597 - Donor Cell-Derived Hematologic Neoplasms: Role of Germline Predisposition and Clonal Hematopoiesis
1437 - Similar Outcome of Adolescents and Young Adults (AYA) and Older Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) without Philadelphia Chromosome (Ph-) Included in the Pethema LAL-2019 Trial

Hernandez-Sanchez, M.

3414 - Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate

Hernando Megido, A.

1790 - Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

Hernando, T.

2005 - Efficacy of Carvykti in Cartitude-4 Versus Other Conventional Treatment Regimens for Lenalidomide-Refractory Multiple Myeloma Patients Using Inverse Probability of Treatment Weighting
3390 - Updated Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2–4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Hernani, R.

471 - Site-Specific Analysis of Extranodal Involvement Reveals Distinct Efficacy Outcomes with CAR T-Cell Therapy in Large B-Cell Lymphoma Patients

Hernanz Soler, N.

3159 - Characteristics of Pediatric and Adolescents and Young Adults (AYA) with Chronic Myeloid Leukemia: Data from the Canarian Registry of CML

Herold, S.

3042.2 - Trial in Progress: A Phase II Trial to Investigate Venetoclax in Combination with Ibrutinib and Rituximab or Conventional Chemoimmunotherapy (Bendamustine and Rituximab) and Ibrutinib in Patients with Treatment-Naive Mantle Cell Lymphoma Not Eligible for High-Dose Therapy – MCL Elderly III
4422.3 - Trials in Progress: Carman - an International, Randomized Phase II Study Evaluating Early Treatment Intensification in Patients with High Risk Mantle Cell Lymphoma Using CAR-T-Cell Treatment after an Abbreviated Induction Therapy with Rituximab and Ibrutinib and 6 Months Ibrutinib Maintenance (Arm A) As Compared to Standard of Care Induction and Maintenance (Arm B)

Herold, T.

918 - CSF1R Targeting T Cell Engaging Bispecific Antibodies Enable Safe and Efficient Immunotherapies in Acute Myeloid Leukemia
2934 - The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients

Heron, S.

2063 - Optimizing Chimeric Antigen Receptor Endodomains for Effector Function and Cell Expansion in iPSC-Derived T-Cell Therapies

Herr, A.

2614 - Phase 1, 3-Sequence Interaction Study of Intravenous Vlx-1005 and Argatroban Shows a Favorable Safety, Pharmacokinetic and Pharmacodynamic Profile in Healthy Volunteers

Herr, M. M.

473 - Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma
525 - Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis
612 - Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy
897 - Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
934 - Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
936 - Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
3337 - Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab
3445 - Influence of Myeloma Cell Expressed CD28 and CD86 on BCMA CAR T Cell Efficacy and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS)
3765 - Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
4712 - Efficacy of Stem Cell Boost (SCB) for Chimeric Antigen Receptor T Cell (CAR-T)-Related Hematologic Toxicity in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)- a Multi-Center Real World Experience

Herr, W.

264 - Immunomodulatory Microbial Metabolites Protect Against Graft-Vs-Host Disease and Enhance Anti-Leukemia Responses in Mice and Patients Receiving Stem Cell Transplantation
780 - Recovery of the Intestinal Microbiome in Patients at Day +100 after Allogeneic Stem Cell Transplantation Is Defined By Microbial Metabolite Profiles and Linked to Long-Term Outcomes
3402 - Allogeneic Hematopoietic Cell Transplantation Promotes Atherosclerosis in Mice Driven By Donor CD8+ T Cells
4904 - Loss of Microbiota-Derived Metabolites Is Associated with Mucosal-Barrier-Injury Bloodstream Infection in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
4917 - Developing Evidence-Based Guidelines for Optimal Patient Communication Prior and Post Allogeneic Stem Cell Transplantation

Herrera, A. F.

459 - A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma
469 - Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes
470 - Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
526 - Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
947 - Clonal Hematopoiesis Is Associated with Non-Myeloid Subsequent Malignant Neoplasms after Autologous Hematopoietic Cell Transplantation
1668 - Brentuximab Vedotin-Based Regimens for Older Patients with Newly Diagnosed Classical Hodgkin Lymphoma – International, Multi-Center Real-World Experience
2976 - HIV-Associated Diffuse Large B-Cell Lymphoma Shows Different Genomic Patterns between EBV-Positive and EBV-Negative Tumors
3534 - Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Vs-Host Disease and Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation: A Case-Control Propensity Matching Analysis
4484 - Final Update of Safety, Efficacy and T-Cell Predictive Biomarkers from a Phase I Trial of Copanlisib+Nivolumab in Patients with Richter’s Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)
1674.1 - Trial in Progress: Open-Label Phase 1 Study to Evaluate Safety of SGN-35C in Adults with Select Relapsed/Refractory Lymphomas (SGN35C-001)
1718.1 - SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)
1742.1 - A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
3132.1 - ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy
4434.2 - CTEP 10590, NORM: Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase II Trial with Either Rituximab or Mosunetuzumab
- Creating a Laboratory and Clinical Research Program From Scratch

Herrera, B.

1850 - Impact of Docirbrutinib (AS-1763) Treatment in CLL: Preclinical Data and Early Clinical Biomarkers

Herrera, D.

3884 - Hindsight 20/20: The Role of Hemoglobin F in Sickle Cell Retinopathy

Herrera de Pablo, E.

1790 - Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

Herrera, F.

1790 - Real-World Outcomes of Momelotinib As an Alternative Therapy to Other JAK Inhibitors in Myelofibrosis Patients with Anemia

Herrera, I.

189 - The High Mobility Group A1 (HMGA1) Chromatin Regulator Induces Inflammatory Signals and Promotes Atherogenesis in Tet2 Mutant Clonal Hematopoiesis

Herrera, M.

1677 - Long-Term Outcomes with Mogamulizumab Alone or in Combination with Other Therapies for the Treatment of Cutaneous T-Cell Lymphoma

Herrera, P.

1512 - Final Results of Quiwi: A Double Blinded, Randomized Pethema Trial Comparing Standard Chemotherapy Plus Quizartinib Versus Placebo in Adult Patients with Newly Diagnosed FLT3-ITD Negative AML
2895 - Correlation of ELN-Risk and Gene Mutations with Quizartinib Efficacy in Patients with FLT3-ITD–Negative Newly Diagnosed Acute Myeloid Leukemia in the Phase 2 Quiwi Pethema Trial
3491 - Clinical Impact of Colonization By Multi-Drug Resistant Organisms in Stem Cell Transplantation

Herrera Puente, P.

1552 - Enhanced Validation of the FLT3-like Gene Expression Signature As a Predictive Biomarker for Quizartinib Response in FLT3-ITD Negative Acute Myeloid Leukemia: Expanded Cohort and Extended Follow-up from the Pethema Quiwi Trial
2874 - A Multicenter, Prospective, Non-Randomized, Phase I-II Trial to Asses the Efficacy and Safety of the Combination or Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
4986 - A Cutting-Edge Bioinformatics Tool for Neoantigen Identification in Unpaired RNA-Seq Samples of AML

Herrera Robles, K.

4000 - External Validation of the French Score in Thrombotic Microangiopathies: Real-World Experience in a Large Retrospective Cohort of 1483 Patients

Herrero, J.

669 - Tumour-Intrinsic Features Shape T-Cell Differentiation through Myeloma Disease Evolution
1283 - Statin Therapy Is Associated with Reduced Clonal Expansion in TET2 Mutated Clonal Haematopoiesis of Indeterminate Potential

Herrick, J.

2515 - Defibrotide Reduces Hypercoagulable State in Patients with Sickle Cell Disease-Related Acute Chest Syndrome (IND 127812)

Herring, K. W.

2422 - Treatment Experience of Patients with Acute Myeloid Leukemia in the Era of Novel Therapies: A Longitudinal Electronic Patient-Reported Outcomes Study

Herrmann, A.

4917 - Developing Evidence-Based Guidelines for Optimal Patient Communication Prior and Post Allogeneic Stem Cell Transplantation

Herrmann, M. D.

108 - Deep Learning Predicts Risk of Large B-Cell Lymphoma Progression upon R-CHOP Therapy from Baseline Histology

Herrscher, R.

4556 - Updated Efficacy and Safety Results of Patients Receiving Selected 100mg Bezuclastinib Dose and Participating in the Open-Label Extension of Summit: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis

Herruzo, B.

3757 - Frailty's Impact on CAR T-Cell Therapy Outcomes in Patients with Lymphoprolipherative Disorders: Insights from a Spanish Multicenter Pilot Study Conducted on Behalf of the Geth-CT

Hersch, M.

4580 - Dual Bclxl and BCL2 Inhibition with Navitoclax (NAV), Venetoclax (VEN), and Decitabine (DEC) for Advanced Myeloid Neoplasms (MN): Safety and Biological Activity in a Phase 1 Study

Herschleb, J.

4976 - Blood Preservation Workflows for Single Cell Technologies Using Off-the-Shelf Reagents

Hershenfeld, S. A.

5093 - Timing of End-of-Treatment PET Scans and Impact on Subsequent Testing in Diffuse Large B-Cell Lymphoma

Hershkovitz-Rokah, O.

3288 - Targeting the PI3K/AKT Pathway and Fatty Acid Synthase in AL Amyloidosis: Mechanistic Insights and Therapeutic Implications

Hershman, D. L.

5042 - Association between Food Insecurity, Financial Toxicity, and Healthcare Utilization in Patients with Lymphoma

Herskovitz, A. Z.

4992 - Deep Learning-Driven 24-Hour Mortality Risk Assessment through Peripheral Blood Smear Morphology in Hospitalized Cancer Patients

Hertenstein, B.

568 - PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial

Herter, S.

990 - Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072
2990 - Evaluation of Anti-Tumor Activity and Impact on T Cell Activation of Glofitamab in Combination with Gemcitabine and Oxaliplatin (Glofit-GemOx)
4180 - Integrated Quantitative Clinical Pharmacology Analysis Identifies Optimal Englumafusp Alfa Dose Range for Proof-of-Concept Study with Glofitamab in Second-Line Large B-Cell Lymphoma Patients

Hertlein, E. K.

1396 - A Randomized Placebo-Controlled Phase 1 Trial in Healthy Volunteers Investigating the Safety, Pharmacokinetics and Pharmacodynamics of a Novel FLT3/IRAK4 Inhibitor, Lomonitinib (ZE46-0134)
2663 - MYD88 Is Mutated in Clonal Hematopoiesis and Drives Altered Immune Cell Populations
2783 - Development of ZE66-0205, a Novel MALT1 Degrader for Treatment of B-Cell Malignancies

Hertzberg, M. S.

3223 - Clinical Response to Azacitidine in Myelodysplastic Neoplasms Is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor Cells In Vivo

Hertzberg, M. S.

582 - A Randomized Phase 2, Investigator-Led Trial of Glofitamab-R-CHOP or Glofitamab-Polatuzumab Vedotin-R-CHP (COALITION) in Younger Patients with High Burden, High-Risk Large B-Cell Lymphoma Demonstrates Safety, Uncompromised Chemotherapy Intensity, a High Rate of Durable Remissions, and Unique FDG-PET Response Characteristics
865 - Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study

Herzberg, F.

1460 - Data-Informed, Refined Immunophenotypic Classification of Adult T-Lineage Acute Lymphoblastic Leukemia

Herzog, R. W.

2573 - A Novel Hemophilia a Mouse Model Shows Expression of a Fluorescent Reporter Under the Endogenous F8 promoter in Subsets of Liver and Kidney Endothelial Cells

Heshmati, Y.

515 - In Vivo HSC Gene Editing for Correction of the Sickle Cell Mutation Using RNA Gene Writers
2197 - Delivery of Gene Writers In Vivo to Hematopoietic Stem Cells and T Cells Using Targeted and Untargeted Lipid Nanoparticles (LNP)
4799 - Targeted Lipid Nanoparticle Delivery of an RNA Gene Writer In Vivo Enables Generation of CAR-T Cells in a Humanized Mouse Model

Heskel, M.

2325 - Disparities in the Diagnostic Evaluation of Asymptomatic “Neutropenia” and Identification of Duffy-Null Phenotype

Heslip, S.

2291 - Using the Serious Illness Conversation Guide (SICG) in Patients with Hematological Malignancies As a Tool to Address Their Perspectives on Palliative Care
3670 - The Serious Illness Conversation Guide Is Meaningful to Patients with Hematologic Malignancies and Impacts Death in Acute Care

Heslop, H. E.

5131 - Statins May Improve Outcomes and Toxicities in Patients Undergoing CD19-Specific CAR T-Cell Therapy for Aggressive B-Cell Lymphomas

Hess, B.

460 - Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early-Stage Classical Hodgkin Lymphoma
473 - Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma
525 - Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis
612 - Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy
2350 - Practical Implications of Multi-Institution Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity (ICANS) Rates in Lymphoma Targeted Bispecific Antibodies (BsAb)

Hess, G.

748 - Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)
1645 - Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II
4394 - Real World Patient Diagnostic and Treatment Patterns in Marginal Zone Lymphoma (MZL): First Results of the Prospective National MZL Registry of the German Lymphoma Alliance
3042.2 - Trial in Progress: A Phase II Trial to Investigate Venetoclax in Combination with Ibrutinib and Rituximab or Conventional Chemoimmunotherapy (Bendamustine and Rituximab) and Ibrutinib in Patients with Treatment-Naive Mantle Cell Lymphoma Not Eligible for High-Dose Therapy – MCL Elderly III
4422.3 - Trials in Progress: Carman - an International, Randomized Phase II Study Evaluating Early Treatment Intensification in Patients with High Risk Mantle Cell Lymphoma Using CAR-T-Cell Treatment after an Abbreviated Induction Therapy with Rituximab and Ibrutinib and 6 Months Ibrutinib Maintenance (Arm A) As Compared to Standard of Care Induction and Maintenance (Arm B)

Hess, J.

1019 - A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome
1894 - Novel Non-Coding Candidate Drivers of Multiple Myeloma Linked to Plasma Cell Tumor Biology and B Cell Development

Hess, L. M.

5033 - Continuity of Care for Patients with Chronic Lymphocytic Leukemia: An Analysis of Real-World Data
5114 - Overall Survival Associated with Real-World Treatment Sequences in Patients with CLL/SLL in the United States

Hessels, J.

553 - A Randomized, Placebo-Controlled, Multicenter Proof-of-Concept (POC) Study to Assess the Safety and Efficacy of the Novel Allosteric AKT Inhibitor, VAD044, in Adults with Hereditary Hemorrhagic Telangiectasia (HHT)

Hester, J.

876 - Mapping the Human Bone Marrow in Myeloproliferative Neoplasia Using Spatial Transcriptomics

Hester, L.

933 - Real-World Characteristics and Outcomes in Patients with Multiple Myeloma Receiving Teclistamab Step-up Doses in Academic Vs. Community Settings
3763 - Design and Methodological Considerations for Real World Data-Derived Progression-Free Survival in Multiple Myeloma
3783 - Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes in Black Patients with Multiple Myeloma Treated with Teclistamab
3792g - Real-World Characteristics, Step-up Dosing Patterns, and Early Safety Outcomes of Patients with Multiple Myeloma Treated with Teclistamab within Vs. after the First Year of FDA Approval

Hester, L. L.

2398 - Dosing Patterns and Early Safety and Effectiveness Outcomes in Patients with Multiple Myeloma Treated with Teclistamab in the Community Setting

Hettinger, G.

116 - Near Universal National Uptake of Dexrazoxane in the Real-World Setting Associated with Reduced Cardiac ICU Care Requirements in Pediatric Acute Myeloid Leukemia
531 - Real-World Generalizability of Clinical Trial Cytomolecular Features By Race and Ethnicity in Pediatric Acute Myeloid Leukemia (AML)

Hettler, D.

5054 - An Inpatient Advance Care Planning Intervention for Older Patients with Hematologic Malignancies: A Single-Arm Pilot Study

Heuck, C.

3357 - Clinical Outcomes in Black Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 Monumental-1 Study
4653 - Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies
4757.1 - Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1–4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody

Heudobler, D.

2883.1 - A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of Cln‑049 for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease

Heurtebise-Chrétien, S.

3480 - FAS Ablation Confers Resistance to Allogeneic CAR-T Rejection By T Cells in Absence of NK Cell Sensitization

Heuser, M.

844 - The Prognostic Impact of Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia with FLT3-ITD Mutations
847 - Prognostic Impact of Subclinical FLT3-ITD Microclones in Patients with Acute Myeloid Leukemia
2934 - The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients
2951 - Prognostic Role of NGS-Based MRD Assessment in FLT3-TKD Mutated Patients with Acute Myeloid Leukemia
2956 - Intra-Tumor Heterogeneity in Core-Binding Factor Acute Myeloid Leukemia
4082 - The Impact of Body Mass Index (BMI) in Patients with Aplastic Anemia Receiving Weight-Adjusted Horse Anti-Thymocyte Globulin (hATG) on Outcome, Response and Relapse Rate
4139 - Characterizing Secondary-Site Mutations in Isocitrate-Dehydrogenase-1 (IDH1)
- Mutation-and MRD-informed Treatment Decisions for the Transplant-Eligible AML Patient

Hevenor, L.

155 - Pharmacological Targeting of IRF4 As a Therapeutic Strategy for Multiple Myeloma
1019 - A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome
1894 - Novel Non-Coding Candidate Drivers of Multiple Myeloma Linked to Plasma Cell Tumor Biology and B Cell Development
1903 - Comprehensive Characterization of the Plasma Proteome of Multiple Myeloma and Its Precursor Conditions and Identification of a Proteomic Signature to Improve Risk Prediction of Disease Progression
4637 - Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages

Hewitt, A.

5028 - MRD Testing in Multiple Myeloma: Modeling the Potential Clinical and Economic Outcomes Based on the Master Trial

Hewitt, K.

1972 - Initial Results from the ASH Research Collaborative’s COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections
2313 - High Concordance between Investigator-Verified Diagnosis and Manual Data Abstraction for Sickle Cell Diagnosis Type: An ASH Research Collaborative Data Hub Validation Study
2393 - Feasibility and Implementation of the ASH Research Collaborative’s COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections
3792e - Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network

Hewitt, K. J.

165 - Lipid-Dependent Roles for SAMD14 in Stress Erythropoiesis
1271 - The Sterile Alpha Motif Protein-1 Transcription Factor Controls Hematopoiesis through Modulation of H3K4 Methylation
3846 - Transcriptional Control of Erythropoiesis Via a Kit-Response Cistrome

Hews-Girard, J.

554 - Clinical and Economic Outcome Analysis of First-Line Immunosuppression in Acquired Hemophilia a

Hexner, E. O.

380 - Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk Gvhd
384 - Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC
588 - Curing CLL: Long-Term Outcomes of Chronic Lymphocytic Leukemia Patients with at Least One Year of Response to CART-19 Therapy
657 - A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia
909 - BTK Inhibition Prevents the Induction of Myeloid-Derived Suppressor Cells in Malignancy and Improves CART Function
3403 - Enforced Expression of Mitochondrial Calcium Uniporter in Donor T Cells Abolishes Gvhd Progression

Hey-Hadavi, J.

2329 - Incidence, Time to Diagnosis, and Therapeutic Landscape of Aplastic Anemia: Results from a Large United States Claims Database

Heym, K. M.

4187 - Retrospective Cohort Analysis of Response and Survival of Children, Adolescents, and Young Adults (CAYA) with Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoma (T-LL) Treated with Curative Intent: A TACL Consortium Study
4190 - Evaluation of Methotrexate Pharmacogenomic Variants to Predict Acute Neurotoxicity in Children with Acute Lymphoblastic Leukemia
4208 - Safety and Feasibility of Blinatumomab As Frontline Therapy for Pediatric Patients with B-Acute Lymphoblastic Leukemia and Lymphoma: St. Jude Total Therapy Study XVII

Heyman, M.

2212 - Mapping the Spatial Proteome of Individual Leukemia Cells Undergoing Fludarabine Treatment
2831 - Cerebrospinal Fluid Flow Cytometry Improves Patient Stratification in Central Nervous System Acute Lymphoblastic Leukaemia but Requires Careful Standardization: Results from the ALLTogether1 CSF-FLOW Sub-Study

Heymann, J.

636 - CD127-Directed Immunotherapy with Lusvertikimab Outperforms Imatinib in Preclinical ABL-Class-Fusion-Positive BCP-ALL

Heyn, S.

2094 - Cellular Composition and Clinical Factors Influencing Manufacturing Outcomes for Anti-BCMA CAR T Cell Therapy in a Large Real-World Cohort of Relapsed/Refractory Multiple Myeloma

Hibbitts, E.

2813 - Utility of a Second Interim Maintenance Phase to Improve Outcomes for Pediatric Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
4195 - Additional Induction Intrathecal Cytarabine for Patients with CNS2 Disease at Diagnosis Is Not Beneficial for Patients with B-ALL Treated on Children's Oncology Group Protocols AALL0932 and AALL1131

Hibbs, S. P.

2531 - Multinational Assessment of Absolute Neutrophil Counts and White Blood Cell Counts Among Healthy Individuals with the Duffy Null Phenotype or Genotype

Hibma, J.

732 - Dose Optimization of Inotuzumab Ozogamicin in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Hicheri, Y.

731 - Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials
1434 - Switch of Asparaginase Formulation Based on Antibody Monitoring in Adults with Philadelphia-Negative Adult Lymphoblastic Leukemia. Results of the Graall-2014 Trial
1496 - Results of a Phase 1, First-in-Human Study of INA03, an Anti-CD71 Antibody-Drug Conjugate in Patients with Relapsed or Refractory (R/R) Acute Leukemias

Hickey, J. W.

4577 - Bone Marrow Spatial Multi-Omics Identifies Reduced Interactions between Hematopoietic Stem Cells and Myeloid Cells in Myelodysplastic Syndrome

Hickey, R.

210 - Disrupting Mitochondrial Dynamics and Metabolism in Leukemic Stem Cells through Mitochondrial PCNA Inhibition: The Role of AOH1996

Hickman, A.

4738 - MagnetisMM-3: Long-Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma

Hickman, A. D.

3754 - Real-World Predictors of Financial Toxicity in Patients with Lymphoma

Hickman, C.

2637 - Rapido: Results from a UK-Wide Audit of 2477 Patients Who Received a Reversal Agent for a Direct Oral Anticoagulant

Hicks, A.

2482 - Bruton Tyrosine Kinase Inhibitor Rilzabrutinib Reduces Vaso-Occlusion and Markers of Inflammation and Adhesion in Transgenic Mice with Sickle Cell Disease

Hicks, C.

2647 - Platelet Quality and Function Variability across Collection Platforms and during Storage: Findings from the Ongoing Chilled Platelet Study in Vitro (CHIPSiv)

Hicks, L. K.

286 - COVID-19 Humoral Immunity Improves with Third and Subsequent Vaccine Doses in Patients with Plasma Cell Dyscrasias, Particularly in Those Receiving antiCD38 Therapy
3668 - Autologous Stem Cell Transplant for HIV-Associated Lymphoma: A Systematic Review and Meta-Analysis
5203 - Reporting of Race and Ethnicity in Randomized Controlled Trials in Hematology

Hicks, S.

3939 - Patient-Specific Platelet Phenotypes in Patients with Immune Thrombocytopenia

Hidaka, M.

2236 - Clinical Utility of Rapid and Comprehensive Genome Profiling Method Using Nanopore Sequencer for Pediatric Leukemia

Hidalgo, C.

2156 - Sativex Oromucosal Spray in Patients with Chronic Graft Versus Host Disease: Effect on Sclerodermal Features and Refractory Muscle Cramps

Hidalgo-Gomez, G.

1935 - Ultra-Deep Sequencing of TP53 in Multiple Myeloma: Double-Hit Prevalence and Clinical Phenotype
2803 - Single Center Experience Combining Multiple Tools for Genetic Diagnosis of B-Cell Acute Lymphoblastic Leukemia

Hidalgo-López, J. E.

3125 - Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Hidalgo-Soto, M.

2230 - Leveraging AI for Predicting Genetic Alterations in Multiple Myeloma through Morphological Analysis of Bone Marrow Aspirates

Hiddemann, W.

2934 - The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients
1527.1 - Trial in Progress: A Randomized-Controlled Phase 2 Study Evaluating Venetoclax Plus Azacitidine Versus Intensive Chemotherapy in Adult Patients with Newly Diagnosed, NPM1-Mutated AML – the SAL/AMLCG Vincent Trial

Hideshima, T.

3278 - Lipid Nanoparticle-Mediated Combinational mRNA Vaccine for Multiple Myeloma: The Next Stage of Cancer Immunotherapy

Hiebert, B.

212 - Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations
215 - Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations

Hiemenz, J. W.

1968 - Soluble B-Cell Maturation Antigen As a Serum Marker of Minimal Residual Disease in Patients with Multiple Myeloma

Hiew, H. J.

2342 - Multi-Centre Real-World Outcomes of Large B-Cell Lymphoma Patients Treated with 2L Axicabtagene Ciloleucel in the UK
3100 - Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications

Higashiyama,, S.

2929 - MS4A3 Serves As a Biomarker Reflecting the Lineage Differentiation and Metabolic Status of Human Acute Myeloid Leukemia Cells

Higgins, A.

303 - Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve Severe Aplastic Anemia: Results of the Diaamond-Ava-First Trial
1318 - Cellular and Cell-Free Genomic Characterization of Patients Receiving Avatrombopag and Immunosuppressive Therapy for Treatment-Naïve Severe Aplastic Anemia

Higgins, K.

3627 - Development of an Age-Appropriate, Multi-Media Educational Digital Hub for Adolescents with Sickle Cell Trait
5008 - Sctalk: A Pilot Trial Using Implementation Science to Improve Documentation and Disclosure of Sickle Cell Trait during Infancy

Higginson-Scott, N.

2562 - Preclinical Polypharmacology of S-1117, a Novel Engineered Fc-Fused IgG Degrading Enzyme, for Chronic Treatment of Autoantibody-Mediated Diseases

Highfill, S. L.

680 - Initial Experience with CD19/CD22 BiCistronic CAR T-Cells in Children and Young Adults with Recurrent or Refractory B-Cell Malignancies

Highland, J.

2303 - Comprehensive Assessment of Adequate Nutrition in Children and Adults with Sickle Cell Disease As Determined By Dietary Guidelines for Americans
2309 - Pain-Specific Patient-Reported Outcomes Are Worse in Adults Compared to Children with Sickle Cell Disease
3893 - Individuals with Sickle Cell Disease Have Decreased Intestinal Microbial Diversity Compared to Healthy Related and Unrelated Black Individuals without Sickle Cell Disease

Higué, J.

58 - Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study

Hiitola, E.

1601 - Clonal Hematopoiesis Mutations and Cell-Free DNA Characteristics in Patients with High-Risk Large B-Cell Lymphomas

Hijiya, N.

307 - Efficacy and Toxicity of Fixed Dose Versus Reduced/PK-Adjusted Dose Pegaspargase in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia: Results of DFCI ALL Consortium Protocol 16-001
311 - Feasibility of Adjusting Risk Group and Risk Group-Based Therapy during Induction in the Treatment of B-Cell Acute Lymphoblastic Leukemia: Results from DFCI ALL Consortium Protocol 16-001
4187 - Retrospective Cohort Analysis of Response and Survival of Children, Adolescents, and Young Adults (CAYA) with Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoma (T-LL) Treated with Curative Intent: A TACL Consortium Study

Hijono, B.

3491 - Clinical Impact of Colonization By Multi-Drug Resistant Organisms in Stem Cell Transplantation

Hilal, T.

523 - Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
652 - The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin
1856 - Outcomes with Venetoclax-Based Treatment in Patients with Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)-Treated, Chemotherapy-Naïve Chronic Lymphocytic Leukemia (CLL): An International Retrospective Study
2345 - Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study
3181 - Subclassification of Erdheim-Chester Disease: Distinct Clinical and Molecular Findings between Classical and Non-Classical Forms
3252 - Utilizing AI-Enabled EKG Algorithms to Identify Atrial Fibrillation Risk in Patients with CLL Receiving BTK Inhibitors
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival

Hilali, A.

571 - Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

Hildebrand, F.

3818 - Outcomes of Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Multicenter Real-World Analysis

Hildebrand, J. A.

2957 - High Grade B-Cell Lymphoma with BCL2 and MYC Rearrangement (Double-Hit High-Grade Lymphoma; DH-HGL): Establishment of a Human Model System for Ex Vivo and In Vivo Studies

Hildebrandt, B.

4308 - Rapid, Reliable, and Comprehensive Identification of MDS-Defining Cytogenetic Changes By a FISH-Panel Containing Six Probes in a Real-World Population of Patients with Suspected AML

Hildebrandt, B.

4498 - Safety of Front-Line R-Mini-CHOP with or without Acalabrutinib in Older Adults with DLBCL – an Interim Analysis of Serious Adverse Events in the Arched / GLA 2022-1 Randomized, Open-Label, Phase 3 Trial

Hildebrandt, G. C.

262 - Stabilization of HIF-1α By the Prolyl Hydroxylase Inhibitor Roxadustat Reduces Gastrointestinal Graft-Versus-Host Disease
3394 - Therapeutic Targeting of the Inflammasome to Mitigate Murine Sclerodermatous Chronic Graft Versus Host Disease
4741 - Hyperbaric Oxygen (HBO) Effects on Blood Count Recovery and Post Transplant Outcomes Following High-Dose Therapy and Autologous HSPC Transplantation for Multiple Myeloma: Final Analysis of the Multicenter Phase II Randomized Clinical Trial

Hildebrandt, M. A.

2345 - Vulnerable Elders Survey (VES-13) and Longitudinal Analysis of Quality of Life in Indolent Non-Hodgkin Lymphoma: A Multi-Institutional Prospective Cohort Study
3764 - Association of Social Determinants of Health Status (SDOH) and Ethnicity with Survival in Multiple Myeloma Patients
4508 - Impact of Pre-Existing Mental Health Disorders (MHD) on CAR T-Cell Therapy Outcomes in Patients with Large B-Cell Lymphoma
5128 - Mortality after Diagnosis of Cardiovascular Disease in Survivors of Adolescent and Young Adult Lymphoma

Hildenbrand, A. K.

605 - Empowering Adolescents and Young Adults with Sickle Cell Disease: Development of a Shared Decision-Making Toolkit for Disease-Modifying Therapies
2247 - Sleep Health in Children and Adolescent with Sickle Cell Disease

Hilder, B. W.

3357 - Clinical Outcomes in Black Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 Monumental-1 Study

Hilgendorf, I.

3560 - Impact of FLT3 Inhibitor Maintenance Therapy on Post-Transplant Outcomes in FLT3-Mutated AML Patients: A Real World Analysis from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)

Hilke, N.

206 - Synergistic Efficacy of Dual Menin and PRMT5 Targeting Against NPM1 mutatedand KMT2A-rearranged Leukemia

Hill, A.

302 - Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study

Hill, B. T.

111 - Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study
748 - Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)
3247 - Real World Experience with Time Limited Venetoclax and Obinutuzumab (VO) for Frontline Treatment of CLL/SLL with MRD Determination By Clonoseq®
3409 - Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL
4388 - Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2
4499 - Loncastuximab Tesirine in Combination with Venetoclax Is Safe and Shows Efficacy in Patients with Relapsed/Refractory Non Hodgkin Lymphoma
4625 - Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study

Hill, C. R.

2283 - Impact of COVID-19 on Multidisciplinary Lymphoma Tumor Boards: An Analysis of Practice and Care Changes

Hill, E.

763 - Proteogenomic Screens Identify Plasma Cell Specific Vulnerabilities to Halt Oncogenic Transcription in Multiple Myeloma
1907 - Novel T-Cell Receptor Signature Linked to Plasma Cell Dyscrasias
4669 - Increased Risk of Monoclonal Gammopathy of Undetermined Significance in US Military Service Members: A Case-Control Study of 1,589 Service Members Deployed to Either Iraq, Germany, or Not-Deployed Ex-US with or without Reported Burn Pit and Toxic Smoke Exposure

Hill, G. R.

905 - Donor XCR1⁺ and CD11b⁺ Dendritic Cells Determine the Severity of Th1 and Th17-Dependent Acute Gvhd within the Gastrointestinal Tract
2149 - Fecal Microbiota Transplantation to Prevent Acute Graft-Versus-Host Disease: First Pre-Planned Interim Analysis of a Randomized Trial
4902 - Cytokines associated with organ manifestations in chronic graft-versus-host disease
4780.1 - Trials in Progress: Decoy-Resistant Interleukin-18 (DR-18) for Relapse or Pre-Emptive Treatment of Measurable Residual Disease after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome (DR. DREAM), a Phase I Trial

Hill, H.

2382 - Dexamethasone for the Management of CRS Related to Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma

Hill, H. A.

3038 - Acalabrutinib with Rituximab Is Highly Effective First Line Treatment for Older Patients with Mantle Cell Lymphoma

Hill, K.

1993 - Feasibility and Target AUC Accuracy of Personalized High Dose Melphalan in Myeloma

Hill, L.

523 - Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
2170 - Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
5092 - Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR^® Registry

Hill, L. C.

4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival

Hill, M.

1283 - Statin Therapy Is Associated with Reduced Clonal Expansion in TET2 Mutated Clonal Haematopoiesis of Indeterminate Potential

Hill, M.

886 - BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Hill, Q. A.

3836 - Part a Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Patients with Warm Autoimmune Hemolytic Anemia (wAIHA): Multicenter, Open-Label, Phase 2b Study

Hillarp, A.

2556 - Patients with Immune Thrombocytopenia Have Higher Proportion of Ultra Large VWF Multimers and Lower ADAMTS13 Activity Than Healthy Controls

Hillberg, C.

2284 - The Impact of Physiotherapy Prehabilitation on Physical Fitness, Length of Stay (LoS), Readmission Rates, Quality of Life (QoL) and Patient Level Costing (PLICS) for Haematopoietic Stem Cell Transplant (HSCT) and Chimeric Antigen Receptor T- Cell (CAR-T) Recipients

Hillen, A.

27 - Stable Contribution of Lineage-Restricted Stem Cells to Steady-State Aged Human Hematopoiesis
4038 - Identification and Characterization of Distinct Pathways for Platelet Replenishment in Steady-State Hematopoiesis

Hillengass, J.

705 - Six-Month Resistance Training Interventions Are Associated with Improvements in Fatigue and Pain in Multiple Myeloma Patients
4678 - Differences in Immune Cell Populations between Individuals with or without MGUS
4701 - MRD By Flow Cytometry and FDG-PET/CT for the Post-Induction Response Assessment in Patients with Multiple Myeloma Treated in the Phase 3 GMMG HD7 Study
5158 - Impact of Social Determinants of Health on Survival Outcomes in Multiple Myeloma Patients at a Major Cancer Center

Hillengass, M.

705 - Six-Month Resistance Training Interventions Are Associated with Improvements in Fatigue and Pain in Multiple Myeloma Patients

Hillerbrandt, A. C.

872 - Mutation-Specific Differences in the Relationship between Obesity and Clonal Hematopoiesis, with a Focus on JAK2^V617F and MPN Prevention

Hillery, C.

606 - An e-Health Pain Assessment Tool Incorporating Animations and Images Is Feasible and Useful for Patients in a Ghanaian Sickle Cell Disease Cohort
2308 - Caregiver and Provider Reports of Symptom Severity, Functionality, and Quality of Life Lack Congruence with Patient Reports in Pediatric Sickle Cell Disease
5065 - Trends of Opioid Prescribing and Vaso-Occlusive Crises in Sickle Cell Disease in the U.S. (2011-2023)

Hillier, K.

1186 - Variation in Diagnostic Evaluation Patterns for Pediatric Evans Syndrome: Survey Results from the Pediatric ITP Consortium of North America (ICON)

Hillier, K.

795 - Pediatric Autoimmune Hemolytic Anemia Is Associated with a High Incidence of an Underlying Immune Disorder and High Mortality Rate

Hillmen, P.

585 - IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study

Hills, G.

3685 - Characterizing Death in Sickle Cell Disease in a National EHR Database: A Population Analysis
- A Step Toward Individualized Mortality Risk Prediction in Patients with Sickle Cell Disease in a National EHR-Derived Population Dataset

Hills, R. K.

59 - A Randomised Comparison of CPX-351 Versus Standard Daunorubicin and Cytarabine Plus Fractionated Gemtuzumab Ozogamicin in Older Adults with AML without Adverse Risk Cytogenetics: Results of the NCRI AML18 Trial

Hiltenbrand, R.

325 - Genetic and Functional Characterization of NUP98-Rearranged Leukemia
825 - The Histone Acetyltransferase MOZ (KAT6A) Is a Molecular Dependency and Therapeutic Target in NUP98-Rearranged Acute Myeloid Leukemia

Hilterbrand, A.

2047 - Enabling Potent T Cell Delivery and Mitigating Key Off-Target Concerns of In Vivo

CAR T Lentiviral Vectors with the Targeted Paramyxovirus Fusogen System

Hilton, E.

2624 - Phase 1 Study of the Safety and Pharmacodynamics of a Single Dose of Vmx-C001 in Healthy Subjects with and without FXa Direct Oral Anticoagulants

Hilton, L.

109 - Retreatment with R-CHOP-like Therapy in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma (DLBCL)

Hilton, L.

231 - Biological and Prognostic Subgroups of Plasmablastic Lymphoma Defined By EBV Status and MYC Rearrangement– an L.L.M.P.P. Study
643 - Comprehensive Characterization and Validation of the Tumor Microenvironment in Patients with Relapsed/Refractory Large B-Cell Lymphoma Identifies Subgroups with Greatest Benefit from CD19 CAR T-Cell Therapy
742 - A Novel Genetics-Based Classification of Advanced Follicular Lymphoma Identifies Prognostic Subgroups Following Bendamustine-Rituximab Immunochemotherapy
855 - CSF2RB Mutations Result in Cytokine-Dependent Gain-of-Function Phenotypes in Classic Hodgkin Lymphoma
2966 - Multiomic Profiling Reveals Pleiotropic Effects of Somatic IRF4-C99R Mutations in Primary Mediastinal Large B-Cell Lymphomas
2974 - The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study

Himberlin, C.

1434 - Switch of Asparaginase Formulation Based on Antibody Monitoring in Adults with Philadelphia-Negative Adult Lymphoblastic Leukemia. Results of the Graall-2014 Trial

Himes, A.

2347 - Acuity of Illness at Initial Presentation Mediates Early Mortality in Adolescent and Young Adult Leukemia

Hine, M.

5052 - U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML)

Hines, A.

2686 - DNMT3A Mutant Clonal Hematopoiesis in Vexas Syndrome Epigenetically Potentiates IL-13 and IL-15 Inflammatory Pathways and Is Associated with Increased Mortality

Hines, M. G.

2050 - Potent Target-Specific Efficacy of CAR T Cells Directed Toward the AML and KMT2A-Rearranged Specific Antigen CLEC2A

Hines, P. C.

2250 - Bridging the Gap for Sickle Cell Disease Patient Data in Sub-Saharan Africa By Expanding Access to Specialty Biomarkers and Clinical Trials
2305 - Voxelotor Therapy Reduces Whole Blood Adhesion to VCAM-1 and P-Selectin, and Shows Modest Improvements in Self-Reported Pain in a Real-World Clinical Setting in a Multi-Center Retrospective Analysis
3875 - Further Validation of Flow Adhesion of Whole Blood to P-Selectin (FA-WB-PSEL) to Assess Targeted P-Selectin Therapies in Sickle Cell Disease (SCD)
4957 - Impact of BEAM-101 Treatment on Red Blood Cell Hemoglobin Expression, Rheology and Sickling Properties: Initial Data from the BEACON Phase 1/2 Study of Autologous CD34⁺ Base Edited Hematopoietic Stem Cells in Sickle Cell Disease

Hines-Dowell, S.

1331 - Outcomes of Germline Genetic Testing in Children with Hematologic Malignancies Undergoing Allogeneic Transplantation

Hingorani, S.

688 - Biomarker Dynamics in Pediatric Transplantation-Associated Thrombotic Microangiopathy (TA-TMA): A Prospective Cohort and Nested Case-Control Study

Hiniker, S.

2116 - A Standard Operating Protocol for Pre-Transplant Low Dose Splenic Radiotherapy for Patients with Myelofibrosis

Hinnershitz, T.

1210 - Safety Biomarkers in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B Without Inhibitors Receiving Prophylactic Marstacimab Treatment: Results From the Phase 3 BASIS Trial

Hino, M.

4542 - Phase I Safety Study of Anti-Transferrin Receptor 1 Antibody (PPMX-T003) in Patients with Polycythemia Vera and Erythrocythemia
4861 - The Diagnostic Accuracy of the Refined EBMT Criteria 2023 for SOS

Hino, T.

2725 - ETV6 Contributes to Maintenance of Leukemia Stem Cells in Acute Myeloid Leukemia with High EVI1 Expression
4148 - Statins Kill Acute Myeloid Leukemia Cells through Low-Density Lipoprotein Receptor-Mediated Unfolded Protein Response Activation

Hinton, H.

990 - Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072
3123 - BP43131, a Phase 1 Dose Escalation Study: CD19 Targeted CD28 Costimulatory Agonist (RO7443904) Combined with Glofitamab Shows Promising Efficacy in Patients with Relapsed/Refractory Aggressive B-NHL
4180 - Integrated Quantitative Clinical Pharmacology Analysis Identifies Optimal Englumafusp Alfa Dose Range for Proof-of-Concept Study with Glofitamab in Second-Line Large B-Cell Lymphoma Patients

Hintzke, M. E.

1554 - Immune-Scape in Myeloid Sarcoma and Acute Myeloid Leukemia

Hinz, M.

1583 - Guiding Treatment and Clinical Management of Patients with CNS Lymphomas By Minimal-Invasive Detection of Circulating Tumor DNA in Cerebrospinal Fluid

Hirabayashi, S.

2706 - Functional Annotation of DDX41 Variants Using Base-Editing and cDNA Expression Library Screenings

Hirabayashi, S.

1835 - Refractory Cytopenia in Childhood Under Watch and Wait Strategy: Safe until Adulthood?

Hiraga, J.

3030 - Treatment and Outcomes of Stage I-II Pulmonary MALT Lymphoma: A Multi-Institutional Observational Study in Japan

Hiramoto, N.

384 - Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC
1332 - A Dedicated System Accounting for Specific Germline/Somatic Genomic Constellations Is Essential to Predict Outcomes in DDX41-Mutant Myeloid Neoplasia
1682 - Comparison of Clinical Characteristics and Prognosis between Aggressive NK-Cell Leukemia and Advanced-Stage Extranodal NK/T-Cell Lymphoma
3030 - Treatment and Outcomes of Stage I-II Pulmonary MALT Lymphoma: A Multi-Institutional Observational Study in Japan
4472 - Trends and Outcomes of Hematopoietic Stem Cell Transplantation for Malignant Lymphoma in Japan between 2006 and 2021

Hiramoto, N.

639 - Deciphering the Heterogeneity of Acute Myeloid Leukemia through Chromatin Accessibility Profiling

Hirano, K.

3090 - Short Diagnosis to Treatment Interval Is Associated with Poor Outcomes in Relapse or Refractory Diffuse Large B-Cell Lymphoma

Hirano, K.

4459 - Low Immunoglobulin G and Low Lymphocyte-Monocyte Ratio at the End of Treatment Predict Early Progression in Diffuse Large B-Cell Lymphoma

Hirano, K.

4851 - Novel Method to Evaluate the Quantitative Immune Functionality of CAR T-Cells to Analyze the Localization Change of CAR Molecules

Hirao, T.

4920 - Single Cord Blood Transplantation Strongly Inhibits Leukemia Relapse and Is Associated with Significantly Better Leukemia-Free and Overall Survival Than HLA-Matched Related Donor in Allo-HSCT for Patients with Acute Myeloid Leukemia in Non-Remission Status

Hirata, J.

469 - Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes

Hirata, K.

3096 - Reduced FDG Uptake in the Brain on Baseline 18FDG PET/CT Predicts Worse Prognosis of Newly Diagnosed Intravascular Large B-Cell Lymphoma and Advanced-Stage Diffuse Large B-Cell Lymphoma

Hiratsuka, T.

2929 - MS4A3 Serves As a Biomarker Reflecting the Lineage Differentiation and Metabolic Status of Human Acute Myeloid Leukemia Cells

Hirayama, A. V.

2028 - Prediction of Therapeutic Potential of CD19 CAR-T Cells for LBCL By Histone Mark Analyses of Core Epigenetic Programming
3422 - TNFα Apoptotic Signaling By Antigen-Engaged CAR T-Cells Mediates Clearance of Target Antigen-Negative Acute Myeloid Leukemia
3772 - Trends in Pre-CAR-T Attrition in Relapsed/Refractory Multiple Myeloma: Prevalence, Risk Factors, and Outcomes at a Tertiary Academic Medical Center

Hirohashi, Y.

2747 - Cyclin D1 Overexpression in Mantle Cell Lymphoma Causes Cellular Dependence on Microhomology-Mediated End-Joining

Hirouchi, T.

949 - CRISPR/Cas9 Library Screens Identified Atp2a2 As an In Vivo Specific Tumor Suppressor in Myeloid Neoplasms

Hirpara, I.

3095 - Global Burden and Trend of Burkitt Lymphoma in 38 OECD Countries from 1990-2021: A Benchmarking Global Analysis for the Gbd 2021

Hirsch, B.

967 - A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO – a Report from the Children’s Oncology Group
2949 - Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children’s Oncology Group

Hirsch, P.

227 - Secondary Genetic Alterations and Measurable Residual Disease in Core Binding Factor Acute Myeloid Leukemia - a Study from the Acute Leukemia French Intergroup
968 - Favourable Outcomes in Newly Diagnosed Paediatric AML with Gemtuzumab Ozogamicin and Risk-Stratified Therapy: Results from the International Phase III Myechild 01 Trial

Hirsh, P.

4553 - Characteristics and Therapeutic Response of Erdheim-Chester Disease Associated with Myeloid Neoplasm, an Observational Multicenter Study

Hirst, M.

1342 - KMT2C Mutations Co-Operate with KMT2A-MLLT1 Fusion to Inhibit Hematopoietic Differentiation in a Zebrafish Model of Infant Leukemia

Hiruy, S.

1964 - Mass Spectrometry (MS)-Based Exent® Solution Reveals High Prevalence of Multiple M-Proteins in African American Patients with Multiple Myeloma (MM) and Precursor Conditions
3769 - Primary Therapy Outcomes By Primary Cytogenetic Subtypes in a Large Cohort of Black Patients with Multiple Myeloma at a Single Center

Hirvensalo, E.

2640 - Low-Molecular-Weight Heparin Benefited Outpatients with High Risk of Venous Thromboembolism Early in COVID-19 Pandemics

Hisada, Y.

- Mouse Xenograft Models of Acute Promyelocytic Leukemia and Coagulopathy

Hisada, Y.

3796 - Disseminated Intravascular Coagulation and Early Thrombo-Hemorrhagic Complications in Acute Promyelocytic Leukemia

Hisrich, B.

1487 - Leukemia Physician’s Perspective on Transplant in Patients with TP53 Mutated Acute Myeloid Leukemia
4184 - The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Hitchens, T. K.

624 - Heme-Mediated Tau Phosphorylation Is Critical for Neuroaxonal Damage and Cognitive Impairment in Sickle Cell Disease

Hitosugi, T.

1880 - Single-Cell Spatial Proteomic Characterization of Clonal Plasma Cell and Immune Cell Metabolism within the Bone Marrow Microenvironment in High-Risk Smoldering Multiple Myeloma and Its Association with Progression to Multiple Myeloma

Hitron, M.

213 - Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia

Hitz, F.

1578 - Clonal Hematopoiesis in Diffuse Large B-Cell Lymphoma: Clinical and Molecular Correlations

Hitz, F.

568 - PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial

Hitzler, J. K.

209 - Identification of DLK1 As a Novel Therapeutic Target in Down Syndrome Myeloid Leukemia
2949 - Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children’s Oncology Group
2808.1 - A Children’s Oncology Group Clinical Trial of Long-Term Outcomes in Survivors of Down Syndrome-Associated Acute Leukemia (ALTE22C1): Clinical Trial in Progress

Hivert, B.

584 - Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group

Hiwase, D.

51 - Venetoclax-Based Measurable Residual Disease Directed Therapy in Acute Myeloid Leukemia Is Associated with Emergent TP53 Microclones in Remission
217 - A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial
244 - TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance
303 - Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve Severe Aplastic Anemia: Results of the Diaamond-Ava-First Trial
664 - Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database
1006 - Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine
1267 - Higher Rate of Red Blood Cell (RBC) Alloimmunization in RBC-Transfused Myelodysplastic Syndrome Compared to Acute Myeloid Leukemia
1304 - Impact of Chronic Inflammation and Cytotoxic Therapy on Bone Marrow Microenvironment of Patients with Autoimmune Rheumatic Diseases and Myeloid Neoplasms
1318 - Cellular and Cell-Free Genomic Characterization of Patients Receiving Avatrombopag and Immunosuppressive Therapy for Treatment-Naïve Severe Aplastic Anemia
1817 - High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent Safety and Tolerability in CMML Patients in Combination with Azacitidine
1825 - Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)
3196 - CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity
3208 - Dynamic Assessment of RBC-Transfusion Dependency (RBC-TD) Improves the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification of MDS
3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
3219 - Clinical Outcomes and Variability Based on Baseline Cytogenetic Risk of Patients with MDS Treated with Hypomethylating Agents: An Analysis from the International Consortium for MDS (icMDS) Validate Database
3223 - Clinical Response to Azacitidine in Myelodysplastic Neoplasms Is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor Cells In Vivo
3799 - Real-World Patterns of Care and Outcomes for Non-Favourable Risk Acute Myeloid Leukemia Treated with Intensive Chemotherapy across Australia and New Zealand- Data Linkage between the ALLG National Blood Cancer Registry (NBCR) and the Australia and New Zealand Transplant and Cellular Therapy (ANZTCT) Registry
4237 - High Burden of Healthcare Utilization in Older Acute Myeloid Leukemia Patients Treated with First-Line Venetoclax-Based Therapies
4591 - Hematologic Improvement and Fatigue Reduction with Elritercept (KER-050) in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS) with Non-Transfusion Dependent Anemia: New Analyses from an Ongoing Phase 2 Trial
4594 - TP53-Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors
4596 - Pathogenic Germline Variants in the DNA Damage Repair Pathway Are Enriched in Patients with Hematologic Malignancies with Prior Exposure to Cytotoxic Therapies Compared to Patients with Multiple Cancers without Prior Exposure
4928 - Clonal Architecture of Donor-Derived Leukemia/Clonal Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplant
4605.1 - Targeting the Myelodysplasia (MDS) Inflammasome with the Oral Wnt/β-Catenin Pathway Inhibitor, ES-3000 in Combination with Oral Decitabine/Cedazuridine (ASTX727) an Australasian Leukaemia and Lymphoma Group Trial (ALLG MDS05/D1)

Hizukuri, Y.

4342 - Prediction of Clinical Response By Phased Variants in Circulating Tumor DNA (ctDNA) in the VALENTINE-PTCL01 Trial of Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)

Hjalgrim, H.

4339 - Genome-Wide Meta-Analysis Identifies Multiple Germline Genetic Variants Associated with Increased Risk of Follicular Lymphoma
4358 - Expanded Genome-Wide Association Study (GWAS) Identifies Nine Novel Germline Risk Loci for Waldenström Macroglobulinemia (WM) and Lymphoplasmacytic Lymphoma (LPL)

Hjorth-Hansen, H.

1780 - Computational Cytomorphological Analyses Identifies Bone Marrow Erythroblast Proportion As a Biomarker of Treatment-Free Remission in CML

Hlavacek, P.

2401 - An Indirect Comparison of Elranatamab’s Progression-Free Survival, Duration of Response, and Overall Survival from MagnetisMM-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma
3367 - Updated Results of a Matching-Adjusted Indirect Comparison of Elranatamab Versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma
3770 - Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study – Interim Results

Hlubocky, F.

2354 - Financial Toxicity, Health-Related Quality of Life, and Medication Adherence Patient-Reported Outcomes (PROs) in Patients with Chronic Lymphocytic Leukemia (CLL) on First-Line Oral Oncolytics

Hmaid, A.

4445 - Delays to Diagnosis of Peripheral T-Cell Lymphoma and Clinical Utility of Molecular Profiling: A UK Multicentre Real-World Study

Hnoosh, A.

118 - The Burden of Transfusion Dependence on Caregivers of Patients with Lower-Risk Myelodysplastic Syndromes in North America and Europe
1832 - Changes in Red Blood Cell Transfusion Burden with Luspatercept Versus Epoetin Alfa in Patients with Lower-Risk Myelodysplastic Syndromes in the Phase 3, Open-Label, Randomized, Controlled COMMANDS Trial
3216 - Health-Related Quality of Life of Luspatercept Versus Epoetin Alfa in Red Blood Cell Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Results from the Final Datacut of the Phase 3 COMMANDS Study
3857 - Luspatercept Improves Fatigue-Related Quality of Life through 5 Years of Treatment in Non-Transfusion Dependent Beta-Thalassemia
5055 - Impact of Luspatercept on Healthcare Resource Use (HCRU) Among Patients with Lower-Risk, Myelodysplastic Syndromes (LR-MDS): A Medical Record Review in Canada, Germany, and Spain

Ho, A. Y. L.

3529 - Haploidentical Transplant Using Selective Ex-vivo TCR-Αβ Depleted and Upfront Memory T-Cell Add-Back Is Associated with Lower Chronic Gvhd and More Favorable Gvhd-Free/Relapse-Free Survival As Compared to Matched Related and Unrelated Donor Transplant for Adults with Hematological Malignancies

Ho, A. D.

1282 - A Senescent Subset in Human Hematopoietic Stem Cell (HSC) Compartment As Target for Senotherapy

Ho, B.

3529 - Haploidentical Transplant Using Selective Ex-vivo TCR-Αβ Depleted and Upfront Memory T-Cell Add-Back Is Associated with Lower Chronic Gvhd and More Favorable Gvhd-Free/Relapse-Free Survival As Compared to Matched Related and Unrelated Donor Transplant for Adults with Hematological Malignancies

Ho, C.

4229 - Comprehensive Genomic Profiling (CGP) of Acute Lymphoblastic Leukemias with Foundation One Heme Identifies Actionable Genomic Alterations and Biomarkers

Ho, C. I.

111 - Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study
783 - Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma: A Single-Center Retrospective Analysis
3245 - A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL
5116 - Quality of Life during Survivorship Following Autologous Stem Cell Transplant for Mantle Cell Lymphoma
1661.2 - A Pilot Trial of Low Dose-Mosunetuzumab for Low-Tumor Burden Indolent B-Cell Lymphoma: Trial in Progress

Ho, F. D. V.

3725 - The Epidemiology of Hematologic Malignancies in East Asia from 1990 to 2021: Estimates from the Global Burden of Disease Study

Ho, G.

2391 - The Impact of Structural Racism and Social Determinants of Health on Fluorescence in Situ Hybridization Testing Among Patients with Multiple Myeloma

Ho, J.

1768 - Prognostic Implication of Framingham Risk Score As a Comorbidity Measure on Treatment Outcomes Following First-Line Tyrosine Kinase Inhibitor in Newly Diagnosed CML Patients

Ho, J.

998 - Trial Update from IMproveMF, an Ongoing, Open-Label, Dose-Escalation and -Expansion, Phase 1/1B Trial to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Novel Combination of Imetelstat with Ruxolitinib in Patients with Intermediate-1, Intermediate-2, or High-Risk Myelofibrosis (MF)
1808.1 - Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial

Ho, K. F.

2000 - Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)

Ho, K.

194 - Disease Correction of a Diamond-Blackfan Anemia Mouse Model Using Non-Genotoxic Conditioning and Hematopoietic Stem Cell Transplantation
4095 - Robust Immune Reconstitution in Fanconi Anemia Mice Post in Utero Hematopoietic Stem Cell Transplantation

HO, K. W.

2379 - Maintenance after Autologous Hematopoietic Cell Transplantation Improves Overall Survival and Progression Free Survival Regardless of Disease Stage at Transplant in Newly Diagnosed Myeloma Patients: A Global, Real-World Analysis from the Worldwide Network for Blood and Marrow Transplantation Global Study
4733 - Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study

Ho, L.

460 - Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early-Stage Classical Hodgkin Lymphoma
3101 - Durability of Complete Responses in Patients from the ECHELON-3 Study
4483 - Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study
4489 - Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

Ho, P. J.

772 - Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial
2000 - Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)
3034 - Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update
3364 - Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma

Ho, R.

4204 - A Retrospective Study of Inotuzumab Ozogamicin in Individuals with Down Syndrome and B-Cell Acute Lymphoblastic Leukemia

Ho, V. T.

102 - Acute GvHD of the Gut Is Associated with Minor Histocompatibility Antigens Cross-Reactive Against Gut-Tropic Viral Epitopes
379 - Heterogeneity of PD-1⁺regulatory T Cells after Low-Dose IL-2 Therapy for Patients with Chronic Graft-Versus-Host Disease
1041 - Effects of GvHD Prophylaxis with Post-Transplant Cyclophosphamide on Immune Reconstitution and TCR Repertoire after Haploidentical and HLA-Matched Transplantation Compared to Prophylaxis with Calcineurin Inhibitor Plus Methotrexate in HLA-Matched Transplantation
1045 - Feasibility, Safety and Efficacy of Oral Maintenance Therapy with Venetoclax Plus Decitabine/Cedazuridine after Venetoclax Plus FluBu2 for High Risk MDS/AML Undergoing RIC Allo-HCT
3500 - BK Virus Reactivation and Disease after Allogeneic Hematopoietic-Cell Transplantation: A Natural History Study
3538 - Impact of Consolidative Cellular Therapy with DLI or Second Transplant in Patients with AML Who Achieve Complete Remission Following Post-Transplant Relapse
4833 - Induction of Graft-Versus-Leukemia Effect with Treg-Depleted DLI Plus Ipilimumab for Myeloid Disease Relapse after HLA-Matched Transplant
4866 - Expression of HLA-B*35 Is Associated with an Increased Risk of CMV Viremia and Clinically Significant CMV Infection in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation
4885 - Early CMV Viral Load Burden Predicts Late Clinically Significant CMV Infections in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation
4911 - Long Term Outcomes of a Randomized Trial of Anti-T Lymphocyte Globulin to Improve Moderate-Severe Chronic Gvhd Free Survival after Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Analysis
4938 - Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes

Ho, W. L.

3966 - Factor VIII (FVIII) Trough Levels of Real-World Severe-Type People with Hemophilia a (PwHA) on rFVIII-Fc Prophylaxis: Clinical Correlates and Effects on Perceivable Bleeding Outcomes

Hoade, Y.

669 - Tumour-Intrinsic Features Shape T-Cell Differentiation through Myeloma Disease Evolution

Hoade, Y.

1283 - Statin Therapy Is Associated with Reduced Clonal Expansion in TET2 Mutated Clonal Haematopoiesis of Indeterminate Potential

Hoang, D. H.

210 - Disrupting Mitochondrial Dynamics and Metabolism in Leukemic Stem Cells through Mitochondrial PCNA Inhibition: The Role of AOH1996

Hoang, H.

194 - Disease Correction of a Diamond-Blackfan Anemia Mouse Model Using Non-Genotoxic Conditioning and Hematopoietic Stem Cell Transplantation
2015 - Evaluation of Bone Marrow in Fanconi Anemia Patients Treated with Briquilimab Antibody-Based Conditioning and TCRαβ⁺ T-Cell/CD19⁺ B-Cell Depleted Haploidentical Grafts
4095 - Robust Immune Reconstitution in Fanconi Anemia Mice Post in Utero Hematopoietic Stem Cell Transplantation

Hoare, M.

2673 - Mutagenic DNA Lesions in Normal Hematopoietic Stem Cells Persist for Years Causing Distinct Patterns of Mutation

Hoban, M.

3427 - In Vivo panCAR-Mediated Depletion of B Cells in Non-Human Primates Using a Circular (oRNA^®) Anti-CD20 CAR

Hobbie, B.

746 - MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naïve Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA Analyses

Hobbs, B. P.

4462 - Utilizing Synthetic Individual Patient Level Cohorts from Machine Learning on Clinical Trials to Define Endpoints for Bispecific Trials in Large B-Cell Lymphoma

Hobbs, G. S.

16 - Anticoagulation Management of Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: A Global Abdominal/Splanchnic Thrombosis Retrospective Observational Study in 486 MPN Patients (GASTRO-MPN)
117 - Multi-Site Randomized Trial of a Collaborative Palliative and Oncology Care Model for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Receiving Non-Intensive Therapy
246 - Prognostic Implications of Pulmonary Hypertension in Myeloproliferative Neoplasms and Predictors of Hematologic Progression
659 - Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)
3188 - Incidence, Risk Factors, and Prognostic Implications of Heart Failure Hospitalizations Among Patients with Myeloproliferative Neoplasms
3811 - Factors Associated with Quality of Life Impairments in Patients with Myeloproliferative Neoplasms: Looking Beyond Symptom Burden
4525 - Clinical Features and Preliminary Investigation of PPM1D-Mutated Myeloproliferative Neoplasms
4560 - Risk of Osteoporosis and Osteoporotic Fractures in Patients with Myeloproliferative Neoplasms
3147.1 - A Multicenter, Open-Label, Phase 1 Clinical Trial of AJ1-11095 Administered As Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed By a Type I JAK2 Inhibitor (JAK2i)
4569.1 - Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis

Hobbs, M.

83 - Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma
1955 - Impact of Serial Serum Free Light Chain Measurements on Response and Progression Assessments in Multiple Myeloma Patients with Measurable Disease
2400 - Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis
3315 - Impact of Multiple High-Risk Cytogenetic Abnormalities on the Survival Outcomes of Patients with Primary Plasma Cell Leukemia
4704 - Flow Cytometry-Based Assessment of the Proportion of Monoclonal Plasma Cells in Synthetic Phase (S-phase) Is an Independent Marker of Adverse Prognosis in Patients with Newly Diagnosed Multiple Myeloma
4716 - Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma
4728 - Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes

Hobbs, W.

512 - Durable Clinical Benefits with Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia
4954 - Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell Disease

Hochberg, B.

2515 - Defibrotide Reduces Hypercoagulable State in Patients with Sickle Cell Disease-Related Acute Chest Syndrome (IND 127812)

Hochberg, E.

1867 - Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)

Hochberg, J.

2515 - Defibrotide Reduces Hypercoagulable State in Patients with Sickle Cell Disease-Related Acute Chest Syndrome (IND 127812)

Hochhaus, A.

406 - Intraindividual Comparison of Recognition of Symptom Burden in MPN between Patient- and Physician-Reported Assessment and Its Impact on Survival – an Analysis By the German Study Group for MPN (GSG-MPN)
475 - Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study
1090 - Reliable Assessment of Iron Deficiency in Patients with Myeloproliferative Neoplasms through Fluorescence Spectroscopy-Based Measurement of Zinc Protoporphyrin (ZPP)
1765 - Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial
1766 - Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) – an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)
1774 - The Combination of Asciminib with ATP Competing Tyrosine Kinase Inhibitors Might Overcome the Negative Impact of ASXL1 Mutations on Molecular Response in Newly Diagnosed CML Patients
2112 - Efficacy and Safety of Donor Lymphocyte Infusion after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients
2934 - The Differential Impact of Secondary-Type Mutations in a Multinational Cohort of 5311 Intensively Treated Acute Myeloid Leukemia Patients
3148 - 5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results
4526 - Asciminib Shows High Efficacy and Favorable Tolerability at 80 Mg Once Daily and 40 Mg Twice Daily in Patients with Chronic Phase Chronic Myelogenous Leukemia Previously Treated with 2 or More Tyrosine Kinase Inhibitors: Primary Analysis from the ASC4OPT Study

Hochman, J.

2542 - Tetraspanin CD37 Regulates Platelet Hyperreactivity and Thrombosis

Hochman, M. J.

324 - Real-World Analysis of CPX-351 Induction in Acute Myeloid Leukemia-Myelodysplasia Related (AML-MR): An Updated Analysis from the Marrow Consortium

Hockaday, A.

585 - IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study
771 - Final Analysis of the Randomised UK MRA Myeloma XI+ Trial Examining Krdc (carfilzomib, lenalidomide, dexamethasone and cyclophosphamide) As Induction Therapy for Newly Diagnosed Multiple Myeloma Patients
1987 - Optimising the Duration of Therapy for Newly Diagnosed Transplant Ineligible Patients – Analysis of Long Term Follow up Data from the UK MRA Myeloma XI Trial
3375 - MRD and Molecular Risk Status Help to Define Optimal Maintenance Delivery Strategies after ASCT: Long Term Outcomes of the UK MRA Myeloma XI Trial Comparing Lenalidomide to Observation

Hocking, J.

5139 - Toxicity Outcomes in Phase 1 Interventional Studies in Plasma Cell Dyscrasias: Heterogeneous Reporting and High Usage of Minimising Language

Hockings, C.

1804 - Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort

Hockley, D.

3464 - Alberta Cellular and Immunotherapy (ACIT) 001, Updated Results of Decentralized Production of Second Generation, Anti-CD19/41BB/CD3z Chimeric Antigen Receptor (CAR) T-Cells in Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) and Aggressive Non-Hodgkin Lymphoma (NHL)
4366 - Gene Expression Profile of Enriched T-Cells Prior to Chimeric Antigen Receptor (CAR) T-Cell Manufacturing Is Predictive of CAR T-Cell Response

Hod, E. A.

23 - Iron Repletion of Iron-Deficient Blood Donors Affects Brain Iron, Myelin, and Neural Network Activation Patterns
3835 - Arginine Metabolism Is a Biomarker of Red Blood Cell and Human Aging

Hoda, D.

1749 - The “Walk through the Clinic Door” Effect: Differences in Survival and Toxicity Based on Site of CAR T Administration in a Default Outpatient CAR T Program

Hodby, K.

2823 - A UK Intention to Treat Analysis of Brexucabtagene Autoleucel for Relapsed or Refractory Adult Acute Lymphoblastic Leukaemia Following 1 Year of Therapy Access

Hodder, A.

2816 - Blinatumomab with De-Escalated Chemotherapy for Infant KMT2A-Rearranged B-Cell Acute Lymphoblastic Leukemia
2830 - A Non-Canonical Lymphoblast in Refractory Childhood T-Cell Acute Lymphoblastic Leukemia

Hodge, D. O.

1981 - Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience

Hodges, G.

3007 - Frontline R-CHOP and BR Have Similar Outcomes By SUV_max in Follicular Lymphoma

Hodges, J.

1065 - Sickle Cell Disease-Related Worry and Associations with Healthcare Utilization in Youth with Sickle Cell Disease
3688 - Health-Related Communication in Adolescents and Young Adults with Sickle Cell Disease

Hodges, P. G.

558 - Long-Term Safety and Effectiveness of Pomalidomide for Bleeding in Hereditary Hemorrhagic Telangiectasia

Hodgkinson, J. T.

1109 - Cereblon-Based Compounds for Induction of HbF

Hodgson, D.

567 - Creation of a Multistate Model to Improve Prognostication across the Disease Course in Advanced Stage Classic Hodgkin Lymphoma (cHL): A Report from the Holistic Consortium
1695 - Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy
2272 - Real-World Comparison of Healthcare Costs and Resource Utilization Among Patients with Relapsed-Refractory Large B-Cell Lymphoma Treated with CAR T-Cell Therapy Versus Historical Standard-of-Care: A Cost-Consequence Analysis in Ontario, Canada
3744 - Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada
4469 - Outcomes of Patients Intended for Autologous Stem Cell Transplantation with CT-Based Partial Response but PET-Based Deauville Score of 5 after Salvage Chemotherapy
5134 - A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada

Hodgson, D.

3082 - Outcomes of Patients with Refractory and Relapsed Primary Mediastinal B Cell Lymphoma: A Canadian Single-Center Analysis
3092 - Outcomes and Predictors of Survival for Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Large Population-Based Analysis

Hodgson, N.

554 - Clinical and Economic Outcome Analysis of First-Line Immunosuppression in Acquired Hemophilia a

Hodgson, R.

1104 - Small Activating RNA-Mediated Induction of HBG Via Liposome Delivery for In Vivo Treatment of Sickle Cell Disease and Beta-Thalassemia

Hodin, C.

4734 - Analysis of Repeat Step-up Dosing and Cytokine Release Syndrome Events Following Prolonged Dosing Intervals of Teclistamab in the Phase 1/2 Majestec-1 Study
4749 - Higher Teclistamab Step-up Dosing in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Results from the Majestec-1 Trial

Hodkinson, B. P.

4653 - Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies

Hodson, D. J.

229 - Pathogenesis and Clinical Relevance of Diffuse Large B-Cell Lymphoma Proteogenotypes
333 - CD70 Deregulation in Follicular Lymphoma at Diagnosis Is Associated with Relapse and Opens New Avenues for Dual CD19-CD70 CAR-T Therapy
989 - A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
1613 - Patient-Derived Follicular Lymphoma Tumoroids: A Tool to Recapitulate Biological Features of Low and High-Grade Lymphoma
2957 - High Grade B-Cell Lymphoma with BCL2 and MYC Rearrangement (Double-Hit High-Grade Lymphoma; DH-HGL): Establishment of a Human Model System for Ex Vivo and In Vivo Studies
3003 - Mechanism of Negative Feedback Regulation of Oncogenic BCR-Signaling in Mature B-Cell Lymphoma
3591 - ASTX295 a Novel Potent MDM2 Antagonist Induces More Than One Mechanism of Programmed Cell Death (PCD) in Lymphoid Malignancies

Hodson, E.

771 - Final Analysis of the Randomised UK MRA Myeloma XI+ Trial Examining Krdc (carfilzomib, lenalidomide, dexamethasone and cyclophosphamide) As Induction Therapy for Newly Diagnosed Multiple Myeloma Patients
1987 - Optimising the Duration of Therapy for Newly Diagnosed Transplant Ineligible Patients – Analysis of Long Term Follow up Data from the UK MRA Myeloma XI Trial
3375 - MRD and Molecular Risk Status Help to Define Optimal Maintenance Delivery Strategies after ASCT: Long Term Outcomes of the UK MRA Myeloma XI Trial Comparing Lenalidomide to Observation

Hodson, M. P.

52 - Overcoming Ven/Aza Resistance through Imetelstat-Mediated Lipophagy in Acute Myeloid Leukemia

Hoeben, A.

1246 - Imaging Predictors of Intracerebral Hemorrhage in Patients with Brain Tumors Treated with Anticoagulation

Hoechsmann, B.

4072 - Monotherapy Treatment with Zaltenibart (OMS906), an Alternative Pathway Masp-3 Inhibitor, Improved Key Hematologic Parameters in Patients with PNH with a Suboptimal Response to Ravulizumab: Interim Results from a Phase 2 Proof-of-Concept Study

Hoefsmit, E. P.

93 - Atalanta-1: A Phase 1/2 Trial of GLPG5101, a Fresh, Stem-like, Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

Hoeg, R. T.

382 - Preliminary Safety and Efficacy of Myeloablative Orca-Q with No GvHD Prophylaxis for Treatment of Advanced Hematologic Malignancies
523 - Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above
694 - Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients
2085 - A Phase I Study of CD19 CAR T-Cells with Escalating Doses of Lymphodepletion with or without Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
4200 - NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival

Hoegner, M.

4688 - Prevalence and Mutational Make-up of Secondary Hematologic Neoplasms in Multiple Myeloma Patients after CAR-T Cell Therapy

Hoehn, D.

342 - Fixed-Duration Epcoritamab + R² Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial
867 - Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma
1627 - Fixed-Duration Epcoritamab in Combination with Bendamustine + Rituximab for First-Line Treatment of Follicular Lymphoma: Initial Results from Epcore NHL-2 Arm 3

Hoehn, G.

4569.2 - A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm

Hoel, M.

397 - Prevalence, Genetic Predispositions and Clinical Consequences of Non-CLL-Type MBL: Screening in 10,330 Individuals

Hoen, B. D.

4228 - The Leukemic Microenvironment Represses Blinatumomab-Dependent Killing in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

Hoenemann, D.

3223 - Clinical Response to Azacitidine in Myelodysplastic Neoplasms Is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor Cells In Vivo

Hoenig, E.

3042.2 - Trial in Progress: A Phase II Trial to Investigate Venetoclax in Combination with Ibrutinib and Rituximab or Conventional Chemoimmunotherapy (Bendamustine and Rituximab) and Ibrutinib in Patients with Treatment-Naive Mantle Cell Lymphoma Not Eligible for High-Dose Therapy – MCL Elderly III

Hoering, A.

766 - Whole Genome Sequencing Reveals Lower Apobec-Mutational Activity in Multiple Myeloma Patients with African Ancestry Compared with Those Having European Ancestry
3378 - Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)
3309.1 - A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
3381.3 - A Phase III Randomized Trial for Frail Newly Diagnosed Multiple Myeloma Patients Comparing Bortezomib- Lenalidomide-Dexamethasone (VRd-Lite followed by Len maintenance) with Daratumumab-Lenalidomide- Dexamethasone (DRd followed by Len+/- Dara Maintenance): SWOG S2209

Hoermann, G.

1341 - Mutant Idh1 Blocks Neutrophil Maturation By Repressing Myeloid Progenitor Programs

Hoesley, J.

159 - The Real-World Performance of the PF4-Dependent P-Selectin Expression Assay (PEA) As the First-Line Functional Assay for the Diagnosis of Heparin-Induced Thrombocytopenia (HIT)

Hoeve, J. T.

2743 - Regulation of Metabolism and Epitranscriptomic Modifications By RNA Binding Protein IGF2BP3

Hoeyer, T.

883 - Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1
1860 - Excellent Clinical Outcomes in Deeply Mutated IGHV Chronic Lymphocytic Leukemia upon Fludarabine and Cyclophosphamide Plus Rituximab

Hoeynck, B.

3663 - Impact of Patient Distance from Center on Outcomes and Cost of Therapy for Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma

Hofbauer, D.

1153 - Deciphering Inflammasome Activation in Gaucher Macrophages and Its Role in the Development of Multiple Myeloma

Hoff, F. W.

4325 - IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy

Hoffman, C.

4629 - Outcomes of Patients with Chronic Lymphocytic Leukemia Discontinuing Bruton Tyrosine Kinase Inhibitors Due to Adverse Effects

Hoffman, J. E.

932 - Tocilizumab Prophylaxis for Patients with Relapsed or Refractory Multiple Myeloma Treated with Teclistamab, Elranatamab or Talquetamab
2389 - Comparison of Debulking Regimens (EPOCH and DCEP) for the Treatment of Relapsed or Refractory Multiple Myeloma
3369 - Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study
5143 - AL Amyloidosis: Understanding the Clinical Prodrome and Delays in Diagnosis

Hoffman, J. E.

1992 - First-in-Human Phase 1 Study of SAR442257 in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin Lymphoma

Hoffman, K.

4167 - Translational Disruption of NRF2 By Zotatifin Enhances Sensitivity to Ferroptosis and CAR-T Cells in Diffuse Large B-Cell Lymphoma

Hoffman, M.

2577 - Rebalancing Hemostasis in Hemophilia: Interplay between Antithrombin and Ancillary Thrombin Inhibitors

Hoffman, R.

1748 - Reduction in Platelet Counts May Predict the Development of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma

Hoffman, R.

8 - TMPRSS6 Antisense Oligonucleotide Therapy Reverses Inflammation in Jak2^V617F Mutant Mice
243 - TP53 Alterations Confer Increased Risk of Leukemic Transformation and Worse Survival As Compared to High Molecular Risk Mutations in Patients with Myeloproliferative Neoplasms
656 - Initial Results from a Phase 1/2 Study Evaluating Divesiran, a Novel Galnac Conjugated siRNA, in Patients with Polycythemia Vera (SANRECO)
873 - Molecular Consequences and Targeting of PPM1D Mutations and Overexpression in Myeloproliferative Neoplasm Stem Cells
1377 - Selinexor Depletes Ruxolitinib Refractory Myelofibrosis Hematopoietic Stem Cells By Inducing Apoptosis and Blunting the Pro-Inflammatory Milieu
2660 - Gut Microbiota Promote Chronic Inflammation in Jak2^V617F Mice
3588 - KT-253, a Highly Potent and Selective MDM2 Protein Degrader, Eliminates Malignant Myelofibrosis Stem/Progenitor Cells
4512 - Role of HMGA2 Overexpression Caused By Specific Genetic HMGA2 Aberrations in Disease Progression in Calreticulin-Mutated Myelofibrosis Patients
4520 - High-Resolution Chromosomal Microarrays Reveals Exon-Level Deletion in Chromosome 12q14.3 in Patients with Myeloproliferative Neoplasms
3147.1 - A Multicenter, Open-Label, Phase 1 Clinical Trial of AJ1-11095 Administered As Oral Monotherapy in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed By a Type I JAK2 Inhibitor (JAK2i)

Hoffman, S.

2358 - Improving Quality of Life Based on Electronic Patient Reported Outcomes in Patients with CLL and MDS: The Mypal Study

Hoffmann, G. V.

918 - CSF1R Targeting T Cell Engaging Bispecific Antibodies Enable Safe and Efficient Immunotherapies in Acute Myeloid Leukemia
4796 - Dissection of Single-Cell Landscapes for the Development of Chimeric Antigen Receptor T Cells in Hodgkin Lymphoma

Hoffmann, M.

236 - Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181
389 - Utilization of Investigations for Neurotoxicity in CD19 and BCMA CART Recipients
579 - Golcadomide (GOLCA) Plus R-CHOP Has High Minimal Residual Disease (MRD) Negativity across High-Risk, Untreated Aggressive B-Cell Lymphoma (a-BCL)
935 - Real-World Experience of Infections with T-Cell Engagers in Multiple Myeloma and Non-Hodgkin’s Lymphoma
2350 - Practical Implications of Multi-Institution Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity (ICANS) Rates in Lymphoma Targeted Bispecific Antibodies (BsAb)
4623 - Mutations in the Bruton Tyrosine Kinase (BTK) Gene in Patients with Chronic Lymphocytic Leukemia (CLL) Receiving BTK Inhibitors (BTKis)
5030 - The Use of the Montreal Cognitive Assessment to Predict Neurotoxicity Post CD19 and BCMA CART
1742.2 - Golseek-1: A Phase 3, Double-Blind, Randomized Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Vs R-CHOP in Patients with Previously Untreated, High-Risk, Large B-Cell Lymphoma
4434.2 - CTEP 10590, NORM: Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase II Trial with Either Rituximab or Mosunetuzumab

Hoffmann, M.

364 - Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
769 - Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)

Hoffmann, M.

1246 - Imaging Predictors of Intracerebral Hemorrhage in Patients with Brain Tumors Treated with Anticoagulation

Hoffmann, P.

264 - Immunomodulatory Microbial Metabolites Protect Against Graft-Vs-Host Disease and Enhance Anti-Leukemia Responses in Mice and Patients Receiving Stem Cell Transplantation

Hoffmann, S.

1877 - The Differences between Ide-Cel and Cilta-Cel in Relapsed Myeloma at Single Cell Resolution

Hoffmann, W.

406 - Intraindividual Comparison of Recognition of Symptom Burden in MPN between Patient- and Physician-Reported Assessment and Its Impact on Survival – an Analysis By the German Study Group for MPN (GSG-MPN)
1090 - Reliable Assessment of Iron Deficiency in Patients with Myeloproliferative Neoplasms through Fluorescence Spectroscopy-Based Measurement of Zinc Protoporphyrin (ZPP)

Hoffmeister, K. M.

3952 - Serum O-Glycan Antigenicity in Pediatric Immune Thrombocytopenia Predicts Disease Persistence
- Unveiling the Sweet Side of Platelet Formation: Exploring the Pivotal Role of Glycans

Hoffmeister, L. M.

228 - Significance of RT-qPCR-Based Measurable Residual Disease for Optimizing the Treatment of Pediatric Acute Myeloid Leukemia
4322 - Comprehensive Analysis of Target and Immune Checkpoint Markers in Pediatric AML

Hoffmeyer, E.

2017 - Off the Shelf Stem Cell Derived Innate Lymphoid Cells Ameliorate Gvhd through IL-9 Induced-T Cell Senescence

Hofman, M. S.

1029 - CAR-T Cell Therapy in Advanced Myeloma with Extramedullary Disease – an In Vivo Imaging and Molecular Monitoring Study (CARAMEL): First Results of Cu-64 Radiolabelled Nanoparticle PET-CT and PET-MRI
4511 - Bridging Radiotherapy to Axicabtagene Ciloleucel (axi-cel) Is Associated with Favourable Outcomes for Large B-Cell Lymphoma (LBCL) in Third-Line and Beyond: An Australian Single-Centre Real-World Experience

Hofmann, F.

2670 - Primary Hematopoietic Cells of Vexas Patients Are Highly Sensitive to Treatment with TAK-243 and Pevonedistat

Hofmann, J.

4358 - Expanded Genome-Wide Association Study (GWAS) Identifies Nine Novel Germline Risk Loci for Waldenström Macroglobulinemia (WM) and Lymphoplasmacytic Lymphoma (LPL)

Hofmann, K.

759 - Richter Syndrome-Associated Genetic Lesions in TP53 and the Cell Cycle Inhibitors CDKN2A and CDKN2B Induce Transformation of a CD5+ B Cell Subset Characterized By a Restricted IGHV Repertoire, Autoreactivity and BCR Dependence

Höfmann, S.

1366 - Loss of IRF2BP2 Drives an Actionable IL-1β/IL-1R Signaling Loop in DLBCL

Hofmann, W. K.

660 - Redefining Prognosis in Patients with KIT D816V Positive Advanced Systemic Mastocytosis on KIT Inhibitors
2670 - Primary Hematopoietic Cells of Vexas Patients Are Highly Sensitive to Treatment with TAK-243 and Pevonedistat
4143 - The Bispecific Innate Cell Engager AFM28 Can Leverage AML Patient’s NK Cells in Addition to Allogeneic NK Cells, Enabling Elimination of CD123+ Leukemic Stem and Progenitor Cells in AML and MDS

Hofmans, M.

2831 - Cerebrospinal Fluid Flow Cytometry Improves Patient Stratification in Central Nervous System Acute Lymphoblastic Leukaemia but Requires Careful Standardization: Results from the ALLTogether1 CSF-FLOW Sub-Study

Hofmeister, C. C.

255 - A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma
283 - National Healthtree Survey on Pain and Opioid Use Patterns and Perceptions Among Patients with Multiple Myeloma
1983 - Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma (SMM)
1993 - Feasibility and Target AUC Accuracy of Personalized High Dose Melphalan in Myeloma
3311 - Risk of Infections in Multiple Myeloma Patients Treated with Bispecific Antibodies
3780 - Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with Early Progression Following Induction with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)
4663 - Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2
4672 - A Slow-Go Treatment in Newly Diagnosed AL Amyloidosis with Severe Cardiomyopathy
4702 - Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes
5142 - Serum Free Light Chain Ratio Is Inversely Proportional to the Egfr, and Has Been Increasing over the Last Decade
5144 - First Ever National Survey on Patient-Reported Efficacy and Safety of Cannabis in Patients with Multiple Myeloma
5152 - Survival of Multiple Myeloma Patients in Epic Cosmos Confounded By Death Reporting

Hofstede-Van Egmond, S.

2554 - The ‘Stop TPO-Receptor Agonist in ITP Patients’ (STIP) Study: Clinical and Immune Modulatory Effects of Romiplostim Tapering

Hofstetter, L.

1668 - Brentuximab Vedotin-Based Regimens for Older Patients with Newly Diagnosed Classical Hodgkin Lymphoma – International, Multi-Center Real-World Experience

Hogan, L. E.

633 - The Role of an Inflammatory Phenotype in Driving Clonal Evolution in B-Acute Lymphoblastic Leukemia
634 - TCL1A Is Associated with Blinatumomab Response and Immune Activation in Pediatric B-ALL
1431 - Premature Immune Aging in Survivors of Childhood Hematologic Malignancies

Hogan, W. J.

380 - Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk Gvhd
384 - Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC
685 - The Composite Health Risk Assessment Model (CHARM) Predicts Risks of Toxicities, Functional and Cognitive Decline Among Survivors of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): A Prospective BMT-CTN Study 1704
695 - Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702
1823 - Venetoclax in Combination with Hypomethylating Agent (HMA) Compared to HMA Alone Improves Response but Not Survival in TP53-mutated High-Risk Myelodysplastic Syndrome: Real-World Mayo Clinic Series
2852 - Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
2869 - Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hotspots: A Retrospective Study of 82 Patients
3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
4247 - Response-Stratified Genetic Risk Model for Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
4918 - Risk of Relapse Post Reduced Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with High-Risk Myeloid Neoplasms Based on Ptcy Vs TAC/MTX Gvhd Prophylaxis
5149 - Characteristics and Outcomes of Patients with Second Hematological Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Hogardt, M.

2866 - Incidence, Risk Factors, and Outcomes of Candida Bloodstream Infections in Hematological and Oncological Patients

Hogeling, S.

1393 - DGAT1 Inhibition Enhances Metformin-Induced Ferroptosis in AML By Targeting Lipid Metabolism

Hogg, G.

1551 - Detection of KMT2A Partial Tandem Duplication in Myeloid Samples By Pacbio® Long Read Sequencing

Hogg, K.

4115 - A Novel in Vitro Model of Pre-Leukemic Competition Reveals “Super-Competitive” TET2-Mutant Hematopoietic Stem Cell Clones

Hogg, P.

2578 - Disulfide Bond Heterogeneity in Factor VIII: Implications for Protein Function and Haemophilia a Therapy

Höglund, M.

639 - Deciphering the Heterogeneity of Acute Myeloid Leukemia through Chromatin Accessibility Profiling
1565 - Resistance to FLT3 Inhibitors in FLT3-Mutated AML Is Associated with CD45RA⁺CD200^-leukemic Cells and Can be Overcome By Combination with SMAC Mimetics
2687 - Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition
4078 - Phase III COMMODORE 1 Trial: 2-Year Efficacy and Safety of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Ravulizumab

Högstrand, K.

27 - Stable Contribution of Lineage-Restricted Stem Cells to Steady-State Aged Human Hematopoiesis
4038 - Identification and Characterization of Distinct Pathways for Platelet Replenishment in Steady-State Hematopoiesis

Hohaus, S.

854 - A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Ctdna
1577 - TP53, CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial
2960 - Non-Coding Mutations of BCL6 in Classical Hodgkin Lymphoma
3013 - Ibrutinib or Chemo-Immunotherapy As Second Line Treatment in Waldenstrom Macroglobulinaemia? a Real-Life Multicentre Study
4362 - Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

Hohaus, S.

578 - Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma

Hohmann, A. F.

88 - A Versatile B Cell Engineering Platform Enables Development of B Cell Medicines for Sustained Delivery of Therapeutic Biologics

Hohmann, H.

3111 - Updated Response and Safety for Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Holappa, E.

4814 - Bone Marrow Stromal Cells Hamper Leukemia Cell Induced NK Cell Activation and Cytotoxicity

Holbro, A.

4003 - Daratumumab for Refractory and Frequently Relapsing Immune Thrombotic Thrombocytopenic Purpura – a Case Series with Long-Term Follow-up

Holbrook, A.

700 - Clinical Outcomes after Hospitalization for Oral Anticoagulant-Related Bleeding

Holden, K.

1551 - Detection of KMT2A Partial Tandem Duplication in Myeloid Samples By Pacbio® Long Read Sequencing

Holderried, T. A.

364 - Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
769 - Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
2003 - Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma
2875 - Active Immunotherapy with Vididencel As Maintenance Treatment in MRD+ AML Patients in CR1 Results in Strong Anti-Tumor Immune Responses and Durable Long-Term Survival in Patients with an Immune Competent Immune Profile
4894 - Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT
4945 - Prognostic Impact of t(9;11) and Del(7q) As Intermediate-Risk Abnormalities in AML Following Allo-Transplant: Insights from the ELN 2022 Classification – an EBMT ALWP Study
5037 - Estimating the Impact on Survival of Not Receiving CAR T Therapy Despite Being Eligible in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Patients in Germany

Holdhoff, M.

3122 - Phase 1 Study of Escalating Doses of Ibrutinib in Teddi-R with Isavuconazole for Relapsed and Refractory Primary DLBCL of the CNS

Holets, M.

1652 - Outcomes in Early Relapse of Follicular Lymphoma Versus Early Histologic Transformation Following Firstline Immunochemotherapy in Follicular Lymphoma

Holewinski, R.

1273 - CD38 Inhibition Enhances Human Hematopoietic Stem Cell Maintenance in Ex Vivo Cultures

Holinstat, M.

2544 - Selectivity and Long Action of In Vivo Efficacy of CS585, a Novel Prostacyclin Receptor Agonist, Compared to FDA-Approved Prostacyclin Agonists Iloprost and Selexipag in the Prevention of Thrombosis
3932 - 12-Hepe Regulates the Antiplatelet Effects of Epa, the ω-3 Fatty Acid
3933 - Comparison of the Anti-Platelet and Anti-Thrombotic Effects of the Dual SGLT1/2 Inhibitor Sotagliflozin to the Relatively Selective SGLT2 Inhibitor Empagliflozin

Holkova, B.

1026 - First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
3364 - Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma

Holland, G.

4121 - A Novel Form of AEBP2-Containing PRC2.2 Is a Genetic Dependency in Germinal Centre B-Cell Lymphoma and Its Targeting Can Overcome Acquired Resistance to EZH2 Inhibition

Holland, H. K.

2363 - Prophylactic Corticosteroids Allow Safe Outpatient Administration of Axicabtagene Ciloleucel with Comparable Toxicities to Other CAR-T Therapies in Large Cell Lymphoma
4913 - The Degree of HLA-DPB1 Mismatch Predicted By Evolutionary Divergence Scoring Informs the Risk of Chronic Graft-Versus-Host Disease after Haploidentical Transplantation with Post-Transplant Cyclophosphamide
4948 - High HLA Evolutionary Divergence in Donor HLA-B Locus Impacts Transplant Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

Holland, H. K.

1450 - Improved Outcomes of Adult Patients with Philadelphia-like Acute Lymphoblastic Leukemia (Ph-Like ALL) Treated within an Integrated Leukemia/Transplant Program with Incorporation of Pediatric Inspired Regimens and Early Allogeneic Transplant
1522 - Comparison of FLAG-Idarubicin to FLAG-Idarubicin Plus Venetoclax for Treatment of Newly Diagnosed AML in Patients Eligible for Intensive Induction. Analysis of 200 Consecutive Patients Treated at a Single Center
3501 - Intensive Conditioning with Fludarabine Plus Melphalan Versus Total Body Irradiation Prior to Haploidentical Transplant and Post-Transplant Cyclophosphamide
3528 - Safety and Efficacy of Ibrutinib Added to Rituximab-Based Primary Therapy of Chronic Graft-Versus-Host-Disease
4912 - Extracorporeal Photopheresis (ECP) in the Era of New Chronic Graft-Versus-Disease (GVHD) Therapies

Hollander, P.

1623 - Plasma Proteomic Profiling Identifies Prognostic Biomarkers in Mantle Cell Lymphoma
2987 - The Composition of Macrophages Has Prognostic Impact in Diffuse Large B-Cell Lymphoma By Spatial Omic Studies
2995 - Rule-Based Machine Learning Analysis of the Blood Proteome Identifies MCL Patients with High Risk of Early Disease Progression

Hollander, S.

648 - Non-Invasive Characterization and Early Detection of Post-Transplant Lymphoproliferative Disorders

Holler, E.

264 - Immunomodulatory Microbial Metabolites Protect Against Graft-Vs-Host Disease and Enhance Anti-Leukemia Responses in Mice and Patients Receiving Stem Cell Transplantation
380 - Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk Gvhd
384 - Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC
780 - Recovery of the Intestinal Microbiome in Patients at Day +100 after Allogeneic Stem Cell Transplantation Is Defined By Microbial Metabolite Profiles and Linked to Long-Term Outcomes
2023 - CD47 Upregulation Inhibits Phagocytic Clearance of Alloreactive Donor T Cells after Allo-HCT

Hollmén, M.

913 - Comprehensive Drug Profiling and CRISPR Screening Reveal Essential Pathways for NK Cell Cytotoxicity
4265 - Encouraging Efficacy of Bexmarilimab with Azacitidine in Relapsed or Refractory MDS in Bexmab Ph1/2 Study

Hollnagel, F.

197 - PARP Inhibitor Treatment Increases DNA Damage in Bone Marrow and Drives Compensatory Changes in Multiple Hematopoietic Stem and Progenitor Cell Populations Contingent on Brca1 Genotype
2243 - Microlearning in Sickle Cell Disease for Clinicians: A Practical Tool for Everyday Practice

Holloman, M.

47 - Differential Role of Crebbp Missense and Truncating Mutations in the Malignant Transformation of Germinal Center B Cells

Holman, M.

2950 - Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia

Holman, T.

3932 - 12-Hepe Regulates the Antiplatelet Effects of Epa, the ω-3 Fatty Acid

Holmberg, H.

4543 - Myelofibrosis Therapies and Risk of Major Bleeding, Thrombotic Events and Mortality, a Matched Nationwide Population-Based Study

Holmberg, L.

3772 - Trends in Pre-CAR-T Attrition in Relapsed/Refractory Multiple Myeloma: Prevalence, Risk Factors, and Outcomes at a Tertiary Academic Medical Center

Holmes, A.

47 - Differential Role of Crebbp Missense and Truncating Mutations in the Malignant Transformation of Germinal Center B Cells
4128 - Role of Glucocorticoid Receptor in Normal and Malignant Germinal Center B Cells

Holmes, C. E.

2252 - Risk Factors for Bleeding after Recent Medical Hospitalization: The Medical Inpatient Thrombosis and Hemostasis Study (MITH)

Holmes, E.

3238 - Patient-Reported Quality of Life Outcomes with Venetoclax-Based First-Line Combinations in CLL: An Analysis from the Phase 3 GAIA/CLL13 Trial

Holmes, H.

3132.1 - ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy

Holmes, L.

2274 - Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy
5047 - Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization

Holmes, M. C.

515 - In Vivo HSC Gene Editing for Correction of the Sickle Cell Mutation Using RNA Gene Writers
2197 - Delivery of Gene Writers In Vivo to Hematopoietic Stem Cells and T Cells Using Targeted and Untargeted Lipid Nanoparticles (LNP)
4799 - Targeted Lipid Nanoparticle Delivery of an RNA Gene Writer In Vivo Enables Generation of CAR-T Cells in a Humanized Mouse Model

Holmes, S.

1027 - Early Safety and Efficacy of CAR-T Cell Therapy in Precursor Myeloma: Results of the CAR-PRISM Study Using Ciltacabtagene Autoleucel in High-Risk Smoldering Myeloma

Holmes-Snowden, P.

1964 - Mass Spectrometry (MS)-Based Exent® Solution Reveals High Prevalence of Multiple M-Proteins in African American Patients with Multiple Myeloma (MM) and Precursor Conditions
2669 - Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy

Holmgaard, R.

2785 - LY4152199, a First-in-Class BAFF-RxCD3 Bispecific Antibody for the Treatment of B Cell Malignancies

Holodja, J.

886 - BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Holowiecki, J.

970 - A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) – Topline Results
4268 - The Experience of Commercially Available CPX-351 Use As First-Line Treatment for Patients with Acute Myeloid Leukemia – a Report of Polish Adult Leukemia Group (PALG)

Holroyd, A.

3354 - Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome – Long-Term Follow-up of the Ukmra Optimum/Muknine Trial

Holsapple, III, E.

4453.1 - First-in-Human Phase 1a Clinical Trial of the Investigational New Drug ST-001, a Novel Nano-Phospholipid Dispersion Formulation of Fenretinide, in Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

Hölscher, A.

114 - Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma

Holshouser, B.

1237 - Comparison of Standard-Dose Versus Fixed-Dose Rituximab for Non-Malignant, Immune-Mediated Hematologic Disorders

Holstein, K.

555 - Sustained Improvement of Survival in Patients Receiving Emicizumab Prophylaxis Instead of Immunosuppression during Early Management of Acquired Hemophilia a (AHA)

Holstein, S. A.

3355 - Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)
3381.3 - A Phase III Randomized Trial for Frail Newly Diagnosed Multiple Myeloma Patients Comparing Bortezomib- Lenalidomide-Dexamethasone (VRd-Lite followed by Len maintenance) with Daratumumab-Lenalidomide- Dexamethasone (DRd followed by Len+/- Dara Maintenance): SWOG S2209

Holtan, S. G.

1042 - Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis

Holtan, S. G.

3445 - Influence of Myeloma Cell Expressed CD28 and CD86 on BCMA CAR T Cell Efficacy and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS)

Holte, H.

231 - Biological and Prognostic Subgroups of Plasmablastic Lymphoma Defined By EBV Status and MYC Rearrangement– an L.L.M.P.P. Study
342 - Fixed-Duration Epcoritamab + R² Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial
1601 - Clonal Hematopoiesis Mutations and Cell-Free DNA Characteristics in Patients with High-Risk Large B-Cell Lymphomas

Holter, W.

2182 - Analysis of Outcomes after Second Allogeneic Stem Cell Transplant in Relapsed Acute Myeloid Leukaemia in Children: A Study from the EBMT Pediatric Diseases Working Party
3563 - Addition of Anti-T-Lymphocyte-Globuline As Graft Versus Host Disease Prophylaxis for Matched Unrelated Donors Equalizes Outcomes with Matched Sibling Donors: Results from the AML SCT-BFM 2007 Trial

Holter-Chakrabarty, J. L.

694 - Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients
- ASH Advocacy

Holtick, U.

114 - Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma
1714 - Inflammation-Based Scores Predict Survival after CD3xCD20 Bispecific T Cell Engagers in R/R LBCL
3554 - Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group

Holtz, M.

2575 - The Gut Microbiome Regulates FVIII Immune Responses

Holub, M.

3840 - Cold Autoimmune Hemolytic Anemia Secondary to Mycoplasma Pneumoniae Infection in Adults: Results from a Large French Observational Study (MYCOLD study)

Holvoet, L.

2522 - Effect of Rituximab on Spleen and Blood B-Cell Subpopulations in Allo-Immunized Children with Sickle Cell Anemia

Holz, M.

1351 - Parallel Sequencing of Transposons and Transcriptomes in Single Cells for Genome-Wide Cancer Gene Discovery

Holzem, A. M.

1060 - CRISPR-TOF Platform: A Single-Cell Approach for Studying Kinase-Dependent Immune-Signaling Dynamics in Human Primary T Cells
1714 - Inflammation-Based Scores Predict Survival after CD3xCD20 Bispecific T Cell Engagers in R/R LBCL

Holzhauer, S.

295 - Efficacy and Safety of Apixaban for Pediatric Patients Requiring Anticoagulation for Treatment of Venous Thromboembolism

Holzmayer, S. J.

1406 - Perforin-Induced Killing in Leukemic Cells Is Driven By NFAT2-Mediated Cytoskeletal Remodeling
3392 - FLT3-ITD Driven CMTM6 Expression Contributes to Immune Escape of Acute Myeloid Leukemia

Holzmüller, V.

3399 - Exploring a Novel Anti-Inflammatory Peptide As a Potential Treatment for Acute Graft-Versus-Host Disease (aGVHD)

Holzwart, N.

4376 - T Cell CD62L Expression Following Nivolumab Therapy Is Associated with Long Term Response to Rituximab-Nivolumab in Treatment Naïve Follicular Lymphoma: Results from the 1^st FLOR Study
4384 - Marginal Zone Lymphoma Is Associated with Dysregulated Peripheral Blood Immunity Which Is Not Changed By Ibrutinib-Venetoclax Treatment

Hom, B.

2892 - Optimizing Venetoclax Duration in Combination with Hypomethylating Agents for Newly Diagnosed AML: Impact on Treatment Response and Survival Outcomes
3566 - Clinical Impact of Pretransplant Blinatumomab in Predominantly Hispanic Adults with B-Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Homann, C.

1090 - Reliable Assessment of Iron Deficiency in Patients with Myeloproliferative Neoplasms through Fluorescence Spectroscopy-Based Measurement of Zinc Protoporphyrin (ZPP)

Homenda, W.

483 - Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis

Homsy, S.

2006 - Anti-BCMA CAR T-Cell Expansion and Its Association with Response and Toxicity in Multiple Myeloma

Hon-Balla, B.

2805 - Diagnosing and Staging Central Nervous System Involvement in Pediatric ALL: A Global Survey on Its Heterogeneity

Honda, H.

4515 - Cbl^Q367P Cooperates with Loss of Tet2 to Drive a Cnl-like Disease Via the NF-Kb Pathway

Honda, K.

2115 - A Retrospective Study of C5b-9 and MASP2 Deposition in Skin Microvasculature As a Prognostic and Diagnostic Tool for Transplant-Associated Thrombotic Microangiopathy

Honeyman, F.

3256 - Preemptive Therapy with Venetoclax for High-Risk Stage a CLL Patients: First Analysis of Prevene, a Phase II Trial of the Filo Group

Hong, A.

3674 - Emergency Medicaid Policies Enabling Equitable Access to Healthcare Coverage for Undocumented Individuals with Hematologic Malignancies across the United States

Hong, B.

2704 - Prospective Genomic Study for Optimizing Clonal Hematopoiesis Surveillance in Bone Marrow Failure Syndromes and Related Cytopenia

Hong, C. L.

563 - Compartmentalized Niche and Spatially Heterogenous Inflammatory Landscape Regulate Tet2^+/-- Mediated Clonal Hematopoiesis

Hong, F.

4743 - MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Hong, H. J.

2892 - Optimizing Venetoclax Duration in Combination with Hypomethylating Agents for Newly Diagnosed AML: Impact on Treatment Response and Survival Outcomes
3566 - Clinical Impact of Pretransplant Blinatumomab in Predominantly Hispanic Adults with B-Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Hong, Jr., J. S.

3353 - Hypogammaglobulinemia and Daratumumab in Multiple Myeloma: Risk Factors, Infections, Immunoglobulin Replacement, and Mortality

Hong, J.

1375 - ATR Inhibitor Elimusertib Suppresses Drug Persister Clones in TP53-Mutated Acute Myeloid Leukemia Via CGAS-Sting-Mediated Cell Death
1495 - PHI-101, a Novel FLT3 TKI, Shows Clinical Efficacy in Relapsed/Refractory FLT3-Mutated AML

Hong, L.

1940 - Study on the Role of Platelet-Activating Factor in Promoting Relapse of Multiple Myeloma after CAR-T Therapy

Hong, L.

3004 - Spatial-Resolved Transcriptomics Reveals Immune Landscape Variations in Primary Central Nervous System Lymphoma (PCNSL) and Diffuse Large B-Cell Lymphoma (DLBCL)

Hong, M.

3165 - Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Hong, M.

1606 - Shallow Whole Genome Sequencing of Circulating Tumor DNA Is Predictive of Outcome in Diffuse Large B-Cell Lymphoma
4385 - Multiome Single Cell Analyses Identify a Distinct CD8+ T Cell Phenotype Linked to Treatment Response in PTLD

Hong, M.

1501 - Decitabine before Low-Dose Cytarabine-Based Chemotherapy Combined with Unrelated Umbilical Cord Blood Stem Cell Microtransplantation and IL-2 Treatment in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
1549 - Single-Cell Transcriptome Analysis Reveals the Novel Subtypes and Therapeutic Implications of T-Lymphoid/Myeloid Mixed-Phenotype Acute Leukemia

Hong, R.

91 - Rituximab, Lenalidomide, and Zanubrutinib (ZR²) with Sequential CAR-T Cell As First-Line Therapy for High-Risk Large B Cell Lymphoma
921 - A Novel Generation of Anti-CD7 Universal CAR-T Therapy for Patients with Relapsed or Refractory CD7 Positive T-ALL/Lbl: A Phase I Clinical Trial
2074 - 1‰ Regular Dose of Metabolically Armored CD19 CAR-T Cells Induces Robust In Vivo Expansion and Complete Remission in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients
2818 - Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia

Hong, S.

2209 - Evaluating Protein Interaction Potential of BCL2 Protein for the Direct Assessment of Inhibitor-Target Engagement in Hematological Cancer

Hong, S.

2295 - Understanding Sociodemographic Barriers in Hematopoietic Stem Cell Transplantation Among Patients with Hematologic Malignancies: Insights from a North Carolina Cohort
4921 - Real-World Clinician Adherence to Screening and Preventive Practices Guidelines for Subsequent Neoplasms Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States
5044 - Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina

Hong, S.

2170 - Clinician Adherence to Screening and Preventive Practices for Non-Malignant Late Effects Among Allogeneic Hematopoietic Cell Transplant Survivors in the United States

Hong, S. H.

4468 - A Comparative Study of [¹⁸f]FDG PET and MRI for Evaluating Treatment Response in Primary CNS Lymphoma Patients Undergoing High-Dose Methotrexate Therapy

Hong, S. G.

516 - CD117 Antibody Conditioning and Multiplex Base Editing Enable Rapid and Robust Fetal Hemoglobin Reactivation in a Rhesus Autologous Transplantation Model

Hong, W. J.

3215 - Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Patients with Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies
4501 - Preliminary Results of a Phase 1, Dose-Escalation Study of PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Hong, X.

1387 - An Orally Active Pan-BCR::ABL1 Degrader Tgrx-3247 Potently Targets a Wide Spectrum of Orthosteric, Allosteric and Compound Mutations Resistant to TKI Therapies

Hong, X.

3071 - Clinical Features and CSF-Ctdna Characteristics in Extranodal Natural Killer/T‐Cell Lymphoma Patients with Central Nervous System Involvement

Hong, Y.

452 - Spatial Architecture of Immune Microenvironment Orchestrating Anti-Lymphoma Immunity and the Response to Immunochemotherapy in EBV+ Diffused Large B Cell Lymphoma Revealed By Imaging Mass Cytometry and Spatial Transcriptome
1621 - CD163+ Macrophages Orchestrate Tumor Immunity By Spatially Fortifying Follicular Lymphoma Against CD8+ T Cells Attack during Early Progression
4379 - Suvmax Linked to Intrafollicular Macrophage Infiltration Is Associated with Poor Outcome of Follicular Lymphoma

Hong, Y.

4158 - Integrated Stress Response Activation Induced By Usnic Acid Alleviates BCL-2 Inhibitor ABT-199 Resistance in Acute Myeloid Leukemia

Hong, Y.

3533 - Regulatory Effects of IL-17A Monoclonal Antibody and Fibronectin on Chronic Graft-Versus-Host Disease

Hong, Y. S.

4054 - Mitochondrial Heteroplasmy Is a Novel Predictor of Chronic Lymphocytic Leukemia Risk

Hong, Y.

2210 - Targeting Intracellular Mutant NPM1 in Acute Myeloid Leukemia with a Novel Peptide-MHC-Specific T-Cell Bispecific Antibody

Hong, Z.

4205 - A Phase 2 Clinical Trial of Anti-CD19 CAR-T (pCAR-19B) in Chinese Pediatric and Young Adult with Relapsed/Refractory (R/R) CD19+ B-ALL: The First Pivotal Study in an Asian Population
4450 - Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study

Hongeng, S.

2194 - Betibeglogene Autotemcel (beti-cel) Gene Addition Therapy Results in Durable Hemoglobin a Production with up to 10 Years of Follow-up with Transfusion-Dependent β-Thalassemia

Hongming, H.

1940 - Study on the Role of Platelet-Activating Factor in Promoting Relapse of Multiple Myeloma after CAR-T Therapy

Honigberg, M. C.

948 - IL-11 Signaling Drives Clonal Hematopoiesis-Associated Cardiac Dysfunction

Honmma, M.

2930 - Combination of Low White Blood Cell Count and Impaired Renal Function Is a Risk Factor for Higher Concentrations of Venetoclax and Prolonged Neutropenia in AML Patients with Venetoclax Combined Regimen: Real World Experience in the Japanese Cohort

Honzik, T.

431 - A Novel Cause of Type 1 VWD: Impaired Exocytosis of Weibel-Palade Bodies Due to Biallelic Mutations in Madd

Hoock, M.

4100 - VISTA As a Mediator of Immune Suppression in AML Initiated By DNMT3A and NPM1 mutations

Hoogenboezem, R.

442 - Hematological Phenotypes in GATA2 Deficiency Syndrome Arise from Secondary Injuries and Maladaptation to Proliferation
4300 - Transcriptional Profiling Directs the Classification of Mixed Phenotype Acute Leukemias into AML, B-ALL or T-ALL

Hoogenboom, J. D.

3456 - Impact of Fludarabine Dosage on Outcomes in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy: A Retrospective Study on Behalf of the Ctiwp of the EBMT
4907 - The Use of MSCs in Steroid-Refractory Acute GvHD in Europe: A Survey from the EBMT Cellular Therapy & Immunobiology Working Party

Hoogendijk, A.

2454 - Lu/BCAM Expression Defines Functionally Distinct Red Blood Cells

Hoogeveen, P. G.

4300 - Transcriptional Profiling Directs the Classification of Mixed Phenotype Acute Leukemias into AML, B-ALL or T-ALL

Hoogland, A. I.

5165 - Meaningful Change in Patient-Reported Outcomes after CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma in Standard of Care: Differences By Race and Ethnicity

Hoogstra, D.

1581 - NPM::ALK Transcript Levels and Anti-ALK Autoantibody Titers As Biomarkers for Outcome in Pediatric ALK+ Anaplastic Large Cell Lymphoma Treated with Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy: COG ANHL12P1

Hooimeijer, L.

127 - Pharmacokinetic-Guided Reduction of Emicizumab in Patients with Congenital Hemophilia a in the Netherlands: Interim Analysis from the Dosemi Study

Hook, C. C.

613 - Assessment of Classical Hematologists and Hematology-Focused Fellowship Programs at NCI-Designated Cancer Centers: Implications for Addressing Workforce Shortages and Enhancing Mentorship Opportunities

Hooper, G. E.

335 - SEC62 Regulates HLA-E Expression in Diffuse Large B-Cell Lymphoma to Function As a Mechanism of Immune Evasion

Hooper, K.

2406 - Racial and Socioeconomic Disparities in Patients with Waldenström’s Macroglobulinemia. a SEER Database Analysis
3314 - Characterizing Genomic Variants Defining a Plasma Cell Disorder Patient Cohort Using a Broad Next Generation Multi-Gene DNA Sequencing Panel

Hooper, R.

4769 - Ezh2 and Intracellular Ca2⁺ Signals Interdependently Coordinate Gvhd and CAR T Cell Responses

Hoover, A.

4887 - Hemorrhagic Cystitis after Allogeneic or Autologous Hematopoietic Cell Transplantation in Pediatric Patients: Continuous Versus Intermittent Mesna

Hoover, K.

5133 - Modeling Longitudinal Quality of Life Changes in Patients Diagnosed with Lymphomas: Heatmap Analysis of Electronic Patient-Reported Outcomes (ePRO) Data from the Bison-PRO Quality of Life Study

Hope, K. J.

2937 - Examining the Clinical Relevance of the AML Plasma Metabolome

Hopkins, C. R.

3473 - In Vivo Persistence and Function of CAR19 T-Cell Products for Pediatric B-Cell Acute Lymphoblastic Leukemia Are Impacted By Media, Cytokine Supplementation and Metabolite Bioavailability during Ex Vivo Manufacturing

Hopkins, L.

120 - Prospective Cohort Study of Non-COVID Infection in Patients with AML/MDS Undergoing Treatment: Implications for Practice

Hopkins, T. D.

4970 - Multi-Omic Transcription Regulatory Network Mapping Identifies Targetable Oncogenic TF-Cofactor Relationship between IRF4 and p300 in Multiple Myeloma, and Is Used to Improve TF Protein-Protein Interaction Methodology

Hoppe, B.

462 - Pembrolizumab in Children, Adolescents, and Young Adults with Low-Risk Classic Hodgkin Lymphoma (cHL) and Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study
2283 - Impact of COVID-19 on Multidisciplinary Lymphoma Tumor Boards: An Analysis of Practice and Care Changes
3055 - Pembrolizumab in Children, Adolescents, and Young Adults with High-Risk Classic Hodgkin Lymphoma (cHL) with Slow Early Response to Front-Line Chemotherapy: Updated Results from the Phase 2 Keynote-667 Study

Hoppe, L.

4143 - The Bispecific Innate Cell Engager AFM28 Can Leverage AML Patient’s NK Cells in Addition to Allogeneic NK Cells, Enabling Elimination of CD123+ Leukemic Stem and Progenitor Cells in AML and MDS

Hoppe, M. M.

3602 - Machine Learning Classification of Spatial Patterns of Malignant Cells Reveals Implications in Prognosis and Tumor Microenvironment Composition in Lymphoma

Hoppe, R. T.

2116 - A Standard Operating Protocol for Pre-Transplant Low Dose Splenic Radiotherapy for Patients with Myelofibrosis
3068 - Pembrolizumab for Front-Line Treatment of Extranodal NK/T-Cell Lymphoma
4369 - Comprehensive Characterization of the Cell States and Ecosystems in Classic Hodgkin Lymphoma Using Single-Cell RNA-Seq, Digital Deconvolution, and Machine Learning

Hoppensteadt Moorman, D.

2638 - Relevance of Blood Cellular Indices with Inflammatory Cytokines in Patients with Pulmonary Embolism

Hopper, M. A.

2977 - Subtype-Specific Mechanisms of Treatment Resistance and Relapse in Diffuse Large B Cell Lymphoma (DLBCL)

Hopper, T.

4508 - Impact of Pre-Existing Mental Health Disorders (MHD) on CAR T-Cell Therapy Outcomes in Patients with Large B-Cell Lymphoma

Hoque, Z.

873 - Molecular Consequences and Targeting of PPM1D Mutations and Overexpression in Myeloproliferative Neoplasm Stem Cells

Hora, M.

3341 - Risk Factors for Suboptimal Treatment in Patients with Newly Diagnosed Multiple Myeloma across US Healthcare Systems
5169 - Evaluation of Socioeconomic Barriers Impacting Patients with Newly Diagnosed Multiple Myeloma

Horacek, J. M.

2806 - Central Nervous System Involvement Does Not Worsen Survival in Hematologic or Molecular Relapse of Adult Acute Lymphoblastic Leukemia Patients – Retrospective Analysis By the Czech Leukemia Study Group for Life (CELL)

Horan, J. T.

967 - A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO – a Report from the Children’s Oncology Group
3516 - Five-Year Outcomes of the “Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease (GVHD) Prophylaxis: A Randomized Controlled Trial” (‘ABA2’)

Horchler, M.

1251 - Higher D-Dimer and Prothrombin Fragment 1+2 in Patients Taking Direct Oral Anticoagulants As Compared to Vitamin K Antagonists

Hordijk, S.

431 - A Novel Cause of Type 1 VWD: Impaired Exocytosis of Weibel-Palade Bodies Due to Biallelic Mutations in Madd

Horesh, N.

1748 - Reduction in Platelet Counts May Predict the Development of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma

Horgan, C.

373 - Significant Incidence of Mixed Donor Chimerism Despite TBI Conditioning in Paediatric B-ALL Patients Bridged to Transplant with Blinatumomab – a Report from the UK and Ireland Paediatric Bone Marrow Transplant/Cellular Therapies Group
3455 - Reproducible Transient, Significant, Early Donor-Derived T-Cell Expansion, Induced By Pooled Granulocyte Transfusion, during Mismatch T-Cell Replete Cord Blood Transplant - an Optimal Platform for Allogeneic Graft Versus Leukaemia: Results of a Prospective Phase I/II Clinical Trial

Horhota, A.

3427 - In Vivo panCAR-Mediated Depletion of B Cells in Non-Human Primates Using a Circular (oRNA^®) Anti-CD20 CAR

Hori, T.

1426 - Prognostic Factors for T-Cell Acute Lymphoblastic Leukemia in Children and Young Adults: ALL-T11 Study Conducted By Japan Children’s Cancer Group and Japan Adult Leukemia Study Group

Horibe, K.

1426 - Prognostic Factors for T-Cell Acute Lymphoblastic Leukemia in Children and Young Adults: ALL-T11 Study Conducted By Japan Children’s Cancer Group and Japan Adult Leukemia Study Group
3203 - Molecular Taxonomy Classification for Transplant Decision Making of Myelodysplastic Syndromes

Horiguchi, H.

3096 - Reduced FDG Uptake in the Brain on Baseline 18FDG PET/CT Predicts Worse Prognosis of Newly Diagnosed Intravascular Large B-Cell Lymphoma and Advanced-Stage Diffuse Large B-Cell Lymphoma

Horiuchi, M.

4861 - The Diagnostic Accuracy of the Refined EBMT Criteria 2023 for SOS

Hormoz, S.

872 - Mutation-Specific Differences in the Relationship between Obesity and Clonal Hematopoiesis, with a Focus on JAK2^V617F and MPN Prevention

Horn, E.

3172 - Advanced Pulmonary Hypertension Shortens Survival in Polycythemia Vera

Horn, P.

901 - Memory CD4⁺ T Cells Recognize Divergent HLA-DP Immunopeptidomes and Contribute to Leukemia Control after Allogeneic HCT

Horna, P.

1858 - Artificial Intelligence-Enhancement of Flow Cytometry Data Accelerates the Identification of Minimal Residual Chronic Lymphocytic Leukemia
3319 - A Comparative Study of Plasma Cell Detection By Peripheral Smear and Peripheral Blood Flow Cytometry
3340 - Presence of Circulating Tumor Cells on Peripheral Blood Flow Cytometry at Best Response Predicts Overall Survival in Multiple Myeloma
4226 - Artificial Intelligence-Enhancement of Flow Cytometry Data Accelerates the Identification of Minimal Residual B Lymphoblastic Leukemia
4704 - Flow Cytometry-Based Assessment of the Proportion of Monoclonal Plasma Cells in Synthetic Phase (S-phase) Is an Independent Marker of Adverse Prognosis in Patients with Newly Diagnosed Multiple Myeloma

Horne, A.

1460 - Data-Informed, Refined Immunophenotypic Classification of Adult T-Lineage Acute Lymphoblastic Leukemia

Hornfeck, E.

1048 - Safety of Fedratinib As a Maintenance Strategy after Allogeneic Hematopoietic Cell Transplant for Myeloproliferative Neoplasms

Horns, J.

1458 - C/EBP Family Member Gene Fusions and Cooperating Genomic Events Define Two Distinct Molecular Sub-Groups in Adult B Precursor ALL
2832 - Recurrent Molecular Variants, Clonal Evolution and Clinical Relevance in T-Cell Lymphoblastic Neoplasia Comparing Lymphoma and Leukemia Samples Derived from Children and Adults

Horns, J. M.

631 - IDH2 Mutations from Clonal Hematopoiesis and Acquired IKZF1 Deletions Define a Novel B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma

Horns, J. J.

1864 - Real-World Comparison of BCL2 Inhibitor and BTK Inhibitor Therapy in the Front-Line Treatment of CLL Including Patients with Del(17p)/TP53 Mutation

Hornung, L.

3900 - Low Bone Density Associates with Severe Outcomes in Young Adults with Sickle Cell Disease

Horny, H. P.

660 - Redefining Prognosis in Patients with KIT D816V Positive Advanced Systemic Mastocytosis on KIT Inhibitors

Horowitz, E. M.

1019 - A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome
1894 - Novel Non-Coding Candidate Drivers of Multiple Myeloma Linked to Plasma Cell Tumor Biology and B Cell Development
1903 - Comprehensive Characterization of the Plasma Proteome of Multiple Myeloma and Its Precursor Conditions and Identification of a Proteomic Signature to Improve Risk Prediction of Disease Progression
4637 - Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages

Horowitz, M. M.

685 - The Composite Health Risk Assessment Model (CHARM) Predicts Risks of Toxicities, Functional and Cognitive Decline Among Survivors of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): A Prospective BMT-CTN Study 1704
695 - Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702
1042 - Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis
2134.1 - Trial in Progress: Cureaa - a Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) #2207

Horowitz, N. A.

237 - Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project
1748 - Reduction in Platelet Counts May Predict the Development of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma
5124 - Epcoritamab for Relapsed/Refractory B Cell Lymphoma – the Israeli Real-World Experience of a Compassionate Use Program

Hörster, K.

4857 - Analysis of Early Apheresis Immunophenotype, Batch Data Variables and Clinical Outcomes for Optimization of CAR-T-Cell Therapy in Aggressive B-Cell Lymphomas

Horton, K.

1381 - S227928: A Novel Anti-CD74 ADC with MCL-1 Inhibitor Payload for the Treatment of Acute Myeloid Leukemia (AML) and Other Hematologic Malignancies

Horton, P. D.

29 - Force Triggers Mitochondrial Biogenesis Necessary for Hematopoietic Stem Cell Specification Via mTORC1

Horton, S. J.

190 - Delayed Trp53 Activation Protects Dnmt3a-Mutant Haematopoietic Stem Cells from Inflammatory Attrition
722 - Acute Resistance to BET Inhibitors Remodels Compensatory Transcriptional Programs Via p300 Co-Activation

Horton, T. M.

313 - Genomic Biomarkers of Poor Outcome in Patients with T-Cell Lymphoblastic Lymphoma

Horvat, N.

9 - Inflammation-Driven NFκB Signaling Represses Ferroportin Transcription in Macrophages Via HDAC 1 and 3

Horvath, C. J.

3981 - A Phase Ia Study of VGA039, a Protein S-Targeting Monoclonal Antibody, in Individuals with Von Willebrand Disease Demonstrates Concentration-Dependent Increases in Thrombin Generation for Reducing Bleeding

Horvath, N.

892 - Efficacy and Safety of Isatuximab, Pomalidomide and Dexamethasone in Relapsed AL Amyloidosis: Interim Results of the Isamyp Phase 2 Joint Study from the IFM and ALLG
1032 - Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1–3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial

Horvathova, M.

794 - uRADAR: European Patients Referral Frame to Improve Access to New Drugs and Therapies in Ultra-Rare Anemia Disorders and Severe Hereditary Spherocytosis

Horwitz, M. S.

198 - CD74 Signaling Regulates Inflammatory Stress to Drive Defective Hematopoiesis and Fitness Advantage of Progenitors in RUNX1-Familial Platelet Disorder

Horwitz, M.

68 - Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma
2295 - Understanding Sociodemographic Barriers in Hematopoietic Stem Cell Transplantation Among Patients with Hematologic Malignancies: Insights from a North Carolina Cohort
4911 - Long Term Outcomes of a Randomized Trial of Anti-T Lymphocyte Globulin to Improve Moderate-Severe Chronic Gvhd Free Survival after Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Analysis
5044 - Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina

Horwitz, S.

454 - Integrating Genomic & Transcriptomic Features for Noninvasive Detection, Characterization, and Monitoring of T-Cell Lymphomas
463 - Dual-Targeted Therapy with Ruxolitinib Plus Duvelisib for T-Cell Lymphoma
465 - Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium
467 - Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC^TM Degrader, in Patients with Non-Hodgkin’s Lymphoma
569 - Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin
980 - Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization
1693 - Subsequent Treatment and Clinical Outcome Following Induction Therapy on a Phase II Study of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL)
1707 - High Grade B-Cell Lymphoma with MYC/BCL6-Rearrangements (R) May Have Inferior Outcomes Compared to BCL2-R Disease
1729 - Devimistat Results in a Low Complete Remission Rate in Heavily Pre-Treated Burkitt Lymphoma
2336 - Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
3053 - Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma
3061 - Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial
3068 - Pembrolizumab for Front-Line Treatment of Extranodal NK/T-Cell Lymphoma
4342 - Prediction of Clinical Response By Phased Variants in Circulating Tumor DNA (ctDNA) in the VALENTINE-PTCL01 Trial of Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)
4346 - Molecular Features Are Associated with Disease Stage in Diffuse Large B-Cell Lymphoma and Reveal Heterogeneity in Patient Outcomes
4429 - Improved Outcomes for Primary Refractory Classical Hodgkin Lymphoma: A Retrospective Analysis
4434 - Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study
4451 - Angioimmunoblastic Versus Non-Angioimmunoblastic Nodal T-Follicular Helper Cell Lymphomas: Single Center Retrospective Analysis on 208 Cases
4474 - A Prospective Geriatric Assessment (GA) Study Predicting Toxicities in Older Adults (OA) with Non-Hodgkin Lymphoma (NHL): Timed up and Go Test (TUG) Time Emerges As a Functional Vital Sign
4485 - Sequential R-CHOP/(R)-ICE and Dose-Adjusted EPOCH-R Are Both Appropriate Frontline Treatments for Newly Diagnosed Primary Mediastinal B-Cell Lymphoma: Results of a Retrospective Analysis
4434.1 - CD38-SADA Pretargeted Radioimmunotherapy (PRIT) with Lutetium 177 (Lu177)-DOTA in Adult Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: A First-in-Human Phase 1 Trial
- Through Thick and Thin: Confronting the Aggressive Cutaneous T-cell Lymphomas

Hose, D.

84 - Impact of Clonal Heterogeneity in Newly Diagnosed, Transplant-Eligible Multiple Myeloma – Subgroup Analysis of the GMMG HD6 Phase III Trial

Hosgood, D.

3200 - Environmental Pollution Is Associated with Higher Risk MDS in a Diverse Urban Cohort and Triggers Inflammation in a Murine Models

Hosing, C.

506 - Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial
1047 - A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
1679 - Large Cell Transformation in Mycosis Fungoides & Sezary Syndrome: An Analysis of 445 Cases
1922 - Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis
1923 - Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis
3514 - Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis
4601 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome
4841 - Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation in Patients with High-Risk Myeloid Malignancies

Hoskin, P.

457 - Involved Field Radiotherapy Versus No Further Treatment in Patients with Newly Diagnosed Stage 1A or 2A Hodgkin Lymphoma and a ‘Negative’ PET Scan after 3 Cycles ABVD. Survival and Cause of Death after a Median of 16 Years Follow-up in the UK RAPID Trial

Hosking, M.

3474 - Development of Induced Pluripotent Stem Cell-Derived T Cells Exhibiting Phenotypic and Functional Attributes of Primary CAR T Cells
4801 - Next-Generation Off-the-Shelf CAR T-Cell Therapy Developed to Eliminate a Broad Spectrum of Pathogenic Cells in Hematological Diseases in the Absence of Conditioning Chemotherapy

Hoskote, C.

3039 - Bing-Neel Syndrome – a Case Series of 46 Patients from the United Kingdom

Hosokawa, K.

1307 - HLA Class I Allele-Deficient Clones Regenerate in Immune Aplastic Anemia without Anti-Thymocyte Globulin
1310 - Long-Term Follow-up of Patients with Aplastic Anemia Enrolled in Phase 2/3 Trials of Immunosuppressive Therapy Plus Romiplostim As a First-Line Treatment: Two-Year Interim Analysis
1311 - Frequent Loss of HLA-B*40:02 from Leukocytes in Male Patients with Hepatitis-Associated Aplastic Anemia
- International Opportunities Hematology

Hosokawa, M. M.

720 - Immune Mechanisms and Cytokine Profiles in Hemophilia a Patients Undergoing Low-Dose ITI and Emicizumab Prophylaxis: Implications for ITI Success and Failure

Hosomichi, K.

1307 - HLA Class I Allele-Deficient Clones Regenerate in Immune Aplastic Anemia without Anti-Thymocyte Globulin
2689 - Efficacy and Safety of Eltrombopag Added to Rabbit Anti-Human Thymocyte Globulin+Cyclosporine in Aplastic Anemia: Results from a Prospective Multicenter Phase II Study

Hosono, N.

213 - Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia
1312 - Efficacy and Safety of Cyclosporine Monotherapy for Patients with Non-Severe Aplastic Anemia Not Requiring Transfusions: Results from a Prospective Multicenter Phase II Study
2889 - Timing of Response with Gilteritinib Monotherapy in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Hosoya, H.

69 - CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up
96 - Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms
386 - Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients (Aged ≥ 80) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
897 - Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
931 - Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)
934 - Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
936 - Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
2006 - Anti-BCMA CAR T-Cell Expansion and Its Association with Response and Toxicity in Multiple Myeloma
2064 - CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma
2223 - Direct Method for Estimating the Fraction of T and B/Plasma Cell-Derived DNA
3337 - Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
4846 - Indolent CD8+ CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucel Therapy for Relapsed/Refractory Multiple Myeloma

Hospital, M. A.

58 - Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study
1378 - Dasatinib Overcomes AML Resistance to BCL2 Inhibition By Indirectly Inhibiting MCL1: From Ex Vivo drug Sensitivity/Resistance Profiling to a Phase II Clinical Trial: A Hemato-BIO Study
1496 - Results of a Phase 1, First-in-Human Study of INA03, an Anti-CD71 Antibody-Drug Conjugate in Patients with Relapsed or Refractory (R/R) Acute Leukemias

Hossain, F.

5083 - Quality of Life, Physical and Mental Health of Patients with Vaccine Induced Immune Thrombotic Thrombocytopenia after Extended Followup

Hossain, J.

5008 - Sctalk: A Pilot Trial Using Implementation Science to Improve Documentation and Disclosure of Sickle Cell Trait during Infancy

Hossain, M.

414 - IGF2BP1 Orchestrates Post-Transcriptional Control of Globin Switching through Direct Binding to Globins and Their Regulators

Hossain, M.

2266 - The Mediating Effects of Racial and Social Health Disparities on Cancer Urgent Care Outcomes: An Urban Cancer Center Experience

Hossain, N.

2275 - Comparison of CRS- and Icans-Related Outcomes for Large B Cell Lymphoma Patients Treated with Commercial Axicabtagene Ciloleucel with or without Prophylactic Dexamethasone
5123 - Real-World Outcomes of Early Relapsed/Refractory Large B Cell Lymphoma Patients Treated with 2^nd Line CAR T Therapy

Hossain, N.

3403 - Enforced Expression of Mitochondrial Calcium Uniporter in Donor T Cells Abolishes Gvhd Progression

Hossain, S.

3304 - Elranatamab in Patients with Daratumumab Relapsed and/or Refractory Light Chain Amyloidosis

Hosseini, M.

2719 - Depletion of CD59 Inhibits the Proliferation and Survival of Acute Myeloid Leukemia Cells By Altering Lipid Raft Composition and Suppression of Raf/MEK/ERK Signaling
4995 - Single-Cell Proteogenomic Analysis of Clonal Evolution in Patient-Derived Xenograft Models of AML Treated with IDH Inhibitors

Hosseini-Moghaddam, S.

286 - COVID-19 Humoral Immunity Improves with Third and Subsequent Vaccine Doses in Patients with Plasma Cell Dyscrasias, Particularly in Those Receiving antiCD38 Therapy

Hosseyni, D.

3382 - Cross-Cohort Correlative Analysis of Clinically High-Risk Patients (pts) Treated with Idecabtagene Vicleucel (ide-cel) in KarMMa-2: Association between Progression-Free Survival (PFS) and Tumor Burden and Immune Status at Apheresis

Hosszu, K. K.

671 - A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma
672 - Immune-MRD Status Informs Tumor-MRD Outcome Prognostication in Multiple Myeloma Patients on Lenalidomide Maintenance
2070 - CD371-Targeted CAR T-Cells Secreting Interleukin-18 Exhibit Robust Expansion and Disease Clearance in Patients with Refractory Acute Myeloid Leukemia
2175 - T- and B-Cell Subset Reconstitution As Predictor of Relapse in Pediatric and Young Adult Allo-Hematopoietic Cell Transplantation Patients
3128 - A Proof-of-Principle of Split-Course Bridging Radiotherapy (SC-BRT) Prior to CAR T-Cell Therapies for Relapsed or Refractory B-Cell Lymphomas: A Phase 1a Pilot Cohort
4850 - Manufacture of Anti-BCMA CAR T Cell Is Feasible after Salvage Autologous or Allogeneic Hematopoietic Stem Cell Transplantation

Hoster, E.

237 - Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project
240 - Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network
859 - Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First – Line Treatment for Waldenström’s Macroglobulinemia: Results of the Multicenter Phase II trial (ECWM-2) of the European Consortium for Waldenström’s Macroglobulinemia
4360 - Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network
3042.2 - Trial in Progress: A Phase II Trial to Investigate Venetoclax in Combination with Ibrutinib and Rituximab or Conventional Chemoimmunotherapy (Bendamustine and Rituximab) and Ibrutinib in Patients with Treatment-Naive Mantle Cell Lymphoma Not Eligible for High-Dose Therapy – MCL Elderly III
4422.3 - Trials in Progress: Carman - an International, Randomized Phase II Study Evaluating Early Treatment Intensification in Patients with High Risk Mantle Cell Lymphoma Using CAR-T-Cell Treatment after an Abbreviated Induction Therapy with Rituximab and Ibrutinib and 6 Months Ibrutinib Maintenance (Arm A) As Compared to Standard of Care Induction and Maintenance (Arm B)

Hotan, Q.

412 - A Novel Genome-Scale CRISPR-Cas12a Screen Identifies Ptpa As a Fetal Hemoglobin Regulator Via BCL11A

Hotta, T.

2081 - Pre-CAR-T GTE Scoring of Electroencephalogram Abnormalities As Predictive Biomarkers for Icans

Hou, C.

3523 - Large-Scale Metabolomic Mendelian Randomization Analysis Identifies Pyridoxate As a Key Factor in Graft-Versus-Host Disease

Hou, H.

1349 - ASXL1 Mutations in AML Are Associated with a Distinct Epigenetic State Which Highlights Vulnerabilities to Specific Epigenetic-Targeted Agents
1373 - Identifying ‘Druggable’ Targets and Preclinically Overcoming Non-Genetic/Adaptive Resistance to Menin Inhibitors in AML with MLL1r or mtNPM1
3142 - Evaluation of the Lethal Activity and Its Mechanism of Tasquinimod in Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase

Hou, H. A.

483 - Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
3678 - Modified Delphi Process to Develop Best Practice Recommendations for Myelofibrosis Management in Routine Clinical Practice in the Asia-Pacific Region (The APAC-MF Alliance)

Hou, H. A.

1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
2951 - Prognostic Role of NGS-Based MRD Assessment in FLT3-TKD Mutated Patients with Acute Myeloid Leukemia
4579 - Incorporating TET2 Variant Allele Frequency Enhances Prognostication in CMML: Insights from 849 Patients across Multiple Institutions

Hou, J. Y.

4313 - Clinical Application for Modification of the 2022 European Leukemianet Genetic Risk Stratification in Pediatric Acute Myeloid Leukemia

Hou, J.

4280 - Azacitidine, Homoharringtonine and Cytarabine Combined with Granulocyte Colony-Stimulating Factor As Frontline Treatment for Older Patients with Acute Myeloid Leukemia: A Prospective, Multicenter, Single-Arm Phase III Study in China
4748 - Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Hou, J. Z.

341 - Escalating Doses of AZD0486, a Novel CD19xCD3 T-Cell Engager, Result in High Complete Remissions with Rapid Clearance of Minimal Residual Disease in Patients with Relapsed/Refractory Follicular Lymphoma
868 - Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in an Ongoing First-in-Human Phase 1 Study: High Complete Responses Seen in CAR-T–Naive and CAR-T–Exposed Patients
2353 - Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Utilization and Clinical Outcomes Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
3253 - Treatment-Emergent Cardiovascular Events Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Treated with Bruton’s Tyrosine Kinase Inhibitors (BTKi)

Hou, L.

1492 - Influence of COVID-19 on Acute Myeloid Leukemia Treatment Efficacy: Insights from a Propensity Score-Matched Cohort Study
2539 - Synergistic Risks: The Impact of HIV on Kaposi Sarcoma and Lymphoma Incidence in Castleman’s Disease

Hou, M.

2548 - Targeting Deacetylase Sirt-1 Reprograms Treg Function in Immune Thrombocytopenia
4748 - Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study
4762 - Subgroup Analyses of Phase 2 Study: Evaluating the Efficacy of Fully Human BCMA-Targeting CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Hou, M.

1187 - Sirolimus Combined Dexamethasone As the First-Line Therapy for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Open-Label, Prospective, Randomized Controlled Clinical Trial

Hou, P. Y.

1358 - Generating a Model of Human CD8⁺ T-Cell Lymphoma from Genetically Modified Normal T-Cells

Hou, S.

2748 - Metabolic Signature of Oxidative Phosphorylation Deficiency with Activated Nucleotide Biosynthesis in Early T-Cell Precursor Acute Lymphoblastic Leukemia

Hou, Y.

2233 - Time Series Deep Neural Network Identifies Lymphoma Patients Suitable for CAR-T Cell Therapy Using EHR Data

Hou, Y.

4647 - A Positive Feedback Loop between YTHDC1 and EP300 Drives Tumorigenesis in Multiple Myeloma

Hou, Y.

2548 - Targeting Deacetylase Sirt-1 Reprograms Treg Function in Immune Thrombocytopenia
- Platelet TGFb1 in the Pathogenesis of Immune Thrombocytopenia Purpura

Hou, Y.

1095 - Benefits of Targeted Next Generation Sequencing (NGS) for Identification of Newborn Hemoglobinopathies: The California Experience

Hou, Z.

1337 - Evi1 Governs Kdm6b-Mediated Histone Demethylation to Regulate the Laptm4b-Driven mTOR Pathway in Hematopoietic Progenitor Cells

Houde, C. A.

2285 - Insufficient Representation and Reporting of Race in the References Forming the Basis of the National Comprehensive Cancer Network Guidelines for Multiple Myeloma
1927.2 - A Decentralized Phase II Open-Label Trial Assessing the Safety and Efficacy of Dapagliflozin in Renal AL Amyloidosis (FLORAL)
3123.4 - An Investigator Initiated Study of RCHOP in Combination with Selinexor (KPT-330) in Diffuse Large B Cell Lymphoma and Richter Transformation

Hough, R.

4206 - Bridging Pediatric B-Cell Acute Lymphoblastic Leukemia (ALL) Patients to CAR-T Cell Therapy: A National Perspective

Hough, S.

3223 - Clinical Response to Azacitidine in Myelodysplastic Neoplasms Is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor Cells In Vivo

Houghton, D. E.

16 - Anticoagulation Management of Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: A Global Abdominal/Splanchnic Thrombosis Retrospective Observational Study in 486 MPN Patients (GASTRO-MPN)
811 - The AI-Mayo PE (AIM PE) Study: Validation of an Artificial Intelligence Algorithm Using Electrocardiograms to Predict Pulmonary Emboli
3996 - Platelet-Activating Anti-PF4 Antibodies in MGUS Patients with Thrombosis
- Artificial Intelligence (AI) and Machine Learning (ML) in the Context of Anticoagulation Management

Houghton, K.

2425 - Real-World Treatment Patterns and Outcomes with Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia

Houk, A.

3706 - The Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Patient Registry: Highlights of the Data from the First Three Years

Houldsworth, J.

1970 - Enhanced Detection of Pathogenic Germline Variants in Plasma Cell Disorders: Impact of a Targeted Genetic Counseling Referral Pathway

Houlston, R. S.

3354 - Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome – Long-Term Follow-up of the Ukmra Optimum/Muknine Trial

Houot, R.

239 - Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy: A Descar-T Study By Lysa Group
528 - Hemophagocytic Lymphohistiocytosis-like Syndrome after Anti-CD19 CAR T-Cells for B-Cell Lymphoma and B-Cell Acute Lymphoblastic Leukemia: A Lysa, Sfce and Graall Study from the Descar-T Registry
577 - Final Analysis of the Safety and Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma
745 - Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial
979 - Prospective, Multicentric, Phase II Randomized Controlled Trial Comparing the Efficacy and Toxicity of Methotrexate to Cyclophosphamide in Large Granular Lymphocyte Leukemia: A French National Study (NCT01976182)
2088 - Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy Manufactured Using a Next-Generation Process, for Severe, Refractory Autoimmune Diseases: Updated Data from Ongoing Phase 1, Multicenter, Open-Label Studies
3129 - A Real-World Weighted Comparison of Tisagenlecleucel and Axicabtagene Ciloleucel CAR T Cells in Relapsed or Refractory Diffuse Large B Cell Lymphoma Aged 75 Years and Older : A Lysa Study from the Descar-T Registry
4479 - Valemetostat Monotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma: Primary Results of the Phase 2 Valym Study from the Lysa
4505 - Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial

Houot, R.

575 - Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa
990 - Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072
4354 - Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study
4388 - Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2

Houran, L.

2516 - Self-Administered Acupressure Improves Pain and Quality of Life in Patients with Sickle Cell Disease

Hourigan, C. S.

59 - A Randomised Comparison of CPX-351 Versus Standard Daunorubicin and Cytarabine Plus Fractionated Gemtuzumab Ozogamicin in Older Adults with AML without Adverse Risk Cytogenetics: Results of the NCRI AML18 Trial
2950 - Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia

Houshmand, M. A.

3293 - The TEMPI Syndrome: A Monoclonal Gammopathy of Clinical Significance Driving Erythropoietin Production

Houshyar, S.

652 - The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin

Houston, B. L.

4583 - Improvement in Quality of Life in MDS Patients Who Become Transfusion Independent after Treatment

Houston, B. L.

4598 - Impact of Frailty in a Prospective Cohort of Patients with MDS Treated with Hypomethylating Agents

Hovanky, V.

2006 - Anti-BCMA CAR T-Cell Expansion and Its Association with Response and Toxicity in Multiple Myeloma

Hovestadt, V.

953 - Targeted Protein Degradation Reveals a Repressive Role of Mecom at the CEBPA Locus to Prevent Differentiation in High-Risk Acute Myeloid Leukemia

Hovestadt, V.

273 - Rapid Epigenomic Classification of Acute Leukemia

Hovsepyan, S.

2870 - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results

How, C. J.

16 - Anticoagulation Management of Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: A Global Abdominal/Splanchnic Thrombosis Retrospective Observational Study in 486 MPN Patients (GASTRO-MPN)
246 - Prognostic Implications of Pulmonary Hypertension in Myeloproliferative Neoplasms and Predictors of Hematologic Progression
3188 - Incidence, Risk Factors, and Prognostic Implications of Heart Failure Hospitalizations Among Patients with Myeloproliferative Neoplasms
3811 - Factors Associated with Quality of Life Impairments in Patients with Myeloproliferative Neoplasms: Looking Beyond Symptom Burden
- Pregnancy: MPN Management Before, During, and After Pregnancy

Howansky, A.

4434.1 - CD38-SADA Pretargeted Radioimmunotherapy (PRIT) with Lutetium 177 (Lu177)-DOTA in Adult Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: A First-in-Human Phase 1 Trial

Howard, Jr., J. F.

2080 - Safety and Tolerability of BCMA-Directed mRNA CAR T-Cell Therapy in Multiple Myeloma and Autoimmune Disease

Howard, J.

2237 - Utilising Patient-Reported Experience Measures to Drive Healthcare Improvements: The Application of Validated PREM Survey Tools in a Haemoglobinopathy Network in South London

Howard, M. T.

2283 - Impact of COVID-19 on Multidisciplinary Lymphoma Tumor Boards: An Analysis of Practice and Care Changes

Howard, M.

4415 - A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study

Howards, P.

393 - Association of Neighbourhood-Level Socioeconomic Deprivation with Mortality Among Patients with Sickle Cell Disease

Howarth, A.

2207 - Selective Inhibition of the m⁶a RNA Reader, YTHDC1, As a Novel Therapeutic Strategy for MYC-Driven Acute Myeloid Leukemia

Howe, A.

5184 - Treatment Patterns of Ropeginterferon Alfa-2b-Njft in the Real-World Setting

Howe, M. D.

2744 - The Mutational Landscape of Extramedullary Multiple Myeloma Reveals Novel Biologic Insights and Potential Therapeutic Targets for Exploration
4635 - The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma
4711 - Radiomics-Based Biomarkers for Risk Stratification in Newly Diagnosed Multiple Myeloma

Howell, D.

590 - Bone Marrow Spatial Signatures Predict Survival Outcomes and Toxicities after CAR-T Therapy in Patients with Relapsed/Refractory Multiple Myeloma

Howell, H.

1092 - Phase 1 Healthy Volunteer Study of DISC-3405, a Recombinant Humanized Antibody Targeting TMPRSS6
1093 - Results from the Beacon Trial: A Phase 2, Randomized, Open-Label Study of Bitopertin in Erythropoietic Protoporphyria

Howell, L.

1535 - Bone Marrow Failure in AML: Residual Neutrophils and Erythroblasts Are Derived By Differentiation from the AML

Howitt, B.

2993 - Resolving the Microarchitecture of Classic and Transformed Follicular Lymphoma By Single Cell Alignment to Spatial Transcriptomes
3536 - Spatial Characterization of Molecular Pathways Suggests the Dysregulation of LGR5 Expressing Fibroblasts in Patients with sclerodermatous Chronic Graft-Vs-Host Disease

Howitt, J.

1551 - Detection of KMT2A Partial Tandem Duplication in Myeloid Samples By Pacbio® Long Read Sequencing

Hoxha, E.

147 - Treg Selection from G-CSF Stimulated Donors Improves Outcomes of Immune-Suppression Free HLA-Haploidentical Hematopoietic Cell Transplantation with T Cell Adoptive Immunotherapy
269 - Safety of 20Gy Total Marrow Irradiation Based Conditioning Regimen for Hematopoietic Cell Transplantation with T Cell Adoptive Immunotherapy

Hoye, K.

919 - CD30.CAR-T Cells Co-Expressing the CCR4 Chemokine Receptor in Relapsed/Refractory Hodgkin Lymphoma
3468 - Phase 1 Trial of CD30-Directed, CCR4 Co-Expressing Chimeric Antigen Receptor T-Cells in Patients with CD30⁺ Cutaneous T-Cell Lymphomas Refractory to Brentuximab Vedotin

Hoyt, C. R.

396 - Identifying Determinants of Sickle Cell Disease Knowledge, Awareness, and Management in St. Louis Area School Districts

Hrabovsky, S.

2806 - Central Nervous System Involvement Does Not Worsen Survival in Hematologic or Molecular Relapse of Adult Acute Lymphoblastic Leukemia Patients – Retrospective Analysis By the Czech Leukemia Study Group for Life (CELL)

Hricko, S.

3081 - Validation of the CNS-IPI-C Prognostic Model in Patients with Systemic DLBCL in the Real World

Hristova, T.

804 - Lifetime Prevalence of Stroke within an Adult Population with Sickle Cell Disease: A Cross-Sectional Study

Hrom, J.

1661.1 - BGB-11417-203, an Ongoing, Phase 2 Study of Sonrotoclax (BGB-11417), a Next-Generation BCL2 Inhibitor, in Patients With Waldenström Macroglobulinemia

Hrusak, O.

635 - Single-Cell Multiomics Reveals a Shared Mechanism of Lineage Switch in DUX4r, ZNF384r, and PAX5 P80R Subtypes of Pediatric Acute Lymphoblastic Leukemia

Hrushesky, W.

3638 - Serious Adverse Drug Reactions (sADRs) Involving Hematology and Resulting in Black Box Warnings or FDA Non-Approval: Results from the First Quarter Century of RADAR/Sonar

Hruskova, A.

1697 - The Survival Improvement of Transplant-Eligible Primary CNS Lymphoma Patients within Last 15 Years

Hrustincova, A.

4571 - Dysregulation of Transposable Elements and Piwi-Interacting RNAs in Myelodysplastic Neoplasms

Hshieh, T. T.

448 - Frailty and Long-Term Survival Among Older Adults with Blood Cancers

Hsi, E. D.

3409 - Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Hsi, E. D.

4361 - Neuronal-Glial and Immune Microenvironment Signatures Show Prognostic Effects in Primary CNS Lymphoma
1661.3 - Trial in Progress – Alliance A052101: A Randomized Phase 3 Trial of Continuous Vs. Intermittent Maintenance Therapy with Zanubrutinib As Upfront Treatment in Older Patients with Mantle Cell Lymphoma
4502.4 - Trial in Progress – Alliance A051901 – Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed By Lenalidomide and Nivolumab Maintenance in Primary Central Nervous System Lymphoma (PCNSL)

Hsia, Y. Y.

4790 - iPSC-Derived CAR-Gamma Delta T with Novel Combinatorial KO Demonstrated Extended Longevity and Profound Anti-Tumor Efficacy without Cytokine Support in Preclinical Studies

Hsiao, C. C.

2804 - The Impacts of Circulating Lymphoblasts and the Day of the First Triple Intrathecal Therapy on the CNS Outcomes of Childhood ALL: The Report of Taiwan Pediatric Oncology Group (TPOG)-ALL-2013
4313 - Clinical Application for Modification of the 2022 European Leukemianet Genetic Risk Stratification in Pediatric Acute Myeloid Leukemia

Hsiao, H. H.

1001 - Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis

Hsieh, E. M.

369 - Autologous CD33CART for Children and Adolescents/Young Adults with Relapsed/Refractory AML: Phase 1/2 Clinical Trial Correlative Biology Analyses Demonstrate Potent in Vitro, In Vivo, and Ex Vivo Anti-Leukemia Activity
4827 - Clinical Factors Associated with Prolonged Cytopenias after CD19 Chimeric Antigen Receptor T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia

Hsieh, L.

709 - Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
3943 - Clinical Study to Determine the Pathogenesis of Autoimmune Thrombocytopenia in Pediatric Patients

Hsieh, M.

177 - A Machine Learning-Based Workflow for Predicting Transplant Outcome in Patients with Sickle Cell Disease
802 - Fertility Preservation Outcomes for People with Ovaries and Sickle Cell Anemia: A Multi-Center Study
1141 - Adding CD117 Antibody to Alemtuzumab, Low Dose Total Body Irradiation (TBI), and Sirolimus for Matched Related Donor (MRD) Hematopoietic Cell Transplant (HCT) in Sickle Cell Disease (SCD): Initial Results
2167 - Recipient-Derived Hematopoietic Cells Are the Source of Hematologic Malignancies after Graft Failure and Mixed Chimerism in Adults with Sickle Cell Disease
2100.1 - Motixafortide for Hematopoietic Stem and Progenitor Cell Mobilization and Collection in Sickle Cell Disease
- Moderator Introduction (Classical Hematology Perspective)

Hsieh, Y.

707 - Real-World Effectiveness of Immunoglobulin Replacement Therapy on Hypogammaglobulinemia and Infectious Complications in Patients with Multiple Myeloma

Hsu, A.

1177 - Association of Platelet Count and Mean Platelet Volume with Severity of Bleeding Events in Patients with Immune Thrombocytopenia

Hsu, B.

217 - A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial
3799 - Real-World Patterns of Care and Outcomes for Non-Favourable Risk Acute Myeloid Leukemia Treated with Intensive Chemotherapy across Australia and New Zealand- Data Linkage between the ALLG National Blood Cancer Registry (NBCR) and the Australia and New Zealand Transplant and Cellular Therapy (ANZTCT) Registry

Hsu, C. A.

2572 - Inhibitor-Positive Hemophilia a Patients-Derived Humanized Mouse Models Revealed the Connection of PD-1/PD-L1 Interactions to Successful Immune Tolerance Induction (ITI) Therapy

Hsu, C. Y.

4790 - iPSC-Derived CAR-Gamma Delta T with Novel Combinatorial KO Demonstrated Extended Longevity and Profound Anti-Tumor Efficacy without Cytokine Support in Preclinical Studies

Hsu, C. C.

2739 - Golcadomide-Mediated Degradation of Aiolos/Ikaros Synergizes with BET Inhibitors through Bidirectional Restructuring of the Directly Regulated Epigenetic Environment in DLBCL

Hsu, F. F.

4790 - iPSC-Derived CAR-Gamma Delta T with Novel Combinatorial KO Demonstrated Extended Longevity and Profound Anti-Tumor Efficacy without Cytokine Support in Preclinical Studies

Hsu, G.

- Best Practices to Support Fellows in the Job Search

Hsu, H.

2367 - Treatment Patterns and Predictors of Survival after First Line Therapy in Large B-Cell Lymphoma in a Real-World US Cohort
3734 - The Patient Journey and Treatment Outcomes Comparing Inpatient Versus Outpatient Axicabtagene Ciloleucel in Non-Hodgkin’s Lymphoma (NHL) - a Large, Multicenter Study

Hsu, J. W.

1968 - Soluble B-Cell Maturation Antigen As a Serum Marker of Minimal Residual Disease in Patients with Multiple Myeloma

Hsu, J.

1293 - iPSC Reprogramming Identifies the Role of Cryptic Drivers in Preleukemic Clonal Evolution

Hsu, J. Y.

1064 - Defining the Impacts of Iron Overload in Children Receiving Hematopoietic Stem Cell Transplantation for Non-Malignant Hematologic Disorders: A Multicenter Analysis

Hsu, J.

2088 - Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy Manufactured Using a Next-Generation Process, for Severe, Refractory Autoimmune Diseases: Updated Data from Ongoing Phase 1, Multicenter, Open-Label Studies
2351 - Non-White and Hispanic Patients Have Significantly Longer Time from Intent to CAR T Infusion (“Brain-to-Vein” Time) in Multiply Relapsed Diffuse Large B Cell Lymphoma

Hsu, J.

346 - Clonal Origin of Therapy-Related Myeloid Neoplasms after Autologous Stem Cell Transplant

Hsu, J.

3088 - Clinical Outcomes of EBV-Positive Compared to EBV-Negative Diffuse Large B Cell Lymphoma in the Modern Era

Hsu, K. C.

637 - Cross-Talk between Leukemic Blasts and T Cells Drives Targetable T Cell Dysfunction in the AML Tumor Microenvironment
2034 - Patterns of Immune Reconstitution and Their Clinical Significance in Aggressive Lymphoma Treated with CAR-T Therapy

Hsu, K. H.

4790 - iPSC-Derived CAR-Gamma Delta T with Novel Combinatorial KO Demonstrated Extended Longevity and Profound Anti-Tumor Efficacy without Cytokine Support in Preclinical Studies

Hsu, L. L.

3630 - Do Jehovah’s Witnesses with Sickle Cell Disease Avoid the Healthcare System?
5008 - Sctalk: A Pilot Trial Using Implementation Science to Improve Documentation and Disclosure of Sickle Cell Trait during Infancy
5066 - Understanding the Menopause Transition in Sickle Cell Disease: An Interim Analysis of the Implementation of the Adapted Menopause Transition Questionnaire

Hsu, P.

3034 - Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update
4398 - Efficacy and Safety of Tisagenlecleucel in Patients with Relapsed/Refractory Follicular Lymphoma: A Real-World Analysis from the Center for Blood and Marrow Transplant Research (CIBMTR) Registry

Hsu, T. L.

4021 - Assessing Venous Thromboembolism Risk in Patients with Multiple Myeloma: A Nationwide Population-Based Study in Taiwan

Hsu, Y. T.

3565 - Allogeneic Stem Cell Transplantation As Consolidation Therapy in Patients with Relapsed-Refractory B-Cell Lymphoma Exposed to Bispecific Antibodies: A Study on Behalf of Grupo Español De Transplante y Terapia Celular (GETH-TC)

Hsu, Y. T.

5137 - Real World Evidence of Tirabrutinib As a Salvage Treatment in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: A Multicenter Study

Hsu, Y. T.

4947 - Effect of Consolidation with Allogeneic Hematopoietic Cell Transplant Versus No Consolidation in Patients with Non-Hodgkin Lymphomas Treated with Bispecific Antibodies

Htet, N. L.

4706 - Impact of Kidney Transplantation on Hospitalization Outcomes in Patients with Multiple Myeloma

Htut, M.

922 - Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)
936 - Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma
1941 - The Microbiome and Clinical Outcome Among Patients with Multiple Myeloma (MM) Following CD38-Directed Antibody Treatment
2069 - BMS-986393, a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1–3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results
3785 - Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel
4758 - Delayed Neurotoxicity after CAR-T in Multiple Myeloma: Results from a Global IMWG Registry

Htut, T. W.

2390 - Updated Meta-Analysis of Phase III Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Pneumonia, Upper Respiratory Tract Infections (URTIs) and Venous Thromboembolism (VTE) in Patients with Multiple Myeloma Treated with Isatuximab

Hu, B.

2053 - CAR-T Cell Subsets and Immune Repertoire Are Associated with Immune-Related Adverse Events and Efficacy after CD19 CAR T-Cell Therapy in B Cell Lymphoma
2373 - Characterizing the US Patient Population Receiving Rituximab with Gemcitabine and Oxaliplatin (R-GemOx) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Using Real-World Data
2669 - Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy

Hu, B.

3845 - HLTF Regulates Erythroid Differentiation through Transcription Factors and Chromatin Landscape Modulation

Hu, B.

1881 - Multi-Omics Integration to Elucidate the Cis-Regulatory Network Re-Wiring upon NSD2 Degradation in t(4;14) Multiple Myeloma

Hu, B.

111 - Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study
236 - Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181
1864 - Real-World Comparison of BCL2 Inhibitor and BTK Inhibitor Therapy in the Front-Line Treatment of CLL Including Patients with Del(17p)/TP53 Mutation
3409 - Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL
4622 - LP-168 (Rocbrutinib), a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton’s Tyrosine Kinase: Updates on the Phase 1 Trial and Initial Results of the CLL Gatekeeper Mutation Cohort
4824 - First Results of IMPT-314, an Autologous Bispecific CD19/CD20 Chimeric Antigen Receptor (CAR) in Enriched Naive and Central Memory T Cells, for the Treatment of Large B Cell Lymphoma (LBCL)

Hu, C.

1337 - Evi1 Governs Kdm6b-Mediated Histone Demethylation to Regulate the Laptm4b-Driven mTOR Pathway in Hematopoietic Progenitor Cells

Hu, C.

4153 - Pharmacological Inhibition of METTL3 Enhances the Acute Myeloid Leukemia Cell Death Induced By Venetoclax Via the METTL3-YTHDF2-FBXW7-MCL1 Axis

Hu, C. C. A.

1673 - Beyond Classical Hodgkin Lymphoma: Long-Term Risks and Secondary Cancers-Insights from the Texas Cancer Registry
1716 - Primary Vitreoretinal Lymphoma with or without Intracranial Involvement: A Single Center Experience
5131 - Statins May Improve Outcomes and Toxicities in Patients Undergoing CD19-Specific CAR T-Cell Therapy for Aggressive B-Cell Lymphomas

Hu, C.

1771 - Comparison of Long-Term Outcomes Among Patients with Chronic Myeloid Leukemia Who Undergo Initial Tyrosine Kinase Inhibitor Dose Reduction Versus Tyrosine Kinase Inhibitor Switch

Hu, C.

3873 - The Intracellular Effects of Anti-Polymerizing RNA Aptamers in Sickled Red Blood Cells

Hu, D.

960 - CD93⁺ Myeloid Cells Suppress T-Cell-Mediated Anti-Tumor Immunity

Hu, D.

1355 - TRIM28 Facilitates Chronic Myeloid Leukemia Progression By Enhancing Sumoylation and Stability of BCR-ABL

Hu, G.

4761 - Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study

Hu, G.

2974 - The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study
4381 - BCL2 Expression Correlates with New Molecular Classification of Anaplastic Large Cell Lymphoma

Hu, H.

101 - Multiomic Analyses Uncover Immune Signatures of Steroid-Refractory Graft-Versus-Host Disease

Hu, H.

922 - Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)
2069 - BMS-986393, a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1–3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results

Hu, H.

4703 - The Impact of Lifestyle Factors and Occupational Exposure on Multiple Myeloma Risk in the Multiethnic Cohort Study

Hu, H.

3595 - High-Accurate Third-Generation Sequencing to Comprehensively Decipher BCR::ABL1 TKIs in-Cis Resistant Mutations

Hu, H.

3949 - Low-Dose Corticosteroids and Eltrombopag in the Treatment of Newly Diagnosed Adult Immune Thrombocytopenia: A Multicenter, Phase 2 Clinical Trial

Hu, H.

2171 - Easix Score Predicts Overall Survival and Non-Relapse Mortality in Elderly Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation

Hu, J.

4255 - Phase 1 Safety and Efficacy of Tuspetinib Plus Venetoclax Combination Therapy in Study Participants with Relapsed or Refractory Acute Myeloid Leukemia (AML) Support Exploration of Triplet Combination Therapy of Tuspetinib Plus Venetoclax and Azacitidine for Newly Diagnosed AML

Hu, J.

304 - Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
2210 - Targeting Intracellular Mutant NPM1 in Acute Myeloid Leukemia with a Novel Peptide-MHC-Specific T-Cell Bispecific Antibody

Hu, J.

1464 - Interferon-Activated Gene Signatures Associate with Chemotherapy Resistance and Sensitivity to JAK-Inhibition in Refractory ETP-ALL

Hu, J.

1338 - ENO1 Activity Inhibition Induce Ferroptosis Susceptibility in BCR-ABL TKIs Resistant CML Cells through GPX4 Autophagy Degradation

Hu, J.

42 - Recurrent ASXL1 Mutations Promote Myeloid Malignancies through Unleashed Condensation

Hu, J.

378 - A Multi-Center Clinical Trial of Allogeneic Hematopoietic Stem Cell Transplants in Transfusion Dependent Thalassemia
1781 - A Phase 2 Study of Olverembatinib for the Treatment of Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement

Hu, J.

633 - The Role of an Inflammatory Phenotype in Driving Clonal Evolution in B-Acute Lymphoblastic Leukemia

Hu, K.

1745 - The Clinical Value of Prognostic Nutritional Index in CAR-T Therapy for Patients with Malignant Lymphoma
3079 - Treatment Outcomes in Patients with R/R CNSL in the Era of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
3103 - EX103, a Newly Re-Designed CD20×CD3 Molecule, Induces High Response in Heavily Pretreated Relapsed/Refractory (R/R) Patients with B-Cell Non-Hodgkin Lymphoma (B-NHL)
3387 - Efficacy and Safety of BCMA-CAR-T Cell Therapy in Relapsed/Refractory Extramedullary Plasmacytoma: Exploring the Role of Consolidation Therapy
4856 - Different T-Cell Activation Approaches Impact the Resulting CART-Cell Products and Possible Clinical Outcomes

Hu, K.

4761 - Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study

Hu, L.

1387 - An Orally Active Pan-BCR::ABL1 Degrader Tgrx-3247 Potently Targets a Wide Spectrum of Orthosteric, Allosteric and Compound Mutations Resistant to TKI Therapies

Hu, L.

2840 - Deciphering Clonal Evolution of Immunoglobulin Heavy Chain Locus Enhances Next-Generation Sequencing-Based Measurable Residual Disease Detection in Adult B-Acute Lymphoblastic Leukemia

Hu, L.

1537 - Genetic Abnormalities Associated with Outcomes in Unfit Patients with Acute Myeloid Leukemia Receiving Less Intensive Therapy in the Real World
2684 - Inhibition of TGF-β in Bone Marrow Endothelial Progenitor Cells Promotes Hematopoietic Recovery in Acute Myeloid Leukemia after Chemotherapy
2815 - Blinatumomab Combined with Venetoclax Increasing the Abundance of CD8 T Cell and NK Cell and Improve the Outcome in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients
4235 - The Bone Marrow Blasts on Day 14 during the Azacitidine Plus Venetoclax Regimen As the Induction Therapy Can Predict the Outcome in Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia

Hu, M.

3240 - Preliminary Data of a Single-Arm, Phase II Study of Orelabrutinib with/without Rituximab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma after BTK Inhibitor Therapy

Hu, M.

4503 - CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium
4434.3 - A Phase II Study of Pembrolizumab+ BEAM before Autologous Stem Cell Transplant (ASCT) Followed By Pembrolizumab Maintenance in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma

Hu, M.

156 - Potent in Vitro and In Vivo Efficacy of Hdz-C123A, a GSPT1 Degrader-Antibody Conjugate Targeting CD123 in Acute Myeloid Leukemia
3015 - Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory B-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study
3057 - Preliminary Efficacy and Safety of the CK1ε/PI3Kδ Dual Inhibitor HZ-H08905 in Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphomas: Results from the Phase 1 HZ-H08905-101 Study

Hu, Q.

2208 - Harnessing Ferroptosis and Photothermal Effects: A New Paradigm in Aggressive Lymphoma Therapy

Hu, Q.

3586 - Discovery of BTC-86, a Novel Second-Generation Menin-MLL Inhibitor to Overcome the Acquired Resistance in MEN1 for R/R Acute Leukemia

Hu, R.

958 - KPT-330 Combined with Radiation Therapy: Effective Central Nervous System Lymphoma Treatment with Reduced Neurotoxicity

Hu, S.

3486 - Comparison of Rabbit ATLG and ATG in Allogeneic Hematopoietic Stem Cell Transplantation for Children with Acquired Severe Aplastic Anemia

Hu, S.

4185 - Clinical Characteristics and Prognostic Analysis of Testicular Relapse in Pediatric Acute Lymphoblastic Leukemia: A Retrospective Multicenter Study from China
4205 - A Phase 2 Clinical Trial of Anti-CD19 CAR-T (pCAR-19B) in Chinese Pediatric and Young Adult with Relapsed/Refractory (R/R) CD19+ B-ALL: The First Pivotal Study in an Asian Population

Hu, S.

1190 - Efficacy and Safety of Pegylated Peptide Agonist of Thrombopoietin Receptor (PN20) in Secondary Prevention of Chemotherapy-Induced Thrombocytopenias: A Multicenter, Single Arm, Phase Ib Trial

Hu, S.

4336 - Myeloid Progenitor Cells with Preleukemic Immunophenotypes Are Common in Myelodysplasia-Related and NPM1-mutated Acute Myeloid Leukemia and Should Not be Interpreted As Measurable Residual Disease

Hu, S.

1769 - A Nomogram for Predicting T315I-Free Survival in Chronic Phase Chronic Myeloid Leukemia Patients: A Multi-Center Retrospective Study
1782 - A Predictive Model for Progression to Overt Primary Myelofibrosis in Early/Prefibrotic Primary Myelofibrosis Patients
1786 - Comparing the Efficacy and Safety of Ruxolitinib in Patients with Lower and Higher Risk Myelofibrosis: A Multi-Center, Single-Arm, Exploratory and Prospective Study

Hu, S. H.

3966 - Factor VIII (FVIII) Trough Levels of Real-World Severe-Type People with Hemophilia a (PwHA) on rFVIII-Fc Prophylaxis: Clinical Correlates and Effects on Perceivable Bleeding Outcomes

Hu, T.

1561 - Integrated Single-Cell Long-Read and Short-Read Sequencing Reveals Critical Molecular Characteristics in Pediatric Acute Myeloid Leukemia

Hu, W.

2786 - Protein Degrader WH25244 Eliminates Venetoclax Resistance Factors: Mutant or Hyperphosphorylated BCL2, and BCL-XL

Hu, W.

3586 - Discovery of BTC-86, a Novel Second-Generation Menin-MLL Inhibitor to Overcome the Acquired Resistance in MEN1 for R/R Acute Leukemia

Hu, W.

2528 - Why Do Peptidyl Arginine Deiminase (PAD) 4-Deficient Mice Have Improved Survival Following Cecal Ligation and Puncture (CLP) Sepsis? Implications for the Role Neutrophil Extracellular Trap (NETs) in Immune Homeostasis

Hu, W.

128 - Reduced Doses of Factor Concentrates and Bypassing Agents to Treat Breakthrough Bleeds in Patients with Hemophilia A and B on Fitusiran Antithrombin-Based Dosing Regimen: ATLAS-OLE

Hu, W.

4319 - Overexpression of GAD1 in Pediatric Acute Myeloid Leukemia Cells Impairs Cytotoxic T Lymphocyte Response to Tumor Cells

Hu, X.

971 - Venetoclax and Decitabine Compared with Standard Intensive Chemotherapy As Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia: Updated Results of a Multicenter, Randomized, Phase 2b Trial
4287 - Hypomethylating Agent and Venetoclax in Newly Diagnosed and Relapsed CBFβ::MYH11(+) Acute Myeloid Leukemia

Hu, X.

624 - Heme-Mediated Tau Phosphorylation Is Critical for Neuroaxonal Damage and Cognitive Impairment in Sickle Cell Disease

Hu, X.

101 - Multiomic Analyses Uncover Immune Signatures of Steroid-Refractory Graft-Versus-Host Disease
268 - Epstein-Barr Virus Reactivation and Post-Transplant Lymphoproliferative Disorders after Allo-HSCT in the Era of Letermovir for Cytomegalovirus Prophylaxis
1044 - A Multicenter Randomized Controlled Trial of Low-Dose Ruxolitinib for Gvhd Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplantation
2109 - Changing Donor Was Critical for the Successful Salvage Second Transplantation for Graft Failure after the First Allogeneic Stem Cell Transplantation: A Chinese Multicenter Retrospective Study
2133 - Invasive Fungal Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in China: A Multicenter Epidemiological Study (CAESAR 2.0)

Hu, X.

3175 - Clinical Characterization of Myeloid Neoplasms Patients with Fanconi Anemia Gene Mutations

Hu, X.

2227 - AI-Driven Quantitation of Blast Cells and Vessel Density in Bone Marrow Biopsies Highlights Limitations of Manual Assessment

Hu, Y.

831 - Disrupting IL10 Signaling Overcomes Compound Copy Number Variation-Driven Clinical Resistance to CDK4/6 and BTK Inhibition in Mantle Cell Lymphoma

Hu, Y.

3367 - Updated Results of a Matching-Adjusted Indirect Comparison of Elranatamab Versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma

Hu, Y.

91 - Rituximab, Lenalidomide, and Zanubrutinib (ZR²) with Sequential CAR-T Cell As First-Line Therapy for High-Risk Large B Cell Lymphoma
921 - A Novel Generation of Anti-CD7 Universal CAR-T Therapy for Patients with Relapsed or Refractory CD7 Positive T-ALL/Lbl: A Phase I Clinical Trial
2074 - 1‰ Regular Dose of Metabolically Armored CD19 CAR-T Cells Induces Robust In Vivo Expansion and Complete Remission in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients
3469 - Comparison of the Efficacy and Adverse Effects of Recipient-Derived Versus Donor-Derived CAR-T Cell Therapy for Post-Transplant Relapse in B-ALL
4201 - CD19 CAR-T Therapy for Patients with Relapsed or Refractory Philadelphia Chromosome–Positive B-Cell Acute Lymphoblastic Leukemia: A Multicenter Study
5170a - Clinical Characteristics and Outcomes of BCMA-Targeted CAR-T Cell Recipients with Coronavirus Disease 2019 during the Omicron Wave: A Retrospective Study

Hu, Y.

92 - IL-10 Expressing CD19 CAR-T Cells Induce Complete Remission and Improve Long-Term Protection in Relapsed or Refractory B-Cell Hematological Malignancies
420 - A Single-Cell Transcriptomic Atlas of Cytokine Storm in CAR-T Therapy, COVID-19, and SLE
2818 - Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia

Hu, Y.

5 - Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3)
1197 - IL-1β Induce CAR-T-Associated Coagulopathy Via the Hsp90/Kallikrein/uPA Pathway
2552 - Improved Health-Related quality of Life (HRQoL) with Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib Vs Placebo in Adults with Previously Treated Immune Thrombocytopenia (ITP): Phase 3 Luna 3 Multicenter Study
2558 - Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China
3404 - HIF-1α Agonist Ameliorates Acute Graft-Versus-Host Disease Via Restraining SIRT1/ PARP1 in Bone Marrow Endothelial Progenitor Cells
3420 - Selinexor Reduces the Immunosuppressive Properties of Macrophages and Synergizes with CD19 CAR-T Cells Against B-Cell Lymphoma
3614 - In Situ Bioorthogonal Labeling for Non-Invasive, Dynamic In Vivo Nirf/PET Imaging of CAR-T Cells
3993 - Gut Microbial Metabolite Butyrate Alleviates the Susceptibility to Septic DIC By Suppressing Caspase-11/ Gsdmd-Dependent Macrophage Pyroptosis
4659 - Polymerase Theta Inhibition Impairs Tumor Growth and Enhances Melphalan-Induced DNA Damage in Multiple Myeloma
4662 - DDX3X Promotes Multiple Myeloma Cell Survival and Proteasome Inhibitor Resistance through Modulation of Stress Granule Assembly and MAPKAPK2 Translation
4816 - Co-Expression of IL-15 and CCL21 Strengthens CAR-NK Cells to Eliminate Tumors in Concert with T Cells and Equips Them with Higher PI3K/AKT/mTOR Signal Signature
4847 - mRNA-Laden Lipid-Nanoparticles-Enabled CD19 CAR-T Cells Engineering for the Eradication of Leukemic Cells
4855 - Efficacy and Safety of Single-Dose Versus Split-Dose Mecapegfilgrastim with Etoposide for Autologous Peripheral Blood Stem Cell Mobilization: A Prospective, Randomized Clinical Trial
5115 - Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Hu, Y.

480 - Olverembatinib As Second-Line (2L) Therapy in Patients (pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-CML)

Hu, Y. C.

327 - Phip Is a Potent Leukemia Oncogene Identified in Acute Myeloid Leukemia (AML) Patients of African Ancestry
620 - A Novel Mouse Model of Hemoglobin-SC Disease: Bridging the Knowledge Gap in Sickle Cell Disease

Hu, Y.

437 - ERAD Activity Distinguishes the Functional Heterogeneity of Hematopoietic Stem Cells

Hu, Z. H.

527 - Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report
609 - Predictors of Early Safety Outcomes with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
5092 - Real-World (RW) Outcomes for Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients (Pts) with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) By High-Risk Features and Prior Treatments: Updated Evidence from the CIBMTR^® Registry

Hu, Z. H.

526 - Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Hu, Z.

2123 - Intensified Conditioning Containing Decitabine Versus Standard Myeloablative Conditioning for Adult Patients with KMT2A-Rearranged Leukemia: A Multicenter Retrospective Study

Hu, Z.

263 - Targeting the Hypoxic Microenvironment in Cutaneous Chronic Graft-Versus-Host Disease through PI3Kδ Inhibition
3391 - Tissue-Resident Double Negative T Cells Mediate Salivary Gland Damage in Chronic Oral Graft-Versus-Host Disease

Hu, Z.

1259 - Development and Validation of a Machine Learning-Based Early Warning System for Predicting Venous Thromboembolism Risk in Hospitalized Lymphoma Patients Undergoing Chemotherapy: A Multicentre, Retrospective Cohort Study

Hu, Z.

2738 - Modeling the Initiation and Progression of Human MLL-Rearranged Precursor B Cell Acute Lymphoblastic Leukemia in Mice
3192 - TET1 Drives Myelodysplastic Syndromes and Represents a Promising Therapeutic Target
4222 - Comprehensive Characterization of Subtype-Specific V(D)J Recombination Features of B-Cell Acute Lymphoblastic Leukemia

Hua, H.

1685 - Endothelial Activation and Stress Index (EASIX) to Predict Survival in T or NK Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis
3914 - Pathological Subtyping, Outcomes, and Survival Trends of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Multicenter Analysis of 464 Patients

Hua, J.

681 - Safety and Efficacy of Bicistronic CD19/CD22 CAR T Cell Therapy in Childhood B Cell Acute Lymphoblastic Leukemia

Hua, V. M.

886 - BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Hua, W. K.

1398 - High HDAC8 Creates Targetable Vulnerabilities in Acute Myeloid Leukemia through Dysregulation of BRCA1-Related RNA Splicing Machinery and Defective DNA Damage Repair

Hua, X.

1455 - KMT2A-Rearranged ALL Requires DYRK1A for Regulation of ERK Signaling and Cell Proliferation

Hua, Y.

2879 - A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia

Huan, C.

4372 - EBV-Infected NKTCL Upregulated MHC-II Imprinted T Cell Exhaustion By Interacting with LAG3

Huang, A.

101 - Multiomic Analyses Uncover Immune Signatures of Steroid-Refractory Graft-Versus-Host Disease
1305 - Deciphering Transcriptome Alterations in Bone Marrow Hematopoiesis at Single-Cell Resolution in Prolonged Thrombocytopenia after Umbilical Cord Blood Transplantation
3441 - L-Arginine Reinforces NK Cell-Mediated GVL Effect in Bone Marrow of AML Patients with Early Relapse Post-Allo-HSCT
3504 - Efficacy and Safety of Hetrombopag in Promoting Platelet Engraftment after Allogeneic Stem Cell Transplantation: A Prospective, Single-Arm Clinical Trail

Huang, A. S. M.

4790 - iPSC-Derived CAR-Gamma Delta T with Novel Combinatorial KO Demonstrated Extended Longevity and Profound Anti-Tumor Efficacy without Cytokine Support in Preclinical Studies

Huang, A.

1498 - Phase 1 Trial Testing the Novel Combination Therapy of Entrectinib and ASTX727 in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Patients
1566 - Combination with Palbociclib Overcomes Venetoclax Resistance Mechanisms and Outperforms Single Agent Efficacy in Acute Myeloid Leukemia

Huang, B. J.

90 - Affinity-Tuned T-Cell Engager for Dual Targeting of B-Myeloid Mixed-Phenotype Acute Leukemia (B-MPAL)
640 - Pursuing Leukemia Stem Cells Definition in Pediatric Acute Myeloid Leukemia
1390 - Belvarafenib Inhibits the Growth of RAS-Mutant Acute Myeloid Leukemia Cell Lines in Vitro and Drives Adaptive Resistance In Vivo
2037 - Development of a Dual-Antigen Targeting CAR-T Therapy Directed Against CD70 and Active Integrin β2 for Acute Myeloid Leukemia

Huang, B.

1549 - Single-Cell Transcriptome Analysis Reveals the Novel Subtypes and Therapeutic Implications of T-Lymphoid/Myeloid Mixed-Phenotype Acute Leukemia

Huang, B.

2842 - Transcriptome-Based Molecular Subtypes Improve the Classification of B Cell Acute Lymphoblastic Leukemia with JAK2 Translocation

Huang, B.

2879 - A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia

Huang, C. C.

740 - A Single Cell Atlas of Follicular Lymphoma across Clinical Stages Defines Tumor B Cell Archetypes, Immune Microenvironment Heterogeneity and Novel Cell States Associated with High-Risk FL
1597 - Single-Cell Atlas of Diffuse Large B-Cell Lymphoma Reveals Integrated Malignant B Cell and Tumor Microenvironment Characteristics Associated with Clinical Response
2967 - Role of Clonal Hematopoiesis (CH) in Lymphoma: Prevalence and Clinical Impact in Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL)
2977 - Subtype-Specific Mechanisms of Treatment Resistance and Relapse in Diffuse Large B Cell Lymphoma (DLBCL)

Huang, C. P.

3410 - Dynamics of Circulating Tumor DNA As a Predictor of Outcomes with Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma from the Transcend NHL-001 Study

Huang, C.

3730 - Efficacy and Safety of Polatuzumab-Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) for Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Real-World, Multi-Center, Retrospective Cohort Study

Huang, C.

4302 - CAR-Machine: CAR-T Cell Target Identification Platform for Pediatric Acute Leukemia and Implementation to Identify Novel Targets for Pediatric AML

Huang, C. Y.

3042.3 - Combination of Glofitamab with Pirtobrutinib in BTK Inhibitor (BTKi)-Naive or Btki-Intolerant Patients with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): A Multicenter Phase 2 Study of the University of California Hematologic Malignancies Consortium

Huang, C.

2152 - Addition of Daclizumab to Standard Graft-Versus-Host Disease Prophylaxis in Patients with Thalassemia Major Undergoing Transplantation from Alternative Donor Hematopoietic Stem-Cell Transplantation: A Single-Center Retrospective Analysis from China

Huang, D. W.

229 - Pathogenesis and Clinical Relevance of Diffuse Large B-Cell Lymphoma Proteogenotypes
451 - Genetic Subclones Reveal Phenotypic Heterogeneity in Diffuse Large B-Cell Lymphoma
750 - Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naïve Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease
1722 - Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis

Huang, D.

2963 - Frequent Copy Gains of Viral LMP-1 Confers Radiosensitivity in Natural-Killer/T Cell Lymphoma
4172 - Therapeutic Repurposing of Brincidofovir in Non-Hodgkin Lymphoma – Potential Synergy with Immune Checkpoint Blockade

Huang, D. C.

- Impact of Mitochondrial Biology on BCL2 Inhibition

Huang, D.

1188 - Efficacy of Combined Herombopag and Recombinant Human Thrombopoietin Therapy Compared to Monotherapy on Platelet Engraftment after Autologous Hematopoietic Stem Cell Transplantation in Patients

Huang, D.

4736 - An Uniquely Designed Asymmetric Bispecific Antibody Against GPRC5D and CD3 (LBL-034) in Patients with Relapsed/Refractory Multiple Myeloma: A Phase I/II, First in Human, Open-Label, Multicenter, Dose Escalation/Expansion Study
4748 - Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Huang, E.

11 - PORT-77, a Novel and Potent Inhibitor of ABCG2, Protects Against Skin Photo Toxicity and Liver Damage in a Mouse Model of Erythropoietic Protoporphyria (EPP)

Huang, E.

2892 - Optimizing Venetoclax Duration in Combination with Hypomethylating Agents for Newly Diagnosed AML: Impact on Treatment Response and Survival Outcomes
3566 - Clinical Impact of Pretransplant Blinatumomab in Predominantly Hispanic Adults with B-Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Huang, E.

4982 - Accelerating Drug Discovery: AI-Powered Indication Exploration for Ropeginterferon Alfa-2b

Huang, F. L.

2804 - The Impacts of Circulating Lymphoblasts and the Day of the First Triple Intrathecal Therapy on the CNS Outcomes of Childhood ALL: The Report of Taiwan Pediatric Oncology Group (TPOG)-ALL-2013
4313 - Clinical Application for Modification of the 2022 European Leukemianet Genetic Risk Stratification in Pediatric Acute Myeloid Leukemia

Huang, F.

998 - Trial Update from IMproveMF, an Ongoing, Open-Label, Dose-Escalation and -Expansion, Phase 1/1B Trial to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Novel Combination of Imetelstat with Ruxolitinib in Patients with Intermediate-1, Intermediate-2, or High-Risk Myelofibrosis (MF)
1808.1 - Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitor in IMpactMF, a Randomized, Open-Label, Phase 3 Trial

Huang, F.

696 - Haploidentical Peripheral Blood Stem Cell Combined with Bone Marrow or Unrelated Cord Blood As Grafts for Acute Leukemia/Myelodysplastic Syndrome: An Open-Label, Multicenter, Randomized, Phase 3 Trial
2123 - Intensified Conditioning Containing Decitabine Versus Standard Myeloablative Conditioning for Adult Patients with KMT2A-Rearranged Leukemia: A Multicenter Retrospective Study
4897 - Signifcance of Intestinal CD8+CD69+CD103+ Tissue-Resident Memory T Cells in Human Intestinal Acute Graft-Versus-Host Disease
4923 - Increased EBV Infection and Relapse Rates Following Haploidentical Hematopoietic Cell Transplantation in the Era of Letermovir for Cytomegalovirus Prophylaxis: A Propensity Score Matching Analysis

Huang, G.

26 - Chromatin Modifier Hmga1 Maintains Hematopoietic Stem Cell Integrity in Stress Conditions
874 - CD38 Overexpressed Monocytes Play a Critical Role in the Fibrogenesis in Myeloproliferative Neoplasms and Can be Used As a Therapeutic Target to Ameliorate Fibrosis
877 - Luspatercept Promotes Heme Biosynthesis and Erythroblast Island Formation in a Novel Low-Risk MDS Mouse Model
2477 - Pharmacological Evaluation of a First-in-Class Hemoglobin Elevating Agent (HbEA) AND017 in a Hbb^d3th β-Thalassemia Mouse Model
2488 - Pharmacological Evaluation of a First-in-Class Hemoglobin Elevating Agent (HbEA) AND017 in Townes SCD Mouse Model
3193 - Aberrant Splicing in CHEK1 Is a Driver of Megakaryocytic Dysplasia in U2AF1^S34F Mutant Myelodysplastic Syndromes
4035 - Loss of Cpt1a Results in Elevated Mitochondrial Reactive Oxygen Species from Glucose-Fueled Mitochondrial Oxidative Phosphorylation and Defective Hematopoietic Stem Cells
4140 - Pharmacological Evaluation of a First-in-Class Hemoglobin Elevating Agent (HbEA) AND017 in a Mouse MDS Model of an Inducible Mutant c-Myc Knock-in

Huang, H.

1575 - MRD-Driven Prophylactic or Pre-Emptive Intervention with Chidamide-Based Treatment for High-Risk AML Relapse Post-Transplantation: A Real-World Experience from a Chinese Single Center

Huang, H.

1636 - Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry
1676 - Clinical Characteristics and Treament Outcomes of 104 Cases of Extranodal NK/T-Cell Lymphoma Undergoing Primary Treatment in Novel Agents Era
3070 - Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
3113 - Cyclophosphamide, Mitoxantrone Hydrochloride Liposome, Vincristine, and Prednisone Regimen with or without Rituximab (CMOP±R) Shows High Efficacy As a First-Line Treatment for Non-Hodgkin's Lymphoma: A Phase II Clinical Trial with Matching-Adjusted Indirect Treatment Comparison (MAIC) Analysis
3251 - Acalabrutinib Versus Chlorambucil Plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia: A Randomized, Multicenter, Open-Label, Phase 3 Study
4442 - Study of Autologous Versus Allogeneic Stem Cell Transplantation in 56 Patients with Advanced High-Risk Extranodal NK/T-Cell Lymphoma

Huang, H.

4693 - Lactate Metabolism-Related Genes to Predict the Clinical Outcome and Molecular Characteristics of Multiple Myeloma

Huang, H.

2188 - Outcome of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia with Wilms Tumor 1 (WT1) Mutation: A Study from the ALWP/EBMT
4942 - Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party

Huang, H.

30 - Clec16a-Mediated Mitophagy Modulates Zebrafish Definitive Hematopoiesis
1739 - Safety and Efficacy in Patients with Advanced Lymphomas from a Global Phase 1a/1b, First-in-Human Study of CS5001, a Novel Anti-ROR1 ADC
2180 - Better Outcome Following Younger Haploidentical Donor Versus Older Matched Unrelated Donor Transplant for Patients with Acute Myeloid Leukemia in First Remission: A Study from the Global Committee and Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
2879 - A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia
3562 - Similar Transplant Outcomes for Haplo and MUD Allo-Hcts in AML Patients Achieving CR2: A Study Analyzing 4030 Allo-HCT Recipients from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
3843 - ULK1 Regulates the Proliferation and Differentiation of Erythroid Progenitors
4761 - Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study
4939 - Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults. a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
4944 - Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Haploidentical Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Huang, H.

92 - IL-10 Expressing CD19 CAR-T Cells Induce Complete Remission and Improve Long-Term Protection in Relapsed or Refractory B-Cell Hematological Malignancies
99 - A Phase II Study to Evaluate the Efficacy and Safety of Pimicotinib (ABSK021) in Chronic Graft Versus Host Disease (cGvHD) after 1 or More Lines of Systemic Treatment
420 - A Single-Cell Transcriptomic Atlas of Cytokine Storm in CAR-T Therapy, COVID-19, and SLE
2649 - Transient Activation of PIEZO1 Mechanosensitive Channel Facilitates Ex Vivo expansion of Hematopoietic Stem Cells

Huang, H.

91 - Rituximab, Lenalidomide, and Zanubrutinib (ZR²) with Sequential CAR-T Cell As First-Line Therapy for High-Risk Large B Cell Lymphoma
97 - JAK/Rock Inhibitor Rovadicitinib for Glucocorticoid-Refractory or -Dependent Chronic Graft-Versus-Host Disease：Updated Results of Multicenter, Phase 1b/2a Trial
843 - The Mutated of KRAS gene Determine the Fate of KMT2A-Rearranged AML Patients
921 - A Novel Generation of Anti-CD7 Universal CAR-T Therapy for Patients with Relapsed or Refractory CD7 Positive T-ALL/Lbl: A Phase I Clinical Trial
1044 - A Multicenter Randomized Controlled Trial of Low-Dose Ruxolitinib for Gvhd Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplantation
2074 - 1‰ Regular Dose of Metabolically Armored CD19 CAR-T Cells Induces Robust In Vivo Expansion and Complete Remission in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients
2171 - Easix Score Predicts Overall Survival and Non-Relapse Mortality in Elderly Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation
2818 - Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia
3400 - Combined Single-Cell and Spatial Transcriptomics Reveals the Cellular Landscape of Bronchiolitis Obliterans Syndrome in Chronic Graft-Versus-Host Disease Mouse Model
3599 - Application of 18F-Fapi PET/MRI in the Assessment of Myelofibrosis: A Multi-Center Prospective Observational Study
4201 - CD19 CAR-T Therapy for Patients with Relapsed or Refractory Philadelphia Chromosome–Positive B-Cell Acute Lymphoblastic Leukemia: A Multicenter Study
5170a - Clinical Characteristics and Outcomes of BCMA-Targeted CAR-T Cell Recipients with Coronavirus Disease 2019 during the Omicron Wave: A Retrospective Study

Huang, H.

3614 - In Situ Bioorthogonal Labeling for Non-Invasive, Dynamic In Vivo Nirf/PET Imaging of CAR-T Cells
4847 - mRNA-Laden Lipid-Nanoparticles-Enabled CD19 CAR-T Cells Engineering for the Eradication of Leukemic Cells

Huang, H.

1759 - Intense Monitoring of JAK2V617F and Wild-Type Hematopoiesis during IFNα Exposure to Dissect Its Mechanism of Action
3134 - Uncovering Non-Canonical Signalling Mediated By JAK2V617F in Myeloproliferative Neoplasms

Huang, H.

825 - The Histone Acetyltransferase MOZ (KAT6A) Is a Molecular Dependency and Therapeutic Target in NUP98-Rearranged Acute Myeloid Leukemia

Huang, H.

1978 - Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: Preliminary Analysis from a Phase 2, Prospective, Multicenter Study

Huang, H. H.

2178 - Single-Agent Ibrutinib Versus Allogeneic Hematopoietic Cell Transplantation for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and del(17p)
4615 - Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up

Huang, H. T.

829 - Decoding the Pivotal Roles of BCL10 Activating Mutations in DLBCL Drug Resistance and Lymphomagenesis

Huang, H.

725 - Aberrant Stemness Transcription Signature Unveils a Mechanism of Chemotherapy Resistance through Blunting p53-Mediated Response in Acute Myeloid Leukemia

Huang, H.

4575 - Single-Cell Transcriptomic Analysis Reveals Distinct Hematopoietic Landscapes and Immune Dysregulation in Der(1;7)(q10;p10) Myelodysplastic Syndromes

Huang, H.

4570 - HMGB3 As a Cargo Protein for XPO1: Implications for Myelodysplastic Syndromes Prognosis and Treatment

Huang, H.

5132 - Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study

Huang, H.

1096 - Pulmonary Dysfunction in Patients with Transfusion-Dependent Thalassemia
2139 - Using T-Lymphocyte Subsets at Engraftment to Predict the Risk of Acute Graft Versus Host Disease in Patients with Thalassemia Major：Development of a New Predictive Nomogram
2152 - Addition of Daclizumab to Standard Graft-Versus-Host Disease Prophylaxis in Patients with Thalassemia Major Undergoing Transplantation from Alternative Donor Hematopoietic Stem-Cell Transplantation: A Single-Center Retrospective Analysis from China

Huang, H.

2738 - Modeling the Initiation and Progression of Human MLL-Rearranged Precursor B Cell Acute Lymphoblastic Leukemia in Mice

Huang, H.

986 - Final Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
5132 - Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study

Huang, H.

3066 - Autologous Transplant Consolidation Vs. Immunotherapy Maintanance Therapy in Patients with Relapsed or Refractory NK/T Lymphoma Treated While in Complete Remission
3071 - Clinical Features and CSF-Ctdna Characteristics in Extranodal Natural Killer/T‐Cell Lymphoma Patients with Central Nervous System Involvement
3072 - Safety, Efficacy, and Pharmacokinetics of Unecritinib (TQ-B3101) in Pediatric Patients with Relapsed/Refractory Anaplastic Lymphoma Kinase Positive Anaplastic Large Cell Lymphoma: A Phase I Study
4448 - Selinexor Combined with Tislelizumab in Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL): Preliminary Results of Arm C, from a Multicenter, Single-Arm, Phase I/II Study, Touch
4450 - Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study

Huang, I.

1684 - Pralatrexate Is Effective in Cytotoxic Cutaneous T-Cell Lymphomas

Huang, J. N.

2691 - Outcomes of Immunosuppressive Therapy in Children Less Than Three Years of Age with Idiopathic Severe Aplastic Anemia: A North American Collaboration

Huang, J.

4790 - iPSC-Derived CAR-Gamma Delta T with Novel Combinatorial KO Demonstrated Extended Longevity and Profound Anti-Tumor Efficacy without Cytokine Support in Preclinical Studies

Huang, J. J.

2377 - Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers
4634.2 - Acalabrutinib and Venetoclax (AV) Combination for 2 Years for Patients with Previously Treated CLL/SLL - the Avenue-2 Trial

Huang, J.

381 - Multi-Omics Immune Profiling of Graft-Versus-Host Disease (GvHD) in Humans

Huang, J.

1769 - A Nomogram for Predicting T315I-Free Survival in Chronic Phase Chronic Myeloid Leukemia Patients: A Multi-Center Retrospective Study
1782 - A Predictive Model for Progression to Overt Primary Myelofibrosis in Early/Prefibrotic Primary Myelofibrosis Patients
1786 - Comparing the Efficacy and Safety of Ruxolitinib in Patients with Lower and Higher Risk Myelofibrosis: A Multi-Center, Single-Arm, Exploratory and Prospective Study
1808 - A Novel JAK2 Inhibitor OB756 in Treatment of Janus Kinase Inhibitor-Naive Patients with Myelofibrosis: A Phase 1/2, Open-Label, Multicenter Study
3180 - First in-Class JAK2 Inhibitor OB756 Therapy for Patients with Polycythemia Vera : A Phase 2, Open-Label, Multicenter Study
4528 - Olverembatinib-Based Therapy in Patients with Philadelphia Chromosome-Positive Acute Leukemia: A Multi-Centre Retrospective Study from China
4529 - Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis

Huang, J.

1770 - A Prognostic Model Guiding Treatment Switch for 5-Year Deep Molecular Response in Chronic Myeloid Leukemia Patients Receiving Initial Imatinib: An Extensive, Multi-Center, Retrospective Study
4540 - Predictive Models for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Huang, J.

4502.1 - Phase 3, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared with Rituximab Plus Gemcitabine and Oxaliplatin in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Huang, J.

268 - Epstein-Barr Virus Reactivation and Post-Transplant Lymphoproliferative Disorders after Allo-HSCT in the Era of Letermovir for Cytomegalovirus Prophylaxis

Huang, J.

1605 - Single-Cell Analysis Reveals an Exhaustion of TEM and CTL CD8⁺ T Cells in Hemophagocytic Lymphohistiocytosis with EBV Infection

Huang, J.

1320 - The Therapeutic Effect of Myeloid-Suppressor Cells Induced By Umbilical Cord Blood CD34⁺cells in Mice with Aplastic Anemia
2697 - Anti-CD38 Monoclonal Antibody Is a Salvage Regimen in Relapsed/Refractory Aplastic Anemia
4029 - Daratumumab Overcome Platelet Transfusion Refractoriness in Patients with Aplastic Anemia: A Pilot Trail

Huang, J.

101 - Multiomic Analyses Uncover Immune Signatures of Steroid-Refractory Graft-Versus-Host Disease
268 - Epstein-Barr Virus Reactivation and Post-Transplant Lymphoproliferative Disorders after Allo-HSCT in the Era of Letermovir for Cytomegalovirus Prophylaxis

Huang, J.

378 - A Multi-Center Clinical Trial of Allogeneic Hematopoietic Stem Cell Transplants in Transfusion Dependent Thalassemia

Huang, J.

420 - A Single-Cell Transcriptomic Atlas of Cytokine Storm in CAR-T Therapy, COVID-19, and SLE
1547 - Comprehensive Clinical and Molecular Characterization Reveals Rara As the Most Frequent Torque Teno Mini Virus Insertion Site and Defines a Distinct Ttmv::Rara Driven APL-like Leukemia Subtype
2748 - Metabolic Signature of Oxidative Phosphorylation Deficiency with Activated Nucleotide Biosynthesis in Early T-Cell Precursor Acute Lymphoblastic Leukemia

Huang, J.

38 - The TFG-ROS1 Fusion Is an Oncogenic Driver of Human Myeloid Leukemia

Huang, J.

4959 - First-in-Human Study of Autologous HBA2-Edited CD34+ Hematopoietic Stem and Progenitor Cells in Alpha-Thalassemia with Constant Spring Mutation
4960 - Updated Safety and Efficacy Results of RM-001, Autologous HBG1/2 Promoter-Modified CD34+ Hematopoietic Stem and Progenitor Cells, in Treating Transfusion-Dependent β-Thalassemia

Huang, J.

3072 - Safety, Efficacy, and Pharmacokinetics of Unecritinib (TQ-B3101) in Pediatric Patients with Relapsed/Refractory Anaplastic Lymphoma Kinase Positive Anaplastic Large Cell Lymphoma: A Phase I Study

Huang, K.

682 - CD19 CAR T-Cell Therapy in Refractory Autoimmune Hemolytic Anemia
4961 - Deciphering Hematopoietic Reconstitution Dynamics of Lentiviral Vector HBB^T87Q-Engineered Hematopoietic Stem Cells Gene Therapy for β-Thalassemia Patients

Huang, K. C.

4982 - Accelerating Drug Discovery: AI-Powered Indication Exploration for Ropeginterferon Alfa-2b

Huang, K.

335 - SEC62 Regulates HLA-E Expression in Diffuse Large B-Cell Lymphoma to Function As a Mechanism of Immune Evasion

Huang, L.

3087 - A Survival Prognostic Model for Gastro-Intestinal Non-Hodgkin Lymphoma

Huang, L.

1786 - Comparing the Efficacy and Safety of Ruxolitinib in Patients with Lower and Higher Risk Myelofibrosis: A Multi-Center, Single-Arm, Exploratory and Prospective Study
3949 - Low-Dose Corticosteroids and Eltrombopag in the Treatment of Newly Diagnosed Adult Immune Thrombocytopenia: A Multicenter, Phase 2 Clinical Trial

Huang, L.

4959 - First-in-Human Study of Autologous HBA2-Edited CD34+ Hematopoietic Stem and Progenitor Cells in Alpha-Thalassemia with Constant Spring Mutation

Huang, L.

3419 - Improving CAR-T Cell Function through a Targeted Cytokine Delivery System Utilizing CAR Target-Modified Extracellular Vesicles

Huang, L.

89 - Targeted-Delivery Strategy of Engineered EV Functionalized By Anti-CD3/CD19 Bi-Specific T-Cell Engager in Treating B-Cell Malignancies
1401 - The Expression of BTG1 in De Novo AML Patients Regulated By Demethylation of Decitabine and Its Evaluation in the Deep Remission of Patients
1447 - Superiority in the Longer Duration of Response and Better Central Nervous System Penetration of CAR-T Cell Therapy over Blinatumomab Infusion for Relapsed/ Refractory B-Cell Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis
3407 - Type I Interferon Impairs the Function of CAR-T Cells By Disrupting Immune Synapse Assembly
4205 - A Phase 2 Clinical Trial of Anti-CD19 CAR-T (pCAR-19B) in Chinese Pediatric and Young Adult with Relapsed/Refractory (R/R) CD19+ B-ALL: The First Pivotal Study in an Asian Population
4276 - Efficacy of Decitabine in Combination with IA Versus IA in Patients with Newly Diagnosed AML, a Multicenter, Prospective, Randomized Controlled Trial
4417 - Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd

Huang, L.

3132 - Tandem CD19/20 CAR-T Showed Durable Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma: Interim Results from a Multicenter Phase I/II Trial

Huang, L.

1675 - The Efficacy and Safty of Chidamide and Azacitidine Combined with Chemotherapy As a First-Line Treatment in T Follicular Helper Lymphomas: A Comprehensive Retrospective Study

Huang, L.

4959 - First-in-Human Study of Autologous HBA2-Edited CD34+ Hematopoietic Stem and Progenitor Cells in Alpha-Thalassemia with Constant Spring Mutation

Huang, L.

1575 - MRD-Driven Prophylactic or Pre-Emptive Intervention with Chidamide-Based Treatment for High-Risk AML Relapse Post-Transplantation: A Real-World Experience from a Chinese Single Center

Huang, L.

2481 - In Vivo Sickle Cell Blood Rheology in Humans with Ventral Tongue Microscopy

Huang, M.

1401 - The Expression of BTG1 in De Novo AML Patients Regulated By Demethylation of Decitabine and Its Evaluation in the Deep Remission of Patients
4276 - Efficacy of Decitabine in Combination with IA Versus IA in Patients with Newly Diagnosed AML, a Multicenter, Prospective, Randomized Controlled Trial

Huang, M.

1447 - Superiority in the Longer Duration of Response and Better Central Nervous System Penetration of CAR-T Cell Therapy over Blinatumomab Infusion for Relapsed/ Refractory B-Cell Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis
3419 - Improving CAR-T Cell Function through a Targeted Cytokine Delivery System Utilizing CAR Target-Modified Extracellular Vesicles

Huang, M.

3407 - Type I Interferon Impairs the Function of CAR-T Cells By Disrupting Immune Synapse Assembly

Huang, M.

999 - A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib

Huang, M.

3843 - ULK1 Regulates the Proliferation and Differentiation of Erythroid Progenitors

Huang, N.

3453 - A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001) and Orthogonal IL-2 (STK-009) in Subjects with Relapsed or Refractory CD19 Expressing Hematologic Malignancies (NCT05665062)

Huang, N.

2187 - Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study

Huang, Q.

2013 - Post-Transplant G-CSF Restores T Cell Homeostasis By Inhibiting Alloreactive T Cells and Promoting Thymic Regeneration
3396 - Gallic Acid Enhances GVL Effects of T Cells without Exacerbating Gvhd after Hematopoietic Stem Cell Transplantation

Huang, Q.

87 - Human IFN-α2- and PD-L1-Modified T Cells (αp-T cells) Inhibit Graft-Versus-Host Disease but Retain Anti-Leukemia Activity

Huang, Q.

2039 - Reprogramming T Cell EZH2 to Counteract CAR T Cell Dysfunction during Tumor Control
4769 - Ezh2 and Intracellular Ca2⁺ Signals Interdependently Coordinate Gvhd and CAR T Cell Responses

Huang, Q.

2566 - Genetic Associations and Platelet Count Trajectories in Gestational Thrombocytopenia and Immune Thrombocytopenia during Pregnancy
3703 - Outcome for Mothers and Neonates Among Pregnant Women with Von Willebrand Disease: A Prospective Nationwide Multicenter Study

Huang, R.

4764 - Single Cell RNA-Seq Analysis Revealed MIF/CD74 Pathway Determinants of BCMA CART Resistance in Relapsed/Refractory Multiple Myeloma

Huang, R.

4229 - Comprehensive Genomic Profiling (CGP) of Acute Lymphoblastic Leukemias with Foundation One Heme Identifies Actionable Genomic Alterations and Biomarkers

Huang, R.

2152 - Addition of Daclizumab to Standard Graft-Versus-Host Disease Prophylaxis in Patients with Thalassemia Major Undergoing Transplantation from Alternative Donor Hematopoietic Stem-Cell Transplantation: A Single-Center Retrospective Analysis from China

Huang, R.

1050 - Updated Results from a Phase Ⅱ Clinical Trial：Safety and Efficacy of Azacitidine and Chidamide Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia
2187 - Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study
2879 - A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia

Huang, R.

1213 - A Specific Coagulation Factor X Activator for on-Demand Treatment in Hemophilia with Inhibitors
2558 - Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

Huang, R.

3469 - Comparison of the Efficacy and Adverse Effects of Recipient-Derived Versus Donor-Derived CAR-T Cell Therapy for Post-Transplant Relapse in B-ALL

Huang, R.

5065 - Trends of Opioid Prescribing and Vaso-Occlusive Crises in Sickle Cell Disease in the U.S. (2011-2023)

Huang, S.

1519 - A Phase I Study of Chidamide in Combination with Dcag and Venetoclax in Acute Myeloid Leukemia: Clinical Safety, Efficacy, and Correlative Analysis

Huang, S.

986 - Final Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Huang, S. Y.

4743 - MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Huang, S.

1062 - Overcoming Immune Escape Via Targeting Akt-Wnt/β-Catenin By Artificial-Intelligence-Powered Peptide-Producing mRNAs
1306 - Characterization of Multicellular Niches Supporting Hematopoietic Stem Cells within Distinct Zones

Huang, S.

2602 - Interpreting High Levels of Unfolded Von Willebrand Factor in Patients with the Antiphospholipid Syndrome

Huang, S.

2840 - Deciphering Clonal Evolution of Immunoglobulin Heavy Chain Locus Enhances Next-Generation Sequencing-Based Measurable Residual Disease Detection in Adult B-Acute Lymphoblastic Leukemia
4972 - Analytical Validation of a Next-Generation Sequencing Assay for Detecting Minimal Residual Disease in Lymphoid Malignancies

Huang, S. W.

4790 - iPSC-Derived CAR-Gamma Delta T with Novel Combinatorial KO Demonstrated Extended Longevity and Profound Anti-Tumor Efficacy without Cytokine Support in Preclinical Studies

Huang, S.

4627 - Efficacy and Safety Results of TQB3909 in Patients (Pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Huang, S. M.

1484 - Venetoclax with Hypomethylating Agents Compared with Priming Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Single Center Retrospective Study
1527 - Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification

Huang, S.

2074 - 1‰ Regular Dose of Metabolically Armored CD19 CAR-T Cells Induces Robust In Vivo Expansion and Complete Remission in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients
2818 - Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia

Huang, S.

1149 - Blood Cell Homeostasis Is Maintained in the Absence of Resident Mononuclear Phagocytes in Fetal Liver and Bone Marrow in CSF1R Knockout Rats
1150 - Transcriptomic Analysis of the Functions of CSF1R-Dependent Macrophages in Postnatal Development in the Rat
1151 - An Inactivating Mutation in Rat IL-34 Reveals Redundant and Nonredundant Functions of CSF1-IL-34 Signalling in Homeostasis and Inflammation

Huang, S.

5095 - Richter Transformation (RT) in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Comparison of Two Eras

Huang, S.

4108 - HoxBlinc LncRNA Reprograms CTCF Independent TADs to Drive Leukemic Transcription and HSC Dysregulation in NUP98 Fusion Transformed Leukemia

Huang, T. C.

2092 - Eltrombopag Plus G-CSF for Peripheral Blood Stem Cell Mobilization: Interim Analysis of a Single Arm, Phase 2 Trial
4466 - The Population-Scale Analysis of DLBCL Patients Receiving Standard-Dose RCHOP Identified Impactful Prognosticators in the Real World
1742.2 - Golseek-1: A Phase 3, Double-Blind, Randomized Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Vs R-CHOP in Patients with Previously Untreated, High-Risk, Large B-Cell Lymphoma

Huang, T.

1008 - IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results

Huang, T.

88 - A Versatile B Cell Engineering Platform Enables Development of B Cell Medicines for Sustained Delivery of Therapeutic Biologics

Huang, T.

2366 - The Impact of Structural Inequity and Adverse Social Determinants of Health on Hematopoietic Cell Transplant Access in Pediatric Patients with Hematologic Malignancies and Myelodysplastic Syndromes

Huang, W.

1401 - The Expression of BTG1 in De Novo AML Patients Regulated By Demethylation of Decitabine and Its Evaluation in the Deep Remission of Patients
4276 - Efficacy of Decitabine in Combination with IA Versus IA in Patients with Newly Diagnosed AML, a Multicenter, Prospective, Randomized Controlled Trial

Huang, W.

3599 - Application of 18F-Fapi PET/MRI in the Assessment of Myelofibrosis: A Multi-Center Prospective Observational Study

Huang, W.

3411 - IL-2-Inducible T Cell Kinase Deficiency Enables Development of Sustainable Chimeric Antigen Receptor T Cell Therapy

Huang, W.

3257.2 - BRAVE: A Phase 2 Trial Evaluating the Efficacy and Safety of Venetoclax in Combination with Bruton’s Tyrosine Kinase Inhibitors in Patients with First-Line Chronic Lymphocytic Leukemia

Huang, W.

4196 - Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: An Updated Report on the Pivotal Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-Cell ALL) in China

Huang, W.

1728 - Polatuzumab Vedotin, Rituximab and Lenalidomide (Pola-R²) As First-Line Therapy for Unfit and Frail Elderly Diffuse Large B-Cell Lymphoma Patients: Preliminary Result of a Prospective, Phase II, Multi-Center Study
1741 - A Phase Ib Clinical Trial Investigating the Safety, Tolerability, and Pharmacokinetics of HX009，a Novel Bsab Dual Targeting PD-1 x CD47，in Patients with EBV⁺ Non-Hodgkin Lymphoma (NHL)
1978 - Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: Preliminary Analysis from a Phase 2, Prospective, Multicenter Study
4417 - Asymptomatic Multicentric Castleman Disease: A Potential Early Stage of Idiopathic Mcd

Huang, W.

1648 - Zanubrutinib Plus Ixazomib & Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia:a Phase II Studyshort Title: Zid for Waldenström Macroglobulinemia
1678 - Γδ and Αβ T-Cell Large Granular Lymphocytic Leukemia Have Similar Characteristics and Outcomes
4349 - Determination of MYD88 and CXCR4 Mutation for Clinical Detection and Their Significance in Waldenström Macroglobulinemia
4439 - Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression
4481 - Response-Driven Dose-Intensified Immunochemotherapy ± Autologous Stem Cell Transplantation in Previously Untreated Patients with High-Risk Aggressive B-Cell Lymphoma: Results of the DLCL002 Phase 2 Trial

Huang, X.

831 - Disrupting IL10 Signaling Overcomes Compound Copy Number Variation-Driven Clinical Resistance to CDK4/6 and BTK Inhibition in Mantle Cell Lymphoma
1886 - CDK4/6 Inhibition Reverses MEIS2 Inhibition of CRL4^CRBN By Both Disrupting MEIS2-CRBN Association and Opposing Regulation of MEIS2 and CRBN Synthesis That Enhances IMiD Therapy in Multiple Myeloma

Huang, X. J.

399 - Hematopoietic Stem Cell Transplantation in Hepatosplenic T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
2938 - Molecular Measurable Residual Disease before Transplantation Independently Predicts Survival and Relapse Risk in Adult KMT2A-Rearranged Acute Myeloid Leukemia
4773 - Donor-Derived Unlicensed NK Cells Promote the Hematopoietic Recovery after Allogeneic Hematopoietic Stem Cell Transplantation

Huang, X. J.

300 - Effects of Low-Molecular-Weight Heparin on Pregnancy Outcomes in Protein S Deficiency: A Prospective, Randomized Controlled Phase II Clinical
378 - A Multi-Center Clinical Trial of Allogeneic Hematopoietic Stem Cell Transplants in Transfusion Dependent Thalassemia
425 - β2-Adrenergic Receptor Agonist Terbutaline Regulates Macrophage Polarization Via HMGB1 in Immune Thrombocytopenia
690 - Parvovirus B19 Originates from Infected Hematopoietic Stem Cells Following Hematopoietic Stem Cell Transplantation
1345 - AIM2 Mediates Immune Evasion of Acute Myeloid Leukemia Cells
1486 - Clinical Features and Prognostic Nomogram for Therapy-Related Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
1504 - TQB3455 Plus Azacitidine in Patients with Newly Diagnosed, Mutant-IDH2 Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Phase 1 Trial
1834 - Myelodysplastic Syndrome Stem Cells Evaluated By Multiparameter Flow Cytometry Are Associated with Posttreatment Relapse: A Prospective Study
2013 - Post-Transplant G-CSF Restores T Cell Homeostasis By Inhibiting Alloreactive T Cells and Promoting Thymic Regeneration
2109 - Changing Donor Was Critical for the Successful Salvage Second Transplantation for Graft Failure after the First Allogeneic Stem Cell Transplantation: A Chinese Multicenter Retrospective Study
2133 - Invasive Fungal Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in China: A Multicenter Epidemiological Study (CAESAR 2.0)
2160 - Evaluation of the Real-World Efficacy of Hetrombopag for the Treatment of Thrombocytopenia Post Allogeneic Hematopoietic Stem Cell Transplantation
2180 - Better Outcome Following Younger Haploidentical Donor Versus Older Matched Unrelated Donor Transplant for Patients with Acute Myeloid Leukemia in First Remission: A Study from the Global Committee and Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
2187 - Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study
2545 - PI3K-AKT Pathway Mediates the Imbalance of Macrophage Polarization in Immune Thrombocytopenia Patients
2566 - Genetic Associations and Platelet Count Trajectories in Gestational Thrombocytopenia and Immune Thrombocytopenia during Pregnancy
2684 - Inhibition of TGF-β in Bone Marrow Endothelial Progenitor Cells Promotes Hematopoietic Recovery in Acute Myeloid Leukemia after Chemotherapy
3396 - Gallic Acid Enhances GVL Effects of T Cells without Exacerbating Gvhd after Hematopoietic Stem Cell Transplantation
3511 - Comparison of Two Conditioning Regimens for Haploidentical Stem Cell Transplantation in Patients with Severe Aplastic Anemia
4074 - TGF-β Pathway Inhibition Improves Hematopoietic Deficiency and Immune Imbalance By Repairing Endothelial Progenitor Cell Function in Aplastic Anemia
4235 - The Bone Marrow Blasts on Day 14 during the Azacitidine Plus Venetoclax Regimen As the Induction Therapy Can Predict the Outcome in Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia
4831 - LILRB4 Synthetic T-Cell Receptor and Antigen Receptor-T (STAR-T) for Refractory/Relapsed Acute Myeloid Leukemia: First-in-Human Phase I Clinical Trial

Huang, X.

1990 - First-in-Human, Phase Ia_, Dose Escalation, Monotherapy Study of QLS32015, a Novel GPRC5D×CD3 T-Cell Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
2187 - Comparison of Outcomes between Haploidentical and Matched Related Donors for Chronic Myelomonocytic Leukemia: A Multicenter Real-World Study
4748 - Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Huang, X.

2785 - LY4152199, a First-in-Class BAFF-RxCD3 Bispecific Antibody for the Treatment of B Cell Malignancies

Huang, X.

3703 - Outcome for Mothers and Neonates Among Pregnant Women with Von Willebrand Disease: A Prospective Nationwide Multicenter Study

Huang, X.

1537 - Genetic Abnormalities Associated with Outcomes in Unfit Patients with Acute Myeloid Leukemia Receiving Less Intensive Therapy in the Real World

Huang, X.

830 - EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin

Huang, X. (.

2668 - Distinct Effects of Cigarette Smoke and e-Cigarette Aerosols on Inflammation and Stem Cell Proliferation in Clonal Hematopoiesis
4058 - Leveraging Clonal Competition between Chip and Aggressive Malignant Clones As a Novel Therapeutic Approach

Huang, X.

2438 - Neighborhood Disadvantage Impacts Outcomes in Patients with Myelodysplastic Syndromes across Different Racial Backgrounds
3212 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome
3817 - Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods
4601 - A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome

Huang, X.

4157 - Targeting Chronic Myeloid Leukemia with Potent and Specific BCR::ABL1 Degraders

Huang, Y.

3260 - Comprehensive Translatomic Analysis of Multiple Myeloma Unveils Novel Insights into Disease Pathogenesis

Huang, Y.

1678 - Γδ and Αβ T-Cell Large Granular Lymphocytic Leukemia Have Similar Characteristics and Outcomes
4439 - Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Huang, Y.

150 - Efficient Generation of CAR-T By the First Coacervate-Based Gene Delivery System

Huang, Y.

4923 - Increased EBV Infection and Relapse Rates Following Haploidentical Hematopoietic Cell Transplantation in the Era of Letermovir for Cytomegalovirus Prophylaxis: A Propensity Score Matching Analysis

Huang, Y.

4104 - Telomere Content Diversity in Myeloid Neoplasia Could Inform on Differential Sensitivity to Telomerase Inhibitors

Huang, Y.

2950 - Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia

Huang, Y.

1564 - Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial
1719 - Nivolumab in Combination with Dose Adjusted (DA) R-EPOCH for First-Line Treatment of Large B-Cell Lymphoma: Results from a Phase II Trial
2432 - Real-World Experience of Venetoclax Target Dosing with Concomitant Posaconazole in Adult Patients with Acute Myeloid Leukemia
3245 - A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL
4324 - Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age
4325 - IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy
4438 - Final Results of a Phase II Study of Brentuximab Vedotin and Lenalidomide in Relapsed and Refractory T-Cell Lymphomas
4629 - Outcomes of Patients with Chronic Lymphocytic Leukemia Discontinuing Bruton Tyrosine Kinase Inhibitors Due to Adverse Effects
5099 - Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy
2907.2 - A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax + Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years
4634.1 - Prospective Randomized Phase 2 Study of Acalabrutinib + Obinutuzumab or Venetoclax in Previously Untreated CLL

Huang, Y. P.

4092 - Germline Variant Burden Warrants Universal Genetic Testing in Pediatric AML

Huang, Y.

1337 - Evi1 Governs Kdm6b-Mediated Histone Demethylation to Regulate the Laptm4b-Driven mTOR Pathway in Hematopoietic Progenitor Cells

Huang, Y.

2035 - CRG-023 Is a Novel Tri-Specific CAR T Product Candidate Engineered to Prevent Antigen Escape and Sustain Durable Anti-Tumor Functionality Against B-Cell Malignancies

Huang, Y. H.

1484 - Venetoclax with Hypomethylating Agents Compared with Priming Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Single Center Retrospective Study
1527 - Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification

Huang, Y. S. V.

116 - Near Universal National Uptake of Dexrazoxane in the Real-World Setting Associated with Reduced Cardiac ICU Care Requirements in Pediatric Acute Myeloid Leukemia
531 - Real-World Generalizability of Clinical Trial Cytomolecular Features By Race and Ethnicity in Pediatric Acute Myeloid Leukemia (AML)

Huang, Y.

627 - Rbmx Regulates YTHDC1 Nuclear Condensates to Promote Nascent Transcription in Acute Myeloid Leukemia

Huang, Y.

2231 - Novel Liquid Biopsy Approach for Detection and Characterization of Disease Progression of Plasma Cell Disorders

Huang, Y.

2753 - Elucidating Transcriptional Heterogeneity in Venetoclax Resistant AMLs

Huang, Y.

4205 - A Phase 2 Clinical Trial of Anti-CD19 CAR-T (pCAR-19B) in Chinese Pediatric and Young Adult with Relapsed/Refractory (R/R) CD19+ B-ALL: The First Pivotal Study in an Asian Population

Huang, Y.

4969 - Discovery of UBE2B and RNF144b As Potential Candidates for Selective Degradation of NPM1c in AML

Huang, Y.

1096 - Pulmonary Dysfunction in Patients with Transfusion-Dependent Thalassemia

Huang, Y.

4138 - Type 2 Diabetes Leads to the Senescence of the Bone Marrow Microenvironment, and the Increase in DNA Damage Repair Function of AML Cells Mediates Anthracycline Resistance through Sasp

Huang, Y.

960 - CD93⁺ Myeloid Cells Suppress T-Cell-Mediated Anti-Tumor Immunity
1345 - AIM2 Mediates Immune Evasion of Acute Myeloid Leukemia Cells

Huang, Z.

3120 - Study of PC-002 (Sepantronium Bromide), a First-in-Class Inhibitor of Deubiquitinases (DUBs) Targeting Myc Degradation in Relapsed/Refractory c-Myc Rearranged High-Grade B Cell Lymphoma (HGBCL): Updated Phase 2 Results

Huang, Z. Q.

1507 - Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens As Induction Therapy for Newly Diagnosed Patients with Immunophenotypically Mature Monocytic AML

Huang, Z.

4276 - Efficacy of Decitabine in Combination with IA Versus IA in Patients with Newly Diagnosed AML, a Multicenter, Prospective, Randomized Controlled Trial

Huang, Z.

4276 - Efficacy of Decitabine in Combination with IA Versus IA in Patients with Newly Diagnosed AML, a Multicenter, Prospective, Randomized Controlled Trial

Huang, Z.

1966 - Serum Metabolite Profile By Targeted Lipomics Approach to Evaluate Drug Resistance and Prognosis in Myeloma Patients
3377 - Anti-CD3/B-Cell Maturation Antigen Bispecific Antibody CM336 in Relapsed/Refractory Multiple Myeloma: An Open-Label, Phase I/II Study

Huang, Z.

483 - Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis
1000 - Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed/Refractory Myelofibrosis

Huang, Z.

839 - Tucidinostat Plus Pediatric-Inspired Chemotherapy As First-Line Therapy for Newly Diagnosed ETP-ALL/Lbl: An Open-Label, Single-Arm, Phase 2 Trial

Huang, Z.

3411 - IL-2-Inducible T Cell Kinase Deficiency Enables Development of Sustainable Chimeric Antigen Receptor T Cell Therapy

Huang, Z.

8 - TMPRSS6 Antisense Oligonucleotide Therapy Reverses Inflammation in Jak2^V617F Mutant Mice
2660 - Gut Microbiota Promote Chronic Inflammation in Jak2^V617F Mice

Huart, A.

891 - Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study
892 - Efficacy and Safety of Isatuximab, Pomalidomide and Dexamethasone in Relapsed AL Amyloidosis: Interim Results of the Isamyp Phase 2 Joint Study from the IFM and ALLG
1979 - Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Hubaud, A.

88 - A Versatile B Cell Engineering Platform Enables Development of B Cell Medicines for Sustained Delivery of Therapeutic Biologics

Hubben, A. K.

1238 - Patient Reported Outcomes during Long-Term Follow-up of Atypical Hemolytic Uremic Syndrome in the Era of Terminal Complement Inhibition
4024 - Concordance between Acr/EULAR and Sapporo Criteria for Antiphospholipid Syndrome: New Domains Unveil Associations with Procoagulant Platelets

Huber, C.

4464 - Primary Vitreoretinal Lymphoma: A Comprehensive Retrospective Analysis of 65 Cases at Two European Centers

Huber, C.

740 - A Single Cell Atlas of Follicular Lymphoma across Clinical Stages Defines Tumor B Cell Archetypes, Immune Microenvironment Heterogeneity and Novel Cell States Associated with High-Risk FL
955 - Deciphering the Mechanism of Action of the Novel Celmod, Golcadomide, during Germinal Center B Cell Immune Response and in a Preclinical Mouse Model of Follicular Lymphoma
1597 - Single-Cell Atlas of Diffuse Large B-Cell Lymphoma Reveals Integrated Malignant B Cell and Tumor Microenvironment Characteristics Associated with Clinical Response

Huber, K.

2525 - Constructing a Computational Workflow for the Identification of Novel Cellular and Molecular Drivers of Human Granulopoiesis
2527 - KLF5 Is a Key Regulator of IMiD-Induced Neutropenia

Huber, S.

Huber, W.

276 - Unraveling Molecular Subgroup-Specific Pathway Dependencies in Chronic Lymphocytic Leukemia through Drug-Perturbed Transcriptomic Profiling and Statistical Modeling
3584 - Cancer Pathway Connectivity Resolved By Drug Perturbation and RNA Sequencing
4383 - Immune Cell Infiltration Impacts Chemotherapy Efficacy in B-NHL

Hubmann, M. C. G.

2411e - Real-World Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Iona-MM Second Interim Analysis

Hübner, J.

723 - CDK8 Inhibition Represses Monocyte-like Gene Expression in Acute Myeloid Leukemia Cells and Antagonizes In Vivo Resistance to FLT3 Inhibition

Huck, J.

4982 - Accelerating Drug Discovery: AI-Powered Indication Exploration for Ropeginterferon Alfa-2b

Huda, T.

5198 - How Balanced Is Gender Representation at ASH? a Cross-Sectional Analysis

Hude, I.

2337 - Bone Mineral Density in Hodgkin Lymphoma Patients Treated with Escalated Beacopp: Focus on Steroid Administration and Age-Related Effects

Hudecek, M.

2007 - Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis

Hudson, C. A.

967 - A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO – a Report from the Children’s Oncology Group

Hudson, M. M.

698 - Late Venous Thromboembolic Events in Survivors of Childhood Cancer: A Report from the St. Jude Lifetime Cohort Study
3714 - Neurocognitive Decline Among Long-Term Survivors of Pediatric Hodgkin Lymphoma: A Report from the St. Jude Lifetime Cohort

Hudson-Lund, B.

1909 - A Novel Segmentation-Based Purity-Informed Approach Accurately Detects Total Copy Number and Its Subclonal Fraction in Myeloma Targeted Panel Sequencing Data
3333 - Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial

Hue, S. S.

3602 - Machine Learning Classification of Spatial Patterns of Malignant Cells Reveals Implications in Prognosis and Tumor Microenvironment Composition in Lymphoma

Huen, A. O.

Hueneman, K.

2663 - MYD88 Is Mutated in Clonal Hematopoiesis and Drives Altered Immune Cell Populations
4572 - The Zymogen Form of Caspase-1 Is Required to Finetune Excessive Cell-Intrinsic Inflammation in Myelodysplastic Syndromes

Hueniken, K.

286 - COVID-19 Humoral Immunity Improves with Third and Subsequent Vaccine Doses in Patients with Plasma Cell Dyscrasias, Particularly in Those Receiving antiCD38 Therapy
1695 - Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy
3744 - Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada

Huerga, S.

4478 - A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms
4798 - Molecular Mechanisms Promoting Long-Term Cytopenia after BCMA CAR-T Therapy in Multiple Myeloma

Huerta, N.

2648 - Mitochondrial Metabolism Underlies Developmental Programming of Hematopoietic Stem Cell Function By Prenatal Folate

Huerta, Y.

2335 - Anaphylaxis Associated with Calaspargase in Pediatric Patients with Acute Lymphoblastic Leukemia
4187 - Retrospective Cohort Analysis of Response and Survival of Children, Adolescents, and Young Adults (CAYA) with Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoma (T-LL) Treated with Curative Intent: A TACL Consortium Study

Hueso, J. A.

2356 - Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)

Hueso, T.

738 - Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE^®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study

Hueso, T.

474 - Post-Therapeutic Tumor Losses of B-Cell Receptor Components CD20/CD19, a New Challenge in the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Huet, S.

2079 - Myeloid Neoplasia after CD19 Directed CAR-T Cells : Cumulative Incidence, Risk Factors and Outcome

Huet, T.

4292 - Immunotherapy with pVAX14 Nucleic Acid in Combination with All-Trans Retinoic Acid (ATRA) in an Acute Promyelocytic Leukemia (APL) Mouse Model Activates Cytotoxic T-Cells and Enhances Immune Responses: A Strategy for Turning “Cold” Tumors “Hot”

Huff, C. A.

3551 - Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

Huffstutler, R.

807 - The Ectopyrase CD73 Is a Critical Checkpoint in Thromboinflammation

Huggins, J.

2001 - Characterizing and Risk Stratifying Musculoskeletal Toxicities after BCMA CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Hughes, A.

313 - Genomic Biomarkers of Poor Outcome in Patients with T-Cell Lymphoblastic Lymphoma
634 - TCL1A Is Associated with Blinatumomab Response and Immune Activation in Pediatric B-ALL

Hughes, C.

3792b - Evaluating Barriers to Enrolment into Multiple Myeloma (MM) Clinical Trials: Results from Health Care Professionals and Patient Survey from the UK Myeloma Research Alliance Equity, Diversity and Inclusivity (EDI) Working Group

Hughes, C. F.

267 - Long-Term Follow up of a Prospective Pilot Study of an α/β T-Lymphocyte Depleted Graft Conditioned with a Reduced Intensity Regimen in Patients with Hematologic Malignancies

Hughes, C.

118 - The Burden of Transfusion Dependence on Caregivers of Patients with Lower-Risk Myelodysplastic Syndromes in North America and Europe

Hughes, D.

2401 - An Indirect Comparison of Elranatamab’s Progression-Free Survival, Duration of Response, and Overall Survival from MagnetisMM-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma
3762 - The Impact of Multiple Myeloma on Care Partner Well-Being, Work Productivity, and Resource Use in the United States and Western Europe
3770 - Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study – Interim Results

Hughes, J.

2525 - Constructing a Computational Workflow for the Identification of Novel Cellular and Molecular Drivers of Human Granulopoiesis
2527 - KLF5 Is a Key Regulator of IMiD-Induced Neutropenia

Hughes, K.

2343 - Medicaid Expansion and Cancer-Specific Survival Among Individuals with Acute Lymphoblastic Leukemia
2371 - Exploring the Intersectionality of Marital Status and Sex on Survival Outcomes in Non-Hodgkin’s Lymphoma

Hughes, M. S.

360 - Development of Anti-Amyloid 11-1F4- CAR Phagocytes for Treatment of AL Amyloidosis

Hughes, T. E.

1040 - Pharmacokinetic (PK) Exposure of 4-Hydroxycyclophosphamide Associates with Clinical Benefits of Reduced-Dose Post-Transplantation Cyclophosphamide: Results of a Completed Phase I/II Trial to De-Escalate Post-Transplantation Cyclophosphamide for HLA-Haploidentical Myeloablative Bone Marrow Transplantation

Hughes, T. P.

475 - Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Pivotal Phase 3 ASC4FIRST Study
476 - Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare
991 - Strong Association between Cancer Gene Variants at Diagnosis, Especially ASXL1, and Emergence of Kinase Domain Mutation-Driven Resistance in CML Patients Despite Frontline Treatment with More Potent BCR::ABL1 Inhibitors
993 - Increased Inflammatory Cytokines in Plasma Are Associated with Sustained Treatment-Free Remission in Chronic Myeloid Leukaemia
996 - Longitudinal Clonal Tracking Reveals That Early and Sensitive Detection of Blood Cancer-Related Gene Variants in Patients with Chronic Myeloid Leukemia Predicts Treatment Failure
1006 - Durable Responses Observed in Chronic Myelomonocytic Leukemia Treated with Lenzilumab and Azacitidine
1765 - Asciminib Provides Long-Term, Durable Molecular Responses in Patients with T315I-Mutated CML-CP: Final Analysis from a Phase 1 Trial
2715 - Imatinib-Sensitive Chronic Myeloid Leukaemia Is Associated with mtDNA Mutations and Reduced Oxphos Capacity
3196 - CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity

Huguet, F.

478 - 18-Months Follow-up of the Trial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting
731 - Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials
1434 - Switch of Asparaginase Formulation Based on Antibody Monitoring in Adults with Philadelphia-Negative Adult Lymphoblastic Leukemia. Results of the Graall-2014 Trial
1440 - Single-Agent Subcutaneous Blinatumomab for Advanced B-Cell Acute Lymphoblastic Leukemia: Long-Term Follow-up from a Phase 1b Dose Expansion Cohort

huguet Mas, M.

2105 - Treosulfan/Fludarabine Versus Thiotepa/Busulfan/Fludarabine for Allogeneic Hematopoietic Cell Transplantation in Patients with Lymphomas in the Ptcy Era: A Study on Behalf of the Grupo Español De Trasplante y Terapia Celular (GETH-TC)

Huhn, S.

84 - Impact of Clonal Heterogeneity in Newly Diagnosed, Transplant-Eligible Multiple Myeloma – Subgroup Analysis of the GMMG HD6 Phase III Trial
364 - Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
493 - Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial
769 - Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)

Hui, H.

4145 - Synergistic Effect of EZH2 Inhibitor Dznep and Flavonoid GL-V9 in AML through Inhibition Hells and Induction of DNA Damage

Hui, S.

269 - Safety of 20Gy Total Marrow Irradiation Based Conditioning Regimen for Hematopoietic Cell Transplantation with T Cell Adoptive Immunotherapy
775 - Multidimensional Analysis of Relapsed Bone Marrow Reveals Cold Immune Microenvironment Post-TMLI in Acute Leukemia Transplant Patients
1394 - Immunotherapeutic Potential and In Vivo Targeting of CD33 Splice Variant Isoform
3393 - Tissue-Specific Myeloablative Conditioning with Total Marrow Irradiation Enhances Gut Microbiome Diversity and Mitigates Gvhd: A Novel Therapeutic Approach

Huić, D.

2337 - Bone Mineral Density in Hodgkin Lymphoma Patients Treated with Escalated Beacopp: Focus on Steroid Administration and Age-Related Effects

Huitema, A. D.

3108 - Brigatinib Monotherapy in Children with R/R ALK+ ALCL, IMT, or Other Solid Tumors: Updated Results from the Brigaped (ITCC-098) Phase 1 Dose-Escalation Study
4876 - Standard Fludarabine Dosing Results in Overexposure in Young Children Undergoing Hematopoietic Cell Transplantation
4265.3 - APAL2020K/ITCC-101: A Phase I Trial of the Menin Inhibitor Ziftomenib in Combination with Chemotherapy in Children with Relapsed/Refractory KMT2A-rearranged, NUP98-rearranged, or NPM1-mutant Acute Leukemias

Hulbert, M. L.

602 - Opportunities for Standardizing Conversations about Curative Therapy for Sickle Cell Disease

Hulin, C.

362 - Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial
774 - The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma
1975 - Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Combination with Daratumumab and Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma: Safety and Efficacy Results from the Phase 1b Monumental-2 Study
2000 - Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)
4653 - Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies
4756 - High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)

Hull, N. J.

880 - Granulocyte Derived Resistin Induces Classical Monocyte Repartition and Immune Suppression in CMML

Huls, G.

1037 - Whole Body CD8⁺ T Cell PET Imaging in Patients with DLBCL before and during Anti-CD19 CAR T Cell Therapy
1350 - The Oncogenic ΔNp73α Isoform Contributes to Aggressiveness in APL By Leading to ATRA Resistance through NANOG/BMP4 Axis Upregulation
1393 - DGAT1 Inhibition Enhances Metformin-Induced Ferroptosis in AML By Targeting Lipid Metabolism
1539 - MLL5-Driven Leukemic Transformation Is Linked to Chromatin Remodeling and Can be Targeted with ATRA in Combination with PARP1 Inhibition
2752 - Molecular Mechanisms Associated with Autophagy Inhibition to Overcome Resistance to FLT3 Inhibitors
2775 - Plinabulin and Selumetinib Enhance M1 Macrophage Traits and Trigger Cell Death in AML
2881 - MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study
4321 - The Oncogenic Function of the Intrinsically Disordered Transcriptional Regulator MN1 Depends on the Chaperone DNAJB6b
4518 - Synergistic Effect of Tamoxifen and Ruxolitinib Combination in Reducing Disease Burden in Myeloproliferative Neoplasms

Hulshof, A. M.

3958 - Whole Genome Sequencing to Elucidate Genetic Modifiers of FVIII Clearance Heterogeneity in Patients with Hemophilia a

Hultcrantz, M.

248 - Genomic Complexity Correlates with the Degree of Marrow Independence of Malignant Plasma Cells in the Context of Extramedullary Disease
496 - ABBV-383 Plus Daratumumab-Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Dose-Escalation and Safety Expansion Study
671 - A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma
672 - Immune-MRD Status Informs Tumor-MRD Outcome Prognostication in Multiple Myeloma Patients on Lenalidomide Maintenance
1944 - Impact of Absolute Lymphocyte Count at Pre-Apheresis and Pre-Lymphodepletion on Chimeric Antigen Receptor (CAR)-T Therapy Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)
3362 - Daratumumab Versus Lenalidomide As Maintenance Therapy in Newly Diagnosed Multiple Myeloma – Interim Efficacy Results of a Randomized Clinical Trial
4735 - Frailty and Outcomes after Bispecific T-Cell Engager Therapy for Patients with Relapsed/Refractory Multiple Myeloma
4850 - Manufacture of Anti-BCMA CAR T Cell Is Feasible after Salvage Autologous or Allogeneic Hematopoietic Stem Cell Transplantation

Hultdin, M.

2831 - Cerebrospinal Fluid Flow Cytometry Improves Patient Stratification in Central Nervous System Acute Lymphoblastic Leukaemia but Requires Careful Standardization: Results from the ALLTogether1 CSF-FLOW Sub-Study

Hultquist, A.

1757 - A Novel in-Vivo Model of Human Myelofibrosis Based on Transplantation of Thrombopoietin Overexpressing CD34+ Cells into Humanized Bone Marrows in NSG Mice Recapitulates Key Disease Hallmarks
4227 - In Situ Spatial mRNA Analysis Implicates Increased TGFB1 and PDGFA1 Expression As Potential Drivers of Fibrosis in Pediatric Acute Lymphoblastic Leukemia

Hultquist, H.

4183 - Initial Cerebrospinal Fluid Blast Clearance Rate in Pediatric B-Lymphoblastic Leukemia Is Associated with Overall Survival

Humala, K.

4869 - Incidence, Clinical Risk Factors, and Biomarkers of SOS/VOD Following Allogeneic HSCT in Adults: A Real-Life Study By the Spanish Group of Hematopoietic Stem Cell Transplantation and Cell Therapy (GETH-TC)

Humayun, L.

2892 - Optimizing Venetoclax Duration in Combination with Hypomethylating Agents for Newly Diagnosed AML: Impact on Treatment Response and Survival Outcomes
3566 - Clinical Impact of Pretransplant Blinatumomab in Predominantly Hispanic Adults with B-Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Humayun, S.

3324 - Impact of Pre-Transplant Depth of Response on Outcomes in Patients with Multiple Myeloma: A Report on Behalf of Pakistan Blood and Marrow Transplant Group

Hume, D. A.

1149 - Blood Cell Homeostasis Is Maintained in the Absence of Resident Mononuclear Phagocytes in Fetal Liver and Bone Marrow in CSF1R Knockout Rats
1150 - Transcriptomic Analysis of the Functions of CSF1R-Dependent Macrophages in Postnatal Development in the Rat
1151 - An Inactivating Mutation in Rat IL-34 Reveals Redundant and Nonredundant Functions of CSF1-IL-34 Signalling in Homeostasis and Inflammation
4033 - Characterization of a Colony Stimulating Factor Receptor (CSF1R) Upstream Regulatory Element in Haematopoiesis

Hume, H. A.

546 - Hydroxyurea Decreases Transfusion Utilization in Ugandan Children with Sickle Cell Anemia: Main Results from the Alternative Dosing and Prevention of Transfusions (ADAPT) Trial

Humes, D.

2196 - Relieving Restriction in Resting CD8+ T Cells Increases Gene Transfer and Improves Tumor Killing after Transduction with CD8-Targeted CD19CAR Fusosome

Hummel, F.

856 - Modulation of the Tumor Microenvironment By CCL19 in Primary CNS Lymphomas
4374 - The Effect of Ibrutinib on the Myeloid Cell Compartment in Central Nervous System Lymphoma Slice Cultures

Humpton, T.

2761 - M2-like Macrophages Transfer Mitochondria to Acute Myeloid Leukaemia Cells Via Tunnelling Nanotubes Promoting Therapy Resistance

Hunault, M.

3483 - Sequential Intensified Conditioning Regimen Allogeneic Transplantation in Younger Adult Patients with Adverse-Risk Acute Myeloid Leukemia: A Multi-Center Prospective Study from the Acute Leukemia French Intergroup on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Hunault, M.

226 - Flow MRD Monitoring Combining Laip/Dfn and CD34+CD38- LSCs Is a Strong Predictor of Outcome in Adult AML Independently of the ELN-2022 Risk: First Results from the Multicentric Acute Leukemia French Intergroup MRD Flow Network
1531 - Inflammatory Biomarkers Predict Response and Survival in Chemotherapy-Ineligible and Untreated Acute Myeloid Leukemia Patients Receiving Venetoclax-Azacytidine As Front-Line Therapy
2905 - Long Term Follow-up Data after Consolidation Therapy with Ponatinib in Combination with Cytarabine in Patients with FLT3 Mutated Acute Myeloid Leukemia in First Complete Remission
4909 - Cyclosporine Versus Cyclosporine Plus Mycophenolate Mofetil in Reduced Intensity Allogeneic Stem Cell Transplantation for Intermediate-Risk AML: A Multi-Center Randomized Study from the Acute Leukemia French Intergroup, on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Hundemer, M.

364 - Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial
493 - Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial
769 - Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
4701 - MRD By Flow Cytometry and FDG-PET/CT for the Post-Induction Response Assessment in Patients with Multiple Myeloma Treated in the Phase 3 GMMG HD7 Study

Hung, K.

1267 - Higher Rate of Red Blood Cell (RBC) Alloimmunization in RBC-Transfused Myelodysplastic Syndrome Compared to Acute Myeloid Leukemia
1780 - Computational Cytomorphological Analyses Identifies Bone Marrow Erythroblast Proportion As a Biomarker of Treatment-Free Remission in CML
3208 - Dynamic Assessment of RBC-Transfusion Dependency (RBC-TD) Improves the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification of MDS
3213 - Evidence-Based Risk Stratification of TP53-Mutated Myeloid Neoplasms
4237 - High Burden of Healthcare Utilization in Older Acute Myeloid Leukemia Patients Treated with First-Line Venetoclax-Based Therapies
4594 - TP53-Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors

Hung, M. S.

2745 - Characterizing and Targeting Follicular Lymphoma's Common Progenitor Cells

Hung, R.

1910 - Preliminary Observations Using 99m-Tc-Peptide p5+14 for the Detection of AL Amyloidosis Using SPECT/CT and Planar Gamma Scintigraphic Imaging

Hung, S.

646 - Tumor Microenvironment Differences between Diagnostic and Relapsed Classic Hodgkin Lymphoma Revealed By Single Cell Transcriptome Sequencing

Hunger, S. P.

1 - Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children’s Oncology Group Study AALL1731
313 - Genomic Biomarkers of Poor Outcome in Patients with T-Cell Lymphoblastic Lymphoma
634 - TCL1A Is Associated with Blinatumomab Response and Immune Activation in Pediatric B-ALL
1464 - Interferon-Activated Gene Signatures Associate with Chemotherapy Resistance and Sensitivity to JAK-Inhibition in Refractory ETP-ALL
2797 - Examining Disparities By Race, Ethnicity, and Socioeconomic Factors in Children and Young Adults with Relapsed Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
2813 - Utility of a Second Interim Maintenance Phase to Improve Outcomes for Pediatric Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
4195 - Additional Induction Intrathecal Cytarabine for Patients with CNS2 Disease at Diagnosis Is Not Beneficial for Patients with B-ALL Treated on Children's Oncology Group Protocols AALL0932 and AALL1131

Hungria, V.

258 - Daratumumab-Based Quadruplet Versus Triplet Induction Regimens in Frontline Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis
362 - Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial
494 - Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial
772 - Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial
773 - Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study
891 - Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study
3359 - Efficacy Outcomes By Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone: Analysis from the Dreamm-7 Trial
3774 - Smoldering Multiple Myeloma in Latin America- Risk Stratification

Hunt, P.

4041 - Loss of Microtubule Protein Stathmin-1 Impairs Autophagy in Hematopoietic Stem Cells

Hunt, S. K.

307 - Efficacy and Toxicity of Fixed Dose Versus Reduced/PK-Adjusted Dose Pegaspargase in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia: Results of DFCI ALL Consortium Protocol 16-001
311 - Feasibility of Adjusting Risk Group and Risk Group-Based Therapy during Induction in the Treatment of B-Cell Acute Lymphoblastic Leukemia: Results from DFCI ALL Consortium Protocol 16-001

Hunter, A. M.

658 - Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study
659 - Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)
1003 - A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)
1005 - Artificial-Intelligence, Data-Driven, Comprehensive Classification of Myeloid Neoplasms Based on Genomic, Morphological and Histological Features
2426 - Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium
3151 - Olverembatinib (HQP1351) Overcomes Resistance/Intolerance to Asciminib and Ponatinib in Patients (pts) with Heavily Pretreated Chronic-Phase Chronic Myeloid Leukemia (CP‑CML): A 1.5-Year Follow-up Update with Comprehensive Exposure-Response (E-R) Analyses
4556 - Updated Efficacy and Safety Results of Patients Receiving Selected 100mg Bezuclastinib Dose and Participating in the Open-Label Extension of Summit: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib in Adult Patients with Nonadvanced Systemic Mastocytosis
5052 - U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML)
4569.1 - Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis

Hunter, B. D.

470 - Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
472 - Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous System (sCNS) Involvement from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
1749 - The “Walk through the Clinic Door” Effect: Differences in Survival and Toxicity Based on Site of CAR T Administration in a Default Outpatient CAR T Program
3132.1 - ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy

Hunter, C. J.

1480 - Toxicity and Efficacy of Isavuconazole Vs Voriconazole As Anti-Fungal Prophylaxis for Patients with Acute Myeloid Leukemia
4184 - The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
4253 - Risk Factors and Predictors of Outcomes after Invasive Fungal Infection Among Patients with Acute Myeloid Leukemia

Hunter, J. K.

1520 - A Phase 1 Study of CPX-351 Plus Gilteritinib in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Hunter, L.

3573.1 - Prospective Observational Cohort Study to Collect Granular Social Determinants of Health Data for Transplant and Cellular Therapy Candidates and Recipients

Hunter, S.

1318 - Cellular and Cell-Free Genomic Characterization of Patients Receiving Avatrombopag and Immunosuppressive Therapy for Treatment-Naïve Severe Aplastic Anemia

Hunter, Z. R.

743 - Single-Cell RNA Analysis of Bone Marrow Mononuclear Cells Reveals Abnormal Activation of T Cells and Monocytes, and Identifies CD35 As a Novel Biomarker and Therapeutic Target in Waldenstrom Macroglobulinemia
834 - Development and Characterization of Novel Dual HCK/BTK Bifunctional Protacs That Potently Inhibit Kinase Function and Demonstrate Robust in Vitro and In Vivo Degradation of Targets for the Treatment of MYD88-Mutated B-Cell Malignancies
1647 - Two-Year Follow-up after Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia
2968 - Multi-Omic Analysis Identifies Deletions in Chr17p and High ROR1 Expression, but Not TP53 Mutations As Predictors of Overall Survival in Patients with Untreated Waldenstrom’s Macroglobulinemia (WM)
2972 - Discovery of Undocumented, Cancer-Specific and Pro-Inflammatory Isoforms of WNK2 That Are Highly Expressed in MYD88 Mutated Waldenström’s Macroglobulinemia and Represent Novel Therapeutic Targets.
2986 - Analysis of Alternative Splicing in Waldenstrom’s Macroglobulinemia Reveals Novel Targets, Insights into IgM Production and Improved Gene Level Expression Estimates
3011 - A Phase II Study of Pirtobrutinib and Venetoclax in Previously Treated Patients with Waldenström Macroglobulinemia: An Interim Analysis
4338 - Genomic Evolution By Serial Single-Cell Sequencing Identifies High Tumor Expression of LYN As a Promoter of Resistance in Waldenstrom’s Macroglobulinemia Undergoing Ibrutinib Monotherapy
4358 - Expanded Genome-Wide Association Study (GWAS) Identifies Nine Novel Germline Risk Loci for Waldenström Macroglobulinemia (WM) and Lymphoplasmacytic Lymphoma (LPL)
4359 - Development and Characterization of a Novel Bifunctional Protac Jh-XIII-05-1 That Shows Potent IRAK1 and IRAK4 Kinase Inhibition and Target Degradation and Is Highly Active in MYD88 Mutated B-Cell Lymphoma Cells Alone and in Combination with BTK- and BCL2- Inhibitors

Huntington, S. F.

387 - Feasibility of Multi-Modal Physical Function Data Collection to Assess Treatment Tolerability in Patients with Lymphoma
782 - Travel Burden and Travel Costs of Bispecific Antibodies in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Relapsed/Refractory Follicular Lymphoma
786 - Real-World Analysis of Insurer Rejection Rates for Specialty Oral Anticancer Prescriptions in a Nationwide Sample of Patients with Blood Cancer
788 - Cost-Effectiveness of Allogeneic Hematopoietic Stem Cell Transplantation Versus Consolidation Chemotherapy for Patients with Intermediate Risk Acute Myeloid Leukemia
1614 - Circulating Biomarkers and CD8+ T-Cell Subpopulations Reveal Evolving Phases of Immune Response in Patients Receiving Mosunetuzumab for Previously Untreated B-Cell Lymphoma
1644 - Mosunetuzumab with Response-Driven Lenalidomide Augmentation As First-Line Therapy for Symptomatic Follicular or Marginal Zone Lymphoma: Interim Analysis of a Multi-Center Phase 2 Study
3644 - Cost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States
3795 - Inequalities in Treatment Utilization Among Older Medicare Beneficiaries with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Induction Therapy

Huntly, B. J.

152 - The Transcriptional Activators p300/Crebbp Are Context-Dependent Functional Repressors of Interferon Genes, Offering Therapeutic Promise in AML
190 - Delayed Trp53 Activation Protects Dnmt3a-Mutant Haematopoietic Stem Cells from Inflammatory Attrition
722 - Acute Resistance to BET Inhibitors Remodels Compensatory Transcriptional Programs Via p300 Co-Activation
844 - The Prognostic Impact of Myelodysplasia-Related Gene Mutations in Acute Myeloid Leukemia with FLT3-ITD Mutations
1830 - Genetic Diversity Drives Differing Morphological and Clinical Presentation and Survival in Myelodysplastic-Type CMML with a Low Absolute Monocyte Count
3186 - Interim Analysis of Promise, a Clinical Study Combining the BET Inhibitor OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis Experiencing an Inadequate Response to Ruxolitinib

Huntsman, E.

1077 - Differential Kinase Activity in Aged Erythrocytes Following Nutrient Replenishment: Insights from Phosphoproteomics and Motif Analysis

Huo, J.

3436 - Targeting the Membrane-Proximal Domain of CD33 to Maximize the Efficacy of Natural Killer Cell-Based Immunotherapies

Huo, J.

4073 - Antithymocyte Globulin Enhances Myeloid-Derived Suppressor Cell Expansion and Function in Severe Aplastic Anemia

Huo, Q.

2474 - TGF-β1 Reverses Hemoglobin Switching in Erythroid Progenitor Cells before Erythropoietin Induction

Huo, S.

2398 - Dosing Patterns and Early Safety and Effectiveness Outcomes in Patients with Multiple Myeloma Treated with Teclistamab in the Community Setting

Huo, X.

1950 - Proliferative CD8 T-Cells: A Novel Immune Microenvironmental Determinant of Outcomes in Multiple Myeloma with Translocation (4;14)

Hupe, H. C.

847 - Prognostic Impact of Subclinical FLT3-ITD Microclones in Patients with Acute Myeloid Leukemia

Hupf, B.

95 - Efficacy and Safety of TAK-007, Cord Blood-Derived CD19 CAR-NK Cells, in Adult Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Huppunen, M. E.

1548 - Efficacy of the Peptide Drug Conjugates Melflufen and OPDC3 in Venetoclax Resistant Acute Myeloid Leukemia

Huq, M. S.

5019 - Development of a Working Definition of Severe Von Willebrand Disease

Hur, J. Y.

1704 - The Clinical Impact of Surgery on Overall Survival of Patients with Intestinal Non‑Hodgkin Lymphoma through a Nationwide Study

Hur, W. S.

1148 - Control of Macrophage Fusion By Sensing the Physical Properties of Fibrin(ogen) Matrices

Hurh, E.

467 - Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC^TM Degrader, in Patients with Non-Hodgkin’s Lymphoma
3366 - Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC^TM Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Hurley, A.

2067 - A Phase 1 Dose Escalation and Expansion Trial of Third-Generation CD19-Directed CAR T-Cells Incorporating CD28 and Toll-like Receptor 2 (TLR2) Co-Stimulation for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (ENABLE-1)

Hurling, C.

4806 - A Regulated Cytokine Engineering Strategy to Augment in Vitro and In Vivo persistence of Allogeneic iPSC Derived CD8 T-Cells

Hurren, R.

2723 - AML Cells Have Increased Mitochondrial RNA Degradation and Inhibiting This Degradation Promotes Cell Differentiation, Decreases Viability, and Increases Sensitivity to Immune-Mediated Killing
2724 - The Exportin, CSE1L, Regulates Ribosome Biogenesis and Is a Selective Dependency in Childhood and Young Adult Acute Myeloid Leukemia
2778 - The Mitochondrial Unfolded Protein Response (UPR^mt) Is Upregulated in Acute Myeloid Leukemia (AML) and Inhibiting the UPR^mt Protease, LONP1, Leads to Mitochondrial Protein Aggregation and Cell Death Selectively in AML

Hurtado Martinez, J. A.

283 - National Healthtree Survey on Pain and Opioid Use Patterns and Perceptions Among Patients with Multiple Myeloma
706 - Patient-Centered Care in Hematology: How Side Effect Severity Influences Decision-Making Autonomy in Relapsed Refractory Multiple Myeloma
2281 - Patient Preferences on Clinical Decision-Making in Myeloma: A 747-Patient Survey
5143 - AL Amyloidosis: Understanding the Clinical Prodrome and Delays in Diagnosis
5144 - First Ever National Survey on Patient-Reported Efficacy and Safety of Cannabis in Patients with Multiple Myeloma

Hurtz, C.

1455 - KMT2A-Rearranged ALL Requires DYRK1A for Regulation of ERK Signaling and Cell Proliferation
4216 - Targeting the SWI/SNF Chromatin Remodeling Complex Subunit SMARCA4 in ALL

Hurwitz, H. M.

5167 - A Pilot Screening and Patient Navigation Program for Early Detection of Multiple Myeloma to Address Cancer Disparities

Hurwitz, S.

2761 - M2-like Macrophages Transfer Mitochondria to Acute Myeloid Leukaemia Cells Via Tunnelling Nanotubes Promoting Therapy Resistance

Hurwitz, S.

1418 - TBL1 Inhibition Eradicates Drug Resistant Leukemia Initiating Cells in T-ALL

Hurwitz, S. N.

2021 - CCR2 Cooperatively Regulates Hematopoietic Stem Cell Homing to the Bone Marrow

Hus, I.

1660 - Acalabrutinib in Patients with Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Subjected to Allogeneic Hematopoietic Stem Cell Transplantation. a Phase 2 Study By the Polish Lymphoma Research Group

Hus, M.

497 - Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis
772 - Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial
970 - A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) – Topline Results
3359 - Efficacy Outcomes By Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone: Analysis from the Dreamm-7 Trial

Hus, M.

496 - ABBV-383 Plus Daratumumab-Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Dose-Escalation and Safety Expansion Study
1323 - Phase III COMMODORE 2 and 1 Trials: Characterization of Breakthrough Hemolysis Events in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab or Eculizumab

Husami, A.

1084 - Loss of ATG5 in Humans Causes Syndromic Congenital Dyserythropoietic Anemia with Impaired Mitophagy in Late Stages of Terminal Erythropoiesis

Husby, S.

1594 - NOTCH1 Mutations Are Associated with Therapy-Resistance in Patients with B-Cell Lymphoma Treated with CD20xCD3 Bispecific Antibodies
3009 - Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma

Huselton, E. J.

224 - Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial
4741 - Hyperbaric Oxygen (HBO) Effects on Blood Count Recovery and Post Transplant Outcomes Following High-Dose Therapy and Autologous HSPC Transplantation for Multiple Myeloma: Final Analysis of the Multicenter Phase II Randomized Clinical Trial

Huskens, D.

3954 - Elevated Microclots with Low D-Dimer As an Indicator of Impaired Plasmin Generation in Patients with Viral Infections
3960 - Evaluating the Clinical Relevance of Thrombin Generation Potential during Emicizumab Therapy

Husnain, M.

2008 - Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy in Relapsed and Refractory Multiple Myeloma – a Meta-Analysis

Hussain, H.

4984 - Deep Learning Unveils Characteristics of Immune B Cell Aging in >17,000 Samples and Identifies Changes in the Immunoglobulin Repertoire Distribution and the Development of Monoclonal Gammopathy

Hussain, R.

3791 - CAR-T Therapy Showdown: Comparative Efficacy and Safety of of Ide-Cel (Idecabtagene vicleucel) and Cilta-Cel (Ciltacabtagene Autoleucel) in Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Study
5160 - Risk of Infection: Real-World Analysis of (Ide-cel) Idecabtagene Vicleucel and (Cilta-cel) Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

Hussaini, M. O.

4551 - Comparison of the Clinicopathological Findings of Patients with SF3B1/JAK2, SF3B1/Calr, or SF3B1/MPL co-Mutations
4578 - Synchronous Dual Hematologic Neoplasms of Myeloid and Lymphoid Lineage Are of Common Clonal Origin
4599 - Comparison of Clinicopathological Features of Patients with Two Spliceosome Gene Co-Mutations
4991 - A Deep-Learning Pipeline for Diagnosis of Myelodysplastic Syndromes/Neoplasms Using Bone Marrow Smears

Hussein, H. K.

1802 - Efficacy and Tolerability of Trametinib in Adults with Histiocytic Neoplasms

Hussein, U.

643 - Comprehensive Characterization and Validation of the Tumor Microenvironment in Patients with Relapsed/Refractory Large B-Cell Lymphoma Identifies Subgroups with Greatest Benefit from CD19 CAR T-Cell Therapy

Hutchaleelaha, A.

11 - PORT-77, a Novel and Potent Inhibitor of ABCG2, Protects Against Skin Photo Toxicity and Liver Damage in a Mouse Model of Erythropoietic Protoporphyria (EPP)

Hutchings, M.

237 - Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project
240 - Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network
342 - Fixed-Duration Epcoritamab + R² Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial
567 - Creation of a Multistate Model to Improve Prognostication across the Disease Course in Advanced Stage Classic Hodgkin Lymphoma (cHL): A Report from the Holistic Consortium
644 - CD19-CD28 (RO7443904) Combination with Glofitamab Enhances T-Cell Proliferation and Effector Function in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)
747 - Acalabrutinib and Rituximab in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma Including a Matched Population-Based External Comparator- the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) Phase II Trial
865 - Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study
988 - Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study
990 - Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072
1594 - NOTCH1 Mutations Are Associated with Therapy-Resistance in Patients with B-Cell Lymphoma Treated with CD20xCD3 Bispecific Antibodies
1737 - Efficacy and Safety of Epcoritamab Monotherapy in Patients with Relapsed or Refractory LBCL Not Previously Exposed to CAR T: Subanalysis of the Epcore NHL-1 Trial
1860 - Excellent Clinical Outcomes in Deeply Mutated IGHV Chronic Lymphocytic Leukemia upon Fludarabine and Cyclophosphamide Plus Rituximab
3009 - Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma
3054 - Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and Prednisone (B-CAP) First-Line Treatment of Advanced-Stage Hodgkin Lymphoma: Final Results of the GHSG-NLG Phase II Bvb Trial
3123 - BP43131, a Phase 1 Dose Escalation Study: CD19 Targeted CD28 Costimulatory Agonist (RO7443904) Combined with Glofitamab Shows Promising Efficacy in Patients with Relapsed/Refractory Aggressive B-NHL
3243 - Safety of Venetoclax Ramp-up before CD20 Antibody Administration in Chronic Lymphocytic Leukemia
4480 - 3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma
4491 - Three-Factor Prediction Model for Grade 2+ Cytokine Release Syndrome in Large B-Cell Lymphoma Patients Receiving Epcoritamab Monotherapy

Hutchins, Z.

4132 - Activating STAT3 Mutations Drive CD38 Expression in T-Large Granular Lymphocytic Leukemia

Hutchinson, L.

1546 - p53 Immunohistochemistry As a High-Specificity Biomarker to Predict Allelic State and Overall Survival in Myelodysplastic Syndrome or Acute Myeloid Leukemia with Mutated TP53
1553 - Characteristics and Clinical Outcomes of Patients with Myeloid Malignancies and Cohesin Mutations

Hutson, A.

4678 - Differences in Immune Cell Populations between Individuals with or without MGUS

Hüttemann, M.

1376 - Loss of Cystathionine-β-Synthase Activity Results in Increased Oxidative Phosphorylation and Cytarabine Resistance in Myeloid Leukemia Associated with Down Syndrome

Huttenlocher, A.

86 - iPSC-Derived CAR Neutrophils Possess Potent Activity Against Solid Tumors In Vivo

Hutter, B.

3577 - Use of Fidanacogene Elaparvovec, a Gene Therapy Vector, to Deliver a Stable, Fully Functional Human Factor IX Transgene for the Treatment of Hemophilia B: A Combined Analysis of Safety

Hutter, C.

3908 - Prognostic Value of BRAFV600E in Peripheral Blood of Children with Langerhans Cell Histiocytosis: A Multicenter Project of the European Consortium for Histiocytosis

Hutter, M.

3548 - Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia: Results of the AML BFM Study Group

Hutter, S.

31 - Genetic Determinants of Hypercoagulability in Complement and Hemostatic Systems Shape the Thrombotic Risk of Paroxysmal Nocturnal Hemoglobinuria
899 - Secondary Cytogenetic and Molecular Genetic Abnormalities in Newly Diagnosed Multiple Myeloma Patients
1819 - Similarities and Differences of DNMT3A, TET2 and ASXL1 Mutations across Ccus, MDS and AML
1836 - Two Ways to Complex Karyotype in MDS - the Role of Del(5q) and TP53
2732 - A Unified Post-Transcriptional Mechanism Regulates Intron Retention in Splicing Factor-Mutant MDS
4104 - Telomere Content Diversity in Myeloid Neoplasia Could Inform on Differential Sensitivity to Telomerase Inhibitors
4213 - Integrateall, a Machine Learning Pipeline for Multi-Level Data Extraction from RNA-Seq Profiles Unravels Novel Drivers and Systematic Subtype Classification in B-Cell Precursor ALL
4318 - Clonal Hematopoiesis Can Precede AML with Defining Cytogenetic Abnormalities - the Frequencies Vary Considerably

Hütter-Krönke, M. L.

5 - Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3)
2552 - Improved Health-Related quality of Life (HRQoL) with Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib Vs Placebo in Adults with Previously Treated Immune Thrombocytopenia (ITP): Phase 3 Luna 3 Multicenter Study

Hüttmann, A.

568 - PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial

Hutzen, B.

1056 - Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager

Hutzler, C.

1010 - Minimal Residual Disease (MRD)-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (CLL)

Huuhtanen, J.

1529 - Comparison of Anti-PD1, Anti-CTLA4 and Anti-TIM3 in Treatment of AML Patients with Single-Cell Transcriptomics Displays Different Effects on Immune Subtypes
3596 - Predicting Antigen-Specific T Cell Immunity Against Wilms Tumor 1 in Hematologic Cancer

Huynh, A.

731 - Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials
749 - Outcome of Hematopoietic Stem Cell Transplantation for Follicular Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
3027 - Hematopoietic Stem Cell Transplantation for Marginal Zone Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
3456 - Impact of Fludarabine Dosage on Outcomes in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy: A Retrospective Study on Behalf of the Ctiwp of the EBMT
3457 - SMART101 Donor T-Lymphoid Progenitors to Accelerate Immune Reconstitution Post HLA Mismatched Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide: Reset-02 First-in-Human Phase I/II
3483 - Sequential Intensified Conditioning Regimen Allogeneic Transplantation in Younger Adult Patients with Adverse-Risk Acute Myeloid Leukemia: A Multi-Center Prospective Study from the Acute Leukemia French Intergroup on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
3562 - Similar Transplant Outcomes for Haplo and MUD Allo-Hcts in AML Patients Achieving CR2: A Study Analyzing 4030 Allo-HCT Recipients from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
4315 - In AML Patients Allografted in First Remission, DNMT3A Mutations Differentially Affect Post-Transplant Outcomes According to Karyotype, NPM1 and FLT3-ITD Mutation Status - from the EBMT-ALWP
4903 - Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe
4909 - Cyclosporine Versus Cyclosporine Plus Mycophenolate Mofetil in Reduced Intensity Allogeneic Stem Cell Transplantation for Intermediate-Risk AML: A Multi-Center Randomized Study from the Acute Leukemia French Intergroup, on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
4946 - Allogeneic Stem-Cell Transplantation for Relapsed/Refractory ALK–Positive Anaplastic Large-Cell Lymphoma: A Study from the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)

Huynh, L.

707 - Real-World Effectiveness of Immunoglobulin Replacement Therapy on Hypogammaglobulinemia and Infectious Complications in Patients with Multiple Myeloma
2613 - Real-World Effectiveness of Ravulizumab Among Adults with Atypical Hemolytic Uremic Syndrome (aHUS) Who Switched to Ravulizumab within 3 Months of Eculizumab Treatment: A Physician Panel-Based Chart Review Study (aHUS IMPACT)

Huynh, M.

3251 - Acalabrutinib Versus Chlorambucil Plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia: A Randomized, Multicenter, Open-Label, Phase 3 Study

Huynh, T.

77 - Nx-2127 and Nx-5948, Two Clinical Stage Cereblon-Recruiting BTK Degraders, Facilitate T Cell Functionality in Chronic Lymphocytic Leukemia

Huynh, T.

907 - Caspase-1 Inhibition Ameliorates CAR T-Cell Apoptosis and Tumor Cell Pyroptosis to Enhance the Efficacy and Safety of CAR T-Cell Therapy
908 - Intrinsic Immunosuppressive Features of Monocytes Suppress CART19 through IL-1 Pathway Modulation in Mantle Cell Lymphoma
4808 - Identification of T Cell Senescence As a Cell Fate Limiting the Antitumor Activity of 41BB-Costimulated CART Cells

Huynh, V. T.

2789 - A Novel Approach Combining Type II JAK Inhibitor Chz-868 with Nutrient Restriction to Augment Cell Death in Philadelphia like Acute Lymphoblastic Leukemia
2846 - GWAS Identifies Pharmacogenetic Markers Associated with Premedication-Related Pegaspargase Hypersensitivity and Toxicities in Pediatric and Adolescent Young Adults (AYAs) with Acute Lymphoblastic Leukemia or Lymphoma

Huynh-Trudeau, G.

1783 - Distinguishing Germline from Acquired Pathogenic CSF3R Variants: Key Diagnostic Features and Clinical Implications

Hwa, Y. L.

83 - Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma
895 - Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
1955 - Impact of Serial Serum Free Light Chain Measurements on Response and Progression Assessments in Multiple Myeloma Patients with Measurable Disease
2400 - Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis
3315 - Impact of Multiple High-Risk Cytogenetic Abnormalities on the Survival Outcomes of Patients with Primary Plasma Cell Leukemia
4704 - Flow Cytometry-Based Assessment of the Proportion of Monoclonal Plasma Cells in Synthetic Phase (S-phase) Is an Independent Marker of Adverse Prognosis in Patients with Newly Diagnosed Multiple Myeloma
4716 - Evaluating the Interaction between Baseline Risk Stratification, Post-Transplant Measurable Residual Disease, and Long-Term Outcomes in Multiple Myeloma
4728 - Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes

Hwang, A.

3327 - Characterization of the Tumor Microenvironment of Diagnostic Bone Marrow Core Biopsies from African American Multiple Myeloma Patients Using Imaging Mass Cytometry

Hwang, D.

4982 - Accelerating Drug Discovery: AI-Powered Indication Exploration for Ropeginterferon Alfa-2b

Hwang, E.

1210 - Safety Biomarkers in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B Without Inhibitors Receiving Prophylactic Marstacimab Treatment: Results From the Phase 3 BASIS Trial

Hwang, H.

1011 - Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
2438 - Neighborhood Disadvantage Impacts Outcomes in Patients with Myelodysplastic Syndromes across Different Racial Backgrounds
3817 - Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods

Hwang, S. Y.

1364 - Leveraging SMARCA4 Dependency of Mantle Cell Lymphomas to Overcome BTK Inhibitor Resistance

Hwang, S. R.

1637 - Association of Sex, Race and Ethnicity with Clinical Characteristics and Survival Outcomes of Mantle Cell Lymphoma: A National Cancer Database Study
3019 - Clinical Characteristics and Outcomes of Aggressive Transformation in Splenic Marginal Zone Lymphoma: An International Study of 111 Patients

Hwang, S.

878 - TGF-β1-SMAD2 Axis Regulates Hematopoiesis and β-Globin Gene Expression Via Super-Enhancer Associated Chromatin Reorganization

Hwang, W. T.

588 - Curing CLL: Long-Term Outcomes of Chronic Lymphocytic Leukemia Patients with at Least One Year of Response to CART-19 Therapy
3473 - In Vivo Persistence and Function of CAR19 T-Cell Products for Pediatric B-Cell Acute Lymphoblastic Leukemia Are Impacted By Media, Cytokine Supplementation and Metabolite Bioavailability during Ex Vivo Manufacturing
3381.1 - A Multi-Institution Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed and Refractory Multiple Myeloma (LimiTec)

Hwang, W. Y. K.

3529 - Haploidentical Transplant Using Selective Ex-vivo TCR-Αβ Depleted and Upfront Memory T-Cell Add-Back Is Associated with Lower Chronic Gvhd and More Favorable Gvhd-Free/Relapse-Free Survival As Compared to Matched Related and Unrelated Donor Transplant for Adults with Hematological Malignancies

Hyatt, H. W.

3722 - Real-World Clinical Outcomes in Patients Initiating Covalent Btki (cBTKi) with and without Incident Cardiovascular Adverse Events By Line of Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
3738 - Healthcare Resource Utilization and Costs in Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Treated with Covalent Btki (cBTKi): Real-World Impact of Cardiovascular Adverse Events

Hyde, K.

1417 - The Polymeric Drug Pamd-Ch17 Induces Mitochondrial Dysfunction and Has Anti-Leukemic Effects
2728 - PTBP1, an RNA Binding Protein and Splicing Regulator, Binds RUNX1 and Co-Localizes at Target Gene Promoters in Leukemia
4112 - HMGB3: A Novel Regulator of Leukemia Proliferation

Hyde, S.

375 - Alemtuzumab, Fludarabine, Melphalan, and Thiotepa As Reduced-Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Inborn Errors of Immunity
2088.1 - NK Cell Immunotherapy to Reduce Relapse after Haploidentical Transplant for High-Risk Pediatric and Young Adult AML

Hyder, M. A.

689 - Characteristics and Risk Factors for BK Virus-Associated Cystitis after Post-Transplant Cyclophosphamide (PTCy) -Based Allogeneic Hematopoietic Cell Transplants (HCT)
1040 - Pharmacokinetic (PK) Exposure of 4-Hydroxycyclophosphamide Associates with Clinical Benefits of Reduced-Dose Post-Transplantation Cyclophosphamide: Results of a Completed Phase I/II Trial to De-Escalate Post-Transplantation Cyclophosphamide for HLA-Haploidentical Myeloablative Bone Marrow Transplantation
2429 - Understanding Barriers to Hematopoietic Cell Transplant (HCT) Access: Socio-Demographic Characteristics and Area Deprivation Index (ADI) of Patients Referred to the National Institutes of Health (NIH) for HCT

Hydren, J. R.

283 - National Healthtree Survey on Pain and Opioid Use Patterns and Perceptions Among Patients with Multiple Myeloma
706 - Patient-Centered Care in Hematology: How Side Effect Severity Influences Decision-Making Autonomy in Relapsed Refractory Multiple Myeloma
2281 - Patient Preferences on Clinical Decision-Making in Myeloma: A 747-Patient Survey
3786 - Satisfaction and Experiences with Talquetamab: Results from Qualitative Patient and Physician Research
5143 - AL Amyloidosis: Understanding the Clinical Prodrome and Delays in Diagnosis
5144 - First Ever National Survey on Patient-Reported Efficacy and Safety of Cannabis in Patients with Multiple Myeloma

Hylkema, T.

2050 - Potent Target-Specific Efficacy of CAR T Cells Directed Toward the AML and KMT2A-Rearranged Specific Antigen CLEC2A
3413 - Discovery and Immunotherapeutic Targeting of the Tumor-Specific Target LAMP5 in Acute Myeloid Leukemia
4793 - Preclinical Efficacy of CD276 (B7-H3) CAR T in Acute Myeloid Leukemia

Hyodo, K.

4870 - Appropriate Threshold of Quantitative Cytomegalovirus DNA Polymerase Chain Reaction for Preemptive Treatment in Stem Cell Transplant Recipients

Hyrenius Wittsten, A.

2769 - Unraveling How Treatment Shapes Clonal Evolution and Resistance in Murine KMT2A-Rearranged Leukemia with Subclonal Kras^G12D

Hysenaj, Z.

2306 - Prevalence of Pulmonary Hypertension in Patients Hospitalized with Sickle Cell Crisis

Hyun, D. W.

1595 - Gut Microbiome Composition As a Prognostic Marker in CD19-Targeting CAR T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Hyung, J.

1659 - Prognostic Analysis of Colorectal Extranodal Marginal Zone Lymphoma of MALT Type: Clinical Outcomes and Implications

Hyzy, S. L.

2873 - A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)

Author Index: H